From	Entry	Reviewed	Entry Name	Protein names	Gene Names	Organism	Length	Sequence	Function [CC]	Miscellaneous [CC]	Gene Ontology (biological process)	Gene Ontology (cellular component)	Gene Ontology (molecular function)	Gene Ontology (GO)	Gene Ontology IDs	PubMed ID	DOI ID	RefSeq	BindingDB	ChEMBL	DrugBank
2z3h	P0C2P0	reviewed	BSD_ASPTE	Blasticidin-S deaminase (EC 3.5.4.23)	bsd	Aspergillus terreus	130	MPLSQEESTLIERATATINSIPISEDYSVASAALSSDGRIFTGVNVYHFTGGPCAELVVLGTAAAAAAGNLTCIVAIGNENRGILSPCGRCRQVLLDLHPGIKAIVKDSDGQPTAVGIRELLPSGYVWEG	FUNCTION: Catalyzes the deamination of the cytosine moiety of the antibiotics blasticidin S, cytomycin and acetylblasticidin S.		response to antibiotic [GO:0046677]	cytosol [GO:0005829]	blasticidin-S deaminase activity [GO:0047711]; cytidine deaminase activity [GO:0004126]; identical protein binding [GO:0042802]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]; blasticidin-S deaminase activity [GO:0047711]; cytidine deaminase activity [GO:0004126]; identical protein binding [GO:0042802]; zinc ion binding [GO:0008270]; response to antibiotic [GO:0046677]	GO:0004126; GO:0005829; GO:0008270; GO:0042802; GO:0046677; GO:0047711	8159161; 10833262; 10089374; 17959604	10.1007/bf00391004; 10.1093/oxfordjournals.jbchem.a022711; 10.1107/s0907444998011809; 10.1074/jbc.m704476200				DB04649;
4aaw	Q8DQ18	reviewed	GLMU_STRR6	Bifunctional protein GlmU [Includes: UDP-N-acetylglucosamine pyrophosphorylase (EC 2.7.7.23) (N-acetylglucosamine-1-phosphate uridyltransferase); Glucosamine-1-phosphate N-acetyltransferase (EC 2.3.1.157)]	glmU spr0891	Streptococcus pneumoniae (strain ATCC BAA-255 / R6)	459	MSNFAIILAAGKGTRMKSDLPKVLHKVAGISMLEHVFRSVGAIQPEKTVTVVGHKAELVEEVLAEQTEFVTQSEQLGTGHAVMMTEPILEGLSGHTLVIAGDTPLITGESLKNLIDFHINHKNVATILTAETDNPFGYGRIVRNDNAEVLRIVEQKDATDFEKQIKEINTGTYVFDNERLFEALKNINTNNAQGEYYITDVIGIFRETGEKVGAYTLKDFDESLGVNDRVALATAESVMRRRINHKHMVNGVSFVNPEATYIDIDVEIAPEVQIEANVILKGQTKIGAETVLTNGTYVVDSTIGAGAVITNSMIEESSVADGVTVGPYAHIRPNSSLGAQVHIGNFVEVKGSSIGENTKAGHLTYIGNCEVGSNVNFGAGTITVNYDGKNKYKTVIGDNVFVGSNSTIIAPVELGDNSLVGAGSTITKDVPADAIAIGRGRQINKDEYATRLPHHPKNQ	FUNCTION: Catalyzes the last two sequential reactions in the de novo biosynthetic pathway for UDP-N-acetylglucosamine (UDP-GlcNAc). The C-terminal domain catalyzes the transfer of acetyl group from acetyl coenzyme A to glucosamine-1-phosphate (GlcN-1-P) to produce N-acetylglucosamine-1-phosphate (GlcNAc-1-P), which is converted into UDP-GlcNAc by the transfer of uridine 5-monophosphate (from uridine 5-triphosphate), a reaction catalyzed by the N-terminal domain. {ECO:0000255|HAMAP-Rule:MF_01631}.		cell morphogenesis [GO:0000902]; cell wall organization [GO:0071555]; lipid A biosynthetic process [GO:0009245]; peptidoglycan biosynthetic process [GO:0009252]; regulation of cell shape [GO:0008360]; UDP-N-acetylglucosamine biosynthetic process [GO:0006048]	cytoplasm [GO:0005737]	glucosamine-1-phosphate N-acetyltransferase activity [GO:0019134]; magnesium ion binding [GO:0000287]; UDP-N-acetylglucosamine diphosphorylase activity [GO:0003977]	cytoplasm [GO:0005737]; glucosamine-1-phosphate N-acetyltransferase activity [GO:0019134]; magnesium ion binding [GO:0000287]; UDP-N-acetylglucosamine diphosphorylase activity [GO:0003977]; cell morphogenesis [GO:0000902]; cell wall organization [GO:0071555]; lipid A biosynthetic process [GO:0009245]; peptidoglycan biosynthetic process [GO:0009252]; regulation of cell shape [GO:0008360]; UDP-N-acetylglucosamine biosynthetic process [GO:0006048]	GO:0000287; GO:0000902; GO:0003977; GO:0005737; GO:0006048; GO:0008360; GO:0009245; GO:0009252; GO:0019134; GO:0071555	11544234; 22297115	10.1128/jb.183.19.5709-5717.2001; 10.1016/j.bmcl.2012.01.016	NP_358485.1;WP_000064394.1;	Q8DQ18;		
4yhj	P32298	reviewed	GRK4_HUMAN	G protein-coupled receptor kinase 4 (EC 2.7.11.16) (G protein-coupled receptor kinase GRK4) (ITI1)	GRK4 GPRK2L GPRK4	Homo sapiens (Human)	578	MELENIVANSLLLKARQGGYGKKSGRSKKWKEILTLPPVSQCSELRHSIEKDYSSLCDKQPIGRRLFRQFCDTKPTLKRHIEFLDAVAEYEVADDEDRSDCGLSILDRFFNDKLAAPLPEIPPDVVTECRLGLKEENPSKKAFEECTRVAHNYLRGEPFEEYQESSYFSQFLQWKWLERQPVTKNTFRHYRVLGKGGFGEVCACQVRATGKMYACKKLQKKRIKKRKGEAMALNEKRILEKVQSRFVVSLAYAYETKDALCLVLTIMNGGDLKFHIYNLGNPGFDEQRAVFYAAELCCGLEDLQRERIVYRDLKPENILLDDRGHIRISDLGLATEIPEGQRVRGRVGTVGYMAPEVVNNEKYTFSPDWWGLGCLIYEMIQGHSPFKKYKEKVKWEEVDQRIKNDTEEYSEKFSEDAKSICRMLLTKNPSKRLGCRGEGAAGVKQHPVFKDINFRRLEANMLEPPFCPDPHAVYCKDVLDIEQFSVVKGIYLDTADEDFYARFATGCVSIPWQNEMIESGCFKDINKSESEEALPLDLDKNIHTPVSRPNRGFFYRLFRRGGCLTMVPSEKEVEPKQC	FUNCTION: Specifically phosphorylates the activated forms of G protein-coupled receptors. GRK4-alpha can phosphorylate rhodopsin and its activity is inhibited by calmodulin; the other three isoforms do not phosphorylate rhodopsin and do not interact with calmodulin. GRK4-alpha and GRK4-gamma phosphorylate DRD3. Phosphorylates ADRB2. {ECO:0000269|PubMed:19520868, ECO:0000269|PubMed:8626439}.		phosphorylation [GO:0016310]; receptor internalization [GO:0031623]; regulation of G protein-coupled receptor signaling pathway [GO:0008277]; regulation of rhodopsin mediated signaling pathway [GO:0022400]; regulation of signal transduction [GO:0009966]; signal transduction [GO:0007165]	cell cortex [GO:0005938]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; photoreceptor disc membrane [GO:0097381]; plasma membrane [GO:0005886]	ATP binding [GO:0005524]; protein kinase activity [GO:0004672]; rhodopsin kinase activity [GO:0050254]	cell cortex [GO:0005938]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; photoreceptor disc membrane [GO:0097381]; plasma membrane [GO:0005886]; ATP binding [GO:0005524]; protein kinase activity [GO:0004672]; rhodopsin kinase activity [GO:0050254]; phosphorylation [GO:0016310]; receptor internalization [GO:0031623]; regulation of G protein-coupled receptor signaling pathway [GO:0008277]; regulation of rhodopsin mediated signaling pathway [GO:0022400]; regulation of signal transduction [GO:0009966]; signal transduction [GO:0007165]	GO:0004672; GO:0005524; GO:0005737; GO:0005829; GO:0005886; GO:0005938; GO:0007165; GO:0008277; GO:0009966; GO:0016310; GO:0022400; GO:0031623; GO:0050254; GO:0097381	1338872; 9092566; 8626439; 8135832; 15815621; 15489334; 16636192; 19520868; 22223895; 17344846	10.1093/hmg/1.9.697; 10.1074/jbc.272.15.10188; 10.1074/jbc.271.11.6403; 10.1006/bbrc.1994.1306; 10.1038/nature03466; 10.1101/gr.2596504; 10.1161/01.hyp.0000222004.74872.17; 10.1074/jbc.m109.003665; 10.1074/mcp.m111.015131; 10.1038/nature05610	NP_001004056.1 [P32298-2];NP_001004057.1 [P32298-4];NP_005298.2 [P32298-3];NP_892027.2 [P32298-1];	P32298;	CHEMBL5861;	
14gs	P09211	reviewed	GSTP1_HUMAN	Glutathione S-transferase P (EC 2.5.1.18) (GST class-pi) (GSTP1-1)	GSTP1 FAEES3 GST3	Homo sapiens (Human)	210	MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ	FUNCTION: Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Involved in the formation of glutathione conjugates of both prostaglandin A2 (PGA2) and prostaglandin J2 (PGJ2) (PubMed:9084911). Participates in the formation of novel hepoxilin regioisomers (PubMed:21046276). Negatively regulates CDK5 activity via p25/p35 translocation to prevent neurodegeneration. {ECO:0000269|PubMed:21046276, ECO:0000269|PubMed:21668448, ECO:0000269|PubMed:9084911}.		cellular response to lipopolysaccharide [GO:0071222]; central nervous system development [GO:0007417]; common myeloid progenitor cell proliferation [GO:0035726]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; hepoxilin biosynthetic process [GO:0051122]; linoleic acid metabolic process [GO:0043651]; negative regulation of acute inflammatory response [GO:0002674]; negative regulation of apoptotic process [GO:0043066]; negative regulation of biosynthetic process [GO:0009890]; negative regulation of canonical NF-kappaB signal transduction [GO:0043124]; negative regulation of ERK1 and ERK2 cascade [GO:0070373]; negative regulation of extrinsic apoptotic signaling pathway [GO:2001237]; negative regulation of fibroblast proliferation [GO:0048147]; negative regulation of interleukin-1 beta production [GO:0032691]; negative regulation of JUN kinase activity [GO:0043508]; negative regulation of leukocyte proliferation [GO:0070664]; negative regulation of MAP kinase activity [GO:0043407]; negative regulation of MAPK cascade [GO:0043409]; negative regulation of monocyte chemotactic protein-1 production [GO:0071638]; negative regulation of nitric-oxide synthase biosynthetic process [GO:0051771]; negative regulation of protein kinase activity [GO:0006469]; negative regulation of stress-activated MAPK cascade [GO:0032873]; negative regulation of tumor necrosis factor production [GO:0032720]; negative regulation of tumor necrosis factor-mediated signaling pathway [GO:0010804]; nitric oxide storage [GO:0035732]; positive regulation of superoxide anion generation [GO:0032930]; prostaglandin metabolic process [GO:0006693]; regulation of ERK1 and ERK2 cascade [GO:0070372]; regulation of stress-activated MAPK cascade [GO:0032872]; response to reactive oxygen species [GO:0000302]; xenobiotic metabolic process [GO:0006805]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; ficolin-1-rich granule lumen [GO:1904813]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; secretory granule lumen [GO:0034774]; TRAF2-GSTP1 complex [GO:0097057]; vesicle [GO:0031982]	dinitrosyl-iron complex binding [GO:0035731]; fatty acid binding [GO:0005504]; glutathione peroxidase activity [GO:0004602]; glutathione transferase activity [GO:0004364]; JUN kinase binding [GO:0008432]; kinase regulator activity [GO:0019207]; nitric oxide binding [GO:0070026]; S-nitrosoglutathione binding [GO:0035730]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; ficolin-1-rich granule lumen [GO:1904813]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; secretory granule lumen [GO:0034774]; TRAF2-GSTP1 complex [GO:0097057]; vesicle [GO:0031982]; dinitrosyl-iron complex binding [GO:0035731]; fatty acid binding [GO:0005504]; glutathione peroxidase activity [GO:0004602]; glutathione transferase activity [GO:0004364]; JUN kinase binding [GO:0008432]; kinase regulator activity [GO:0019207]; nitric oxide binding [GO:0070026]; S-nitrosoglutathione binding [GO:0035730]; cellular response to lipopolysaccharide [GO:0071222]; central nervous system development [GO:0007417]; common myeloid progenitor cell proliferation [GO:0035726]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; hepoxilin biosynthetic process [GO:0051122]; linoleic acid metabolic process [GO:0043651]; negative regulation of acute inflammatory response [GO:0002674]; negative regulation of apoptotic process [GO:0043066]; negative regulation of biosynthetic process [GO:0009890]; negative regulation of canonical NF-kappaB signal transduction [GO:0043124]; negative regulation of ERK1 and ERK2 cascade [GO:0070373]; negative regulation of extrinsic apoptotic signaling pathway [GO:2001237]; negative regulation of fibroblast proliferation [GO:0048147]; negative regulation of interleukin-1 beta production [GO:0032691]; negative regulation of JUN kinase activity [GO:0043508]; negative regulation of leukocyte proliferation [GO:0070664]; negative regulation of MAP kinase activity [GO:0043407]; negative regulation of MAPK cascade [GO:0043409]; negative regulation of monocyte chemotactic protein-1 production [GO:0071638]; negative regulation of nitric-oxide synthase biosynthetic process [GO:0051771]; negative regulation of protein kinase activity [GO:0006469]; negative regulation of stress-activated MAPK cascade [GO:0032873]; negative regulation of tumor necrosis factor production [GO:0032720]; negative regulation of tumor necrosis factor-mediated signaling pathway [GO:0010804]; nitric oxide storage [GO:0035732]; positive regulation of superoxide anion generation [GO:0032930]; prostaglandin metabolic process [GO:0006693]; regulation of ERK1 and ERK2 cascade [GO:0070372]; regulation of stress-activated MAPK cascade [GO:0032872]; response to reactive oxygen species [GO:0000302]; xenobiotic metabolic process [GO:0006805]	GO:0000302; GO:0002674; GO:0004364; GO:0004602; GO:0005504; GO:0005576; GO:0005615; GO:0005634; GO:0005737; GO:0005739; GO:0005829; GO:0006469; GO:0006693; GO:0006749; GO:0006805; GO:0007417; GO:0008432; GO:0009890; GO:0010804; GO:0019207; GO:0031982; GO:0032691; GO:0032720; GO:0032872; GO:0032873; GO:0032930; GO:0034774; GO:0035726; GO:0035730; GO:0035731; GO:0035732; GO:0043066; GO:0043124; GO:0043407; GO:0043409; GO:0043508; GO:0043651; GO:0048147; GO:0051122; GO:0051771; GO:0070026; GO:0070062; GO:0070372; GO:0070373; GO:0070664; GO:0071222; GO:0071638; GO:0097057; GO:1901687; GO:1904813; GO:2001237	3664469; 3196325; 2542132; 2466554; 9092542; 15489334; 3979555; 3864155; 3395118; 12665801; 9150948; 2327795; 1567427; 1540159; 8433974; 9084911; 19269317; 19254954; 19608861; 21269460; 21046276; 21668448; 22223895; 22814378; 23186163; 24275569; 25944712; 1522586; 9012673; 9245401; 9398518; 9351803; 10441116; 9485454; 19396894; 19808963	10.1042/bj2550079; 10.1016/0378-1119(89)90377-6; 10.1074/jbc.272.15.10004; 10.1101/gr.2596504; 10.1016/0014-5793(85)80324-0; 10.1073/pnas.82.21.7202; 10.1016/0003-9861(88)90564-4; 10.1038/nbt810; 10.1002/elps.1150180344; 10.1016/0003-9861(90)90277-6; 10.1016/0006-291x(92)91177-r; 10.1016/0006-291x(92)91848-k; 10.1093/protein/6.1.93; 10.1021/tx9601770; 10.1016/j.freeradbiomed.2009.02.025; 10.1074/jbc.m808153200; 10.1126/science.1175371; 10.1186/1752-0509-5-17; 10.1007/s11745-010-3485-1; 10.1111/j.1471-4159.2011.07343.x; 10.1074/mcp.m111.015131; 10.1073/pnas.1210303109; 10.1021/pr300630k; 10.1016/j.jprot.2013.11.014; 10.1002/pmic.201400617; 10.1016/0022-2836(92)90692-d; 10.1021/bi962316i; 10.1021/bi970805s; 10.1006/jmbi.1997.1364; 10.1016/s0969-2126(97)00281-5; 10.1021/bi990668u; 10.1021/bi971902o; 10.1002/anie.200900185; 10.1158/0008-5472.can-09-1314	NP_000843.1;	P09211;	CHEMBL3902;	DB01834;DB03814;DB00316;DB14001;DB00321;DB01008;DB04972;DB00958;DB00291;DB02633;DB00515;DB01242;DB00363;DB11672;DB14635;DB14002;DB03619;DB11831;DB00903;DB00773;DB06246;DB05460;DB00143;DB03310;DB03003;DB13014;DB00526;DB14924;DB08370;DB03686;DB04132;DB01915;DB07849;DB00197;DB00163;
2v3r	P62694	reviewed	GUX1_HYPJE	Exoglucanase 1 (EC 3.2.1.91) (1,4-beta-cellobiohydrolase) (Cellobiohydrolase 7A) (Cel7A) (Exocellobiohydrolase I) (CBHI) (Exoglucanase I)	cbh1	Hypocrea jecorina (Trichoderma reesei)	513	MYRKLAVISAFLATARAQSACTLQSETHPPLTWQKCSSGGTCTQQTGSVVIDANWRWTHATNSSTNCYDGNTWSSTLCPDNETCAKNCCLDGAAYASTYGVTTSGNSLSIGFVTQSAQKNVGARLYLMASDTTYQEFTLLGNEFSFDVDVSQLPCGLNGALYFVSMDADGGVSKYPTNTAGAKYGTGYCDSQCPRDLKFINGQANVEGWEPSSNNANTGIGGHGSCCSEMDIWEANSISEALTPHPCTTVGQEICEGDGCGGTYSDNRYGGTCDPDGCDWNPYRLGNTSFYGPGSSFTLDTTKKLTVVTQFETSGAINRYYVQNGVTFQQPNAELGSYSGNELNDDYCTAEEAEFGGSSFSDKGGLTQFKKATSGGMVLVMSLWDDYYANMLWLDSTYPTNETSSTPGAVRGSCSTSSGVPAQVESQSPNAKVTFSNIKFGPIGSTGNPSGGNPPGGNRGTTTTRRPATTTGSSPGPTQSHYGQCGGIGYSGPTVCASGTTCQVLNPYYSQCL	FUNCTION: Exocellobiohydrolases (CBH) that catalyzes the hydrolysis of 1,4-beta-D-glucosidic bonds in cellulose to release the disaccharide cellobiose (Ref.4). The degradation of cellulose involves an interplay between different cellulolytic enzymes. Hydrolysis starts with endoglucanases (EGs), which cut internal beta-1,4-glucosidic bonds in cellulose to reduce the polymerization degree of the substrate and create new chain ends for exocellobiohydrolases (CBHs). The CBHs release the disaccharide cellobiose from the non-reducing end of the cellulose polymer chain. Finally, beta-1,4-glucosidases hydrolyze the cellobiose and other short cello-oligosaccharides into glucose units (Probable). {ECO:0000269|Ref.4, ECO:0000305}.	MISCELLANEOUS: T.reesei produces two different exocellobiohydrolases. They are unique in that they can hydrolyze crystalline cellulose in the absence of endoglucanases.	cellulose catabolic process [GO:0030245]	extracellular region [GO:0005576]	cellulose 1,4-beta-cellobiosidase activity [GO:0016162]; cellulose binding [GO:0030248]	extracellular region [GO:0005576]; cellulose 1,4-beta-cellobiosidase activity [GO:0016162]; cellulose binding [GO:0030248]; cellulose catabolic process [GO:0030245]	GO:0005576; GO:0016162; GO:0030245; GO:0030248	9746354; 2554967; 8036495; 9041630; 9466911; 24341799; 26307003	10.1038/nbt1083-691; 10.1016/0014-5793(80)81006-4; 10.1038/nbt1083-687; 10.1046/j.1432-1327.1998.2560119.x; 10.1016/0014-5793(89)80136-X; 10.1021/bi00444a016; 10.1126/science.8036495; 10.1002/pro.5560060204; 10.1006/jmbi.1997.1437; 10.1021/ja410291u; 10.1111/febs.13500				
4rn0	Q9BY41	reviewed	HDAC8_HUMAN	Histone deacetylase 8 (HD8) (EC 3.5.1.98) (Protein deacetylase HDAC8) (EC 3.5.1.-) (Protein decrotonylase HDAC8) (EC 3.5.1.-)	HDAC8 HDACL1 CDA07	Homo sapiens (Human)	377	MEEPEEPADSGQSLVPVYIYSPEYVSMCDSLAKIPKRASMVHSLIEAYALHKQMRIVKPKVASMEEMATFHTDAYLQHLQKVSQEGDDDHPDSIEYGLGYDCPATEGIFDYAAAIGGATITAAQCLIDGMCKVAINWSGGWHHAKKDEASGFCYLNDAVLGILRLRRKFERILYVDLDLHHGDGVEDAFSFTSKVMTVSLHKFSPGFFPGTGDVSDVGLGKGRYYSVNVPIQDGIQDEKYYQICESVLKEVYQAFNPKAVVLQLGADTIAGDPMCSFNMTPVGIGKCLKYILQWQLATLILGGGGYNLANTARCWTYLTGVILGKTLSSEIPDHEFFTAYGPDYVLEITPSCRPDRNEPHRIQQILNYIKGNLKHVV	FUNCTION: Histone deacetylase that catalyzes the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4) (PubMed:10748112, PubMed:10922473, PubMed:10926844, PubMed:14701748, PubMed:28497810). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events (PubMed:10748112, PubMed:10922473, PubMed:10926844, PubMed:14701748). Histone deacetylases act via the formation of large multiprotein complexes (PubMed:10748112, PubMed:10922473, PubMed:10926844, PubMed:14701748). Also involved in the deacetylation of cohesin complex protein SMC3 regulating release of cohesin complexes from chromatin (PubMed:22885700). May play a role in smooth muscle cell contractility (PubMed:15772115). In addition to protein deacetylase activity, also has protein-lysine deacylase activity: acts as a protein decrotonylase by mediating decrotonylation ((2E)-butenoyl) of histones (PubMed:28497810). {ECO:0000269|PubMed:10748112, ECO:0000269|PubMed:10922473, ECO:0000269|PubMed:10926844, ECO:0000269|PubMed:14701748, ECO:0000269|PubMed:15772115, ECO:0000269|PubMed:22885700, ECO:0000269|PubMed:28497810}.		chromatin organization [GO:0006325]; mitotic sister chromatid cohesion [GO:0007064]; negative regulation of protein ubiquitination [GO:0031397]; negative regulation of transcription by RNA polymerase II [GO:0000122]; regulation of protein stability [GO:0031647]; regulation of telomere maintenance [GO:0032204]	cytoplasm [GO:0005737]; histone deacetylase complex [GO:0000118]; nuclear chromosome [GO:0000228]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]	DNA-binding transcription factor binding [GO:0140297]; histone deacetylase activity [GO:0004407]; histone decrotonylase activity [GO:0160009]; Hsp70 protein binding [GO:0030544]; Hsp90 protein binding [GO:0051879]; metal ion binding [GO:0046872]; protein lysine deacetylase activity [GO:0033558]	cytoplasm [GO:0005737]; histone deacetylase complex [GO:0000118]; nuclear chromosome [GO:0000228]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; DNA-binding transcription factor binding [GO:0140297]; histone deacetylase activity [GO:0004407]; histone decrotonylase activity [GO:0160009]; Hsp70 protein binding [GO:0030544]; Hsp90 protein binding [GO:0051879]; metal ion binding [GO:0046872]; protein lysine deacetylase activity [GO:0033558]; chromatin organization [GO:0006325]; mitotic sister chromatid cohesion [GO:0007064]; negative regulation of protein ubiquitination [GO:0031397]; negative regulation of transcription by RNA polymerase II [GO:0000122]; regulation of protein stability [GO:0031647]; regulation of telomere maintenance [GO:0032204]	GO:0000118; GO:0000122; GO:0000228; GO:0004407; GO:0005634; GO:0005654; GO:0005737; GO:0006325; GO:0007064; GO:0030544; GO:0031397; GO:0031647; GO:0032204; GO:0033558; GO:0046872; GO:0051879; GO:0140297; GO:0160009	10748112; 10926844; 10922473; 8889548; 14702039; 15772651; 15489334; 10756090; 11533236; 12509458; 14701748; 15772115; 16538051; 16809764; 22889856; 22885700; 28497810; 15242608; 17721440; 19053282	10.1074/jbc.m908988199; 10.1042/bj3500199; 10.1016/s0014-5793(00)01813-5; 10.1101/gr.6.9.791; 10.1038/ng1285; 10.1038/nature03440; 10.1101/gr.2596504; 10.1006/geno.2000.6128; 10.1128/mcb.21.19.6470-6483.2001; 10.1128/mcb.23.2.607-619.2003; 10.1128/mcb.24.2.765-773.2004; 10.1096/fj.04-2303fje; 10.1097/01.pas.0000188029.63706.31; 10.1128/mcb.01971-05; 10.1136/jmedgenet-2012-100921; 10.1038/nature11316; 10.1038/cr.2017.68; 10.1016/j.str.2004.04.012; 10.1038/sj.embor.7401047; 10.1021/bi801610c	NP_001159890.1 [Q9BY41-4];NP_001159891.1 [Q9BY41-5];NP_001159892.1 [Q9BY41-8];NP_001159894.1 [Q9BY41-7];NP_001159920.1 [Q9BY41-6];NP_060956.1 [Q9BY41-1];	Q9BY41;	CHEMBL3192;	DB07350;DB02565;DB07586;DB12565;DB05015;DB08168;DB01262;DB11841;DB14490;DB14491;DB14488;DB14501;DB14489;DB12645;DB01592;DB02917;DB06603;DB06819;DB03766;DB12847;DB06176;DB04297;DB00313;DB02546;DB01593;DB14487;DB14533;DB14548;
1fmc	P0AET8	reviewed	HDHA_ECOLI	7alpha-hydroxysteroid dehydrogenase (7alpha-HSDH) (EC 1.1.1.159) (NAD-dependent 7alpha-hydroxysteroid dehydrogenase)	hdhA hsdH b1619 JW1611	Escherichia coli (strain K12)	255	MFNSDNLRLDGKCAIITGAGAGIGKEIAITFATAGASVVVSDINADAANHVVDEIQQLGGQAFACRCDITSEQELSALADFAISKLGKVDILVNNAGGGGPKPFDMPMADFRRAYELNVFSFFHLSQLVAPEMEKNGGGVILTITSMAAENKNINMTSYASSKAAASHLVRNMAFDLGEKNIRVNGIAPGAILTDALKSVITPEIEQKMLQHTPIRRLGQPQDIANAALFLCSPAASWVSGQILTVSGGGVQELN	FUNCTION: 7alpha-hydroxysteroid dehydrogenase involved in the metabolism of bile acids. Catalyzes the NAD(+)-dependent oxidation of the 7alpha-hydroxy group of 7alpha-hydroxysteroids, such as the major human bile acids cholate and chenodeoxycholate, to the corresponding 7-oxosteroids. To a lesser extent, can also act on taurochenodeoxycholate, taurocholate and glycocholate (PubMed:2007545). Can also use glycochenodeoxycholate as substrate (PubMed:8672472). Is not able to use NADP(+) instead of NAD(+) as the electron acceptor (PubMed:2007545). {ECO:0000269|PubMed:2007545, ECO:0000269|PubMed:8672472}.		bile acid catabolic process [GO:0030573]; lipid catabolic process [GO:0016042]	cytosol [GO:0005829]; protein-containing complex [GO:0032991]	chenodeoxycholate 7-alpha-dehydrogenase (NAD+) activity [GO:0106281]; cholate 7-alpha-dehydrogenase activity [GO:0008709]; identical protein binding [GO:0042802]; NAD binding [GO:0051287]	cytosol [GO:0005829]; protein-containing complex [GO:0032991]; chenodeoxycholate 7-alpha-dehydrogenase (NAD+) activity [GO:0106281]; cholate 7-alpha-dehydrogenase activity [GO:0008709]; identical protein binding [GO:0042802]; NAD binding [GO:0051287]; bile acid catabolic process [GO:0030573]; lipid catabolic process [GO:0016042]	GO:0005829; GO:0008709; GO:0016042; GO:0030573; GO:0032991; GO:0042802; GO:0051287; GO:0106281	2007545; 9097039; 9278503; 16738553; 8672472; 9722677	10.1128/jb.173.7.2173-2179.1991; 10.1093/dnares/3.6.363; 10.1126/science.277.5331.1453; 10.1038/msb4100049; 10.1021/bi951904d; 10.1093/oxfordjournals.jbchem.a022159	NP_416136.1;WP_000483353.1;			DB02123;
3daf	Q58194	reviewed	HMD_METJA	5,10-methenyltetrahydromethanopterin hydrogenase (EC 1.12.98.2) (H(2)-dependent methylene-H(4)MPT dehydrogenase) (H(2)-forming N(5),N(10)-methylenetetrahydromethanopterin dehydrogenase) (N(5),N(10)-methenyltetrahydromethanopterin hydrogenase)	hmd MJ0784	Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) (Methanococcus jannaschii)	358	MKIAILGAGCYRTHAAAGITNFMRACEVAKEVGKPEIALTHSSITYGAELLHLVPDVKEVIVSDPCFAEEPGLVVIDEFDPKEVMEAHLSGNPESIMPKIREVVKAKAKELPKPPKACIHLVHPEDVGLKVTSDDREAVEGADIVITWLPKGNKQPDIIKKFADAIPEGAIVTHACTIPTTKFAKIFKDLGREDLNITSYHPGCVPEMKGQVYIAEGYASEEAVNKLYEIGKIARGKAFKMPANLIGPVCDMCSAVTATVYAGLLAYRDAVTKILGAPADFAQMMADEALTQIHNLMKEKGIANMEEALDPAALLGTADSMCFGPLAEILPTALKVLEKHKVVEEEGKTKCEIMSQKE	FUNCTION: Catalyzes the reversible reduction of methenyl-H(4)MPT(+) to methylene-H(4)MPT. {ECO:0000250}.		L-proline biosynthetic process [GO:0055129]; methanogenesis, from carbon dioxide [GO:0019386]; one-carbon metabolic process [GO:0006730]		N5,N10-methenyltetrahydromethanopterin hydrogenase activity [GO:0047068]; pyrroline-5-carboxylate reductase activity [GO:0004735]	N5,N10-methenyltetrahydromethanopterin hydrogenase activity [GO:0047068]; pyrroline-5-carboxylate reductase activity [GO:0004735]; L-proline biosynthetic process [GO:0055129]; methanogenesis, from carbon dioxide [GO:0019386]; one-carbon metabolic process [GO:0006730]	GO:0004735; GO:0006730; GO:0019386; GO:0047068; GO:0055129	8688087	10.1126/science.273.5278.1058	WP_010870290.1;			
1a2g	P00431	reviewed	CCPR_YEAST	Cytochrome c peroxidase, mitochondrial (CCP) (EC 1.11.1.5)	CCP1 CCP CPO YKR066C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	361	MTTAVRLLPSLGRTAHKRSLYLFSAAAAAAAAATFAYSQSQKRSSSSPGGGSNHGWNNWGKAAALASTTPLVHVASVEKGRSYEDFQKVYNAIALKLREDDEYDNYIGYGPVLVRLAWHTSGTWDKHDNTGGSYGGTYRFKKEFNDPSNAGLQNGFKFLEPIHKEFPWISSGDLFSLGGVTAVQEMQGPKIPWRCGRVDTPEDTTPDNGRLPDADKDADYVRTFFQRLNMNDREVVALMGAHALGKTHLKNSGYEGPWGAANNVFTNEFYLNLLNEDWKLEKNDANNEQWDSKSGYMMLPTDYSLIQDPKYLSIVKEYANDQDKFFKDFSKAFEKLLENGITFPKDAPSPFIFKTLEEQGL	FUNCTION: Destroys radicals which are normally produced within the cells and which are toxic to biological systems. {ECO:0000269|PubMed:2851317}.	MISCELLANEOUS: Present with 6730 molecules/cell in log phase SD medium. {ECO:0000269|PubMed:14562106}.	cellular response to oxidative stress [GO:0034599]; hydrogen peroxide catabolic process [GO:0042744]; response to reactive oxygen species [GO:0000302]	mitochondrial intermembrane space [GO:0005758]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]	cytochrome-c peroxidase activity [GO:0004130]; heme binding [GO:0020037]; metal ion binding [GO:0046872]; peroxidase activity [GO:0004601]	mitochondrial intermembrane space [GO:0005758]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; cytochrome-c peroxidase activity [GO:0004130]; heme binding [GO:0020037]; metal ion binding [GO:0046872]; peroxidase activity [GO:0004601]; cellular response to oxidative stress [GO:0034599]; hydrogen peroxide catabolic process [GO:0042744]; response to reactive oxygen species [GO:0000302]	GO:0000302; GO:0004130; GO:0004601; GO:0005739; GO:0005758; GO:0005759; GO:0020037; GO:0034599; GO:0042744; GO:0046872	6294090; 8196765; 24374639; 17322287; 6257176; 6286684; 2851317; 12774122; 14562106; 17245427; 18407956; 22984289; 6092361; 2169873; 8384877; 8673607; 10722697; 11170452	10.1016/s0021-9258(18)33392-1; 10.1038/369371a0; 10.1534/g3.113.008995; 10.1101/gr.6037607; 10.1016/0003-9861(80)90219-2; 10.1016/s0021-9258(18)33950-4; 10.1021/bi00417a008; 10.1038/nature01633; 10.1038/nature02046; 10.1038/sj.emboj.7601514; 10.1074/mcp.m700468-mcp200; 10.1074/mcp.m112.021105; 10.1016/s0021-9258(18)90651-4; 10.1021/bi00483a003; 10.1021/bi00064a014; 10.1038/nsb0796-626; 10.1074/jbc.275.12.8582; 10.1021/bi002089r	NP_012992.1;			
5w2g	Q8NFU5	reviewed	IPMK_HUMAN	Inositol polyphosphate multikinase (EC 2.7.1.140) (EC 2.7.1.151) (EC 2.7.1.153) (Inositol 1,3,4,6-tetrakisphosphate 5-kinase)	IPMK IMPK	Homo sapiens (Human)	416	MATEPPSPLRVEAPGPPEMRTSPAIESTPEGTPQPAGGRLRFLNGCVPLSHQVAGHMYGKDKVGILQHPDGTVLKQLQPPPRGPRELEFYNMVYAADCFDGVLLELRKYLPKYYGIWSPPTAPNDLYLKLEDVTHKFNKPCIMDVKIGQKSYDPFASSEKIQQQVSKYPLMEEIGFLVLGMRVYHVHSDSYETENQHYGRSLTKETIKDGVSRFFHNGYCLRKDAVAASIQKIEKILQWFENQKQLNFYASSLLFVYEGSSQPTTTKLNDRTLAEKFLSKGQLSDTEVLEYNNNFHVLSSTANGKIESSVGKSLSKMYARHRKIYTKKHHSQTSLKVENLEQDNGWKSMSQEHLNGNVLSQLEKVFYHLPTGCQEIAEVEVRMIDFAHVFPSNTIDEGYVYGLKHLISVLRSILDN	FUNCTION: Inositol phosphate kinase with a broad substrate specificity (PubMed:12027805, PubMed:12223481, PubMed:28882892, PubMed:30420721, PubMed:30624931). Phosphorylates inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) first to inositol 1,3,4,5-tetrakisphosphate and then to inositol 1,3,4,5,6-pentakisphosphate (Ins(1,3,4,5,6)P5) (PubMed:12027805, PubMed:12223481, PubMed:28882892, PubMed:30624931). Phosphorylates inositol 1,3,4,6-tetrakisphosphate (Ins(1,3,4,6)P4) (PubMed:12223481). Phosphorylates inositol 1,4,5,6-tetrakisphosphate (Ins(1,4,5,6)P4) (By similarity). Phosphorylates glycero-3-phospho-1D-myo-inositol 4,5-bisphosphate to glycero-3-phospho-1D-myo-inositol 3,4,5-trisphosphate (PubMed:28882892, PubMed:30420721). Plays an important role in MLKL-mediated necroptosis via its role in the biosynthesis of inositol pentakisphosphate (InsP5) and inositol hexakisphosphate (InsP6). Binding of these highly phosphorylated inositol phosphates to MLKL mediates the release of an N-terminal auto-inhibitory region, leading to activation of the kinase. Essential for activated phospho-MLKL to oligomerize and localize to the cell membrane during necroptosis (PubMed:29883610). Required for normal embryonic development, probably via its role in the biosynthesis of inositol 1,3,4,5,6-pentakisphosphate (Ins(1,3,4,5,6)P5) and inositol hexakisphosphate (InsP6) (By similarity). {ECO:0000250|UniProtKB:Q7TT16, ECO:0000269|PubMed:12027805, ECO:0000269|PubMed:12223481, ECO:0000269|PubMed:28882892, ECO:0000269|PubMed:29883610, ECO:0000269|PubMed:30420721, ECO:0000269|PubMed:30624931}.		inositol phosphate biosynthetic process [GO:0032958]; inositol phosphate metabolic process [GO:0043647]; inositol trisphosphate metabolic process [GO:0032957]; necroptotic process [GO:0070266]; phosphatidylinositol metabolic process [GO:0046488]; phosphorylation [GO:0016310]	cytoplasm [GO:0005737]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]	1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934]; ATP binding [GO:0005524]; flavonoid binding [GO:0097243]; inositol tetrakisphosphate 3-kinase activity [GO:0000824]; inositol tetrakisphosphate 5-kinase activity [GO:0047326]; inositol tetrakisphosphate 6-kinase activity [GO:0000825]; inositol tetrakisphosphate kinase activity [GO:0051765]; inositol-1,4,5-trisphosphate 3-kinase activity [GO:0008440]; inositol-1,4,5-trisphosphate 6-kinase activity [GO:0000823]; metal ion binding [GO:0046872]; myo-inositol-1,2,3,4,6-heptakisphosphate 5-kinase activity [GO:0102732]	cytoplasm [GO:0005737]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; 1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934]; ATP binding [GO:0005524]; flavonoid binding [GO:0097243]; inositol tetrakisphosphate 3-kinase activity [GO:0000824]; inositol tetrakisphosphate 5-kinase activity [GO:0047326]; inositol tetrakisphosphate 6-kinase activity [GO:0000825]; inositol tetrakisphosphate kinase activity [GO:0051765]; inositol-1,4,5-trisphosphate 3-kinase activity [GO:0008440]; inositol-1,4,5-trisphosphate 6-kinase activity [GO:0000823]; metal ion binding [GO:0046872]; myo-inositol-1,2,3,4,6-heptakisphosphate 5-kinase activity [GO:0102732]; inositol phosphate biosynthetic process [GO:0032958]; inositol phosphate metabolic process [GO:0043647]; inositol trisphosphate metabolic process [GO:0032957]; necroptotic process [GO:0070266]; phosphatidylinositol metabolic process [GO:0046488]; phosphorylation [GO:0016310]	GO:0000823; GO:0000824; GO:0000825; GO:0005524; GO:0005634; GO:0005654; GO:0005737; GO:0008440; GO:0016310; GO:0032957; GO:0032958; GO:0043647; GO:0046488; GO:0046872; GO:0046934; GO:0047326; GO:0051765; GO:0070266; GO:0097243; GO:0102732	12027805; 12223481; 15489334; 18691976; 19369195; 23186163; 29883610; 28882892; 30420721; 30624931	10.1042/bj20020327; 10.1074/jbc.m206134200; 10.1101/gr.2596504; 10.1016/j.molcel.2008.07.007; 10.1074/mcp.m800588-mcp200; 10.1021/pr300630k; 10.1016/j.molcel.2018.05.010; 10.1074/jbc.m117.801845; 10.1038/s41598-018-34941-3; 10.1021/acs.jmedchem.8b01593	NP_689416.1;	Q8NFU5;	CHEMBL4523401;	
3dzh	P28907	reviewed	CD38_HUMAN	ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (EC 3.2.2.-) (EC 3.2.2.6) (2'-phospho-ADP-ribosyl cyclase) (2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase) (EC 2.4.99.20) (2'-phospho-cyclic-ADP-ribose transferase) (ADP-ribosyl cyclase 1) (ADPRC 1) (Cyclic ADP-ribose hydrolase 1) (cADPR hydrolase 1) (T10) (CD antigen CD38)	CD38	Homo sapiens (Human)	300	MANCEFSPVSGDKPCCRLSRRAQLCLGVSILVLILVVVLAVVVPRWRQQWSGPGTTKRFPETVLARCVKYTEIHPEMRHVDCQSVWDAFKGAFISKHPCNITEEDYQPLMKLGTQTVPCNKILLWSRIKDLAHQFTQVQRDMFTLEDTLLGYLADDLTWCGEFNTSKINYQSCPDWRKDCSNNPVSVFWKTVSRRFAEAACDVVHVMLNGSRSKIFDKNSTFGSVEVHNLQPEKVQTLEAWVIHGGREDSRDLCQDPTIKELESIISKRNIQFSCKNIYRPDKFLQCVKNPEDSSCTSEI	FUNCTION: Synthesizes cyclic ADP-ribose (cADPR), a second messenger for glucose-induced insulin secretion (PubMed:7961800, PubMed:8253715). Synthesizes the Ca(2+) mobilizer nicotinate-adenine dinucleotide phosphate, NAADP(+), from 2'-phospho-cADPR and nicotinic acid, as well as from NADP(+) and nicotinic acid. At both pH 5.0 and pH 7.4 preferentially transforms 2'-phospho-cADPR into NAADP(+), while preferentially cleaving NADP(+) to cADPR and ADPRP rather than into NADDP(+) (PubMed:16690024). Has cADPR hydrolase activity (PubMed:7961800, PubMed:8253715). {ECO:0000269|PubMed:16690024, ECO:0000269|PubMed:7961800, ECO:0000269|PubMed:8253715}.	MISCELLANEOUS: A cell surface antigen recognized in lymophocytes by multiple mAbs. {ECO:0000269|PubMed:2319135}.; MISCELLANEOUS: [Isoform 2]: May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. {ECO:0000305}.	apoptotic signaling pathway [GO:0097190]; artery smooth muscle contraction [GO:0014824]; B cell proliferation [GO:0042100]; B cell receptor signaling pathway [GO:0050853]; female pregnancy [GO:0007565]; long-term synaptic depression [GO:0060292]; NAD metabolic process [GO:0019674]; negative regulation of apoptotic process [GO:0043066]; negative regulation of bone resorption [GO:0045779]; negative regulation of DNA-templated transcription [GO:0045892]; negative regulation of neuron projection development [GO:0010977]; positive regulation of B cell proliferation [GO:0030890]; positive regulation of cell growth [GO:0030307]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of DNA-templated transcription [GO:0045893]; positive regulation of insulin secretion [GO:0032024]; positive regulation of vasoconstriction [GO:0045907]; response to estradiol [GO:0032355]; response to hydroperoxide [GO:0033194]; response to hypoxia [GO:0001666]; response to interleukin-1 [GO:0070555]; response to progesterone [GO:0032570]; response to retinoic acid [GO:0032526]; response to xenobiotic stimulus [GO:0009410]; signal transduction [GO:0007165]	basolateral plasma membrane [GO:0016323]; cell surface [GO:0009986]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; nuclear membrane [GO:0031965]; plasma membrane [GO:0005886]	identical protein binding [GO:0042802]; NAD+ nucleosidase activity [GO:0003953]; NAD+ nucleotidase, cyclic ADP-ribose generating [GO:0061809]; phosphorus-oxygen lyase activity [GO:0016849]; transferase activity [GO:0016740]	basolateral plasma membrane [GO:0016323]; cell surface [GO:0009986]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; nuclear membrane [GO:0031965]; plasma membrane [GO:0005886]; identical protein binding [GO:0042802]; NAD+ nucleosidase activity [GO:0003953]; NAD+ nucleotidase, cyclic ADP-ribose generating [GO:0061809]; phosphorus-oxygen lyase activity [GO:0016849]; transferase activity [GO:0016740]; apoptotic signaling pathway [GO:0097190]; artery smooth muscle contraction [GO:0014824]; B cell proliferation [GO:0042100]; B cell receptor signaling pathway [GO:0050853]; female pregnancy [GO:0007565]; long-term synaptic depression [GO:0060292]; NAD metabolic process [GO:0019674]; negative regulation of apoptotic process [GO:0043066]; negative regulation of bone resorption [GO:0045779]; negative regulation of DNA-templated transcription [GO:0045892]; negative regulation of neuron projection development [GO:0010977]; positive regulation of B cell proliferation [GO:0030890]; positive regulation of cell growth [GO:0030307]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of DNA-templated transcription [GO:0045893]; positive regulation of insulin secretion [GO:0032024]; positive regulation of vasoconstriction [GO:0045907]; response to estradiol [GO:0032355]; response to hydroperoxide [GO:0033194]; response to hypoxia [GO:0001666]; response to interleukin-1 [GO:0070555]; response to progesterone [GO:0032570]; response to retinoic acid [GO:0032526]; response to xenobiotic stimulus [GO:0009410]; signal transduction [GO:0007165]	GO:0001666; GO:0003953; GO:0005886; GO:0007165; GO:0007204; GO:0007565; GO:0009410; GO:0009986; GO:0010977; GO:0014824; GO:0016020; GO:0016323; GO:0016740; GO:0016849; GO:0019674; GO:0030307; GO:0030890; GO:0031965; GO:0032024; GO:0032355; GO:0032526; GO:0032570; GO:0033194; GO:0042100; GO:0042802; GO:0043066; GO:0045779; GO:0045892; GO:0045893; GO:0045907; GO:0050853; GO:0060292; GO:0061809; GO:0070062; GO:0070555; GO:0097190	2319135; 9074508; 15489334; 1471258; 8253715; 7961800; 14759258; 16690024; 19159218; 19349973; 21269460; 25944712; 16154090; 9754820	10.4049/jimmunol.144.7.2811; 10.1016/s0378-1119(96)00723-8; 10.1101/gr.2596504; 10.1016/0968-0004(92)90337-9; 10.1016/s0021-9258(19)74275-6; 10.1016/s0021-9258(19)61940-x; 10.1186/gb-2004-5-2-r8; 10.1016/j.bbrc.2006.04.096; 10.1021/pr8008012; 10.1038/nbt.1532; 10.1186/1752-0509-5-17; 10.1002/pmic.201400617; 10.1016/j.str.2005.05.012; 10.1007/s001250051026	NP_001766.2 [P28907-1];	P28907;	CHEMBL4660;	DB09331;DB14811;DB16370;
3g51	P18654	reviewed	KS6A3_MOUSE	Ribosomal protein S6 kinase alpha-3 (S6K-alpha-3) (EC 2.7.11.1) (90 kDa ribosomal protein S6 kinase 3) (p90-RSK 3) (p90RSK3) (MAP kinase-activated protein kinase 1b) (MAPK-activated protein kinase 1b) (MAPKAP kinase 1b) (MAPKAPK-1b) (Ribosomal S6 kinase 2) (RSK-2) (pp90RSK2)	Rps6ka3 Mapkapk1b Rps6ka-rs1 Rsk2	Mus musculus (Mouse)	740	MPLAQLADPWQKMAVESPSDSAENGQQIMDEPMGEEEINPQTEEGSIKEIAITHHVKEGHEKADPSQFELLKVLGQGSFGKVFLVKKISGSDARQLYAMKVLKKATLKVRDRVRTKMERDILVEVNHPFIVKLHYAFQTEGKLYLILDFLRGGDLFTRLSKEVMFTEEDVKFYLAELALALDHLHSLGIIYRDLKPENILLDEEGHIKLTDFGLSKESIDHEKKAYSFCGTVEYMAPEVVNRRGHTQSADWWSFGVLMFEMLTGTLPFQGKDRKETMTMILKAKLGMPQFLSPEAQSLLRMLFKRNPANRLGAGPDGVEEIKRHSFFSTIDWNKLYRREIHPPFKPATGRPEDTFYFDPEFTAKTPKDSPGIPPSANAHQLFRGFSFVAITSDDESQAMQTVGVHSIVQQLHRNSIQFTDGYEVKEDIGVGSYSVCKRCIHKATNMEFAVKIIDKSKRDPTEEIEILLRYGQHPNIITLKDVYDDGKYVYVVTELMKGGELLDKILRQKFFSEREASAVLFTITKTVEYLHAQGVVHRDLKPSNILYVDESGNPESIRICDFGFAKQLRAENGLLMTPCYTANFVAPEVLKRQGYDAACDIWSLGVLLYTMLTGYTPFANGPDDTPEEILARIGSGKFSLSGGYWNSVSDTAKDLVSKMLHVDPHQRLTAALVLRHPWIVHWDQLPQYQLNRQDAPHLVKGAMAATYSALNRNQSPVLEPVGRSTLAQRRGIKKITSTAL	FUNCTION: Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1 (PubMed:10856237, PubMed:15109498). In fibroblast, is required for EGF-stimulated phosphorylation of CREB1 and histone H3 at 'Ser-10', which results in the subsequent transcriptional activation of several immediate-early genes (By similarity). In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP (By similarity). Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity (By similarity). Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the preinitiation complex (By similarity). In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation (By similarity). Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway (By similarity). Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function (By similarity). Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4) (By similarity). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression (PubMed:14504289). In LPS-stimulated dendritic cells, is involved in TLR4-induced macropinocytosis, and in myeloma cells, acts as effector of FGFR3-mediated transformation signaling, after direct phosphorylation at Tyr-529 by FGFR3 (PubMed:17785202, PubMed:17906627). Negatively regulates EGF-induced MAPK1/3 phosphorylation via phosphorylation of SOS1 (PubMed:22827337). Phosphorylates SOS1 at 'Ser-1134' and 'Ser-1161' that create YWHAB and YWHAE binding sites and which contribute to the negative regulation of MAPK1/3 phosphorylation (PubMed:22827337). Phosphorylates EPHA2 at 'Ser-897', the RPS6KA-EPHA2 signaling pathway controls cell migration (By similarity). Acts as a regulator of osteoblast differentiation by mediating phosphorylation of ATF4, thereby promoting ATF4 transactivation activity (PubMed:15109498). {ECO:0000250|UniProtKB:P51812, ECO:0000269|PubMed:10856237, ECO:0000269|PubMed:14504289, ECO:0000269|PubMed:15109498, ECO:0000269|PubMed:17785202, ECO:0000269|PubMed:17906627, ECO:0000269|PubMed:22827337}.		cell cycle [GO:0007049]; intracellular signal transduction [GO:0035556]; phosphorylation [GO:0016310]; positive regulation of transcription by RNA polymerase II [GO:0045944]; response to lipopolysaccharide [GO:0032496]; toll-like receptor signaling pathway [GO:0002224]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]	ATP binding [GO:0005524]; cysteine-type endopeptidase inhibitor activity involved in apoptotic process [GO:0043027]; magnesium ion binding [GO:0000287]; protein kinase binding [GO:0019901]; protein serine kinase activity [GO:0106310]; protein serine/threonine kinase activity [GO:0004674]; ribosomal protein S6 kinase activity [GO:0004711]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; ATP binding [GO:0005524]; cysteine-type endopeptidase inhibitor activity involved in apoptotic process [GO:0043027]; magnesium ion binding [GO:0000287]; protein kinase binding [GO:0019901]; protein serine kinase activity [GO:0106310]; protein serine/threonine kinase activity [GO:0004674]; ribosomal protein S6 kinase activity [GO:0004711]; cell cycle [GO:0007049]; intracellular signal transduction [GO:0035556]; phosphorylation [GO:0016310]; positive regulation of transcription by RNA polymerase II [GO:0045944]; response to lipopolysaccharide [GO:0032496]; toll-like receptor signaling pathway [GO:0002224]	GO:0000287; GO:0002224; GO:0004674; GO:0004711; GO:0005524; GO:0005654; GO:0005730; GO:0005737; GO:0005829; GO:0007049; GO:0016310; GO:0019901; GO:0032496; GO:0035556; GO:0043027; GO:0045944; GO:0106310	12016217; 19468303; 2779569; 10480933; 10856237; 14504289; 15109498; 17785202; 17906627; 21183079; 22827337; 18084304; 19956600	10.1074/jbc.m202663200; 10.1371/journal.pbio.1000112; 10.1128/mcb.9.9.3850-3859.1989; 10.1074/jbc.274.38.27168; 10.1093/emboj/19.12.2924; 10.1074/jbc.m306614200; 10.1016/s0092-8674(04)00344-7; 10.1016/j.ccr.2007.08.003; 10.1038/ni1517; 10.1016/j.cell.2010.12.001; 10.1042/bj20120938; 10.1038/nsmb1347; 10.1371/journal.pone.0008044	NP_683747.1;	P18654;	CHEMBL3297641;	
1coy	P22637	reviewed	CHOD_BREST	Cholesterol oxidase (CHOD) (EC 1.1.3.6) (Cholesterol isomerase) (EC 5.3.3.1)	choB	Brevibacterium sterolicum	552	MTDSRANRADATRGVASVSRRRFLAGAGLTAGAIALSSMSTSASAAPSRTLADGDRVPALVIGSGYGGAVAALRLTQAGIPTQIVEMGRSWDTPGSDGKIFCGMLNPDKRSMWLADKTDQPVSNFMGFGINKSIDRYVGVLDSERFSGIKVYQGRGVGGGSLVNGGMAVTPKRNYFEEILPSVDSNEMYNKYFPRANTGLGVNNIDQAWFESTEWYKFARTGRKTAQRSGFTTAFVPNVYDFEYMKKEAAGQVTKSGLGGEVIYGNNAGKKSLDKTYLAQAAATGKLTITTLHRVTKVAPATGSGYSVTMEQIDEQGNVVATKVVTADRVFFAAGSVGTSKLLVSMKAQGHLPNLSSQVGEGWGNNGNIMVGRANHMWDATGSKQATIPTMGIDNWADPTAPIFAEIAPLPAGLETYVSLYLAITKNPERARFQFNSGTGKVDLTWAQSQNQKGIDMAKKVFDKINQKEGTIYRTDLFGVYFKTWGDDFTYHPLGGVLLNKATDNFGRLPEYPGLYVVDGSLVPGNVGVNPFVTITRLAERNMDKIISSDIQ	FUNCTION: Catalyzes the oxidation and isomerization of cholesterol to cholestenone (4-cholesten-3-one), which is an initial step in the cholesterol degradation process. {ECO:0000305|PubMed:9535702}.		cholesterol catabolic process [GO:0006707]	extracellular region [GO:0005576]	cholesterol oxidase activity [GO:0016995]; flavin adenine dinucleotide binding [GO:0050660]; steroid delta-isomerase activity [GO:0004769]	extracellular region [GO:0005576]; cholesterol oxidase activity [GO:0016995]; flavin adenine dinucleotide binding [GO:0050660]; steroid delta-isomerase activity [GO:0004769]; cholesterol catabolic process [GO:0006707]	GO:0004769; GO:0005576; GO:0006707; GO:0016995; GO:0050660	1879703; 2271066; 9535702; 2051487	10.1016/0378-1119(91)90397-t; 10.1016/0006-291x(90)90734-5; 10.1006/prep.1997.0855; 10.1016/0022-2836(91)90192-9				DB03147;DB01708;
2jjg	P9WQ77	reviewed	LAT_MYCTU	Probable L-lysine-epsilon aminotransferase (L-lysine aminotransferase) (EC 2.6.1.36) (Lysine 6-aminotransferase)	lat Rv3290c MTCY71.30	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	449	MAAVVKSVALAGRPTTPDRVHEVLGRSMLVDGLDIVLDLTRSGGSYLVDAITGRRYLDMFTFVASSALGMNPPALVDDREFHAELMQAALNKPSNSDVYSVAMARFVETFARVLGDPALPHLFFVEGGALAVENALKAAFDWKSRHNQAHGIDPALGTQVLHLRGAFHGRSGYTLSLTNTKPTITARFPKFDWPRIDAPYMRPGLDEPAMAALEAEALRQARAAFETRPHDIACFVAEPIQGEGGDRHFRPEFFAAMRELCDEFDALLIFDEVQTGCGLTGTAWAYQQLDVAPDIVAFGKKTQVCGVMAGRRVDEVADNVFAVPSRLNSTWGGNLTDMVRARRILEVIEAEGLFERAVQHGKYLRARLDELAADFPAVVLDPRGRGLMCAFSLPTTADRDELIRQLWQRAVIVLPAGADTVRFRPPLTVSTAEIDAAIAAVRSALPVVT		MISCELLANEOUS: Was identified as a high-confidence drug target.	antibiotic biosynthetic process [GO:0017000]; gamma-aminobutyric acid catabolic process [GO:0009450]	cytosol [GO:0005829]	4-aminobutyrate transaminase activity [GO:0003867]; L-lysine 6-transaminase activity [GO:0045484]; pyridoxal phosphate binding [GO:0030170]	cytosol [GO:0005829]; 4-aminobutyrate transaminase activity [GO:0003867]; L-lysine 6-transaminase activity [GO:0045484]; pyridoxal phosphate binding [GO:0030170]; antibiotic biosynthetic process [GO:0017000]; gamma-aminobutyric acid catabolic process [GO:0009450]	GO:0003867; GO:0005829; GO:0009450; GO:0017000; GO:0030170; GO:0045484	9634230; 19099550; 21969609	10.1038/31159; 10.1186/1752-0509-2-109; 10.1074/mcp.m111.011445	NP_217807.1;WP_003900004.1;	P9WQ77;	CHEMBL2259247;	DB08071;
2rhy	Q9Y468	reviewed	LMBL1_HUMAN	Lethal(3)malignant brain tumor-like protein 1 (H-l(3)mbt) (H-l(3)mbt protein) (L(3)mbt-like) (L(3)mbt protein homolog) (L3MBTL1)	L3MBTL1 KIAA0681 L3MBT L3MBTL	Homo sapiens (Human)	840	MHLVAGDSPGSGPHLPATAFIIPASSATLGLPSSALDVSCFPREPIHVGAPEQVAGCEPVSATVLPQLSAGPASSSTSTVRLLEWTEAAAPPPGGGLRFRISEYKPLNMAGVEQPPSPELRQEGVTEYEDGGAPAGDGEAGPQQAEDHPQNPPEDPNQDPPEDDSTCQCQACGPHQAAGPDLGSSNDGCPQLFQERSVIVENSSGSTSASELLKPMKKRKRREYQSPSEEESEPEAMEKQEEGKDPEGQPTASTPESEEWSSSQPATGEKKECWSWESYLEEQKAITAPVSLFQDSQAVTHNKNGFKLGMKLEGIDPQHPSMYFILTVAEVCGYRLRLHFDGYSECHDFWVNANSPDIHPAGWFEKTGHKLQPPKGYKEEEFSWSQYLRSTRAQAAPKHLFVSQSHSPPPLGFQVGMKLEAVDRMNPSLVCVASVTDVVDSRFLVHFDNWDDTYDYWCDPSSPYIHPVGWCQKQGKPLTPPQDYPDPDNFCWEKYLEETGASAVPTWAFKVRPPHSFLVNMKLEAVDRRNPALIRVASVEDVEDHRIKIHFDGWSHGYDFWIDADHPDIHPAGWCSKTGHPLQPPLGPREPSSASPGGCPPLSYRSLPHTRTSKYSFHHRKCPTPGCDGSGHVTGKFTAHHCLSGCPLAERNQSRLKAELSDSEASARKKNLSGFSPRKKPRHHGRIGRPPKYRKIPQEDFQTLTPDVVHQSLFMSALSAHPDRSLSVCWEQHCKLLPGVAGISASTVAKWTIDEVFGFVQTLTGCEDQARLFKDEARIVRVTHVSGKTLVWTVAQLGDLVCSDHLQEGKGILETGVHSLLCSLPTHLLAKLSFASDSQY	FUNCTION: Polycomb group (PcG) protein that specifically recognizes and binds mono- and dimethyllysine residues on target proteins, therey acting as a 'reader' of a network of post-translational modifications. PcG proteins maintain the transcriptionally repressive state of genes: acts as a chromatin compaction factor by recognizing and binding mono- and dimethylated histone H1b/H1-4 at 'Lys-26' (H1bK26me1 and H1bK26me2) and histone H4 at 'Lys-20' (H4K20me1 and H4K20me2), leading to condense chromatin and repress transcription. Recognizes and binds p53/TP53 monomethylated at 'Lys-382', leading to repress p53/TP53-target genes. Also recognizes and binds RB1/RB monomethylated at 'Lys-860'. Participates in the ETV6-mediated repression. Probably plays a role in cell proliferation. Overexpression induces multinucleated cells, suggesting that it is required to accomplish normal mitosis. {ECO:0000269|PubMed:17540172, ECO:0000269|PubMed:18408754, ECO:0000269|PubMed:20870719, ECO:0000269|PubMed:20870725}.	MISCELLANEOUS: The L3MBTL1 locus is imprinted. Paternal inherited gene is expressed, while the maternal inherited gene is silenced.	chromatin organization [GO:0006325]; hemopoiesis [GO:0030097]; heterochromatin formation [GO:0031507]; negative regulation of DNA-templated transcription [GO:0045892]; regulation of cell cycle [GO:0051726]; regulation of megakaryocyte differentiation [GO:0045652]; regulation of mitotic nuclear division [GO:0007088]	chromatin [GO:0000785]; chromatin lock complex [GO:0061793]; condensed chromosome [GO:0000793]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]	chromatin binding [GO:0003682]; histone binding [GO:0042393]; identical protein binding [GO:0042802]; methylated histone binding [GO:0035064]; nucleosome binding [GO:0031491]; SAM domain binding [GO:0032093]; zinc ion binding [GO:0008270]	chromatin [GO:0000785]; chromatin lock complex [GO:0061793]; condensed chromosome [GO:0000793]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; chromatin binding [GO:0003682]; histone binding [GO:0042393]; identical protein binding [GO:0042802]; methylated histone binding [GO:0035064]; nucleosome binding [GO:0031491]; SAM domain binding [GO:0032093]; zinc ion binding [GO:0008270]; chromatin organization [GO:0006325]; hemopoiesis [GO:0030097]; heterochromatin formation [GO:0031507]; negative regulation of DNA-templated transcription [GO:0045892]; regulation of cell cycle [GO:0051726]; regulation of megakaryocyte differentiation [GO:0045652]; regulation of mitotic nuclear division [GO:0007088]	GO:0000785; GO:0000793; GO:0003682; GO:0005634; GO:0005654; GO:0006325; GO:0007088; GO:0008270; GO:0030097; GO:0031491; GO:0031507; GO:0032093; GO:0035064; GO:0042393; GO:0042802; GO:0045652; GO:0045892; GO:0051726; GO:0061793	10445843; 14702039; 17974005; 11780052; 15489334; 9734811; 12588862; 15123827; 17540172; 18408754; 20870719; 22120668; 23186163; 12842041; 18042461; 18026117; 20870725	10.1038/sj.onc.1202732; 10.1038/ng1285; 10.1186/1471-2164-8-399; 10.1038/414865a; 10.1101/gr.2596504; 10.1093/dnares/5.3.169; 10.1074/jbc.m300592200; 10.1073/pnas.0308195101; 10.1016/j.cell.2007.03.048; 10.1038/onc.2008.67; 10.1074/jbc.m110.137612; 10.1038/nsmb.2188; 10.1021/pr300630k; 10.1016/s0969-2126(03)00127-8; 10.1016/j.molcel.2007.10.023; 10.1038/nsmb1340; 10.1074/jbc.m110.139527	NP_056293.4 [Q9Y468-1];NP_115479.4 [Q9Y468-5];	Q9Y468;	CHEMBL1287622;	DB03814;
2pqw	Q9Y468	reviewed	LMBL1_HUMAN	Lethal(3)malignant brain tumor-like protein 1 (H-l(3)mbt) (H-l(3)mbt protein) (L(3)mbt-like) (L(3)mbt protein homolog) (L3MBTL1)	L3MBTL1 KIAA0681 L3MBT L3MBTL	Homo sapiens (Human)	840	MHLVAGDSPGSGPHLPATAFIIPASSATLGLPSSALDVSCFPREPIHVGAPEQVAGCEPVSATVLPQLSAGPASSSTSTVRLLEWTEAAAPPPGGGLRFRISEYKPLNMAGVEQPPSPELRQEGVTEYEDGGAPAGDGEAGPQQAEDHPQNPPEDPNQDPPEDDSTCQCQACGPHQAAGPDLGSSNDGCPQLFQERSVIVENSSGSTSASELLKPMKKRKRREYQSPSEEESEPEAMEKQEEGKDPEGQPTASTPESEEWSSSQPATGEKKECWSWESYLEEQKAITAPVSLFQDSQAVTHNKNGFKLGMKLEGIDPQHPSMYFILTVAEVCGYRLRLHFDGYSECHDFWVNANSPDIHPAGWFEKTGHKLQPPKGYKEEEFSWSQYLRSTRAQAAPKHLFVSQSHSPPPLGFQVGMKLEAVDRMNPSLVCVASVTDVVDSRFLVHFDNWDDTYDYWCDPSSPYIHPVGWCQKQGKPLTPPQDYPDPDNFCWEKYLEETGASAVPTWAFKVRPPHSFLVNMKLEAVDRRNPALIRVASVEDVEDHRIKIHFDGWSHGYDFWIDADHPDIHPAGWCSKTGHPLQPPLGPREPSSASPGGCPPLSYRSLPHTRTSKYSFHHRKCPTPGCDGSGHVTGKFTAHHCLSGCPLAERNQSRLKAELSDSEASARKKNLSGFSPRKKPRHHGRIGRPPKYRKIPQEDFQTLTPDVVHQSLFMSALSAHPDRSLSVCWEQHCKLLPGVAGISASTVAKWTIDEVFGFVQTLTGCEDQARLFKDEARIVRVTHVSGKTLVWTVAQLGDLVCSDHLQEGKGILETGVHSLLCSLPTHLLAKLSFASDSQY	FUNCTION: Polycomb group (PcG) protein that specifically recognizes and binds mono- and dimethyllysine residues on target proteins, therey acting as a 'reader' of a network of post-translational modifications. PcG proteins maintain the transcriptionally repressive state of genes: acts as a chromatin compaction factor by recognizing and binding mono- and dimethylated histone H1b/H1-4 at 'Lys-26' (H1bK26me1 and H1bK26me2) and histone H4 at 'Lys-20' (H4K20me1 and H4K20me2), leading to condense chromatin and repress transcription. Recognizes and binds p53/TP53 monomethylated at 'Lys-382', leading to repress p53/TP53-target genes. Also recognizes and binds RB1/RB monomethylated at 'Lys-860'. Participates in the ETV6-mediated repression. Probably plays a role in cell proliferation. Overexpression induces multinucleated cells, suggesting that it is required to accomplish normal mitosis. {ECO:0000269|PubMed:17540172, ECO:0000269|PubMed:18408754, ECO:0000269|PubMed:20870719, ECO:0000269|PubMed:20870725}.	MISCELLANEOUS: The L3MBTL1 locus is imprinted. Paternal inherited gene is expressed, while the maternal inherited gene is silenced.	chromatin organization [GO:0006325]; hemopoiesis [GO:0030097]; heterochromatin formation [GO:0031507]; negative regulation of DNA-templated transcription [GO:0045892]; regulation of cell cycle [GO:0051726]; regulation of megakaryocyte differentiation [GO:0045652]; regulation of mitotic nuclear division [GO:0007088]	chromatin [GO:0000785]; chromatin lock complex [GO:0061793]; condensed chromosome [GO:0000793]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]	chromatin binding [GO:0003682]; histone binding [GO:0042393]; identical protein binding [GO:0042802]; methylated histone binding [GO:0035064]; nucleosome binding [GO:0031491]; SAM domain binding [GO:0032093]; zinc ion binding [GO:0008270]	chromatin [GO:0000785]; chromatin lock complex [GO:0061793]; condensed chromosome [GO:0000793]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; chromatin binding [GO:0003682]; histone binding [GO:0042393]; identical protein binding [GO:0042802]; methylated histone binding [GO:0035064]; nucleosome binding [GO:0031491]; SAM domain binding [GO:0032093]; zinc ion binding [GO:0008270]; chromatin organization [GO:0006325]; hemopoiesis [GO:0030097]; heterochromatin formation [GO:0031507]; negative regulation of DNA-templated transcription [GO:0045892]; regulation of cell cycle [GO:0051726]; regulation of megakaryocyte differentiation [GO:0045652]; regulation of mitotic nuclear division [GO:0007088]	GO:0000785; GO:0000793; GO:0003682; GO:0005634; GO:0005654; GO:0006325; GO:0007088; GO:0008270; GO:0030097; GO:0031491; GO:0031507; GO:0032093; GO:0035064; GO:0042393; GO:0042802; GO:0045652; GO:0045892; GO:0051726; GO:0061793	10445843; 14702039; 17974005; 11780052; 15489334; 9734811; 12588862; 15123827; 17540172; 18408754; 20870719; 22120668; 23186163; 12842041; 18042461; 18026117; 20870725	10.1038/sj.onc.1202732; 10.1038/ng1285; 10.1186/1471-2164-8-399; 10.1038/414865a; 10.1101/gr.2596504; 10.1093/dnares/5.3.169; 10.1074/jbc.m300592200; 10.1073/pnas.0308195101; 10.1016/j.cell.2007.03.048; 10.1038/onc.2008.67; 10.1074/jbc.m110.137612; 10.1038/nsmb.2188; 10.1021/pr300630k; 10.1016/s0969-2126(03)00127-8; 10.1016/j.molcel.2007.10.023; 10.1038/nsmb1340; 10.1074/jbc.m110.139527	NP_056293.4 [Q9Y468-1];NP_115479.4 [Q9Y468-5];	Q9Y468;	CHEMBL1287622;	DB03814;
4g3d	Q99558	reviewed	M3K14_HUMAN	Mitogen-activated protein kinase kinase kinase 14 (EC 2.7.11.25) (NF-kappa-beta-inducing kinase) (HsNIK) (Serine/threonine-protein kinase NIK)	MAP3K14 NIK	Homo sapiens (Human)	947	MAVMEMACPGAPGSAVGQQKELPKAKEKTPPLGKKQSSVYKLEAVEKSPVFCGKWEILNDVITKGTAKEGSEAGPAAISIIAQAECENSQEFSPTFSERIFIAGSKQYSQSESLDQIPNNVAHATEGKMARVCWKGKRRSKARKKRKKKSSKSLAHAGVALAKPLPRTPEQESCTIPVQEDESPLGAPYVRNTPQFTKPLKEPGLGQLCFKQLGEGLRPALPRSELHKLISPLQCLNHVWKLHHPQDGGPLPLPTHPFPYSRLPHPFPFHPLQPWKPHPLESFLGKLACVDSQKPLPDPHLSKLACVDSPKPLPGPHLEPSCLSRGAHEKFSVEEYLVHALQGSVSSGQAHSLTSLAKTWAARGSRSREPSPKTEDNEGVLLTEKLKPVDYEYREEVHWATHQLRLGRGSFGEVHRMEDKQTGFQCAVKKVRLEVFRAEELMACAGLTSPRIVPLYGAVREGPWVNIFMELLEGGSLGQLVKEQGCLPEDRALYYLGQALEGLEYLHSRRILHGDVKADNVLLSSDGSHAALCDFGHAVCLQPDGLGKSLLTGDYIPGTETHMAPEVVLGRSCDAKVDVWSSCCMMLHMLNGCHPWTQFFRGPLCLKIASEPPPVREIPPSCAPLTAQAIQEGLRKEPIHRVSAAELGGKVNRALQQVGGLKSPWRGEYKEPRHPPPNQANYHQTLHAQPRELSPRAPGPRPAEETTGRAPKLQPPLPPEPPEPNKSPPLTLSKEESGMWEPLPLSSLEPAPARNPSSPERKATVPEQELQQLEIELFLNSLSQPFSLEEQEQILSCLSIDSLSLSDDSEKNPSKASQSSRDTLSSGVHSWSSQAEARSSSWNMVLARGRPTDTPSYFNGVKVQIQSLNGEHLHIREFHRVKVGDIATGISSQIPAAAFSLVTKDGQPVRYDMEVPDSGIDLQCTLAPDGSFAWSWRVKHGQLENRP	FUNCTION: Lymphotoxin beta-activated kinase which seems to be exclusively involved in the activation of NF-kappa-B and its transcriptional activity. Phosphorylates CHUK/IKKA, thereby promoting proteolytic processing of NFKB2/P100, which leads to NF-kappa-B activation via the non-canonical pathway (PubMed:25406581, PubMed:29230214). Has an essential role in the non-canonical NF-kappa-B signaling that regulates genes encoding molecules involved in B-cell survival, lymphoid organogenesis, and immune response (PubMed:25406581). Could act in a receptor-selective manner. {ECO:0000269|PubMed:15084608, ECO:0000269|PubMed:25406581}.		canonical NF-kappaB signal transduction [GO:0007249]; cellular response to mechanical stimulus [GO:0071260]; defense response to virus [GO:0051607]; immune response [GO:0006955]; non-canonical NF-kappaB signal transduction [GO:0038061]; phosphorylation [GO:0016310]	cytosol [GO:0005829]; fibrillar center [GO:0001650]; intracellular membrane-bounded organelle [GO:0043231]; nucleoplasm [GO:0005654]	ATP binding [GO:0005524]; MAP kinase kinase kinase activity [GO:0004709]; protein kinase activity [GO:0004672]; protein serine kinase activity [GO:0106310]; protein serine/threonine kinase activity [GO:0004674]	cytosol [GO:0005829]; fibrillar center [GO:0001650]; intracellular membrane-bounded organelle [GO:0043231]; nucleoplasm [GO:0005654]; ATP binding [GO:0005524]; MAP kinase kinase kinase activity [GO:0004709]; protein kinase activity [GO:0004672]; protein serine kinase activity [GO:0106310]; protein serine/threonine kinase activity [GO:0004674]; canonical NF-kappaB signal transduction [GO:0007249]; cellular response to mechanical stimulus [GO:0071260]; defense response to virus [GO:0051607]; immune response [GO:0006955]; non-canonical NF-kappaB signal transduction [GO:0038061]; phosphorylation [GO:0016310]	GO:0001650; GO:0004672; GO:0004674; GO:0004709; GO:0005524; GO:0005654; GO:0005829; GO:0006955; GO:0007249; GO:0016310; GO:0038061; GO:0043231; GO:0051607; GO:0071260; GO:0106310	9020361; 14702039; 15489334; 12874243; 12853971; 15084608; 15173580; 15951441; 17237370; 20501937; 30341167; 22718757; 22921830; 17344846; 20682767; 25406581; 29230214	10.1038/385540a0; 10.1038/ng1285; 10.1101/gr.2596504; 10.4049/jimmunol.171.3.1500; 10.1038/sj.onc.1206532; 10.1074/jbc.m403286200; 10.1073/pnas.0402851101; 10.1074/jbc.m501670200; 10.4049/jimmunol.178.3.1256; 10.1126/scisignal.2000778; 10.1042/bcj20180163; 10.1074/jbc.m112.366658; 10.1016/j.str.2012.07.013; 10.1038/nature05610; 10.1074/jbc.m110.129551; 10.1038/ncomms6360; 10.3389/fimmu.2017.01624	NP_003945.2;XP_011523743.1;	Q99558;	CHEMBL5888;	
5bur	P23971	reviewed	MENE_BACSU	2-succinylbenzoate--CoA ligase (EC 6.2.1.26) (o-succinylbenzoyl-CoA synthetase) (OSB-CoA synthetase)	menE BSU30790	Bacillus subtilis (strain 168)	486	MLTEQPNWLMQRAQLTPERIALIYEDQTVTFAELFAASKRMAEQLAAHSVRKGDTAAILLQNRAEMVYAVHACFLLGVKAVLLNTKLSTHERLFQLEDSGSGFLLTDSSFEKKEYEHIVQTIDVDELMKEAAEEIEIEAYMQMDATATLMYTSGTTGKPKGVQQTFGNHYFSAVSSALNLGITEQDRWLIALPLFHISGLSALFKSVIYGMTVVLHQRFSVSDVLHSINRHEVTMISAVQTMLASLLEETNRCPESIRCILLGGGPAPLPLLEECREKGFPVFQSYGMTETCSQIVTLSPEFSMEKLGSAGKPLFSCEIKIERDGQVCEPYEHGEIMVKGPNVMKSYFNRESANEASFQNGWLKTGDLGYLDNEGFLYVLDRRSDLIISGGENIYPAEVESVLLSHPAVAEAGVSGAEDKKWGKVPHAYLVLHKPVSAGELTDYCKERLAKYKIPAKFFVLDRLPRNASNKLLRNQLKDARKGELL	FUNCTION: Converts 2-succinylbenzoate (OSB) to 2-succinylbenzoyl-CoA (OSB-CoA). {ECO:0000255|HAMAP-Rule:MF_00731}.		menaquinone biosynthetic process [GO:0009234]		ATP binding [GO:0005524]; CoA-ligase activity [GO:0016405]; o-succinylbenzoate-CoA ligase activity [GO:0008756]	ATP binding [GO:0005524]; CoA-ligase activity [GO:0016405]; o-succinylbenzoate-CoA ligase activity [GO:0008756]; menaquinone biosynthetic process [GO:0009234]	GO:0005524; GO:0008756; GO:0009234; GO:0016405	1629163; 8566759; 9387221; 9384377	10.1128/jb.174.15.5063-5071.1992; 10.1016/0378-1119(95)00662-1; 10.1099/00221287-143-11-3431; 10.1038/36786	NP_390957.1;WP_003229056.1;			
3gs6	Q9KU37	reviewed	NAGZ_VIBCH	Beta-hexosaminidase (EC 3.2.1.52) (Beta-N-acetylhexosaminidase) (N-acetyl-beta-glucosaminidase)	nagZ VC_0692	Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961)	330	MGPLWLDVAGYELSAEDREILQHPTVGGVILFGRNYHDNQQLLALNKAIRQAAKRPILIGVDQEGGRVQRFREGFSRIPPAQYYARAENGVELAEQGGWLMAAELIAHDVDLSFAPVLDMGFACKAIGNRAFGEDVQTVLKHSSAFLRGMKAVGMATTGKHFPGHGAVIADSHLETPYDERETIAQDMAIFRAQIEAGVLDAMMPAHVVYPHYDAQPASGSSYWLKQVLREELGFKGIVFSDDLSMEGAAVMGGPVERSHQALVAGCDMILICNKREAAVEVLDNLPIMEVPQAEALLKKQQFSYSELKRLERWQQASANMQRLIEQFSE	FUNCTION: Plays a role in peptidoglycan recycling by cleaving the terminal beta-1,4-linked N-acetylglucosamine (GlcNAc) from peptide-linked peptidoglycan fragments, giving rise to free GlcNAc, anhydro-N-acetylmuramic acid and anhydro-N-acetylmuramic acid-linked peptides. Plays a role in beta-lactam antibiotic resistance via its role in generating anhydro-N-acetylmuramic acid-linked peptides; these peptides function as signaling molecules that induce high-level expression of the beta-lactamase AmpC. {ECO:0000255|HAMAP-Rule:MF_00364, ECO:0000269|PubMed:17439950, ECO:0000269|PubMed:19499593, ECO:0000269|PubMed:24009110}.		carbohydrate metabolic process [GO:0005975]; cell cycle [GO:0007049]; cell division [GO:0051301]; cell wall organization [GO:0071555]; peptidoglycan biosynthetic process [GO:0009252]; peptidoglycan turnover [GO:0009254]; regulation of cell shape [GO:0008360]; response to antibiotic [GO:0046677]	cytoplasm [GO:0005737]	beta-N-acetylhexosaminidase activity [GO:0004563]; N-acetyl-beta-D-galactosaminidase activity [GO:0102148]	cytoplasm [GO:0005737]; beta-N-acetylhexosaminidase activity [GO:0004563]; N-acetyl-beta-D-galactosaminidase activity [GO:0102148]; carbohydrate metabolic process [GO:0005975]; cell cycle [GO:0007049]; cell division [GO:0051301]; cell wall organization [GO:0071555]; peptidoglycan biosynthetic process [GO:0009252]; peptidoglycan turnover [GO:0009254]; regulation of cell shape [GO:0008360]; response to antibiotic [GO:0046677]	GO:0004563; GO:0005737; GO:0005975; GO:0007049; GO:0008360; GO:0009252; GO:0009254; GO:0046677; GO:0051301; GO:0071555; GO:0102148	10952301; 24009110; 17439950; 19499593	10.1038/35020000; 10.1002/cbic.201300395; 10.1074/jbc.m700084200; 10.1002/pro.137	NP_230341.1;WP_000529115.1;		CHEMBL1075035;	DB07432;DB08704;
1r1h	P08473	reviewed	NEP_HUMAN	Neprilysin (EC 3.4.24.11) (Atriopeptidase) (Common acute lymphocytic leukemia antigen) (CALLA) (Enkephalinase) (Neutral endopeptidase 24.11) (NEP) (Neutral endopeptidase) (Skin fibroblast elastase) (SFE) (CD antigen CD10)	MME EPN	Homo sapiens (Human)	750	MGKSESQMDITDINTPKPKKKQRWTPLEISLSVLVLLLTIIAVTMIALYATYDDGICKSSDCIKSAARLIQNMDATTEPCTDFFKYACGGWLKRNVIPETSSRYGNFDILRDELEVVLKDVLQEPKTEDIVAVQKAKALYRSCINESAIDSRGGEPLLKLLPDIYGWPVATENWEQKYGASWTAEKAIAQLNSKYGKKVLINLFVGTDDKNSVNHVIHIDQPRLGLPSRDYYECTGIYKEACTAYVDFMISVARLIRQEERLPIDENQLALEMNKVMELEKEIANATAKPEDRNDPMLLYNKMTLAQIQNNFSLEINGKPFSWLNFTNEIMSTVNISITNEEDVVVYAPEYLTKLKPILTKYSARDLQNLMSWRFIMDLVSSLSRTYKESRNAFRKALYGTTSETATWRRCANYVNGNMENAVGRLYVEAAFAGESKHVVEDLIAQIREVFIQTLDDLTWMDAETKKRAEEKALAIKERIGYPDDIVSNDNKLNNEYLELNYKEDEYFENIIQNLKFSQSKQLKKLREKVDKDEWISGAAVVNAFYSSGRNQIVFPAGILQPPFFSAQQSNSLNYGGIGMVIGHEITHGFDDNGRNFNKDGDLVDWWTQQSASNFKEQSQCMVYQYGNFSWDLAGGQHLNGINTLGENIADNGGLGQAYRAYQNYIKKNGEEKLLPGLDLNHKQLFFLNFAQVWCGTYRPEYAVNSIKTDVHSPGNFRIIGTLQNSAEFSEAFHCRKNSYMNPEKKCRVW	FUNCTION: Thermolysin-like specificity, but is almost confined on acting on polypeptides of up to 30 amino acids (PubMed:15283675, PubMed:6208535, PubMed:6349683, PubMed:8168535). Biologically important in the destruction of opioid peptides such as Met- and Leu-enkephalins by cleavage of a Gly-Phe bond (PubMed:17101991, PubMed:6349683). Catalyzes cleavage of bradykinin, substance P and neurotensin peptides (PubMed:6208535). Able to cleave angiotensin-1, angiotensin-2 and angiotensin 1-9 (PubMed:15283675, PubMed:6349683). Involved in the degradation of atrial natriuretic factor (ANF) and brain natriuretic factor (BNP(1-32)) (PubMed:16254193, PubMed:2531377, PubMed:2972276). Displays UV-inducible elastase activity toward skin preelastic and elastic fibers (PubMed:20876573). {ECO:0000269|PubMed:15283675, ECO:0000269|PubMed:17101991, ECO:0000269|PubMed:20876573, ECO:0000269|PubMed:2531377, ECO:0000269|PubMed:27588448, ECO:0000269|PubMed:2972276, ECO:0000269|PubMed:6208535, ECO:0000269|PubMed:6349683}.	MISCELLANEOUS: Important cell surface marker in the diagnostic of human acute lymphocytic leukemia. {ECO:0000269|PubMed:2528730, ECO:0000269|PubMed:2968607, ECO:0000269|PubMed:2971756}.	amyloid-beta clearance [GO:0097242]; amyloid-beta clearance by cellular catabolic process [GO:0150094]; amyloid-beta metabolic process [GO:0050435]; bradykinin catabolic process [GO:0010815]; cellular response to cytokine stimulus [GO:0071345]; cellular response to UV-A [GO:0071492]; cellular response to UV-B [GO:0071493]; creatinine metabolic process [GO:0046449]; hormone catabolic process [GO:0042447]; kidney development [GO:0001822]; learning or memory [GO:0007611]; lung development [GO:0030324]; neuropeptide processing [GO:0061837]; peptide metabolic process [GO:0006518]; placenta development [GO:0001890]; positive regulation of long-term synaptic potentiation [GO:1900273]; positive regulation of neurogenesis [GO:0050769]; protein catabolic process [GO:0030163]; protein processing [GO:0016485]; proteolysis [GO:0006508]; replicative senescence [GO:0090399]; response to estrogen [GO:0043627]; sensory perception of pain [GO:0019233]; substance P catabolic process [GO:0010814]	axon [GO:0030424]; brush border [GO:0005903]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; cytoplasmic vesicle [GO:0031410]; dendrite [GO:0030425]; early endosome [GO:0005769]; extracellular exosome [GO:0070062]; focal adhesion [GO:0005925]; membrane [GO:0016020]; membrane raft [GO:0045121]; neuron projection terminus [GO:0044306]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]; presynapse [GO:0098793]; secretory granule membrane [GO:0030667]; synapse [GO:0045202]; synaptic vesicle [GO:0008021]; trans-Golgi network [GO:0005802]	cardiolipin binding [GO:1901612]; endopeptidase activity [GO:0004175]; exopeptidase activity [GO:0008238]; metalloendopeptidase activity [GO:0004222]; oligopeptidase activity [GO:0070012]; peptide binding [GO:0042277]; phosphatidylserine binding [GO:0001786]; protein homodimerization activity [GO:0042803]; zinc ion binding [GO:0008270]	axon [GO:0030424]; brush border [GO:0005903]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; cytoplasmic vesicle [GO:0031410]; dendrite [GO:0030425]; early endosome [GO:0005769]; extracellular exosome [GO:0070062]; focal adhesion [GO:0005925]; membrane [GO:0016020]; membrane raft [GO:0045121]; neuron projection terminus [GO:0044306]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]; presynapse [GO:0098793]; secretory granule membrane [GO:0030667]; synapse [GO:0045202]; synaptic vesicle [GO:0008021]; trans-Golgi network [GO:0005802]; cardiolipin binding [GO:1901612]; endopeptidase activity [GO:0004175]; exopeptidase activity [GO:0008238]; metalloendopeptidase activity [GO:0004222]; oligopeptidase activity [GO:0070012]; peptide binding [GO:0042277]; phosphatidylserine binding [GO:0001786]; protein homodimerization activity [GO:0042803]; zinc ion binding [GO:0008270]; amyloid-beta clearance [GO:0097242]; amyloid-beta clearance by cellular catabolic process [GO:0150094]; amyloid-beta metabolic process [GO:0050435]; bradykinin catabolic process [GO:0010815]; cellular response to cytokine stimulus [GO:0071345]; cellular response to UV-A [GO:0071492]; cellular response to UV-B [GO:0071493]; creatinine metabolic process [GO:0046449]; hormone catabolic process [GO:0042447]; kidney development [GO:0001822]; learning or memory [GO:0007611]; lung development [GO:0030324]; neuropeptide processing [GO:0061837]; peptide metabolic process [GO:0006518]; placenta development [GO:0001890]; positive regulation of long-term synaptic potentiation [GO:1900273]; positive regulation of neurogenesis [GO:0050769]; protein catabolic process [GO:0030163]; protein processing [GO:0016485]; proteolysis [GO:0006508]; replicative senescence [GO:0090399]; response to estrogen [GO:0043627]; sensory perception of pain [GO:0019233]; substance P catabolic process [GO:0010814]	GO:0001786; GO:0001822; GO:0001890; GO:0004175; GO:0004222; GO:0005737; GO:0005769; GO:0005802; GO:0005886; GO:0005903; GO:0005925; GO:0006508; GO:0006518; GO:0007611; GO:0008021; GO:0008238; GO:0008270; GO:0009986; GO:0010814; GO:0010815; GO:0016020; GO:0016485; GO:0019233; GO:0030163; GO:0030324; GO:0030424; GO:0030425; GO:0030667; GO:0031410; GO:0042277; GO:0042447; GO:0042803; GO:0043025; GO:0043627; GO:0044306; GO:0045121; GO:0045202; GO:0046449; GO:0050435; GO:0050769; GO:0061837; GO:0070012; GO:0070062; GO:0071345; GO:0071492; GO:0071493; GO:0090399; GO:0097242; GO:0098793; GO:0150094; GO:1900273; GO:1901612	2971756; 2968607; 2528730; 14702039; 15489334; 3162217; 6349683; 6208535; 2972276; 2531377; 8168535; 12754519; 15283675; 16254193; 17101991; 20876573; 19756956; 22766194; 24275569; 27588448; 26991897; 27583304; 26931059; 27102936; 10669592; 14747736; 17704566	10.1084/jem.168.4.1247; 10.1073/pnas.85.13.4819; 10.1073/pnas.86.18.7103; 10.1038/ng1285; 10.1101/gr.2596504; 10.1016/0014-5793(88)80828-7; 10.1021/bi00282a035; 10.1016/0196-9781(84)90020-2; 10.1042/bj2540531; 10.1016/0196-9781(89)90131-9; 10.1111/j.1432-1033.1994.tb18760.x; 10.1038/nbt827; 10.1042/bj20040634; 10.1373/clinchem.2005.057638; 10.1073/pnas.0605865103; 10.1074/jbc.m110.161547; 10.1007/s11010-009-0253-8; 10.1016/j.bbagen.2012.06.017; 10.1016/j.jprot.2013.11.014; 10.1016/j.ajhg.2016.07.008; 10.1002/ana.24612; 10.1212/nxg.0000000000000094; 10.1038/srep22413; 10.1038/srep24333; 10.1006/jmbi.1999.3492; 10.1107/s0907444903027410; 10.1107/s0907444907036281	NP_000893.2;NP_009218.2;NP_009219.2;NP_009220.2;XP_006713709.1;XP_006713710.1;XP_011511157.1;XP_011511158.1;XP_011511159.1;	P08473;	CHEMBL1944;	DB08575;DB02597;DB00616;DB11623;DB05796;DB06655;DB02558;DB02062;DB00886;DB02557;DB09292;DB13928;DB08626;
1dxo	P15559	reviewed	NQO1_HUMAN	NAD(P)H dehydrogenase [quinone] 1 (EC 1.6.5.2) (Azoreductase) (DT-diaphorase) (DTD) (Menadione reductase) (NAD(P)H:quinone oxidoreductase 1) (Phylloquinone reductase) (Quinone reductase 1) (QR1)	NQO1 DIA4 NMOR1	Homo sapiens (Human)	274	MVGRRALIVLAHSERTSFNYAMKEAAAAALKKKGWEVVESDLYAMNFNPIISRKDITGKLKDPANFQYPAESVLAYKEGHLSPDIVAEQKKLEAADLVIFQFPLQWFGVPAILKGWFERVFIGEFAYTYAAMYDKGPFRSKKAVLSITTGGSGSMYSLQGIHGDMNVILWPIQSGILHFCGFQVLEPQLTYSIGHTPADARIQILEGWKKRLENIWDETPLYFAPSSLFDLNFQAGFLMKKEVQDEEKNKKFGLSVGHHLGKSIPTDNQIKARK	FUNCTION: Flavin-containing quinone reductase that catalyzes two-electron reduction of quinones to hydroquinones using either NADH or NADPH as electron donors. In a ping-pong kinetic mechanism, the electrons are sequentially transferred from NAD(P)H to flavin cofactor and then from reduced flavin to the quinone, bypassing the formation of semiquinone and reactive oxygen species (By similarity) (PubMed:8999809, PubMed:9271353). Regulates cellular redox state primarily through quinone detoxification. Reduces components of plasma membrane redox system such as coenzyme Q and vitamin quinones, producing antioxidant hydroquinone forms. In the process may function as superoxide scavenger to prevent hydroquinone oxidation and facilitate excretion (PubMed:15102952, PubMed:8999809, PubMed:9271353). Alternatively, can activate quinones and their derivatives by generating redox reactive hydroquinones with DNA cross-linking antitumor potential (PubMed:8999809). Acts as a gatekeeper of the core 20S proteasome known to degrade proteins with unstructured regions. Upon oxidative stress, interacts with tumor suppressors TP53 and TP73 in a NADH-dependent way and inhibits their ubiquitin-independent degradation by the 20S proteasome (PubMed:15687255, PubMed:28291250). {ECO:0000250|UniProtKB:P05982, ECO:0000269|PubMed:15102952, ECO:0000269|PubMed:15687255, ECO:0000269|PubMed:28291250, ECO:0000269|PubMed:8999809, ECO:0000269|PubMed:9271353}.	MISCELLANEOUS: Quinone reductase accepts electrons from both NADH and NADPH with equal efficiency.	cell redox homeostasis [GO:0045454]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to metal ion [GO:0071248]; cellular response to oxidative stress [GO:0034599]; innate immune response [GO:0045087]; NADH oxidation [GO:0006116]; NADPH oxidation [GO:0070995]; negative regulation of apoptotic process [GO:0043066]; negative regulation of protein catabolic process [GO:0042177]; nitric oxide biosynthetic process [GO:0006809]; positive regulation of neuron apoptotic process [GO:0043525]; protein catabolic process [GO:0030163]; protein polyubiquitination [GO:0000209]; removal of superoxide radicals [GO:0019430]; response to alkaloid [GO:0043279]; response to amine [GO:0014075]; response to carbohydrate [GO:0009743]; response to electrical stimulus [GO:0051602]; response to estradiol [GO:0032355]; response to ethanol [GO:0045471]; response to flavonoid [GO:1905395]; response to hormone [GO:0009725]; response to hydrogen sulfide [GO:1904880]; response to ischemia [GO:0002931]; response to L-glutamine [GO:1904844]; response to lipopolysaccharide [GO:0032496]; response to nutrient [GO:0007584]; response to oxidative stress [GO:0006979]; response to testosterone [GO:0033574]; response to tetrachloromethane [GO:1904772]; response to toxic substance [GO:0009636]; synaptic transmission, cholinergic [GO:0007271]; ubiquinone metabolic process [GO:0006743]; vitamin E metabolic process [GO:0042360]; vitamin K metabolic process [GO:0042373]; xenobiotic metabolic process [GO:0006805]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; dendrite [GO:0030425]; neuronal cell body [GO:0043025]; nucleus [GO:0005634]; synapse [GO:0045202]	cytochrome-b5 reductase activity, acting on NAD(P)H [GO:0004128]; identical protein binding [GO:0042802]; NAD(P)H dehydrogenase (quinone) activity [GO:0003955]; NADH dehydrogenase (quinone) activity [GO:0050136]; NADPH dehydrogenase (quinone) activity [GO:0008753]; RNA binding [GO:0003723]; superoxide dismutase activity [GO:0004784]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; dendrite [GO:0030425]; neuronal cell body [GO:0043025]; nucleus [GO:0005634]; synapse [GO:0045202]; cytochrome-b5 reductase activity, acting on NAD(P)H [GO:0004128]; identical protein binding [GO:0042802]; NAD(P)H dehydrogenase (quinone) activity [GO:0003955]; NADH dehydrogenase (quinone) activity [GO:0050136]; NADPH dehydrogenase (quinone) activity [GO:0008753]; RNA binding [GO:0003723]; superoxide dismutase activity [GO:0004784]; cell redox homeostasis [GO:0045454]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to metal ion [GO:0071248]; cellular response to oxidative stress [GO:0034599]; innate immune response [GO:0045087]; NADH oxidation [GO:0006116]; NADPH oxidation [GO:0070995]; negative regulation of apoptotic process [GO:0043066]; negative regulation of protein catabolic process [GO:0042177]; nitric oxide biosynthetic process [GO:0006809]; positive regulation of neuron apoptotic process [GO:0043525]; protein catabolic process [GO:0030163]; protein polyubiquitination [GO:0000209]; removal of superoxide radicals [GO:0019430]; response to alkaloid [GO:0043279]; response to amine [GO:0014075]; response to carbohydrate [GO:0009743]; response to electrical stimulus [GO:0051602]; response to estradiol [GO:0032355]; response to ethanol [GO:0045471]; response to flavonoid [GO:1905395]; response to hormone [GO:0009725]; response to hydrogen sulfide [GO:1904880]; response to ischemia [GO:0002931]; response to L-glutamine [GO:1904844]; response to lipopolysaccharide [GO:0032496]; response to nutrient [GO:0007584]; response to oxidative stress [GO:0006979]; response to testosterone [GO:0033574]; response to tetrachloromethane [GO:1904772]; response to toxic substance [GO:0009636]; synaptic transmission, cholinergic [GO:0007271]; ubiquinone metabolic process [GO:0006743]; vitamin E metabolic process [GO:0042360]; vitamin K metabolic process [GO:0042373]; xenobiotic metabolic process [GO:0006805]	GO:0000209; GO:0002931; GO:0003723; GO:0003955; GO:0004128; GO:0004784; GO:0005634; GO:0005737; GO:0005829; GO:0006116; GO:0006743; GO:0006805; GO:0006809; GO:0006979; GO:0007271; GO:0007584; GO:0008753; GO:0009636; GO:0009725; GO:0009743; GO:0014075; GO:0019430; GO:0030163; GO:0030425; GO:0032355; GO:0032496; GO:0033574; GO:0034599; GO:0042177; GO:0042360; GO:0042373; GO:0042802; GO:0043025; GO:0043066; GO:0043279; GO:0043525; GO:0045087; GO:0045202; GO:0045454; GO:0045471; GO:0050136; GO:0051602; GO:0070301; GO:0070995; GO:0071248; GO:1904772; GO:1904844; GO:1904880; GO:1905395	2843525; 1657151; 14702039; 15616553; 15489334; 8999809; 9271353; 15102952; 15687255; 21269460; 21636573; 23186163; 28112733; 28291250; 10543876; 10706635; 11735396; 11587640; 16700548; 1737339; 10447260	10.1016/s0021-9258(18)68280-8; 10.1021/bi00108a007; 10.1038/ng1285; 10.1038/nature03187; 10.1101/gr.2596504; 10.1074/jbc.272.3.1437; 10.1124/mol.52.2.300; 10.1124/mol.65.5.1238; 10.1101/gad.319905; 10.1186/1752-0509-5-17; 10.1074/jbc.m111.241554; 10.1021/pr300630k; 10.1038/nsmb.3366; 10.1038/srep44532; 10.1021/jm991060m; 10.1073/pnas.97.7.3177; 10.1021/bi011324i; 10.1016/s0969-2126(01)00636-0; 10.1021/bi0600087; 10.1002/(sici)1098-1004(1999)14:1<67::aid-humu8>3.0.co;2-5	NP_000894.1 [P15559-1];NP_001020604.1 [P15559-2];NP_001020605.1 [P15559-3];	P15559;	CHEMBL3623;	DB07385;DB02395;DB03626;DB14001;DB04392;DB09061;DB00958;DB02633;DB00515;DB14002;DB00266;DB00997;DB01927;DB02400;DB03147;DB00170;DB00526;DB00252;DB04090;DB00163;
1gg5	P15559	reviewed	NQO1_HUMAN	NAD(P)H dehydrogenase [quinone] 1 (EC 1.6.5.2) (Azoreductase) (DT-diaphorase) (DTD) (Menadione reductase) (NAD(P)H:quinone oxidoreductase 1) (Phylloquinone reductase) (Quinone reductase 1) (QR1)	NQO1 DIA4 NMOR1	Homo sapiens (Human)	274	MVGRRALIVLAHSERTSFNYAMKEAAAAALKKKGWEVVESDLYAMNFNPIISRKDITGKLKDPANFQYPAESVLAYKEGHLSPDIVAEQKKLEAADLVIFQFPLQWFGVPAILKGWFERVFIGEFAYTYAAMYDKGPFRSKKAVLSITTGGSGSMYSLQGIHGDMNVILWPIQSGILHFCGFQVLEPQLTYSIGHTPADARIQILEGWKKRLENIWDETPLYFAPSSLFDLNFQAGFLMKKEVQDEEKNKKFGLSVGHHLGKSIPTDNQIKARK	FUNCTION: Flavin-containing quinone reductase that catalyzes two-electron reduction of quinones to hydroquinones using either NADH or NADPH as electron donors. In a ping-pong kinetic mechanism, the electrons are sequentially transferred from NAD(P)H to flavin cofactor and then from reduced flavin to the quinone, bypassing the formation of semiquinone and reactive oxygen species (By similarity) (PubMed:8999809, PubMed:9271353). Regulates cellular redox state primarily through quinone detoxification. Reduces components of plasma membrane redox system such as coenzyme Q and vitamin quinones, producing antioxidant hydroquinone forms. In the process may function as superoxide scavenger to prevent hydroquinone oxidation and facilitate excretion (PubMed:15102952, PubMed:8999809, PubMed:9271353). Alternatively, can activate quinones and their derivatives by generating redox reactive hydroquinones with DNA cross-linking antitumor potential (PubMed:8999809). Acts as a gatekeeper of the core 20S proteasome known to degrade proteins with unstructured regions. Upon oxidative stress, interacts with tumor suppressors TP53 and TP73 in a NADH-dependent way and inhibits their ubiquitin-independent degradation by the 20S proteasome (PubMed:15687255, PubMed:28291250). {ECO:0000250|UniProtKB:P05982, ECO:0000269|PubMed:15102952, ECO:0000269|PubMed:15687255, ECO:0000269|PubMed:28291250, ECO:0000269|PubMed:8999809, ECO:0000269|PubMed:9271353}.	MISCELLANEOUS: Quinone reductase accepts electrons from both NADH and NADPH with equal efficiency.	cell redox homeostasis [GO:0045454]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to metal ion [GO:0071248]; cellular response to oxidative stress [GO:0034599]; innate immune response [GO:0045087]; NADH oxidation [GO:0006116]; NADPH oxidation [GO:0070995]; negative regulation of apoptotic process [GO:0043066]; negative regulation of protein catabolic process [GO:0042177]; nitric oxide biosynthetic process [GO:0006809]; positive regulation of neuron apoptotic process [GO:0043525]; protein catabolic process [GO:0030163]; protein polyubiquitination [GO:0000209]; removal of superoxide radicals [GO:0019430]; response to alkaloid [GO:0043279]; response to amine [GO:0014075]; response to carbohydrate [GO:0009743]; response to electrical stimulus [GO:0051602]; response to estradiol [GO:0032355]; response to ethanol [GO:0045471]; response to flavonoid [GO:1905395]; response to hormone [GO:0009725]; response to hydrogen sulfide [GO:1904880]; response to ischemia [GO:0002931]; response to L-glutamine [GO:1904844]; response to lipopolysaccharide [GO:0032496]; response to nutrient [GO:0007584]; response to oxidative stress [GO:0006979]; response to testosterone [GO:0033574]; response to tetrachloromethane [GO:1904772]; response to toxic substance [GO:0009636]; synaptic transmission, cholinergic [GO:0007271]; ubiquinone metabolic process [GO:0006743]; vitamin E metabolic process [GO:0042360]; vitamin K metabolic process [GO:0042373]; xenobiotic metabolic process [GO:0006805]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; dendrite [GO:0030425]; neuronal cell body [GO:0043025]; nucleus [GO:0005634]; synapse [GO:0045202]	cytochrome-b5 reductase activity, acting on NAD(P)H [GO:0004128]; identical protein binding [GO:0042802]; NAD(P)H dehydrogenase (quinone) activity [GO:0003955]; NADH dehydrogenase (quinone) activity [GO:0050136]; NADPH dehydrogenase (quinone) activity [GO:0008753]; RNA binding [GO:0003723]; superoxide dismutase activity [GO:0004784]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; dendrite [GO:0030425]; neuronal cell body [GO:0043025]; nucleus [GO:0005634]; synapse [GO:0045202]; cytochrome-b5 reductase activity, acting on NAD(P)H [GO:0004128]; identical protein binding [GO:0042802]; NAD(P)H dehydrogenase (quinone) activity [GO:0003955]; NADH dehydrogenase (quinone) activity [GO:0050136]; NADPH dehydrogenase (quinone) activity [GO:0008753]; RNA binding [GO:0003723]; superoxide dismutase activity [GO:0004784]; cell redox homeostasis [GO:0045454]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to metal ion [GO:0071248]; cellular response to oxidative stress [GO:0034599]; innate immune response [GO:0045087]; NADH oxidation [GO:0006116]; NADPH oxidation [GO:0070995]; negative regulation of apoptotic process [GO:0043066]; negative regulation of protein catabolic process [GO:0042177]; nitric oxide biosynthetic process [GO:0006809]; positive regulation of neuron apoptotic process [GO:0043525]; protein catabolic process [GO:0030163]; protein polyubiquitination [GO:0000209]; removal of superoxide radicals [GO:0019430]; response to alkaloid [GO:0043279]; response to amine [GO:0014075]; response to carbohydrate [GO:0009743]; response to electrical stimulus [GO:0051602]; response to estradiol [GO:0032355]; response to ethanol [GO:0045471]; response to flavonoid [GO:1905395]; response to hormone [GO:0009725]; response to hydrogen sulfide [GO:1904880]; response to ischemia [GO:0002931]; response to L-glutamine [GO:1904844]; response to lipopolysaccharide [GO:0032496]; response to nutrient [GO:0007584]; response to oxidative stress [GO:0006979]; response to testosterone [GO:0033574]; response to tetrachloromethane [GO:1904772]; response to toxic substance [GO:0009636]; synaptic transmission, cholinergic [GO:0007271]; ubiquinone metabolic process [GO:0006743]; vitamin E metabolic process [GO:0042360]; vitamin K metabolic process [GO:0042373]; xenobiotic metabolic process [GO:0006805]	GO:0000209; GO:0002931; GO:0003723; GO:0003955; GO:0004128; GO:0004784; GO:0005634; GO:0005737; GO:0005829; GO:0006116; GO:0006743; GO:0006805; GO:0006809; GO:0006979; GO:0007271; GO:0007584; GO:0008753; GO:0009636; GO:0009725; GO:0009743; GO:0014075; GO:0019430; GO:0030163; GO:0030425; GO:0032355; GO:0032496; GO:0033574; GO:0034599; GO:0042177; GO:0042360; GO:0042373; GO:0042802; GO:0043025; GO:0043066; GO:0043279; GO:0043525; GO:0045087; GO:0045202; GO:0045454; GO:0045471; GO:0050136; GO:0051602; GO:0070301; GO:0070995; GO:0071248; GO:1904772; GO:1904844; GO:1904880; GO:1905395	2843525; 1657151; 14702039; 15616553; 15489334; 8999809; 9271353; 15102952; 15687255; 21269460; 21636573; 23186163; 28112733; 28291250; 10543876; 10706635; 11735396; 11587640; 16700548; 1737339; 10447260	10.1016/s0021-9258(18)68280-8; 10.1021/bi00108a007; 10.1038/ng1285; 10.1038/nature03187; 10.1101/gr.2596504; 10.1074/jbc.272.3.1437; 10.1124/mol.52.2.300; 10.1124/mol.65.5.1238; 10.1101/gad.319905; 10.1186/1752-0509-5-17; 10.1074/jbc.m111.241554; 10.1021/pr300630k; 10.1038/nsmb.3366; 10.1038/srep44532; 10.1021/jm991060m; 10.1073/pnas.97.7.3177; 10.1021/bi011324i; 10.1016/s0969-2126(01)00636-0; 10.1021/bi0600087; 10.1002/(sici)1098-1004(1999)14:1<67::aid-humu8>3.0.co;2-5	NP_000894.1 [P15559-1];NP_001020604.1 [P15559-2];NP_001020605.1 [P15559-3];	P15559;	CHEMBL3623;	DB07385;DB02395;DB03626;DB14001;DB04392;DB09061;DB00958;DB02633;DB00515;DB14002;DB00266;DB00997;DB01927;DB02400;DB03147;DB00170;DB00526;DB00252;DB04090;DB00163;
5q0k	Q15788	reviewed	NCOA1_HUMAN	Nuclear receptor coactivator 1 (NCoA-1) (EC 2.3.1.48) (Class E basic helix-loop-helix protein 74) (bHLHe74) (Protein Hin-2) (RIP160) (Renal carcinoma antigen NY-REN-52) (Steroid receptor coactivator 1) (SRC-1)	NCOA1 BHLHE74 SRC1	Homo sapiens (Human)	1441	MSGLGDSSSDPANPDSHKRKGSPCDTLASSTEKRRREQENKYLEELAELLSANISDIDSLSVKPDKCKILKKTVDQIQLMKRMEQEKSTTDDDVQKSDISSSSQGVIEKESLGPLLLEALDGFFFVVNCEGRIVFVSENVTSYLGYNQEELMNTSVYSILHVGDHAEFVKNLLPKSLVNGVPWPQEATRRNSHTFNCRMLIHPPDEPGTENQEACQRYEVMQCFTVSQPKSIQEDGEDFQSCLICIARRLPRPPAITGVESFMTKQDTTGKIISIDTSSLRAAGRTGWEDLVRKCIYAFFQPQGREPSYARQLFQEVMTRGTASSPSYRFILNDGTMLSAHTKCKLCYPQSPDMQPFIMGIHIIDREHSGLSPQDDTNSGMSIPRVNPSVNPSISPAHGVARSSTLPPSNSNMVSTRINRQQSSDLHSSSHSNSSNSQGSFGCSPGSQIVANVALNQGQASSQSSNPSLNLNNSPMEGTGISLAQFMSPRRQVTSGLATRPRMPNNSFPPNISTLSSPVGMTSSACNNNNRSYSNIPVTSLQGMNEGPNNSVGFSASSPVLRQMSSQNSPSRLNIQPAKAESKDNKEIASILNEMIQSDNSSSDGKPLDSGLLHNNDRLSDGDSKYSQTSHKLVQLLTTTAEQQLRHADIDTSCKDVLSCTGTSNSASANSSGGSCPSSHSSLTERHKILHRLLQEGSPSDITTLSVEPDKKDSASTSVSVTGQVQGNSSIKLELDASKKKESKDHQLLRYLLDKDEKDLRSTPNLSLDDVKVKVEKKEQMDPCNTNPTPMTKPTPEEIKLEAQSQFTADLDQFDQLLPTLEKAAQLPGLCETDRMDGAVTSVTIKSEILPASLQSATARPTSRLNRLPELELEAIDNQFGQPGTGDQIPWTNNTVTAINQSKSEDQCISSQLDELLCPPTTVEGRNDEKALLEQLVSFLSGKDETELAELDRALGIDKLVQGGGLDVLSERFPPQQATPPLIMEERPNLYSQPYSSPSPTANLPSPFQGMVRQKPSLGTMPVQVTPPRGAFSPGMGMQPRQTLNRPPAAPNQLRLQLQQRLQGQQQLIHQNRQAILNQFAATAPVGINMRSGMQQQITPQPPLNAQMLAQRQRELYSQQHRQRQLIQQQRAMLMRQQSFGNNLPPSSGLPVQMGNPRLPQGAPQQFPYPPNYGTNPGTPPASTSPFSQLAANPEASLANRNSMVSRGMTGNIGGQFGTGINPQMQQNVFQYPGAGMVPQGEANFAPSLSPGSSMVPMPIPPPQSSLLQQTPPASGYQSPDMKAWQQGAIGNNNVFSQAVQNQPTPAQPGVYNNMSITVSMAGGNTNVQNMNPMMAQMQMSSLQMPGMNTVCPEQINDPALRHTGLYCNQLSSTDLLKTEADGTQQVQQVQVFADVQCTVNLVGGDPYLNQPGPLGTQKPTSGPQTPQAQQKSLLQQLLTE	FUNCTION: Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion. Involved in the coactivation of different nuclear receptors, such as for steroids (PGR, GR and ER), retinoids (RXRs), thyroid hormone (TRs) and prostanoids (PPARs). Also involved in coactivation mediated by STAT3, STAT5A, STAT5B and STAT6 transcription factors. Displays histone acetyltransferase activity toward H3 and H4; the relevance of such activity remains however unclear. Plays a central role in creating multisubunit coactivator complexes that act via remodeling of chromatin, and possibly acts by participating in both chromatin remodeling and recruitment of general transcription factors. Required with NCOA2 to control energy balance between white and brown adipose tissues. Required for mediating steroid hormone response. Isoform 2 has a higher thyroid hormone-dependent transactivation activity than isoform 1 and isoform 3. {ECO:0000269|PubMed:10449719, ECO:0000269|PubMed:12954634, ECO:0000269|PubMed:7481822, ECO:0000269|PubMed:9223281, ECO:0000269|PubMed:9223431, ECO:0000269|PubMed:9296499, ECO:0000269|PubMed:9427757}.	MISCELLANEOUS: [Isoform 2]: Major form. Contains a domain at its C-terminus (1241-1399) that is able to mediate transactivation. {ECO:0000305}.	cellular response to hormone stimulus [GO:0032870]; cellular response to Thyroglobulin triiodothyronine [GO:1904017]; cerebellum development [GO:0021549]; cerebral cortex development [GO:0021987]; estrous cycle [GO:0044849]; hippocampus development [GO:0021766]; hypothalamus development [GO:0021854]; labyrinthine layer morphogenesis [GO:0060713]; lactation [GO:0007595]; male gonad development [GO:0008584]; male mating behavior [GO:0060179]; mRNA transcription by RNA polymerase II [GO:0042789]; peroxisome proliferator activated receptor signaling pathway [GO:0035357]; positive regulation of adipose tissue development [GO:1904179]; positive regulation of apoptotic process [GO:0043065]; positive regulation of DNA-templated transcription [GO:0045893]; positive regulation of female receptivity [GO:0045925]; positive regulation of neuron differentiation [GO:0045666]; positive regulation of transcription by RNA polymerase II [GO:0045944]; positive regulation of transcription from RNA polymerase II promoter by galactose [GO:0000435]; regulation of cellular response to insulin stimulus [GO:1900076]; regulation of thyroid hormone mediated signaling pathway [GO:0002155]; response to estradiol [GO:0032355]; response to progesterone [GO:0032570]; response to retinoic acid [GO:0032526]	chromatin [GO:0000785]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; protein-containing complex [GO:0032991]; RNA polymerase II transcription regulator complex [GO:0090575]; transcription regulator complex [GO:0005667]	chromatin binding [GO:0003682]; histone acetyltransferase activity [GO:0004402]; nuclear estrogen receptor binding [GO:0030331]; nuclear receptor binding [GO:0016922]; nuclear receptor coactivator activity [GO:0030374]; nuclear retinoid X receptor binding [GO:0046965]; protein dimerization activity [GO:0046983]; RNA polymerase II transcription regulatory region sequence-specific DNA binding [GO:0000977]; transcription coactivator activity [GO:0003713]	chromatin [GO:0000785]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; protein-containing complex [GO:0032991]; RNA polymerase II transcription regulator complex [GO:0090575]; transcription regulator complex [GO:0005667]; chromatin binding [GO:0003682]; histone acetyltransferase activity [GO:0004402]; nuclear estrogen receptor binding [GO:0030331]; nuclear receptor binding [GO:0016922]; nuclear receptor coactivator activity [GO:0030374]; nuclear retinoid X receptor binding [GO:0046965]; protein dimerization activity [GO:0046983]; RNA polymerase II transcription regulatory region sequence-specific DNA binding [GO:0000977]; transcription coactivator activity [GO:0003713]; cellular response to hormone stimulus [GO:0032870]; cellular response to Thyroglobulin triiodothyronine [GO:1904017]; cerebellum development [GO:0021549]; cerebral cortex development [GO:0021987]; estrous cycle [GO:0044849]; hippocampus development [GO:0021766]; hypothalamus development [GO:0021854]; labyrinthine layer morphogenesis [GO:0060713]; lactation [GO:0007595]; male gonad development [GO:0008584]; male mating behavior [GO:0060179]; mRNA transcription by RNA polymerase II [GO:0042789]; peroxisome proliferator activated receptor signaling pathway [GO:0035357]; positive regulation of adipose tissue development [GO:1904179]; positive regulation of apoptotic process [GO:0043065]; positive regulation of DNA-templated transcription [GO:0045893]; positive regulation of female receptivity [GO:0045925]; positive regulation of neuron differentiation [GO:0045666]; positive regulation of transcription by RNA polymerase II [GO:0045944]; positive regulation of transcription from RNA polymerase II promoter by galactose [GO:0000435]; regulation of cellular response to insulin stimulus [GO:1900076]; regulation of thyroid hormone mediated signaling pathway [GO:0002155]; response to estradiol [GO:0032355]; response to progesterone [GO:0032570]; response to retinoic acid [GO:0032526]	GO:0000435; GO:0000785; GO:0000977; GO:0002155; GO:0003682; GO:0003713; GO:0004402; GO:0005634; GO:0005654; GO:0005667; GO:0005829; GO:0005886; GO:0007595; GO:0008584; GO:0016922; GO:0021549; GO:0021766; GO:0021854; GO:0021987; GO:0030331; GO:0030374; GO:0032355; GO:0032526; GO:0032570; GO:0032870; GO:0032991; GO:0035357; GO:0042789; GO:0043065; GO:0044849; GO:0045666; GO:0045893; GO:0045925; GO:0045944; GO:0046965; GO:0046983; GO:0060179; GO:0060713; GO:0090575; GO:1900076; GO:1904017; GO:1904179	8754792; 9427757; 9575154; 15815621; 15489334; 7481822; 11831720; 15313887; 9223431; 9296499; 9223281; 10508479; 10567404; 10449719; 10660621; 10722692; 10594042; 11250900; 11773079; 12039952; 12138096; 12529333; 12954634; 12917342; 15367689; 16957778; 16606617; 17116691; 17525332; 18690216; 19413330; 19786558; 20047962; 20068231; 23186163; 25219498; 28112733; 28698609; 9744270; 11698662; 11864604	10.1210/endo.137.8.8754792; 10.1093/emboj/17.1.232; 10.1074/jbc.273.20.12101; 10.1038/nature03466; 10.1101/gr.2596504; 10.1126/science.270.5240.1354; 10.1006/viro.1995.1161; 10.1158/0008-5472.can-04-0844; 10.1006/bbrc.1997.6911; 10.1038/38304; 10.1073/pnas.94.15.7879; 10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5; 10.1074/jbc.274.48.34283; 10.1073/pnas.96.17.9485; 10.1074/jbc.275.6.4475; 10.1074/jbc.275.12.8540; 10.1128/mcb.20.1.402-415.2000; 10.1093/emboj/20.6.1341; 10.1074/jbc.m111486200; 10.1074/jbc.m201053200; 10.1074/jbc.m203556200; 10.1074/jbc.m207148200; 10.1074/jbc.m303644200; 10.1128/mcb.23.17.6210-6220.2003; 10.1128/mcb.24.19.8716-8726.2004; 10.1038/sj.emboj.7601306; 10.1074/jbc.m512616200; 10.1128/mcb.01360-06; 10.1126/science.1140321; 10.1038/nchembio.106; 10.1021/ac9004309; 10.1124/mol.109.057000; 10.1093/nar/gkp1203; 10.1126/scisignal.2000475; 10.1021/pr300630k; 10.1016/j.molcel.2014.08.007; 10.1038/nsmb.3366; 10.1038/s41598-017-05081-x; 10.1038/25931; 10.1073/pnas.241410198; 10.1016/s1097-2765(02)00444-6	NP_003734.3 [Q15788-1];NP_671756.1 [Q15788-2];NP_671766.1 [Q15788-3];XP_005264682.1;XP_005264683.1;XP_005264685.1;XP_016860657.1;XP_016860658.1;	Q15788;	CHEMBL1615387;	DB07530;DB06908;DB08220;DB08742;DB07119;DB07009;DB07557;DB07236;DB07230;DB07150;DB07198;DB06927;DB08915;DB04652;DB06875;DB01645;DB07215;DB07724;DB08231;DB06832;DB07080;
5q0k	Q96RI1	reviewed	NR1H4_HUMAN	Bile acid receptor (Farnesoid X-activated receptor) (Farnesol receptor HRR-1) (Nuclear receptor subfamily 1 group H member 4) (Retinoid X receptor-interacting protein 14) (RXR-interacting protein 14)	NR1H4 BAR FXR HRR1 RIP14	Homo sapiens (Human)	486	MVMQFQGLENPIQISPHCSCTPSGFFMEMMSMKPAKGVLTEQVAGPLGQNLEVEPYSQYSNVQFPQVQPQISSSSYYSNLGFYPQQPEEWYSPGIYELRRMPAETLYQGETEVAEMPVTKKPRMGASAGRIKGDELCVVCGDRASGYHYNALTCEGCKGFFRRSITKNAVYKCKNGGNCVMDMYMRRKCQECRLRKCKEMGMLAECMYTGLLTEIQCKSKRLRKNVKQHADQTVNEDSEGRDLRQVTSTTKSCREKTELTPDQQTLLHFIMDSYNKQRMPQEITNKILKEEFSAEENFLILTEMATNHVQVLVEFTKKLPGFQTLDHEDQIALLKGSAVEAMFLRSAEIFNKKLPSGHSDLLEERIRNSGISDEYITPMFSFYKSIGELKMTQEEYALLTAIVILSPDRQYIKDREAVEKLQEPLLDVLQKLCKIHQPENPQHFACLLGRLTELRTFNHHHAEMLMSWRVNDHKFTPLLCEIWDVQ	FUNCTION: Ligand-activated transcription factor. Receptor for bile acids (BAs) such as chenodeoxycholic acid (CDCA), lithocholic acid, deoxycholic acid (DCA) and allocholic acid (ACA). Plays a essential role in BA homeostasis through the regulation of genes involved in BA synthesis, conjugation and enterohepatic circulation. Also regulates lipid and glucose homeostasis and is involved innate immune response (PubMed:10334992, PubMed:10334993, PubMed:21383957, PubMed:22820415). The FXR-RXR heterodimer binds predominantly to farnesoid X receptor response elements (FXREs) containing two inverted repeats of the consensus sequence 5'-AGGTCA-3' in which the monomers are spaced by 1 nucleotide (IR-1) but also to tandem repeat DR1 sites with lower affinity, and can be activated by either FXR or RXR-specific ligands. It is proposed that monomeric nuclear receptors such as NR5A2/LRH-1 bound to coregulatory nuclear responsive element (NRE) halfsites located in close proximity to FXREs modulate transcriptional activity (By similarity). In the liver activates transcription of the corepressor NR0B2 thereby indirectly inhibiting CYP7A1 and CYP8B1 (involved in BA synthesis) implicating at least in part histone demethylase KDM1A resulting in epigenomic repression, and SLC10A1/NTCP (involved in hepatic uptake of conjugated BAs). Activates transcription of the repressor MAFG (involved in regulation of BA synthesis) (By similarity). Activates transcription of SLC27A5/BACS and BAAT (involved in BA conjugation), ABCB11/BSEP (involved in bile salt export) by directly recruiting histone methyltransferase CARM1, and ABCC2/MRP2 (involved in secretion of conjugated BAs) and ABCB4 (involved in secretion of phosphatidylcholine in the small intestine) (PubMed:12754200, PubMed:15471871, PubMed:17895379). Activates transcription of SLC27A5/BACS and BAAT (involved in BA conjugation), ABCB11/BSEP (involved in bile salt export) by directly recruiting histone methyltransferase CARM1, and ABCC2/MRP2 (involved in secretion of conjugated BAs) and ABCB4 (involved in secretion of phosphatidylcholine in the small intestine) (PubMed:10514450, PubMed:15239098, PubMed:16269519). In the intestine activates FGF19 expression and secretion leading to hepatic CYP7A1 repression (PubMed:12815072, PubMed:19085950). The function also involves the coordinated induction of hepatic KLB/beta-klotho expression (By similarity). Regulates transcription of liver UGT2B4 and SULT2A1 involved in BA detoxification; binding to the UGT2B4 promoter seems to imply a monomeric transactivation independent of RXRA (PubMed:12806625, PubMed:16946559). Modulates lipid homeostasis by activating liver NR0B2/SHP-mediated repression of SREBF1 (involved in de novo lipogenesis), expression of PLTP (involved in HDL formation), SCARB1 (involved in HDL hepatic uptake), APOE, APOC1, APOC4, PPARA (involved in beta-oxidation of fatty acids), VLDLR and SDC1 (involved in the hepatic uptake of LDL and IDL remnants), and inhibiting expression of MTTP (involved in VLDL assembly (PubMed:12554753, PubMed:12660231, PubMed:15337761). Increases expression of APOC2 (promoting lipoprotein lipase activity implicated in triglyceride clearance) (PubMed:11579204). Transrepresses APOA1 involving a monomeric competition with NR2A1 for binding to a DR1 element (PubMed:11927623, PubMed:21804189). Also reduces triglyceride clearance by inhibiting expression of ANGPTL3 and APOC3 (both involved in inhibition of lipoprotein lipase) (PubMed:12891557). Involved in glucose homeostasis by modulating hepatic gluconeogenesis through activation of NR0B2/SHP-mediated repression of respective genes. Modulates glycogen synthesis (inducing phosphorylation of glycogen synthase kinase-3) (By similarity). Modulates glucose-stimulated insulin secretion and is involved in insulin resistance (PubMed:20447400). Involved in intestinal innate immunity. Plays a role in protecting the distal small intestine against bacterial overgrowth and preservation of the epithelial barrier (By similarity). Down-regulates inflammatory cytokine expression in several types of immune cells including macrophages and mononuclear cells (PubMed:21242261). Mediates trans-repression of TLR4-induced cytokine expression; the function seems to require its sumoylation and prevents N-CoR nuclear receptor corepressor clearance from target genes such as IL1B and NOS2 (PubMed:19864602). Involved in the TLR9-mediated protective mechanism in intestinal inflammation. Plays an anti-inflammatory role in liver inflammation; proposed to inhibit pro-inflammatory (but not antiapoptotic) NF-kappa-B signaling) (By similarity). {ECO:0000250|UniProtKB:Q60641, ECO:0000250|UniProtKB:Q62735, ECO:0000269|PubMed:10334992, ECO:0000269|PubMed:10334993, ECO:0000269|PubMed:10514450, ECO:0000269|PubMed:11579204, ECO:0000269|PubMed:11927623, ECO:0000269|PubMed:12554753, ECO:0000269|PubMed:12660231, ECO:0000269|PubMed:12718892, ECO:0000269|PubMed:12754200, ECO:0000269|PubMed:12806625, ECO:0000269|PubMed:12815072, ECO:0000269|PubMed:12891557, ECO:0000269|PubMed:14684751, ECO:0000269|PubMed:15239098, ECO:0000269|PubMed:15337761, ECO:0000269|PubMed:15471871, ECO:0000269|PubMed:16269519, ECO:0000269|PubMed:16946559, ECO:0000269|PubMed:17895379, ECO:0000269|PubMed:18621523, ECO:0000269|PubMed:19085950, ECO:0000269|PubMed:19410460, ECO:0000269|PubMed:19586769, ECO:0000269|PubMed:19864602, ECO:0000269|PubMed:20447400, ECO:0000269|PubMed:21242261, ECO:0000269|PubMed:21804189, ECO:0000269|PubMed:23928191, ECO:0000305|PubMed:21383957, ECO:0000305|PubMed:22820415}.; FUNCTION: [Isoform 1]: Promotes transcriptional activation of target genes NR0B2/SHP (inducible by unconjugated CDCA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and FABP6/IBAP; low activity for ABCB11/BSEP (inducible by unconjugated CDCA, DCA and ACA); not inducible by taurine- and glycine-amidated CDCA. {ECO:0000269|PubMed:23928191}.; FUNCTION: [Isoform 2]: Promotes transcriptional activation of target genes ABCB11/BSEP (inducible by unconjugated CDCA, DCA and ACA), NR0B2/SHP (inducible by unconjugated CDCA DCA and ACA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and FABP6/IBAP; not inducible by taurine- and glycine-amidated CDCA. {ECO:0000269|PubMed:23928191}.; FUNCTION: [Isoform 3]: Promotes transcriptional activation of target genes NR0B2/SHP (inducible by unconjugated CDCA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and IBAP; low activity for ABCB11/BSEP (inducible by unconjugated CDCA, DCA and ACA); not inducible by taurine- and glycine-amidated CDCA. {ECO:0000269|PubMed:23928191}.; FUNCTION: [Isoform 4]: Promotes transcriptional activation of target genes ABCB11/BSEP (inducible by unconjugated CDCA, ACA and DCA), NR0B2/SHP (inducible by unconjugated CDCA, ACA and DCA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and FABP6/IBAP; most efficient isoform compared to isoforms 1 to 3; not inducible by taurine- and glycine-amidated CDCA. {ECO:0000269|PubMed:23928191, ECO:0000269|PubMed:26888176}.	MISCELLANEOUS: Ursodeoxycholic acid (UDCA), a natural agonist of FXR, is approved to treat primary biliary cirrhosis. However, effects are discussed controversial. UDCA is also used to dissolve (cholesterol) gallstones as alternative to surgery. {ECO:0000305|PubMed:23235576}.; MISCELLANEOUS: [Isoform 1]: Produced by alternative promoter usage.; MISCELLANEOUS: [Isoform 2]: Produced by alternative splicing of isoform 1. {ECO:0000305}.; MISCELLANEOUS: [Isoform 3]: Produced by alternative promoter usage. {ECO:0000305}.; MISCELLANEOUS: [Isoform 4]: Produced by alternative splicing of isoform 3. {ECO:0000305}.; MISCELLANEOUS: [Isoform 5]: Produced by alternative splicing of isoform 3. {ECO:0000305}.	bile acid metabolic process [GO:0008206]; bile acid signaling pathway [GO:0038183]; cell differentiation [GO:0030154]; cell-cell junction assembly [GO:0007043]; cellular response to bile acid [GO:1903413]; cellular response to fatty acid [GO:0071398]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to organonitrogen compound [GO:0071417]; cholesterol homeostasis [GO:0042632]; defense response to bacterium [GO:0042742]; fatty acid homeostasis [GO:0055089]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; intracellular bile acid receptor signaling pathway [GO:0038185]; intracellular glucose homeostasis [GO:0001678]; intracellular receptor signaling pathway [GO:0030522]; intracellular triglyceride homeostasis [GO:0035356]; negative regulation of apoptotic process [GO:0043066]; negative regulation of canonical NF-kappaB signal transduction [GO:0043124]; negative regulation of inflammatory response [GO:0050728]; negative regulation of interleukin-1 production [GO:0032692]; negative regulation of interleukin-2 production [GO:0032703]; negative regulation of interleukin-6 production [GO:0032715]; negative regulation of monocyte chemotactic protein-1 production [GO:0071638]; negative regulation of transcription by RNA polymerase II [GO:0000122]; negative regulation of tumor necrosis factor production [GO:0032720]; negative regulation of tumor necrosis factor-mediated signaling pathway [GO:0010804]; negative regulation of type II interferon production [GO:0032689]; negative regulation of very-low-density lipoprotein particle remodeling [GO:0010903]; nitrogen catabolite activation of transcription from RNA polymerase II promoter [GO:0001080]; Notch signaling pathway [GO:0007219]; positive regulation of adipose tissue development [GO:1904179]; positive regulation of ammonia assimilation cycle [GO:2001250]; positive regulation of DNA-templated transcription [GO:0045893]; positive regulation of glutamate metabolic process [GO:2000213]; positive regulation of insulin receptor signaling pathway [GO:0046628]; positive regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0035774]; positive regulation of interleukin-17 production [GO:0032740]; positive regulation of phosphatidic acid biosynthetic process [GO:1905695]; positive regulation of transcription by RNA polymerase II [GO:0045944]; regulation of bile acid biosynthetic process [GO:0070857]; regulation of cholesterol metabolic process [GO:0090181]; regulation of DNA-templated transcription [GO:0006355]; regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0061178]; regulation of low-density lipoprotein particle clearance [GO:0010988]; regulation of transcription by RNA polymerase II [GO:0006357]; regulation of urea metabolic process [GO:0034255]; toll-like receptor 9 signaling pathway [GO:0034162]; transcription by RNA polymerase II [GO:0006366]	chromatin [GO:0000785]; euchromatin [GO:0000791]; nucleoplasm [GO:0005654]; receptor complex [GO:0043235]	bile acid binding [GO:0032052]; bile acid receptor activity [GO:0038181]; chenodeoxycholic acid binding [GO:1902122]; DNA-binding transcription activator activity, RNA polymerase II-specific [GO:0001228]; DNA-binding transcription factor activity [GO:0003700]; DNA-binding transcription factor activity, RNA polymerase II-specific [GO:0000981]; nuclear receptor activity [GO:0004879]; nuclear receptor binding [GO:0016922]; nuclear retinoid X receptor binding [GO:0046965]; RNA polymerase II cis-regulatory region sequence-specific DNA binding [GO:0000978]; RNA polymerase II transcription regulatory region sequence-specific DNA binding [GO:0000977]; sequence-specific DNA binding [GO:0043565]; transcription cis-regulatory region binding [GO:0000976]; transcription coregulator binding [GO:0001221]; zinc ion binding [GO:0008270]	chromatin [GO:0000785]; euchromatin [GO:0000791]; nucleoplasm [GO:0005654]; receptor complex [GO:0043235]; bile acid binding [GO:0032052]; bile acid receptor activity [GO:0038181]; chenodeoxycholic acid binding [GO:1902122]; DNA-binding transcription activator activity, RNA polymerase II-specific [GO:0001228]; DNA-binding transcription factor activity [GO:0003700]; DNA-binding transcription factor activity, RNA polymerase II-specific [GO:0000981]; nuclear receptor activity [GO:0004879]; nuclear receptor binding [GO:0016922]; nuclear retinoid X receptor binding [GO:0046965]; RNA polymerase II cis-regulatory region sequence-specific DNA binding [GO:0000978]; RNA polymerase II transcription regulatory region sequence-specific DNA binding [GO:0000977]; sequence-specific DNA binding [GO:0043565]; transcription cis-regulatory region binding [GO:0000976]; transcription coregulator binding [GO:0001221]; zinc ion binding [GO:0008270]; bile acid metabolic process [GO:0008206]; bile acid signaling pathway [GO:0038183]; cell differentiation [GO:0030154]; cell-cell junction assembly [GO:0007043]; cellular response to bile acid [GO:1903413]; cellular response to fatty acid [GO:0071398]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to organonitrogen compound [GO:0071417]; cholesterol homeostasis [GO:0042632]; defense response to bacterium [GO:0042742]; fatty acid homeostasis [GO:0055089]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; intracellular bile acid receptor signaling pathway [GO:0038185]; intracellular glucose homeostasis [GO:0001678]; intracellular receptor signaling pathway [GO:0030522]; intracellular triglyceride homeostasis [GO:0035356]; negative regulation of apoptotic process [GO:0043066]; negative regulation of canonical NF-kappaB signal transduction [GO:0043124]; negative regulation of inflammatory response [GO:0050728]; negative regulation of interleukin-1 production [GO:0032692]; negative regulation of interleukin-2 production [GO:0032703]; negative regulation of interleukin-6 production [GO:0032715]; negative regulation of monocyte chemotactic protein-1 production [GO:0071638]; negative regulation of transcription by RNA polymerase II [GO:0000122]; negative regulation of tumor necrosis factor production [GO:0032720]; negative regulation of tumor necrosis factor-mediated signaling pathway [GO:0010804]; negative regulation of type II interferon production [GO:0032689]; negative regulation of very-low-density lipoprotein particle remodeling [GO:0010903]; nitrogen catabolite activation of transcription from RNA polymerase II promoter [GO:0001080]; Notch signaling pathway [GO:0007219]; positive regulation of adipose tissue development [GO:1904179]; positive regulation of ammonia assimilation cycle [GO:2001250]; positive regulation of DNA-templated transcription [GO:0045893]; positive regulation of glutamate metabolic process [GO:2000213]; positive regulation of insulin receptor signaling pathway [GO:0046628]; positive regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0035774]; positive regulation of interleukin-17 production [GO:0032740]; positive regulation of phosphatidic acid biosynthetic process [GO:1905695]; positive regulation of transcription by RNA polymerase II [GO:0045944]; regulation of bile acid biosynthetic process [GO:0070857]; regulation of cholesterol metabolic process [GO:0090181]; regulation of DNA-templated transcription [GO:0006355]; regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0061178]; regulation of low-density lipoprotein particle clearance [GO:0010988]; regulation of transcription by RNA polymerase II [GO:0006357]; regulation of urea metabolic process [GO:0034255]; toll-like receptor 9 signaling pathway [GO:0034162]; transcription by RNA polymerase II [GO:0006366]	GO:0000122; GO:0000785; GO:0000791; GO:0000976; GO:0000977; GO:0000978; GO:0000981; GO:0001080; GO:0001221; GO:0001228; GO:0001678; GO:0003700; GO:0004879; GO:0005654; GO:0006355; GO:0006357; GO:0006366; GO:0006954; GO:0007043; GO:0007219; GO:0008206; GO:0008270; GO:0010804; GO:0010903; GO:0010988; GO:0016922; GO:0030154; GO:0030522; GO:0032052; GO:0032689; GO:0032692; GO:0032703; GO:0032715; GO:0032720; GO:0032740; GO:0034162; GO:0034255; GO:0035356; GO:0035774; GO:0038181; GO:0038183; GO:0038185; GO:0042632; GO:0042742; GO:0043066; GO:0043124; GO:0043235; GO:0043565; GO:0045087; GO:0045893; GO:0045944; GO:0046628; GO:0046965; GO:0050728; GO:0055089; GO:0061178; GO:0070857; GO:0071222; GO:0071398; GO:0071417; GO:0071638; GO:0090181; GO:1902122; GO:1903413; GO:1904179; GO:1905695; GO:2000213; GO:2001250	12062799; 14702039; 16541075; 15489334; 10514450; 10334992; 10334993; 11579204; 11927623; 12016314; 12815072; 12806625; 12891557; 12660231; 12754200; 12554753; 15202934; 14684751; 15239098; 15187081; 15337761; 15471871; 15911693; 16269519; 16946559; 17681172; 17895379; 18668687; 17931734; 18755856; 19833092; 19393742; 19883617; 19864602; 19085950; 19805516; 19556342; 20447400; 21383957; 21242261; 21804189; 22820415; 22345554; 23235576; 23928191; 23546875; 23462506; 26888176; 12718892; 12718893; 18621523; 18391212; 19410460; 19586769; 19159286; 20095622; 30275017	10.1016/s0378-1119(02)00557-7; 10.1038/ng1285; 10.1038/nature04569; 10.1101/gr.2596504; 10.1074/jbc.274.42.29749; 10.1126/science.284.5418.1362; 10.1126/science.284.5418.1365; 10.1210/mend.15.10.0712; 10.1172/jci14505; 10.1126/science.1070477; 10.1101/gad.1083503; 10.1016/s0016-5085(03)00388-3; 10.1016/s0016-5085(03)00896-5; 10.1074/jbc.m302505200; 10.1074/jbc.m302128200; 10.1210/me.2002-0120; 10.1042/bj20040432; 10.1074/jbc.m306422200; 10.1002/hep.20295; 10.1074/jbc.m405126200; 10.1074/jbc.m404255200; 10.1074/jbc.m410021200; 10.1124/mol.105.012104; 10.1152/ajpgi.00430.2005; 10.2133/dmpk.21.315; 10.1053/j.gastro.2007.05.015; 10.1073/pnas.0706736104; 10.1002/hep.22431; 10.1016/j.jhep.2007.07.027; 10.1210/me.2008-0092; 10.1016/j.bbrc.2009.10.040; 10.1016/j.bbadis.2009.04.004; 10.1016/j.cmet.2009.09.009; 10.4049/jimmunol.0803978; 10.1002/hep.22627; 10.1128/mcb.00825-09; 10.1210/me.2009-0099; 10.1016/j.febslet.2010.04.068; 10.1621/nrs.08005; 10.1136/gut.2010.212159; 10.1172/jci45277; 10.1016/j.bbalip.2012.07.004; 10.1152/ajpgi.00441.2011; 10.1002/14651858.cd000551.pub3; 10.1016/j.bcp.2013.07.022; 10.1074/jbc.m112.443937; 10.1124/mol.113.084772; 10.1038/ncomms10713; 10.1016/s1097-2765(03)00104-7; 10.1016/s1097-2765(03)00112-6; 10.1016/j.bmcl.2008.06.073; 10.1073/pnas.0710981105; 10.1016/j.bmcl.2009.04.047; 10.1016/j.bmcl.2009.06.062; 10.1021/jm8014124; 10.1021/jm901650u; 10.1074/jbc.ra118.004652	NP_001193906.1 [Q96RI1-1];NP_001193907.1 [Q96RI1-5];NP_001193908.1 [Q96RI1-1];NP_001193921.1 [Q96RI1-4];NP_001193922.1 [Q96RI1-3];NP_005114.1 [Q96RI1-2];XP_011537342.1 [Q96RI1-1];	Q96RI1;	CHEMBL2047;	DB08220;DB00132;DB04557;DB06777;DB02659;DB03619;DB02509;DB02545;DB11605;DB16255;DB05990;DB04348;DB16343;DB01586;
5b08	I6WU39	reviewed	OLIAC_CANSA	Olivetolic acid cyclase (EC 4.4.1.26)	OAC	Cannabis sativa (Hemp) (Marijuana)	101	MAVKHLIVLKFKDEITEAQKEEFFKTYVNLVNIIPAMKDVYWGKDVTQKNKEEGYTHIVEVTFESVETIQDYIIHPAHVGFGDVYRSFWEKLLIFDYTPRK	FUNCTION: Involved in the biosynthesis of cannabinoids-related terpenophenolic natural products, which have pharmacological activity (PubMed:22802619). Polyketide cyclase which functions in concert with OLS/TKS to form olivetolic acid (PubMed:22802619, PubMed:26783002). Has no intrinsic polyketide synthase activity and requires the presence of OLS to produce olivetolic acid (PubMed:22802619). {ECO:0000269|PubMed:22802619, ECO:0000269|PubMed:26783002}.		cannabinoid biosynthetic process [GO:1901696]; olivetolic acid biosynthetic process [GO:1901697]; pollen tube adhesion [GO:0009865]; terpenoid biosynthetic process [GO:0016114]	cytoplasm [GO:0005737]	cyclase activity [GO:0009975]; lyase activity [GO:0016829]; metal ion binding [GO:0046872]	cytoplasm [GO:0005737]; cyclase activity [GO:0009975]; lyase activity [GO:0016829]; metal ion binding [GO:0046872]; cannabinoid biosynthetic process [GO:1901696]; olivetolic acid biosynthetic process [GO:1901697]; pollen tube adhesion [GO:0009865]; terpenoid biosynthetic process [GO:0016114]	GO:0005737; GO:0009865; GO:0009975; GO:0016114; GO:0016829; GO:0046872; GO:1901696; GO:1901697	22802619; 17712812; 30468448; 26783002	10.1073/pnas.1200330109; 10.1002/cbdv.200790145; 10.1039/c8np00077h; 10.1111/febs.13654				
2azy	P00592	reviewed	PA21B_PIG	Phospholipase A2, major isoenzyme (EC 3.1.1.4) (Group IB phospholipase A2) (Phosphatidylcholine 2-acylhydrolase 1B)	PLA2G1B	Sus scrofa (Pig)	146	MKFLVLAVLLTVGAAQEGISSRALWQFRSMIKCAIPGSHPLMDFNNYGCYCGLGGSGTPVDELDRCCETHDNCYRDAKNLDSCKFLVDNPYTESYSYSCSNTEITCNSKNNACEAFICNCDRNAAICFSKAPYNKEHKNLDTKKYC	FUNCTION: Secretory calcium-dependent phospholipase A2 that primarily targets dietary phospholipids in the intestinal tract (PubMed:17603006). Hydrolyzes the ester bond of the fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) with preference for phosphatidylethanolamines and phosphatidylglycerols over phosphatidylcholines (By similarity). May play a role in the biosynthesis of N-acyl ethanolamines that regulate energy metabolism and inflammation in the intestinal tract. Hydrolyzes N-acyl phosphatidylethanolamines to N-acyl lysophosphatidylethanolamines, which are further cleaved by a lysophospholipase D to release N-acyl ethanolamines (By similarity). May act in an autocrine and paracrine manner (By similarity). Has anti-helminth activity in a process regulated by gut microbiota. Upon helminth infection of intestinal epithelia, directly affects phosphatidylethanolamine contents in the membrane of helminth larvae, likely controlling an array of phospholipid-mediated cellular processes such as membrane fusion and cell division while providing for better immune recognition, ultimately reducing larvae integrity and infectivity (By similarity). {ECO:0000250|UniProtKB:P04054, ECO:0000250|UniProtKB:P04055, ECO:0000250|UniProtKB:Q9Z0Y2, ECO:0000269|PubMed:17603006}.	MISCELLANEOUS: Loss of activity upon alkylation of His-70 with p-bromo phenacyl bromide; Ca(2+) and Ba(2+) protect against inactivation.	cellular response to insulin stimulus [GO:0032869]; fatty acid biosynthetic process [GO:0006633]; intracellular signal transduction [GO:0035556]; leukotriene biosynthetic process [GO:0019370]; lipid catabolic process [GO:0016042]; neutrophil chemotaxis [GO:0030593]; neutrophil mediated immunity [GO:0002446]; phosphatidylcholine metabolic process [GO:0046470]; phosphatidylglycerol metabolic process [GO:0046471]; phospholipid metabolic process [GO:0006644]; positive regulation of calcium ion transport into cytosol [GO:0010524]; positive regulation of cell population proliferation [GO:0008284]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of immune response [GO:0050778]; positive regulation of interleukin-8 production [GO:0032757]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of podocyte apoptotic process [GO:1904635]; positive regulation of transcription by RNA polymerase II [GO:0045944]; regulation of glucose import [GO:0046324]	cell surface [GO:0009986]; extracellular region [GO:0005576]	bile acid binding [GO:0032052]; calcium ion binding [GO:0005509]; calcium-dependent phospholipase A2 activity [GO:0047498]; phospholipase A2 activity [GO:0004623]; phospholipid binding [GO:0005543]; signaling receptor binding [GO:0005102]	cell surface [GO:0009986]; extracellular region [GO:0005576]; bile acid binding [GO:0032052]; calcium ion binding [GO:0005509]; calcium-dependent phospholipase A2 activity [GO:0047498]; phospholipase A2 activity [GO:0004623]; phospholipid binding [GO:0005543]; signaling receptor binding [GO:0005102]; cellular response to insulin stimulus [GO:0032869]; fatty acid biosynthetic process [GO:0006633]; intracellular signal transduction [GO:0035556]; leukotriene biosynthetic process [GO:0019370]; lipid catabolic process [GO:0016042]; neutrophil chemotaxis [GO:0030593]; neutrophil mediated immunity [GO:0002446]; phosphatidylcholine metabolic process [GO:0046470]; phosphatidylglycerol metabolic process [GO:0046471]; phospholipid metabolic process [GO:0006644]; positive regulation of calcium ion transport into cytosol [GO:0010524]; positive regulation of cell population proliferation [GO:0008284]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of immune response [GO:0050778]; positive regulation of interleukin-8 production [GO:0032757]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of podocyte apoptotic process [GO:1904635]; positive regulation of transcription by RNA polymerase II [GO:0045944]; regulation of glucose import [GO:0046324]	GO:0002446; GO:0004623; GO:0005102; GO:0005509; GO:0005543; GO:0005576; GO:0006633; GO:0006644; GO:0008284; GO:0009986; GO:0010524; GO:0016042; GO:0019370; GO:0030593; GO:0032052; GO:0032757; GO:0032869; GO:0035556; GO:0043406; GO:0045944; GO:0046324; GO:0046470; GO:0046471; GO:0047498; GO:0048146; GO:0050778; GO:0051092; GO:1904635	3295782; 3028739; 5528841; 884127; 4919729; 2498336; 17603006; 6876174; 2254938; 2215698; 2007145; 7664098; 7556053; 7703697	10.1093/nar/15.9.3743; 10.1089/dna.1.1986.5.519; 10.1016/0005-2795(70)90195-9; 10.1016/0005-2795(77)90076-9; 10.1016/0005-2795(70)90196-0; 10.1016/s0021-9258(18)81764-1; 10.1016/j.bbamem.2007.05.019; 10.1016/s0022-2836(83)80328-3; 10.1016/s0022-2836(05)80332-8; 10.1038/347689a0; 10.1021/bi00226a022; 10.1038/nsb0595-402; 10.1002/j.1460-2075.1995.tb00086.x; 10.1007/bf00208802	NP_001004037.1;	P00592;	CHEMBL4715;	
5i0b	O96013	reviewed	PAK4_HUMAN	Serine/threonine-protein kinase PAK 4 (EC 2.7.11.1) (p21-activated kinase 4) (PAK-4)	PAK4 KIAA1142	Homo sapiens (Human)	591	MFGKRKKRVEISAPSNFEHRVHTGFDQHEQKFTGLPRQWQSLIEESARRPKPLVDPACITSIQPGAPKTIVRGSKGAKDGALTLLLDEFENMSVTRSNSLRRDSPPPPARARQENGMPEEPATTARGGPGKAGSRGRFAGHSEAGGGSGDRRRAGPEKRPKSSREGSGGPQESSRDKRPLSGPDVGTPQPAGLASGAKLAAGRPFNTYPRADTDHPSRGAQGEPHDVAPNGPSAGGLAIPQSSSSSSRPPTRARGAPSPGVLGPHASEPQLAPPACTPAAPAVPGPPGPRSPQREPQRVSHEQFRAALQLVVDPGDPRSYLDNFIKIGEGSTGIVCIATVRSSGKLVAVKKMDLRKQQRRELLFNEVVIMRDYQHENVVEMYNSYLVGDELWVVMEFLEGGALTDIVTHTRMNEEQIAAVCLAVLQALSVLHAQGVIHRDIKSDSILLTHDGRVKLSDFGFCAQVSKEVPRRKSLVGTPYWMAPELISRLPYGPEVDIWSLGIMVIEMVDGEPPYFNEPPLKAMKMIRDNLPPRLKNLHKVSPSLKGFLDRLLVRDPAQRATAAELLKHPFLAKAGPPASIVPLMRQNRTR	FUNCTION: Serine/threonine protein kinase that plays a role in a variety of different signaling pathways including cytoskeleton regulation, cell migration, growth, proliferation or cell survival. Activation by various effectors including growth factor receptors or active CDC42 and RAC1 results in a conformational change and a subsequent autophosphorylation on several serine and/or threonine residues. Phosphorylates and inactivates the protein phosphatase SSH1, leading to increased inhibitory phosphorylation of the actin binding/depolymerizing factor cofilin. Decreased cofilin activity may lead to stabilization of actin filaments. Phosphorylates LIMK1, a kinase that also inhibits the activity of cofilin. Phosphorylates integrin beta5/ITGB5 and thus regulates cell motility. Phosphorylates ARHGEF2 and activates the downstream target RHOA that plays a role in the regulation of assembly of focal adhesions and actin stress fibers. Stimulates cell survival by phosphorylating the BCL2 antagonist of cell death BAD. Alternatively, inhibits apoptosis by preventing caspase-8 binding to death domain receptors in a kinase independent manner. Plays a role in cell-cycle progression by controlling levels of the cell-cycle regulatory protein CDKN1A and by phosphorylating RAN. {ECO:0000269|PubMed:11278822, ECO:0000269|PubMed:11313478, ECO:0000269|PubMed:14560027, ECO:0000269|PubMed:15660133, ECO:0000269|PubMed:20507994, ECO:0000269|PubMed:20631255, ECO:0000269|PubMed:20805321, ECO:0000269|PubMed:26607847}.		apoptotic process [GO:0006915]; cell cycle [GO:0007049]; cell migration [GO:0016477]; cellular response to organic cyclic compound [GO:0071407]; cytoskeleton organization [GO:0007010]; dendritic spine development [GO:0060996]; intracellular signal transduction [GO:0035556]; negative regulation of endothelial cell apoptotic process [GO:2000352]; phosphorylation [GO:0016310]; positive regulation of angiogenesis [GO:0045766]; regulation of cell growth [GO:0001558]; regulation of MAPK cascade [GO:0043408]; signal transduction [GO:0007165]	adherens junction [GO:0005912]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; focal adhesion [GO:0005925]; Golgi apparatus [GO:0005794]	ATP binding [GO:0005524]; cadherin binding involved in cell-cell adhesion [GO:0098641]; protein kinase activity [GO:0004672]; protein serine kinase activity [GO:0106310]; protein serine/threonine kinase activity [GO:0004674]	adherens junction [GO:0005912]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; focal adhesion [GO:0005925]; Golgi apparatus [GO:0005794]; ATP binding [GO:0005524]; cadherin binding involved in cell-cell adhesion [GO:0098641]; protein kinase activity [GO:0004672]; protein serine kinase activity [GO:0106310]; protein serine/threonine kinase activity [GO:0004674]; apoptotic process [GO:0006915]; cell cycle [GO:0007049]; cell migration [GO:0016477]; cellular response to organic cyclic compound [GO:0071407]; cytoskeleton organization [GO:0007010]; dendritic spine development [GO:0060996]; intracellular signal transduction [GO:0035556]; negative regulation of endothelial cell apoptotic process [GO:2000352]; phosphorylation [GO:0016310]; positive regulation of angiogenesis [GO:0045766]; regulation of cell growth [GO:0001558]; regulation of MAPK cascade [GO:0043408]; signal transduction [GO:0007165]	GO:0001558; GO:0004672; GO:0004674; GO:0005524; GO:0005737; GO:0005794; GO:0005829; GO:0005912; GO:0005925; GO:0006915; GO:0007010; GO:0007049; GO:0007165; GO:0016310; GO:0016477; GO:0035556; GO:0043408; GO:0045766; GO:0060996; GO:0071407; GO:0098641; GO:0106310; GO:2000352	9822598; 10574461; 14702039; 17974005; 15489334; 11278822; 11313478; 12356872; 14560027; 15660133; 15827085; 17081983; 18691976; 18669648; 19369195; 19690332; 20507994; 20805321; 20631255; 11950587; 20070256; 20068231; 21269460; 21406692; 23186163; 24130170; 24275569; 24129315; 30189201; 26607847; 17344846	10.1093/emboj/17.22.6527; 10.1093/dnares/6.5.329; 10.1038/ng1285; 10.1186/1471-2164-8-399; 10.1101/gr.2596504; 10.1074/jbc.m011046200; 10.1128/mcb.21.10.3523-3533.2001; 10.1083/jcb.200207008; 10.1128/mcb.23.21.7838-7848.2003; 10.1038/sj.emboj.7600543; 10.1242/jcs.02313; 10.1016/j.cell.2006.09.026; 10.1016/j.molcel.2008.07.007; 10.1073/pnas.0805139105; 10.1074/mcp.m800588-mcp200; 10.1126/scisignal.2000007; 10.1074/jbc.m110.123497; 10.1083/jcb.200912056; 10.1091/mbc.e10-05-0429; 10.1016/s1357-2725(01)00158-3; 10.1042/bj20091173; 10.1126/scisignal.2000475; 10.1186/1752-0509-5-17; 10.1126/scisignal.2001570; 10.1021/pr300630k; 10.1093/carcin/bgt338; 10.1016/j.jprot.2013.11.014; 10.1074/mcp.o113.027870; 10.1016/j.jmb.2018.08.028; 10.1038/ncomms9681; 10.1038/nature05610	NP_001014831.1 [O96013-1];NP_001014832.1 [O96013-1];NP_001014834.1 [O96013-3];NP_001014835.1 [O96013-3];NP_005875.1 [O96013-1];XP_011524618.1 [O96013-1];XP_011524619.1 [O96013-1];XP_011524620.1;XP_011524621.1;XP_011524622.1 [O96013-3];	O96013;	CHEMBL4482;	DB12010;
1phk	P00518	reviewed	PHKG1_RABIT	Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform (EC 2.7.11.19) (Phosphorylase kinase subunit gamma-1) (Serine/threonine-protein kinase PHKG1) (EC 2.7.11.1, EC 2.7.11.26)	PHKG1 PHKG	Oryctolagus cuniculus (Rabbit)	387	MTRDAALPGSHSTHGFYENYEPKEILGRGVSSVVRRCIHKPTCKEYAVKIIDVTGGGSFSAEEVQELREATLKEVDILRKVSGHPNIIQLKDTYETNTFFFLVFDLMKKGELFDYLTEKVTLSEKETRKIMRALLEVICALHKLNIVHRDLKPENILLDDDMNIKLTDFGFSCQLDPGEKLREVCGTPSYLAPEIIECSMNDNHPGYGKEVDMWSTGVIMYTLLAGSPPFWHRKQMLMLRMIMSGNYQFGSPEWDDYSDTVKDLVSRFLVVQPQKRYTAEEALAHPFFQQYVVEEVRHFSPRGKFKVICLTVLASVRIYYQYRRVKPVTREIVIRDPYALRPLRRLIDAYAFRIYGHWVKKGQQQNRAALFENTPKAVLFSLAEDDY	FUNCTION: Catalytic subunit of the phosphorylase b kinase (PHK), which mediates the neural and hormonal regulation of glycogen breakdown (glycogenolysis) by phosphorylating and thereby activating glycogen phosphorylase. In vitro, phosphorylates PYGM, TNNI3, MAPT/TAU, GAP43 and NRGN/RC3. {ECO:0000269|PubMed:8454596, ECO:0000269|PubMed:8999860}.		glycogen biosynthetic process [GO:0005978]; phosphorylation [GO:0016310]	phosphorylase kinase complex [GO:0005964]; skeletal muscle myofibril [GO:0098723]	ATP binding [GO:0005524]; calmodulin binding [GO:0005516]; phosphorylase kinase activity [GO:0004689]; protein serine kinase activity [GO:0106310]; tau-protein kinase activity [GO:0050321]	phosphorylase kinase complex [GO:0005964]; skeletal muscle myofibril [GO:0098723]; ATP binding [GO:0005524]; calmodulin binding [GO:0005516]; phosphorylase kinase activity [GO:0004689]; protein serine kinase activity [GO:0106310]; tau-protein kinase activity [GO:0050321]; glycogen biosynthetic process [GO:0005978]; phosphorylation [GO:0016310]	GO:0004689; GO:0005516; GO:0005524; GO:0005964; GO:0005978; GO:0016310; GO:0050321; GO:0098723; GO:0106310	3609320; 6541504; 2507540; 8454596; 7673209; 7663944; 8999860; 9362479	10.1016/0014-5793(87)80871-2; 10.1021/bi00313a027; 10.1016/s0021-9258(18)71472-5; 10.1016/s0021-9258(18)53240-3; 10.1074/jbc.270.38.22283; 10.1016/s0969-2126(01)00180-0; 10.1016/s0021-9258(19)67481-8; 10.1093/emboj/16.22.6646	NP_001095175.1;XP_008247862.1;			
4keu	Q97VT7	reviewed	PHP_SACS2	Aryldialkylphosphatase (EC 3.1.8.1) (Paraoxonase) (SsoPox) (Phosphotriesterase-like lactonase)	php SSO2522	Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) (Sulfolobus solfataricus)	314	MRIPLVGKDSIESKDIGFTLIHEHLRVFSEAVRQQWPHLYNEDEEFRNAVNEVKRAMQFGVKTIVDPTVMGLGRDIRFMEKVVKATGINLVAGTGIYIYIDLPFYFLNRSIDEIADLFIHDIKEGIQGTLNKAGFVKIAADEPGITKDVEKVIRAAAIANKETKVPIITHSNAHNNTGLEQQRILTEEGVDPGKILIGHLGDTDNIDYIKKIADKGSFIGLDRYGLDLFLPVDKRNETTLRLIKDGYSDKIMISHDYCCTIDWGTAKPEYKPKLAPRWSITLIFEDTIPFLKRNGVNEEVIATIFKENPKKFFS	FUNCTION: Has a low paraoxonase activity. Also active, but with a lower activity, against other organo-phosphorus insecticides such as Dursban, Coumaphos, pNP-butanoate or parathion. {ECO:0000269|PubMed:15909078}.		catabolic process [GO:0009056]		aryldialkylphosphatase activity [GO:0004063]; zinc ion binding [GO:0008270]	aryldialkylphosphatase activity [GO:0004063]; zinc ion binding [GO:0008270]; catabolic process [GO:0009056]	GO:0004063; GO:0008270; GO:0009056	15909078; 11427726; 18486146	10.1007/s00792-005-0445-4; 10.1073/pnas.141222098; 10.1016/j.jmb.2008.04.022	WP_009988477.1;			
4q8b	P07788	reviewed	COTA_BACSU	Laccase (EC 1.10.3.2) (Bilirubin oxidase) (EC 1.3.3.5) (Spore coat protein A)	cotA pig BSU06300	Bacillus subtilis (strain 168)	513	MTLEKFVDALPIPDTLKPVQQSKEKTYYEVTMEECTHQLHRDLPPTRLWGYNGLFPGPTIEVKRNENVYVKWMNNLPSTHFLPIDHTIHHSDSQHEEPEVKTVVHLHGGVTPDDSDGYPEAWFSKDFEQTGPYFKREVYHYPNQQRGAILWYHDHAMALTRLNVYAGLVGAYIIHDPKEKRLKLPSDEYDVPLLITDRTINEDGSLFYPSAPENPSPSLPNPSIVPAFCGETILVNGKVWPYLEVEPRKYRFRVINASNTRTYNLSLDNGGDFIQIGSDGGLLPRSVKLNSFSLAPAERYDIIIDFTAYEGESIILANSAGCGGDVNPETDANIMQFRVTKPLAQKDESRKPKYLASYPSVQHERIQNIRTLKLAGTQDEYGRPVLLLNNKRWHDPVTETPKVGTTEIWSIINPTRGTHPIHLHLVSFRVLDRRPFDIARYQESGELSYTGPAVPPPPSEKGWKDTIQAHAGEVLRIAATFGPYSGRYVWHCHILEHEDYDMMRPMDITDPHK	FUNCTION: Multicopper oxidase that catalyzes the oxidation of a variety of substrates, including phenolic and non-phenolic compounds. Substrates include syringaldazine (SGZ), 2,6-dimethoxyphenol (2,6-DMP) and the non-phenolic compound 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) (PubMed:11514528, PubMed:11884407, PubMed:18307408, PubMed:20200715, PubMed:22481612, PubMed:27050268). Has no tyrosinase activity (PubMed:11514528). Is implicated in the biosynthesis of a brownish pigment that characterizes sporulating colonies of B.subtilis, and which appears to be a melanin-like product and to confer protection against UV light (PubMed:11514528, PubMed:11884407, PubMed:2821284). {ECO:0000269|PubMed:11514528, ECO:0000269|PubMed:11884407, ECO:0000269|PubMed:18307408, ECO:0000269|PubMed:20200715, ECO:0000269|PubMed:22481612, ECO:0000269|PubMed:27050268, ECO:0000269|PubMed:2821284}.; FUNCTION: In vitro, also shows strong bilirubin oxidase (BOD) activity, and can catalyze the oxidation of free bilirubin (UB), direct bilirubin (conjugated with glucuronic acid, DB) and ditaurobilirubin. {ECO:0000269|PubMed:16391148, ECO:0000269|PubMed:33618226}.		sporulation resulting in formation of a cellular spore [GO:0030435]	outer membrane-bounded periplasmic space [GO:0030288]	copper ion binding [GO:0005507]; oxidoreductase activity [GO:0016491]	outer membrane-bounded periplasmic space [GO:0030288]; copper ion binding [GO:0005507]; oxidoreductase activity [GO:0016491]; sporulation resulting in formation of a cellular spore [GO:0030435]	GO:0005507; GO:0016491; GO:0030288; GO:0030435	8969499; 9455482; 9384377; 2821284; 3135411; 11514528; 11884407; 12198312; 16391148; 22481612; 30030754; 33618226; 12637519; 14764581; 16234932; 18307408; 20822511; 20200715; 22281748; 27050268; 29722464	10.1099/13500872-142-11-3027; 10.1093/dnares/4.5.335; 10.1038/36786; 10.1016/0022-2836(87)90506-7; 10.1016/0022-2836(88)90536-0; 10.1128/jb.183.18.5426-5430.2001; 10.1074/jbc.m200827200; 10.1107/s0907444902011575; 10.1128/aem.72.1.972-975.2006; 10.1039/c2dt12067d; 10.1007/s12033-018-0103-6; 10.1016/j.bbrc.2021.01.094; 10.1074/jbc.m301251200; 10.1074/jbc.m314000200; 10.1039/b504806k; 10.1042/bj20080166; 10.1186/1472-6807-10-28; 10.1039/b922734b; 10.1107/s0907444911054503; 10.1107/s2053230x1600426x; 10.1002/cbic.201800236	NP_388511.1;WP_003243170.1;			
1djy	P10688	reviewed	PLCD1_RAT	1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1 (EC 3.1.4.11) (Phosphoinositide phospholipase C-delta-1) (Phospholipase C-III) (PLC-III) (Phospholipase C-delta-1) (PLC-delta-1)	Plcd1	Rattus norvegicus (Rat)	756	MDSGRDFLTLHGLQDDPDLQALLKGSQLLKVKSSSWRRERFYKLQEDCKTIWQESRKVMRSPESQLFSIEDIQEVRMGHRTEGLEKFARDIPEDRCFSIVFKDQRNTLDLIAPSPADAQHWVQGLRKIIHHSGSMDQRQKLQHWIHSCLRKADKNKDNKMNFKELKDFLKELNIQVDDGYARKIFRECDHSQTDSLEDEEIETFYKMLTQRAEIDRAFEEAAGSAETLSVERLVTFLQHQQREEEAGPALALSLIERYEPSETAKAQRQMTKDGFLMYLLSADGNAFSLAHRRVYQDMDQPLSHYLVSSSHNTYLLEDQLTGPSSTEAYIRALCKGCRCLELDCWDGPNQEPIIYHGYTFTSKILFCDVLRAIRDYAFKASPYPVILSLENHCSLEQQRVMARHLRAILGPILLDQPLDGVTTSLPSPEQLKGKILLKGKKLGGLLPAGGENGSEATDVSDEVEAAEMEDEAVRSQVQHKPKEDKLKLVPELSDMIIYCKSVHFGGFSSPGTSGQAFYEMASFSESRALRLLQESGNGFVRHNVSCLSRIYPAGWRTDSSNYSPVEMWNGGCQIVALNFQTPGPEMDVYLGCFQDNGGCGYVLKPAFLRDPNTTFNSRALTQGPWWRPERLRVRIISGQQLPKVNKNKNSIVDPKVIVEIHGVGRDTGSRQTAVITNNGFNPRWDMEFEFEVTVPDLALVRFMVEDYDSSSKNDFIGQSTIPWNSLKQGYRHVHLLSKNGDQHPSATLFVKISIQD	FUNCTION: The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes (PubMed:16000311). Essential for trophoblast and placental development (By similarity). Binds phosphatidylinositol 4,5-bisphosphate (By similarity). {ECO:0000250|UniProtKB:P51178, ECO:0000250|UniProtKB:Q8R3B1, ECO:0000269|PubMed:16000311}.		angiogenesis [GO:0001525]; G protein-coupled receptor signaling pathway [GO:0007186]; labyrinthine layer blood vessel development [GO:0060716]; lipid catabolic process [GO:0016042]; phosphatidylinositol metabolic process [GO:0046488]; phosphatidylinositol-mediated signaling [GO:0048015]; phospholipase C-activating G protein-coupled receptor signaling pathway [GO:0007200]; positive regulation of inositol trisphosphate biosynthetic process [GO:0032962]; positive regulation of norepinephrine secretion [GO:0010701]; regulation of cell population proliferation [GO:0042127]; regulation of cytosolic calcium ion concentration [GO:0051480]; release of sequestered calcium ion into cytosol [GO:0051209]; response to aluminum ion [GO:0010044]; response to calcium ion [GO:0051592]; response to hyperoxia [GO:0055093]; response to organonitrogen compound [GO:0010243]; response to peptide hormone [GO:0043434]; response to prostaglandin F [GO:0034696]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrial membrane [GO:0031966]	calcium ion binding [GO:0005509]; calcium-dependent phospholipid binding [GO:0005544]; enzyme binding [GO:0019899]; GTPase activating protein binding [GO:0032794]; inositol 1,4,5 trisphosphate binding [GO:0070679]; phosphatidic acid binding [GO:0070300]; phosphatidylinositol phosphate binding [GO:1901981]; phosphatidylinositol phospholipase C activity [GO:0004435]; phosphatidylinositol-4,5-bisphosphate binding [GO:0005546]; phospholipase C activity [GO:0004629]; phospholipid binding [GO:0005543]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrial membrane [GO:0031966]; calcium ion binding [GO:0005509]; calcium-dependent phospholipid binding [GO:0005544]; enzyme binding [GO:0019899]; GTPase activating protein binding [GO:0032794]; inositol 1,4,5 trisphosphate binding [GO:0070679]; phosphatidic acid binding [GO:0070300]; phosphatidylinositol phosphate binding [GO:1901981]; phosphatidylinositol phospholipase C activity [GO:0004435]; phosphatidylinositol-4,5-bisphosphate binding [GO:0005546]; phospholipase C activity [GO:0004629]; phospholipid binding [GO:0005543]; angiogenesis [GO:0001525]; G protein-coupled receptor signaling pathway [GO:0007186]; labyrinthine layer blood vessel development [GO:0060716]; lipid catabolic process [GO:0016042]; phosphatidylinositol metabolic process [GO:0046488]; phosphatidylinositol-mediated signaling [GO:0048015]; phospholipase C-activating G protein-coupled receptor signaling pathway [GO:0007200]; positive regulation of inositol trisphosphate biosynthetic process [GO:0032962]; positive regulation of norepinephrine secretion [GO:0010701]; regulation of cell population proliferation [GO:0042127]; regulation of cytosolic calcium ion concentration [GO:0051480]; release of sequestered calcium ion into cytosol [GO:0051209]; response to aluminum ion [GO:0010044]; response to calcium ion [GO:0051592]; response to hyperoxia [GO:0055093]; response to organonitrogen compound [GO:0010243]; response to peptide hormone [GO:0043434]; response to prostaglandin F [GO:0034696]	GO:0001525; GO:0004435; GO:0004629; GO:0005509; GO:0005543; GO:0005544; GO:0005546; GO:0005737; GO:0005829; GO:0007186; GO:0007200; GO:0010044; GO:0010243; GO:0010701; GO:0016042; GO:0019899; GO:0031966; GO:0032794; GO:0032962; GO:0034696; GO:0042127; GO:0043434; GO:0046488; GO:0048015; GO:0051209; GO:0051480; GO:0051592; GO:0055093; GO:0060716; GO:0070300; GO:0070679; GO:1901981	3390863; 1684614; 1313009; 9565585; 16000311; 12054611; 24098488; 8521504; 8784353; 8602259; 9062102	10.1016/0092-8674(88)90548-x; 10.1097/00004872-199111000-00004; 10.1016/s0021-9258(19)50458-6; 10.1074/jbc.273.19.11650; 10.1074/jbc.m500629200; 10.1016/s0006-291x(02)00197-3; 10.1371/journal.pone.0076399; 10.1016/0092-8674(95)90219-8; 10.1038/nsb0996-788; 10.1038/380595a0; 10.1021/bi962466t	NP_058731.1;	P10688;	CHEMBL1914273;	
5l1v	E3VWI3	reviewed	PNTM_STRAE	Pentalenolactone synthase (EC 1.14.19.8) (Pentalenolactone biosynthesis protein M)	pntM	Streptomyces arenae	398	MTDLPRLPFDNPDIMGIAPQMLALQKEGPIARVGTAGEDAWLVTRYDEVRTLLADRRLRLSNPNPQPSAKSAARAFMVALMAGDDHETEPARHAQMRSLLIPRFSTRRLRLMKTRIEHHVDELLDQLAASAPPVDLHRVLSFRLPTMVVCDLLGVPLADRERFGQWARGTFDQSDNEHSANTFQQVVDYMLELVARKRVEPGDDILSELIAEKDGALSDADIAHLGNAVLLFGYETTIVRIDLGTLLLLRNPVQRAQLAEDPGLAPAAVEEILRLGVGGKGSNALIPRYAHGDITVGETVIRTGDAVMLAIGAANYDDRAFPDGGLFDLTRVRPRSHLAFGHGARHCIGRTLARIELTAVFERLFRRLPDLRLAVPEESLRWQEHRITGGFDEIPVTF	FUNCTION: Catalyzes the final step in the biosynthesis of the sesquiterpenoid antibiotic pentalenolactone by mediating the oxidative rearrangement of pentalenolactone F to pentalenolactone. {ECO:0000269|PubMed:21284395}.		antibiotic biosynthetic process [GO:0017000]; cholesterol catabolic process [GO:0006707]; pentalenolactone biosynthetic process [GO:1901780]		cholest-4-en-3-one 26-monooxygenase activity [GO:0036199]; heme binding [GO:0020037]; iron ion binding [GO:0005506]; oxidoreductase activity, acting on the CH-CH group of donors, iron-sulfur protein as acceptor [GO:0016636]; steroid hydroxylase activity [GO:0008395]	cholest-4-en-3-one 26-monooxygenase activity [GO:0036199]; heme binding [GO:0020037]; iron ion binding [GO:0005506]; oxidoreductase activity, acting on the CH-CH group of donors, iron-sulfur protein as acceptor [GO:0016636]; steroid hydroxylase activity [GO:0008395]; antibiotic biosynthetic process [GO:0017000]; cholesterol catabolic process [GO:0006707]; pentalenolactone biosynthetic process [GO:1901780]	GO:0005506; GO:0006707; GO:0008395; GO:0016636; GO:0017000; GO:0020037; GO:0036199; GO:1901780	21284395	10.1021/ja111279h				
4zfa	P14779	reviewed	CPXB_PRIM2	Bifunctional cytochrome P450/NADPH--P450 reductase (Cytochrome P450(BM-3)) (Cytochrome P450BM-3) (Fatty acid monooxygenase) (Flavocytochrome P450 BM3) [Includes: Cytochrome P450 102A1 (EC 1.14.14.1); NADPH--cytochrome P450 reductase (EC 1.6.2.4)]	cyp102A1 cyp102 BG04_163	Priestia megaterium (strain ATCC 14581 / DSM 32 / CCUG 1817 / JCM 2506 / NBRC 15308 / NCIMB 9376 / NCTC 10342 / NRRL B-14308 / VKM B-512 / Ford 19) (Bacillus megaterium)	1049	MTIKEMPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACDESRFDKNLSQALKFVRDFAGDGLFTSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIAVQLVQKWERLNADEHIEVPEDMTRLTLDTIGLCGFNYRFNSFYRDQPHPFITSMVRALDEAMNKLQRANPDDPAYDENKRQFQEDIKVMNDLVDKIIADRKASGEQSDDLLTHMLNGKDPETGEPLDDENIRYQIITFLIAGHETTSGLLSFALYFLVKNPHVLQKAAEEAARVLVDPVPSYKQVKQLKYVGMVLNEALRLWPTAPAFSLYAKEDTVLGGEYPLEKGDELMVLIPQLHRDKTIWGDDVEEFRPERFENPSAIPQHAFKPFGNGQRACIGQQFALHEATLVLGMMLKHFDFEDHTNYELDIKETLTLKPEGFVVKAKSKKIPLGGIPSPSTEQSAKKVRKKAENAHNTPLLVLYGSNMGTAEGTARDLADIAMSKGFAPQVATLDSHAGNLPREGAVLIVTASYNGHPPDNAKQFVDWLDQASADEVKGVRYSVFGCGDKNWATTYQKVPAFIDETLAAKGAENIADRGEADASDDFEGTYEEWREHMWSDVAAYFNLDIENSEDNKSTLSLQFVDSAADMPLAKMHGAFSTNVVASKELQQPGSARSTRHLEIELPKEASYQEGDHLGVIPRNYEGIVNRVTARFGLDASQQIRLEAEEEKLAHLPLAKTVSVEELLQYVELQDPVTRTQLRAMAAKTVCPPHKVELEALLEKQAYKEQVLAKRLTMLELLEKYPACEMKFSEFIALLPSIRPRYYSISSSPRVDEKQASITVSVVSGEAWSGYGEYKGIASNYLAELQEGDTITCFISTPQSEFTLPKDPETPLIMVGPGTGVAPFRGFVQARKQLKEQGQSLGEAHLYFGCRSPHEDYLYQEELENAQSEGIITLHTAFSRMPNQPKTYVQHVMEQDGKKLIELLDQGAHFYICGDGSQMAPAVEATLMKSYADVHQVSEADARLWLQQLEEKGRYAKDVWAG	FUNCTION: Functions as a fatty acid monooxygenase (PubMed:11695892, PubMed:14653735, PubMed:16403573, PubMed:16566047, PubMed:17077084, PubMed:1727637, PubMed:17868686, PubMed:18004886, PubMed:18298086, PubMed:18619466, PubMed:18721129, PubMed:19492389, PubMed:20180779, PubMed:21110374, PubMed:21875028, PubMed:3106359, PubMed:7578081). Catalyzes hydroxylation of fatty acids at omega-1, omega-2 and omega-3 positions (PubMed:1727637, PubMed:21875028). Shows activity toward medium and long-chain fatty acids, with optimum chain lengths of 12, 14 and 16 carbons (lauric, myristic, and palmitic acids). Able to metabolize some of these primary metabolites to secondary and tertiary products (PubMed:1727637). Marginal activity towards short chain lengths of 8-10 carbons (PubMed:1727637, PubMed:18619466). Hydroxylates highly branched fatty acids, which play an essential role in membrane fluidity regulation (PubMed:16566047). Also displays a NADPH-dependent reductase activity in the C-terminal domain, which allows electron transfer from NADPH to the heme iron of the cytochrome P450 N-terminal domain (PubMed:11695892, PubMed:14653735, PubMed:16403573, PubMed:16566047, PubMed:17077084, PubMed:1727637, PubMed:17868686, PubMed:18004886, PubMed:18298086, PubMed:18619466, PubMed:18721129, PubMed:19492389, PubMed:20180779, PubMed:21110374, PubMed:21875028, PubMed:3106359, PubMed:7578081). Involved in inactivation of quorum sensing signals of other competing bacteria by oxidazing efficiently acyl homoserine lactones (AHLs), molecules involved in quorum sensing signaling pathways, and their lactonolysis products acyl homoserines (AHs) (PubMed:18020460). {ECO:0000269|PubMed:11695892, ECO:0000269|PubMed:14653735, ECO:0000269|PubMed:16403573, ECO:0000269|PubMed:16566047, ECO:0000269|PubMed:17077084, ECO:0000269|PubMed:1727637, ECO:0000269|PubMed:17868686, ECO:0000269|PubMed:18004886, ECO:0000269|PubMed:18020460, ECO:0000269|PubMed:18298086, ECO:0000269|PubMed:18619466, ECO:0000269|PubMed:18721129, ECO:0000269|PubMed:19492389, ECO:0000269|PubMed:20180779, ECO:0000269|PubMed:21110374, ECO:0000269|PubMed:21875028, ECO:0000269|PubMed:3106359, ECO:0000269|PubMed:7578081}.		metabolic process [GO:0008152]; response to hormone [GO:0009725]	cytosol [GO:0005829]	aromatase activity [GO:0070330]; flavin adenine dinucleotide binding [GO:0050660]; FMN binding [GO:0010181]; heme binding [GO:0020037]; identical protein binding [GO:0042802]; iron ion binding [GO:0005506]; NADPH-hemoprotein reductase activity [GO:0003958]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen [GO:0016712]	cytosol [GO:0005829]; aromatase activity [GO:0070330]; flavin adenine dinucleotide binding [GO:0050660]; FMN binding [GO:0010181]; heme binding [GO:0020037]; identical protein binding [GO:0042802]; iron ion binding [GO:0005506]; NADPH-hemoprotein reductase activity [GO:0003958]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen [GO:0016712]; metabolic process [GO:0008152]; response to hormone [GO:0009725]	GO:0003958; GO:0005506; GO:0005829; GO:0008152; GO:0009725; GO:0010181; GO:0016712; GO:0020037; GO:0042802; GO:0050660; GO:0070330	2544578; 25931591; 1544926; 3106359; 1727637; 16566047; 18020460; 8342039; 15299332; 7578081; 9033595; 10051560; 11695889; 11695892; 14653735; 15020590; 16403573; 18004886; 17429965; 17077084; 17868686; 18298086; 18619466; 18721129; 19492389; 20180779; 21110374; 20947800; 21875028	10.1016/s0021-9258(18)60416-8; 10.1128/genomea.00151-15; 10.1016/s0021-9258(18)42797-4; 10.1016/s0021-9258(18)48295-6; 10.1016/0003-9861(92)90045-x; 10.1002/cbic.200500444; 10.1021/bi701945j; 10.1126/science.8342039; 10.1107/s0907444994009194; 10.1021/bi00045a014; 10.1038/nsb0297-140; 10.1073/pnas.96.5.1863; 10.1021/bi010717e; 10.1021/bi011197q; 10.1021/ja035731o; 10.1074/jbc.m401717200; 10.1016/j.jinorgbio.2005.11.020; 10.1021/bi701667m; 10.1021/ja067036x; 10.1074/jbc.m607949200; 10.1016/j.jmb.2007.08.015; 10.1021/bi7023964; 10.1016/j.jmb.2008.06.060; 10.1042/bj20081133; 10.1002/cbic.200900279; 10.1042/bj20091603; 10.1002/cbic.201000421; 10.1073/pnas.1012381107; 10.1021/bi201099j	WP_034650526.1;	P14779;	CHEMBL4630872;	DB08086;DB03440;DB04257;
2rma	P62937	reviewed	PPIA_HUMAN	Peptidyl-prolyl cis-trans isomerase A (PPIase A) (EC 5.2.1.8) (Cyclophilin A) (Cyclosporin A-binding protein) (Rotamase A) [Cleaved into: Peptidyl-prolyl cis-trans isomerase A, N-terminally processed]	PPIA CYPA	Homo sapiens (Human)	165	MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE	FUNCTION: Catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides (PubMed:2001362, PubMed:20676357, PubMed:21245143, PubMed:21593166, PubMed:25678563). Exerts a strong chemotactic effect on leukocytes partly through activation of one of its membrane receptors BSG/CD147, initiating a signaling cascade that culminates in MAPK/ERK activation (PubMed:11943775, PubMed:21245143). Activates endothelial cells (ECs) in a pro-inflammatory manner by stimulating activation of NF-kappa-B and ERK, JNK and p38 MAP-kinases and by inducing expression of adhesion molecules including SELE and VCAM1 (PubMed:15130913). Induces apoptosis in ECs by promoting the FOXO1-dependent expression of CCL2 and BCL2L11 which are involved in EC chemotaxis and apoptosis (PubMed:31063815). In response to oxidative stress, initiates proapoptotic and antiapoptotic signaling in ECs via activation of NF-kappa-B and AKT1 and up-regulation of antiapoptotic protein BCL2 (PubMed:23180369). Negatively regulates MAP3K5/ASK1 kinase activity, autophosphorylation and oxidative stress-induced apoptosis mediated by MAP3K5/ASK1 (PubMed:26095851). Necessary for the assembly of TARDBP in heterogeneous nuclear ribonucleoprotein (hnRNP) complexes and regulates TARDBP binding to RNA UG repeats and TARDBP-dependent expression of HDAC6, ATG7 and VCP which are involved in clearance of protein aggregates (PubMed:25678563). Plays an important role in platelet activation and aggregation (By similarity). Regulates calcium mobilization and integrin ITGA2B:ITGB3 bidirectional signaling via increased ROS production as well as by facilitating the interaction between integrin and the cell cytoskeleton (By similarity). Binds heparan sulfate glycosaminoglycans (PubMed:11943775). Inhibits replication of influenza A virus (IAV) (PubMed:19207730). Inhibits ITCH/AIP4-mediated ubiquitination of matrix protein 1 (M1) of IAV by impairing the interaction of ITCH/AIP4 with M1, followed by the suppression of the nuclear export of M1, and finally reduction of the replication of IAV (PubMed:22347431, PubMed:30328013). {ECO:0000250|UniProtKB:P17742, ECO:0000269|PubMed:11943775, ECO:0000269|PubMed:15130913, ECO:0000269|PubMed:19207730, ECO:0000269|PubMed:2001362, ECO:0000269|PubMed:20676357, ECO:0000269|PubMed:21245143, ECO:0000269|PubMed:21593166, ECO:0000269|PubMed:22347431, ECO:0000269|PubMed:23180369, ECO:0000269|PubMed:25678563, ECO:0000269|PubMed:26095851, ECO:0000269|PubMed:30328013, ECO:0000269|PubMed:31063815}.; FUNCTION: (Microbial infection) May act as a mediator between human SARS coronavirus nucleoprotein and BSG/CD147 in the process of invasion of host cells by the virus (PubMed:15688292). {ECO:0000269|PubMed:15688292}.; FUNCTION: (Microbial infection) Stimulates RNA-binding ability of HCV NS5A in a peptidyl-prolyl cis-trans isomerase activity-dependent manner. {ECO:0000269|PubMed:21593166}.		activation of protein kinase B activity [GO:0032148]; apoptotic process [GO:0006915]; cell adhesion molecule production [GO:0060352]; cellular response to oxidative stress [GO:0034599]; endothelial cell activation [GO:0042118]; leukocyte chemotaxis [GO:0030595]; lipid droplet organization [GO:0034389]; negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902176]; negative regulation of protein K48-linked ubiquitination [GO:0061944]; negative regulation of protein kinase activity [GO:0006469]; negative regulation of protein phosphorylation [GO:0001933]; negative regulation of stress-activated MAPK cascade [GO:0032873]; negative regulation of viral life cycle [GO:1903901]; neuron differentiation [GO:0030182]; neutrophil chemotaxis [GO:0030593]; platelet activation [GO:0030168]; platelet aggregation [GO:0070527]; positive regulation of MAPK cascade [GO:0043410]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of protein dephosphorylation [GO:0035307]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of protein secretion [GO:0050714]; positive regulation of viral genome replication [GO:0045070]; protein folding [GO:0006457]; protein peptidyl-prolyl isomerization [GO:0000413]; regulation of apoptotic signaling pathway [GO:2001233]; regulation of viral genome replication [GO:0045069]; response to hypoxia [GO:0001666]; viral release from host cell [GO:0019076]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; ficolin-1-rich granule lumen [GO:1904813]; focal adhesion [GO:0005925]; membrane [GO:0016020]; nucleus [GO:0005634]; protein-containing complex [GO:0032991]; secretory granule lumen [GO:0034774]; vesicle [GO:0031982]	cyclosporin A binding [GO:0016018]; heparan sulfate binding [GO:1904399]; integrin binding [GO:0005178]; peptidyl-prolyl cis-trans isomerase activity [GO:0003755]; RNA binding [GO:0003723]; unfolded protein binding [GO:0051082]; virion binding [GO:0046790]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; ficolin-1-rich granule lumen [GO:1904813]; focal adhesion [GO:0005925]; membrane [GO:0016020]; nucleus [GO:0005634]; protein-containing complex [GO:0032991]; secretory granule lumen [GO:0034774]; vesicle [GO:0031982]; cyclosporin A binding [GO:0016018]; heparan sulfate binding [GO:1904399]; integrin binding [GO:0005178]; peptidyl-prolyl cis-trans isomerase activity [GO:0003755]; RNA binding [GO:0003723]; unfolded protein binding [GO:0051082]; virion binding [GO:0046790]; activation of protein kinase B activity [GO:0032148]; apoptotic process [GO:0006915]; cell adhesion molecule production [GO:0060352]; cellular response to oxidative stress [GO:0034599]; endothelial cell activation [GO:0042118]; leukocyte chemotaxis [GO:0030595]; lipid droplet organization [GO:0034389]; negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902176]; negative regulation of protein K48-linked ubiquitination [GO:0061944]; negative regulation of protein kinase activity [GO:0006469]; negative regulation of protein phosphorylation [GO:0001933]; negative regulation of stress-activated MAPK cascade [GO:0032873]; negative regulation of viral life cycle [GO:1903901]; neuron differentiation [GO:0030182]; neutrophil chemotaxis [GO:0030593]; platelet activation [GO:0030168]; platelet aggregation [GO:0070527]; positive regulation of MAPK cascade [GO:0043410]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of protein dephosphorylation [GO:0035307]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of protein secretion [GO:0050714]; positive regulation of viral genome replication [GO:0045070]; protein folding [GO:0006457]; protein peptidyl-prolyl isomerization [GO:0000413]; regulation of apoptotic signaling pathway [GO:2001233]; regulation of viral genome replication [GO:0045069]; response to hypoxia [GO:0001666]; viral release from host cell [GO:0019076]	GO:0000413; GO:0001666; GO:0001933; GO:0001934; GO:0003723; GO:0003755; GO:0005178; GO:0005576; GO:0005615; GO:0005634; GO:0005737; GO:0005829; GO:0005925; GO:0006457; GO:0006469; GO:0006915; GO:0016018; GO:0016020; GO:0019076; GO:0030168; GO:0030182; GO:0030593; GO:0030595; GO:0031982; GO:0032148; GO:0032873; GO:0032991; GO:0034389; GO:0034599; GO:0034774; GO:0035307; GO:0042118; GO:0043410; GO:0045069; GO:0045070; GO:0046790; GO:0050714; GO:0051082; GO:0051092; GO:0060352; GO:0061944; GO:0070062; GO:0070527; GO:1902176; GO:1903901; GO:1904399; GO:1904813; GO:2001233	3297675; 2197089; 14702039; 19054851; 12853948; 15489334; 7657784; 12665801; 2001362; 8513493; 11353871; 11943775; 14654843; 15130913; 15688292; 16527992; 19413330; 19207730; 19608861; 20147391; 20676357; 20068231; 21269460; 21245143; 21593166; 22223895; 22347431; 22814378; 23180369; 23186163; 24275569; 26095851; 25678563; 25489052; 25944712; 28112733; 30328013; 31063815; 1896075; 1946361; 8421501; 8263916; 8652511; 9385632; 9769216; 12218175; 12357034; 8421500; 9299338; 20364129	10.1002/j.1460-2075.1987.tb04843.x; 10.1111/j.1432-1033.1990.tb15598.x; 10.1038/ng1285; 10.1038/nmeth.1273; 10.1038/nature01782; 10.1101/gr.2596504; 10.1093/oxfordjournals.humrep.a136138; 10.1038/nbt810; 10.1021/bi00223a003; 10.1016/0092-8674(93)90637-6; 10.1073/pnas.111583198; 10.1074/jbc.m201593200; 10.1038/nature02166; 10.1161/01.atv.0000130664.51010.28; 10.1086/427811; 10.1161/01.res.0000216405.85080.a6; 10.1021/ac9004309; 10.1111/j.1462-5822.2009.01286.x; 10.1126/science.1175371; 10.1128/jvi.02168-09; 10.1371/journal.pbio.1000439; 10.1126/scisignal.2000475; 10.1186/1752-0509-5-17; 10.1074/jbc.c110.181347; 10.1128/jvi.00393-11; 10.1074/mcp.m111.015131; 10.1371/journal.pone.0031063; 10.1073/pnas.1210303109; 10.1007/s10753-012-9578-7; 10.1021/pr300630k; 10.1016/j.jprot.2013.11.014; 10.1016/j.bbrc.2015.06.078; 10.1093/brain/awv005; 10.1093/hmg/ddu611; 10.1002/pmic.201400617; 10.1038/nsmb.3366; 10.1007/s12250-018-0058-6; 10.1016/j.cellsig.2019.04.014; 10.1038/353276a0; 10.1073/pnas.88.21.9483; 10.1038/361091a0; 10.1006/jmbi.1993.1664; 10.1021/bi9602775; 10.1002/pro.5560061103; 10.1006/jmbi.1998.2108; 10.1073/pnas.192206699; 10.1073/pnas.212504399; 10.1038/361088a0; 10.1006/jmbi.1997.1220; 10.1038/nchembio.342	NP_001287910.1 [P62937-2];NP_066953.1 [P62937-1];	P62937;	CHEMBL1949;	DB01742;DB11638;DB09130;DB00091;DB02419;DB00172;DB03393;
3b6h	Q16647	reviewed	PTGIS_HUMAN	Prostacyclin synthase (EC 5.3.99.4) (Hydroperoxy icosatetraenoate dehydratase) (EC 4.2.1.152) (Prostaglandin I2 synthase)	PTGIS CYP8 CYP8A1	Homo sapiens (Human)	500	MAWAALLGLLAALLLLLLLSRRRTRRPGEPPLDLGSIPWLGYALDFGKDAASFLTRMKEKHGDIFTILVGGRYVTVLLDPHSYDAVVWEPRTRLDFHAYAIFLMERIFDVQLPHYSPSDEKARMKLTLLHRELQALTEAMYTNLHAVLLGDATEAGSGWHEMGLLDFSYSFLLRAGYLTLYGIEALPRTHESQAQDRVHSADVFHTFRQLDRLLPKLARGSLSVGDKDHMCSVKSRLWKLLSPARLARRAHRSKWLESYLLHLEEMGVSEEMQARALVLQLWATQGNMGPAAFWLLLFLLKNPEALAAVRGELESILWQAEQPVSQTTTLPQKVLDSTPVLDSVLSESLRLTAAPFITREVVVDLAMPMADGREFNLRRGDRLLLFPFLSPQRDPEIYTDPEVFKYNRFLNPDGSEKKDFYKDGKRLKNYNMPWGAGHNHCLGRSYAVNSIKQFVFLVLVHLDLELINADVEIPEFDLSRYGFGLMQPEHDVPVRYRIRP	FUNCTION: Catalyzes the biosynthesis and metabolism of eicosanoids. Catalyzes the isomerization of prostaglandin H2 to prostacyclin (= prostaglandin I2), a potent mediator of vasodilation and inhibitor of platelet aggregation (PubMed:12372404, PubMed:15115769, PubMed:18032380, PubMed:25623425). Additionally, displays dehydratase activity, toward hydroperoxyeicosatetraenoates (HPETEs), especially toward (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoate (15(S)-HPETE) (PubMed:17459323). {ECO:0000269|PubMed:12372404, ECO:0000269|PubMed:15115769, ECO:0000269|PubMed:17459323, ECO:0000269|PubMed:18032380, ECO:0000269|PubMed:25623425}.		apoptotic signaling pathway [GO:0097190]; cellular response to hypoxia [GO:0071456]; cellular response to interleukin-1 [GO:0071347]; cellular response to interleukin-6 [GO:0071354]; cyclooxygenase pathway [GO:0019371]; icosanoid metabolic process [GO:0006690]; NAD biosynthesis via nicotinamide riboside salvage pathway [GO:0034356]; negative regulation of inflammatory response [GO:0050728]; negative regulation of NF-kappaB transcription factor activity [GO:0032088]; negative regulation of nitric oxide biosynthetic process [GO:0045019]; positive regulation of angiogenesis [GO:0045766]; positive regulation of execution phase of apoptosis [GO:1900119]; positive regulation of peroxisome proliferator activated receptor signaling pathway [GO:0035360]; prostaglandin biosynthetic process [GO:0001516]	caveola [GO:0005901]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; extracellular space [GO:0005615]; nucleus [GO:0005634]	heme binding [GO:0020037]; hydroperoxy icosatetraenoate dehydratase activity [GO:0106256]; iron ion binding [GO:0005506]; monooxygenase activity [GO:0004497]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen [GO:0016705]; prostaglandin-I synthase activity [GO:0008116]	caveola [GO:0005901]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; extracellular space [GO:0005615]; nucleus [GO:0005634]; heme binding [GO:0020037]; hydroperoxy icosatetraenoate dehydratase activity [GO:0106256]; iron ion binding [GO:0005506]; monooxygenase activity [GO:0004497]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen [GO:0016705]; prostaglandin-I synthase activity [GO:0008116]; apoptotic signaling pathway [GO:0097190]; cellular response to hypoxia [GO:0071456]; cellular response to interleukin-1 [GO:0071347]; cellular response to interleukin-6 [GO:0071354]; cyclooxygenase pathway [GO:0019371]; icosanoid metabolic process [GO:0006690]; NAD biosynthesis via nicotinamide riboside salvage pathway [GO:0034356]; negative regulation of inflammatory response [GO:0050728]; negative regulation of NF-kappaB transcription factor activity [GO:0032088]; negative regulation of nitric oxide biosynthetic process [GO:0045019]; positive regulation of angiogenesis [GO:0045766]; positive regulation of execution phase of apoptosis [GO:1900119]; positive regulation of peroxisome proliferator activated receptor signaling pathway [GO:0035360]; prostaglandin biosynthetic process [GO:0001516]	GO:0001516; GO:0004497; GO:0005506; GO:0005615; GO:0005634; GO:0005783; GO:0005789; GO:0005901; GO:0006690; GO:0008116; GO:0016705; GO:0019371; GO:0020037; GO:0032088; GO:0034356; GO:0035360; GO:0045019; GO:0045766; GO:0050728; GO:0071347; GO:0071354; GO:0071456; GO:0097190; GO:0106256; GO:1900119	8185632; 11281454; 11780052; 15489334; 12372404; 15115769; 17459323; 25623425; 17020766; 18032380	10.1006/bbrc.1994.1652; 10.1007/s004390000444; 10.1038/414865a; 10.1101/gr.2596504; 10.1016/s0006-291x(02)02341-0; 10.1093/jb/mvh059; 10.1016/j.abb.2007.03.012; 10.1016/j.abb.2015.01.012; 10.1016/j.jmb.2006.09.039; 10.1074/jbc.m707470200	NP_000952.1;	Q16647;	CHEMBL4428;	DB08675;DB01240;DB00812;
2zen	Q16769	reviewed	QPCT_HUMAN	Glutaminyl-peptide cyclotransferase (EC 2.3.2.5) (Glutaminyl cyclase) (QC) (sQC) (Glutaminyl-tRNA cyclotransferase) (Glutamyl cyclase) (EC)	QPCT	Homo sapiens (Human)	361	MAGGRHRRVVGTLHLLLLVAALPWASRGVSPSASAWPEEKNYHQPAILNSSALRQIAEGTSISEMWQNDLQPLLIERYPGSPGSYAARQHIMQRIQRLQADWVLEIDTFLSQTPYGYRSFSNIISTLNPTAKRHLVLACHYDSKYFSHWNNRVFVGATDSAVPCAMMLELARALDKKLLSLKTVSDSKPDLSLQLIFFDGEEAFLHWSPQDSLYGSRHLAAKMASTPHPPGARGTSQLHGMDLLVLLDLIGAPNPTFPNFFPNSARWFERLQAIEHELHELGLLKDHSLEGRYFQNYSYGGVIQDDHIPFLRRGVPVLHLIPSPFPEVWHTMDDNEENLDESTIDNLNKILQVFVLEYLHL	FUNCTION: Responsible for the biosynthesis of pyroglutamyl peptides. Has a bias against acidic and tryptophan residues adjacent to the N-terminal glutaminyl residue and a lack of importance of chain length after the second residue. Also catalyzes N-terminal pyroglutamate formation. In vitro, catalyzes pyroglutamate formation of N-terminally truncated form of APP amyloid-beta peptides [Glu-3]-amyloid-beta. May be involved in the N-terminal pyroglutamate formation of several amyloid-related plaque-forming peptides. {ECO:0000269|PubMed:15063747, ECO:0000269|PubMed:18486145, ECO:0000269|PubMed:21288892}.		peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferase [GO:0017186]; protein modification process [GO:0036211]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; ficolin-1-rich granule lumen [GO:1904813]; specific granule lumen [GO:0035580]; tertiary granule lumen [GO:1904724]	glutaminyl-peptide cyclotransferase activity [GO:0016603]; zinc ion binding [GO:0008270]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; ficolin-1-rich granule lumen [GO:1904813]; specific granule lumen [GO:0035580]; tertiary granule lumen [GO:1904724]; glutaminyl-peptide cyclotransferase activity [GO:0016603]; zinc ion binding [GO:0008270]; peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferase [GO:0017186]; protein modification process [GO:0036211]	GO:0005576; GO:0008270; GO:0016603; GO:0017186; GO:0035580; GO:0036211; GO:0070062; GO:1904724; GO:1904813	7999256; 14702039; 15815621; 15489334; 15063747; 18486145; 16135565; 18072935; 21671571; 21288892	10.1677/jme.0.0130077; 10.1038/ng1285; 10.1038/nature03466; 10.1101/gr.2596504; 10.1016/s0014-5793(04)00300-x; 10.1016/j.jmb.2008.03.078; 10.1073/pnas.0504184102; 10.1042/bj20071073; 10.1021/bi200249h; 10.1074/jbc.m110.208595	NP_036545.1 [Q16769-1];	Q16769;	CHEMBL4508;	DB04581;DB04636;DB04622;
4p6p	Q9KKP2	reviewed	RIBB_VIBCH	3,4-dihydroxy-2-butanone 4-phosphate synthase (DHBP synthase) (EC 4.1.99.12)	ribB VC_A1060	Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961)	218	MNQSSLLAEFGDPITRVENALQALREGRGVLLLDDEDRENEGDIIYAVESLTTAQMALMIRECSGIVCLCLTEAQADRLALPPMVVNNNSANQTAFTVSIEAKHGVTTGVSAQDRVTTIKTAANPQAKPEDLARPGHVFPLRARAGGVLARRGHTEGTVDLMQMAGLQPAGVLCELTNPDGSMAKTPEIIEFGKLHNMPVLTIEDMVQYRIQFDLKLA	FUNCTION: Catalyzes the conversion of D-ribulose 5-phosphate to formate and 3,4-dihydroxy-2-butanone 4-phosphate. {ECO:0000255|HAMAP-Rule:MF_00180}.		riboflavin biosynthetic process [GO:0009231]	cytosol [GO:0005829]	3,4-dihydroxy-2-butanone-4-phosphate synthase activity [GO:0008686]; GTP cyclohydrolase II activity [GO:0003935]; magnesium ion binding [GO:0000287]; manganese ion binding [GO:0030145]	cytosol [GO:0005829]; 3,4-dihydroxy-2-butanone-4-phosphate synthase activity [GO:0008686]; GTP cyclohydrolase II activity [GO:0003935]; magnesium ion binding [GO:0000287]; manganese ion binding [GO:0030145]; riboflavin biosynthetic process [GO:0009231]	GO:0000287; GO:0003935; GO:0005829; GO:0008686; GO:0009231; GO:0030145	10952301	10.1038/35020000	NP_233442.1;WP_001076646.1;			
3u5y	Q9SPP9	reviewed	RG1_RAUSE	Raucaffricine-O-beta-D-glucosidase (Raucaffricine beta-glucosidase) (RsRG) (EC 3.2.1.125) (Vomilenine glucosyltransferase) (RsVGT) (EC 2.4.1.219)	RG VGT	Rauvolfia serpentina (Serpentine wood) (Ophioxylon serpentinum)	540	MATQSSAVIDSNDATRISRSDFPADFIMGTGSSAYQIEGGARDGGRGPSIWDTFTHRRPDMIRGGTNGDVAVDSYHLYKEDVNILKNLGLDAYRFSISWSRVLPGGRLSGGVNKEGINYYNNLIDGLLANGIKPFVTLFHWDVPQALEDEYGGFLSPRIVDDFCEYAELCFWEFGDRVKHWMTLNEPWTFSVHGYATGLYAPGRGRTSPEHVNHPTVQHRCSTVAPQCICSTGNPGTEPYWVTHHLLLAHAAAVELYKNKFQRGQEGQIGISHATQWMEPWDENSASDVEAAARALDFMLGWFMEPITSGDYPKSMKKFVGSRLPKFSPEQSKMLKGSYDFVGLNYYTASYVTNASTNSSGSNNFSYNTDIHVTYETDRNGVPIGPQSGSDWLLIYPEGIRKILVYTKKTYNVPLIYVTENGVDDVKNTNLTLSEARKDSMRLKYLQDHIFNVRQAMNDGVNVKGYFAWSLLDNFEWGEGYGVRFGIIHIDYNDNFARYPKDSAVWLMNSFHKNISKLPAVKRSIREDDEEQVSSKRLRK	FUNCTION: Glucosidase specifically involved in alkaloid biosynthesis leading to the accumulation of several alkaloids, including ajmaline, an important plant-derived pharmaceutical used in the treatment of heart disorders. {ECO:0000269|PubMed:10975500}.		alkaloid biosynthetic process [GO:0009821]; carbohydrate metabolic process [GO:0005975]		raucaffricine beta-glucosidase activity [GO:0050247]; vomilenine glucosyltransferase activity [GO:0050506]	raucaffricine beta-glucosidase activity [GO:0050247]; vomilenine glucosyltransferase activity [GO:0050506]; alkaloid biosynthetic process [GO:0009821]; carbohydrate metabolic process [GO:0005975]	GO:0005975; GO:0009821; GO:0050247; GO:0050506	10975500; 22004291; 22704651	10.1016/s0031-9422(00)00175-8; 10.1021/cb200267w; 10.1016/j.phytochem.2012.05.009				
4f1m	Q6XHB2	reviewed	ROCO4_DICDI	Probable serine/threonine-protein kinase roco4 (EC 2.7.11.1) (Ras of complex proteins and C-terminal of roc 4)	roco4 DDB_G0288251	Dictyostelium discoideum (Social amoeba)	1726	MDSSQQLQESQQLQQQYTRVGIDVIGPMKDLIISVMNSLDTTFKIINETYRIVYFDTDETKLTSSNLDSDDEEFESDDDADEEADLQIQASCNLYTFDGKNRQSVDEIKRIVQHLNETQSQQNDNQAVPVIPTFFVVVNIGVGPSFVSEIKSAAGTTQFIEWIVNDQASKEVFKVSTNLLSHHKKQIELTHACTVGDVNYLDQIILSGVSTDQLKEAHKAGHAIVFDSLLTHNSNSLVVTGTMALLGAIVENGDRKGKRLSLSRSNLSRFPMSITQMCTHLVELDLSDNKITELPKDIQLLKSLRILILRGNLLEDIPLEICYLGDLKILELQENPLNNFPLSVVQSGTKNLLLFCKNILERKKSETWNKVKLMFVGQEGVGKTSLCQALKGSKKKKAELQVTGDTVSTEGVKIQNIKNKKVEFHAWDFGGQQVFYPTHQFFLTTHALYLVVFKLTDPNFAERVNYWVRQVKSNSSGAVPAIFLVGTHSDVCTPEQLQEAESILKANFVKYSRVKENTINFVCCATGKGIKELKKRLIHEAEKSHLIKKDIPGNYMVLEARLTNRGANPGRMAVSGSPIGGGSSAQLSSNAINSQKERYIDYDDYMNECKLSHLQPEEIKGATDFLHNLGIILHFDTPTLKNLVVLDPQWLADVMSSLITFSHNWIKRGILNHSELVAVWGGKYDQSLWPLLLKLLEKFEVSYELPNIAKSLIPSLLPEDAEGEISTIKDREWVTLPQAIESGRCQVFGCDYNFDFMPLGFFARLLLRILLISGVEVRTYWRNGVLLDILTPEQVKLQQSKQQQLQQQQQQQNNNESNDSSVNNNNNNNNNNNNNNIINSSSSSSLNLTQTSTSTSPSKLSLNNSQINNSNSTLNSQQLINPSVSPLSSTTPRHQALITFIKKKSFESKDKDSYKLNIEVRSFNTTIEKDHSASLFFQQILFTIDTLLASSYVGLEITRMIPCIHCVQKNPRADPYYFDFSSCISALQDGKPHLFCRNDPSIPVRIDYIAPDLCLKKVPTLADNEIEYEKQIGKGGFGLVHKGRLVKDKSVVAIKSLILGDSEGETEMIEKFQEFQREVFIMSNLNHPNIVKLYGLMHNPPRMVMEFVPCGDLYHRLLDKAHPIKWSVKLRLMLDIALGIEYMQNQNPPIVHRDLRSPNIFLQSLDENAPVCAKVADFGLSQQSVHSVSGLLGNFQWMAPETIGAEEESYTEKADTYSFAMILYTILTGEGPFDEYSYGKIKFINMIREEGLRPTIPEDCPPRLRNVIELCWSGDPKKRPHFSYIVKELSELRNGNTTSTTTNTSSTTNNLNSANVSIASTSSNADDGSQTNNNNNNNNNNNNNNNNNSGSSIALSPSRSFEQQTTTTTTTTTSPSSPSTSFINSSGSYNTESYSVASSSTTNLLNTLNNANQPVNFIGTASVHKKMEVLAGVEAGETVWTKSADSSLCFWSTKKGHLINELKCPHTVATTMMIKVGKYIWEATNSNGIYIWDMGTMTIVQQLTTPHKGDVCLHFVEYGDNNGVWSGGSEGTVCLWDMQTFEKKHSFSLESAITAMSYFGNNTLYIASGSHIVVFKTKTLLMNVNQNWKHSTGSITSILAMKDEVWSGGSDGRIYIWKVKNEFELQKVQSLEAHHEKITSLIHLEDNVLSGSTDKCISLFKISDPKKPFTTQEHHKQGVTSIVKVQSHIVWAITSDTTTPLVLWNIPQKWEKKTANGILPRLKFFR			mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; phosphorylation [GO:0016310]; phototaxis [GO:0042331]; response to reactive oxygen species [GO:0000302]; signal transduction [GO:0007165]; sorocarp stalk development [GO:0031150]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrion [GO:0005739]	ATP binding [GO:0005524]; GTP binding [GO:0005525]; protein kinase activity [GO:0004672]; protein serine kinase activity [GO:0106310]; protein serine/threonine kinase activity [GO:0004674]; protein tyrosine kinase activity [GO:0004713]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrion [GO:0005739]; ATP binding [GO:0005524]; GTP binding [GO:0005525]; protein kinase activity [GO:0004672]; protein serine kinase activity [GO:0106310]; protein serine/threonine kinase activity [GO:0004674]; protein tyrosine kinase activity [GO:0004713]; mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; phosphorylation [GO:0016310]; phototaxis [GO:0042331]; response to reactive oxygen species [GO:0000302]; signal transduction [GO:0007165]; sorocarp stalk development [GO:0031150]	GO:0000302; GO:0004672; GO:0004674; GO:0004713; GO:0005524; GO:0005525; GO:0005737; GO:0005739; GO:0005829; GO:0006120; GO:0007165; GO:0016310; GO:0031150; GO:0042331; GO:0106310	14654223; 15875012	10.1016/j.bbamcr.2003.08.008; 10.1038/nature03481	XP_636808.1;			
4tqr	Q97W02	reviewed	DPO4_SACS2	DNA polymerase IV (Pol IV) (EC 2.7.7.7)	dbh dpo4 SSO2448	Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) (Sulfolobus solfataricus)	352	MIVLFVDFDYFYAQVEEVLNPSLKGKPVVVCVFSGRFEDSGAVATANYEARKFGVKAGIPIVEAKKILPNAVYLPMRKEVYQQVSSRIMNLLREYSEKIEIASIDEAYLDISDKVRDYREAYNLGLEIKNKILEKEKITVTVGISKNKVFAKIAADMAKPNGIKVIDDEEVKRLIRELDIADVPGIGNITAEKLKKLGINKLVDTLSIEFDKLKGMIGEAKAKYLISLARDEYNEPIRTRVRKSIGRIVTMKRNSRNLEEIKPYLFRAIEESYYKLDKRIPKAIHVVAVTEDLDIVSRGRTFPHGISKETAYSESVKLLQKILEEDERKIRRIGVRFSKFIEAIGLDKFFDT	FUNCTION: Poorly processive, error-prone DNA polymerase involved in untargeted mutagenesis. Copies undamaged DNA at stalled replication forks, which arise in vivo from mismatched or misaligned primer ends. These misaligned primers can be extended by PolIV. Exhibits no 3'-5' exonuclease (proofreading) activity. It is involved in translesional synthesis.		DNA-templated DNA replication [GO:0006261]; error-prone translesion synthesis [GO:0042276]; SOS response [GO:0009432]	cytosol [GO:0005829]	damaged DNA binding [GO:0003684]; DNA-directed DNA polymerase activity [GO:0003887]; magnesium ion binding [GO:0000287]	cytosol [GO:0005829]; damaged DNA binding [GO:0003684]; DNA-directed DNA polymerase activity [GO:0003887]; magnesium ion binding [GO:0000287]; DNA-templated DNA replication [GO:0006261]; error-prone translesion synthesis [GO:0042276]; SOS response [GO:0009432]	GO:0000287; GO:0003684; GO:0003887; GO:0005829; GO:0006261; GO:0009432; GO:0042276	11427726; 11713310; 11919199; 11595188; 19054331	10.1073/pnas.141222098; 10.1093/nar/29.22.4607; 10.1074/jbc.m202021200; 10.1016/s0092-8674(01)00515-3; 10.1111/j.1365-2958.2008.06553.x	WP_009993137.1;			
4lfu	P07026	reviewed	SDIA_ECOLI	Regulatory protein SdiA	sdiA b1916 JW1901	Escherichia coli (strain K12)	240	MQDKDFFSWRRTMLLRFQRMETAEEVYHEIELQAQQLEYDYYSLCVRHPVPFTRPKVAFYTNYPEAWVSYYQAKNFLAIDPVLNPENFSQGHLMWNDDLFSEAQPLWEAARAHGLRRGVTQYLMLPNRALGFLSFSRCSAREIPILSDELQLKMQLLVRESLMALMRLNDEIVMTPEMNFSKREKEILRWTAEGKTSAEIAMILSISENTVNFHQKNMQKKINAPNKTQVACYAAATGLI	FUNCTION: Activates cell division by specifically increasing transcription from one of the two promoters that lie immediately upstream of the ftsQAZ gene cluster. Activates ydiV expression in response to extracellular autoinducer AI-1 (Vibrio fischeri autoinducer oxoC6). {ECO:0000269|PubMed:18560382, ECO:0000269|PubMed:1915297}.		cell cycle [GO:0007049]; cell division [GO:0051301]; positive regulation of DNA-templated transcription initiation [GO:2000144]		DNA binding [GO:0003677]	DNA binding [GO:0003677]; cell cycle [GO:0007049]; cell division [GO:0051301]; positive regulation of DNA-templated transcription initiation [GO:2000144]	GO:0003677; GO:0007049; GO:0051301; GO:2000144	3515318; 9097040; 9278503; 16738553; 1915297; 18560382; 16307757	10.1093/nar/14.5.2301; 10.1093/dnares/3.6.379; 10.1126/science.277.5331.1453; 10.1038/msb4100049; 10.1002/j.1460-2075.1991.tb04900.x; 10.1038/cr.2008.67; 10.1016/j.jmb.2005.10.041	NP_416426.1;WP_001152715.1;		CHEMBL4523168;	DB07928;
3jyh	Q9UHL4	reviewed	DPP2_HUMAN	Dipeptidyl peptidase 2 (EC 3.4.14.2) (Dipeptidyl aminopeptidase II) (Dipeptidyl peptidase 7) (Dipeptidyl peptidase II) (DPP II) (Quiescent cell proline dipeptidase)	DPP7 DPP2 QPP	Homo sapiens (Human)	492	MGSAPWAPVLLLALGLRGLQAGARRAPDPGFQERFFQQRLDHFNFERFGNKTFPQRFLVSDRFWVRGEGPIFFYTGNEGDVWAFANNSAFVAELAAERGALLVFAEHRYYGKSLPFGAQSTQRGHTELLTVEQALADFAELLRALRRDLGAQDAPAIAFGGSYGGMLSAYLRMKYPHLVAGALAASAPVLAVAGLGDSNQFFRDVTADFEGQSPKCTQGVREAFRQIKDLFLQGAYDTVRWEFGTCQPLSDEKDLTQLFMFARNAFTVLAMMDYPYPTDFLGPLPANPVKVGCDRLLSEAQRITGLRALAGLVYNASGSEHCYDIYRLYHSCADPTGCGTGPDARAWDYQACTEINLTFASNNVTDMFPDLPFTDELRQRYCLDTWGVWPRPDWLLTSFWGGDLRAASNIIFSNGNLDPWAGGGIRRNLSASVIAVTIQGGAHHLDLRASHPEDPASVVEARKLEATIIGEWVKAARREQQPALRGGPRLSL	FUNCTION: Plays an important role in the degradation of some oligopeptides. {ECO:0000269|PubMed:15487984}.		lysosomal protein catabolic process [GO:1905146]; proteolysis [GO:0006508]	azurophil granule lumen [GO:0035578]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; Golgi apparatus [GO:0005794]; intracellular membrane-bounded organelle [GO:0043231]; vesicle [GO:0031982]	aminopeptidase activity [GO:0004177]; dipeptidyl-peptidase activity [GO:0008239]; serine-type exopeptidase activity [GO:0070008]; serine-type peptidase activity [GO:0008236]	azurophil granule lumen [GO:0035578]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; Golgi apparatus [GO:0005794]; intracellular membrane-bounded organelle [GO:0043231]; vesicle [GO:0031982]; aminopeptidase activity [GO:0004177]; dipeptidyl-peptidase activity [GO:0008239]; serine-type exopeptidase activity [GO:0070008]; serine-type peptidase activity [GO:0008236]; lysosomal protein catabolic process [GO:1905146]; proteolysis [GO:0006508]	GO:0004177; GO:0005576; GO:0005794; GO:0006508; GO:0008236; GO:0008239; GO:0031982; GO:0035578; GO:0043231; GO:0070008; GO:0070062; GO:1905146	10567372; 14702039; 15164053; 15489334; 11067927; 19159218; 21269460; 24275569; 25944712; 15487984	10.1074/jbc.274.48.34053; 10.1038/ng1285; 10.1038/nature02465; 10.1101/gr.2596504; 10.4049/jimmunol.165.10.5695; 10.1021/pr8008012; 10.1186/1752-0509-5-17; 10.1016/j.jprot.2013.11.014; 10.1002/pmic.201400617; 10.1042/bj20041156	NP_037511.2;	Q9UHL4;	CHEMBL3976;	
4iwq	Q9UHD2	reviewed	TBK1_HUMAN	Serine/threonine-protein kinase TBK1 (EC 2.7.11.1) (NF-kappa-B-activating kinase) (T2K) (TANK-binding kinase 1)	TBK1 NAK	Homo sapiens (Human)	729	MQSTSNHLWLLSDILGQGATANVFRGRHKKTGDLFAIKVFNNISFLRPVDVQMREFEVLKKLNHKNIVKLFAIEEETTTRHKVLIMEFCPCGSLYTVLEEPSNAYGLPESEFLIVLRDVVGGMNHLRENGIVHRDIKPGNIMRVIGEDGQSVYKLTDFGAARELEDDEQFVSLYGTEEYLHPDMYERAVLRKDHQKKYGATVDLWSIGVTFYHAATGSLPFRPFEGPRRNKEVMYKIITGKPSGAISGVQKAENGPIDWSGDMPVSCSLSRGLQVLLTPVLANILEADQEKCWGFDQFFAETSDILHRMVIHVFSLQQMTAHKIYIHSYNTATIFHELVYKQTKIISSNQELIYEGRRLVLEPGRLAQHFPKTTEENPIFVVSREPLNTIGLIYEKISLPKVHPRYDLDGDASMAKAITGVVCYACRIASTLLLYQELMRKGIRWLIELIKDDYNETVHKKTEVVITLDFCIRNIEKTVKVYEKLMKINLEAAELGEISDIHTKLLRLSSSQGTIETSLQDIDSRLSPGGSLADAWAHQEGTHPKDRNVEKLQVLLNCMTEIYYQFKKDKAERRLAYNEEQIHKFDKQKLYYHATKAMTHFTDECVKKYEAFLNKSEEWIRKMLHLRKQLLSLTNQCFDIEEEVSKYQEYTNELQETLPQKMFTASSGIKHTMTPIYPSSNTLVEMTLGMKKLKEEMEGVVKELAENNHILERFGSLTMDGGLRNVDCL	FUNCTION: Serine/threonine kinase that plays an essential role in regulating inflammatory responses to foreign agents (PubMed:10581243, PubMed:11839743, PubMed:12692549, PubMed:12702806, PubMed:14703513, PubMed:15367631, PubMed:15485837, PubMed:18583960, PubMed:21138416, PubMed:23453971, PubMed:23453972, PubMed:23746807, PubMed:25636800, PubMed:26611359, PubMed:32404352). Following activation of toll-like receptors by viral or bacterial components, associates with TRAF3 and TANK and phosphorylates interferon regulatory factors (IRFs) IRF3 and IRF7 as well as DDX3X (PubMed:12692549, PubMed:12702806, PubMed:14703513, PubMed:15367631, PubMed:18583960, PubMed:25636800). This activity allows subsequent homodimerization and nuclear translocation of the IRFs leading to transcriptional activation of pro-inflammatory and antiviral genes including IFNA and IFNB (PubMed:12702806, PubMed:15367631, PubMed:25636800, PubMed:32972995). In order to establish such an antiviral state, TBK1 form several different complexes whose composition depends on the type of cell and cellular stimuli (PubMed:23453971, PubMed:23453972, PubMed:23746807). Plays a key role in IRF3 activation: acts by first phosphorylating innate adapter proteins MAVS, STING1 and TICAM1 on their pLxIS motif, leading to recruitment of IRF3, thereby licensing IRF3 for phosphorylation by TBK1 (PubMed:25636800, PubMed:30842653). Phosphorylated IRF3 dissociates from the adapter proteins, dimerizes, and then enters the nucleus to induce expression of interferons (PubMed:25636800). Thus, several scaffolding molecules including FADD, TRADD, MAVS, AZI2, TANK or TBKBP1/SINTBAD can be recruited to the TBK1-containing-complexes (PubMed:21931631). Under particular conditions, functions as a NF-kappa-B effector by phosphorylating NF-kappa-B inhibitor alpha/NFKBIA, IKBKB or RELA to translocate NF-Kappa-B to the nucleus (PubMed:10783893, PubMed:15489227). Restricts bacterial proliferation by phosphorylating the autophagy receptor OPTN/Optineurin on 'Ser-177', thus enhancing LC3 binding affinity and antibacterial autophagy (PubMed:21617041). Phosphorylates SMCR8 component of the C9orf72-SMCR8 complex, promoting autophagosome maturation (PubMed:27103069). Phosphorylates ATG8 proteins MAP1LC3C and GABARAPL2, thereby preventing their delipidation and premature removal from nascent autophagosomes (PubMed:31709703). Phosphorylates and activates AKT1 (PubMed:21464307). Seems to play a role in energy balance regulation by sustaining a state of chronic, low-grade inflammation in obesity, wich leads to a negative impact on insulin sensitivity (By similarity). Attenuates retroviral budding by phosphorylating the endosomal sorting complex required for transport-I (ESCRT-I) subunit VPS37C (PubMed:21270402). Phosphorylates Borna disease virus (BDV) P protein (PubMed:16155125). Plays an essential role in the TLR3- and IFN-dependent control of herpes virus HSV-1 and HSV-2 infections in the central nervous system (PubMed:22851595). Acts both as a positive and negative regulator of the mTORC1 complex, depending on the context: activates mTORC1 in response to growth factors by catalyzing phosphorylation of MTOR, while it limits the mTORC1 complex by promoting phosphorylation of RPTOR (PubMed:29150432, PubMed:31530866). {ECO:0000250|UniProtKB:Q9WUN2, ECO:0000269|PubMed:10581243, ECO:0000269|PubMed:10783893, ECO:0000269|PubMed:11839743, ECO:0000269|PubMed:12692549, ECO:0000269|PubMed:12702806, ECO:0000269|PubMed:14703513, ECO:0000269|PubMed:15367631, ECO:0000269|PubMed:15485837, ECO:0000269|PubMed:15489227, ECO:0000269|PubMed:16155125, ECO:0000269|PubMed:18583960, ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402, ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041, ECO:0000269|PubMed:21931631, ECO:0000269|PubMed:22851595, ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23453972, ECO:0000269|PubMed:23746807, ECO:0000269|PubMed:25636800, ECO:0000269|PubMed:26611359, ECO:0000269|PubMed:27103069, ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:30842653, ECO:0000269|PubMed:31530866, ECO:0000269|PubMed:31709703, ECO:0000269|PubMed:32972995}.	MISCELLANEOUS: In cancer cells, pathological TBK1 activation promotes oncogenic transformation by suppressing programmed cell death. Mechanistically, the RALB-SEC5/EXOC2-TBK1 signaling cascade seems to participate in both innate immune signaling and cell transformation. Additionally, TBK1 supports oncogenesis by directly phosphorylating and activating AKT1 at the exocyst (PubMed:21042276). {ECO:0000305|PubMed:21042276}.	activation of innate immune response [GO:0002218]; antiviral innate immune response [GO:0140374]; canonical NF-kappaB signal transduction [GO:0007249]; cGAS/STING signaling pathway [GO:0140896]; cytoplasmic pattern recognition receptor signaling pathway [GO:0002753]; defense response to Gram-positive bacterium [GO:0050830]; defense response to virus [GO:0051607]; dendritic cell proliferation [GO:0044565]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; negative regulation of gene expression [GO:0010629]; negative regulation of TORC1 signaling [GO:1904262]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-threonine phosphorylation [GO:0018107]; positive regulation of autophagy [GO:0010508]; positive regulation of canonical NF-kappaB signal transduction [GO:0043123]; positive regulation of interferon-alpha production [GO:0032727]; positive regulation of interferon-beta production [GO:0032728]; positive regulation of macroautophagy [GO:0016239]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of TORC1 signaling [GO:1904263]; positive regulation of transcription by RNA polymerase II [GO:0045944]; positive regulation of type I interferon production [GO:0032481]; positive regulation of type I interferon-mediated signaling pathway [GO:0060340]; positive regulation of xenophagy [GO:1904417]; protein phosphorylation [GO:0006468]; regulation of type I interferon production [GO:0032479]; response to virus [GO:0009615]; toll-like receptor 4 signaling pathway [GO:0034142]; type I interferon-mediated signaling pathway [GO:0060337]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; intracellular membrane-bounded organelle [GO:0043231]; nucleoplasm [GO:0005654]; serine/threonine protein kinase complex [GO:1902554]	ATP binding [GO:0005524]; identical protein binding [GO:0042802]; nucleic acid binding [GO:0003676]; phosphoprotein binding [GO:0051219]; protein kinase activity [GO:0004672]; protein phosphatase binding [GO:0019903]; protein serine kinase activity [GO:0106310]; protein serine/threonine kinase activity [GO:0004674]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; intracellular membrane-bounded organelle [GO:0043231]; nucleoplasm [GO:0005654]; serine/threonine protein kinase complex [GO:1902554]; ATP binding [GO:0005524]; identical protein binding [GO:0042802]; nucleic acid binding [GO:0003676]; phosphoprotein binding [GO:0051219]; protein kinase activity [GO:0004672]; protein phosphatase binding [GO:0019903]; protein serine kinase activity [GO:0106310]; protein serine/threonine kinase activity [GO:0004674]; activation of innate immune response [GO:0002218]; antiviral innate immune response [GO:0140374]; canonical NF-kappaB signal transduction [GO:0007249]; cGAS/STING signaling pathway [GO:0140896]; cytoplasmic pattern recognition receptor signaling pathway [GO:0002753]; defense response to Gram-positive bacterium [GO:0050830]; defense response to virus [GO:0051607]; dendritic cell proliferation [GO:0044565]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; negative regulation of gene expression [GO:0010629]; negative regulation of TORC1 signaling [GO:1904262]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-threonine phosphorylation [GO:0018107]; positive regulation of autophagy [GO:0010508]; positive regulation of canonical NF-kappaB signal transduction [GO:0043123]; positive regulation of interferon-alpha production [GO:0032727]; positive regulation of interferon-beta production [GO:0032728]; positive regulation of macroautophagy [GO:0016239]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of TORC1 signaling [GO:1904263]; positive regulation of transcription by RNA polymerase II [GO:0045944]; positive regulation of type I interferon production [GO:0032481]; positive regulation of type I interferon-mediated signaling pathway [GO:0060340]; positive regulation of xenophagy [GO:1904417]; protein phosphorylation [GO:0006468]; regulation of type I interferon production [GO:0032479]; response to virus [GO:0009615]; toll-like receptor 4 signaling pathway [GO:0034142]; type I interferon-mediated signaling pathway [GO:0060337]	GO:0002218; GO:0002753; GO:0003676; GO:0004672; GO:0004674; GO:0005524; GO:0005654; GO:0005737; GO:0005829; GO:0006468; GO:0006954; GO:0007249; GO:0009615; GO:0010508; GO:0010629; GO:0016239; GO:0018105; GO:0018107; GO:0019903; GO:0032479; GO:0032481; GO:0032727; GO:0032728; GO:0033138; GO:0034142; GO:0042802; GO:0043123; GO:0043231; GO:0044565; GO:0045087; GO:0045944; GO:0050830; GO:0051219; GO:0051607; GO:0060337; GO:0060340; GO:0106310; GO:0140374; GO:0140896; GO:1902554; GO:1904262; GO:1904263; GO:1904417	10581243; 10783893; 14702039; 15489334; 11839743; 14530355; 12692549; 12702806; 14560022; 14703513; 14739303; 15485837; 15489227; 15367631; 16281057; 15841462; 16155125; 17018283; 17599067; 18583960; 18636086; 18691976; 19419966; 19153231; 19369195; 19483718; 19416887; 20628368; 21145761; 20375222; 20174559; 21269460; 21447600; 21903422; 21813773; 21270402; 21931631; 21464307; 21617041; 21042276; 21138416; 19010780; 22750291; 22306015; 22851595; 22945920; 22388039; 23186163; 24478431; 24706939; 25943890; 25736436; 26513235; 25803835; 25636800; 27692986; 27103069; 26611359; 27776110; 28011935; 28848048; 28680969; 28871090; 28904192; 28373913; 29150432; 30354798; 29251827; 30021900; 31320558; 31530866; 32185393; 32979938; 31709703; 32404352; 33226137; 32366851; 34084167; 32466380; 37086853; 36802409; 23453971; 23453972; 23746807; 30842653; 17344846; 32972995	10.1093/emboj/18.23.6694; 10.1038/35008109; 10.1038/ng1285; 10.1101/gr.2596504; 10.1074/jbc.m110474200; 10.4049/jimmunol.171.8.4304; 10.1038/ni921; 10.1126/science.1081315; 10.1128/mcb.23.21.7780-7793.2003; 10.1074/jbc.m310616200; 10.1074/jbc.m311629200; 10.1074/jbc.m411037200; 10.1074/jbc.m409825200; 10.1128/jvi.78.19.10636-10649.2004; 10.1038/sj.emboj.7600863; 10.1002/hep.20666; 10.1073/pnas.0502883102; 10.1016/j.cell.2006.08.034; 10.1038/sj.emboj.7601773; 10.1038/emboj.2008.126; 10.1038/embor.2008.136; 10.1016/j.molcel.2008.07.007; 10.1074/jbc.m808233200; 10.1128/jvi.01875-08; 10.1074/mcp.m800588-mcp200; 10.1038/ni.1742; 10.1073/pnas.0900818106; 10.1038/cr.2010.103; 10.1016/j.immuni.2010.11.021; 10.1099/vir.0.020552-0; 10.1371/journal.ppat.1000778; 10.1186/1752-0509-5-17; 10.1093/hmg/ddr123; 10.1016/j.immuni.2011.06.014; 10.4049/jimmunol.1100963; 10.4049/jimmunol.1000262; 10.1371/journal.pone.0023971; 10.1073/pnas.1016132108; 10.1126/science.1205405; 10.1038/onc.2010.493; 10.1042/bj20101701; 10.1074/jbc.m805905200; 10.1016/j.cellsig.2012.06.017; 10.1016/j.exer.2011.12.021; 10.1084/jem.20111316; 10.1084/jem.20120024; 10.1038/ni.2239; 10.1021/pr300630k; 10.1128/jvi.03021-13; 10.1093/jmcb/mju015; 10.1007/s00401-015-1436-x; 10.15252/embr.201439637; 10.1038/gene.2015.46; 10.1038/nn.4000; 10.1126/science.aaa2630; 10.1016/j.molcel.2016.08.029; 10.15252/embj.201593350; 10.1093/jmcb/mjv068; 10.1038/ni.3588; 10.4049/jimmunol.1601194; 10.1074/jbc.m117.805127; 10.1128/msphere.00234-17; 10.1038/s41564-017-0017-2; 10.1128/jvi.01156-17; 10.1038/celldisc.2017.6; 10.15252/embj.201696164; 10.1091/mbc.e18-02-0115; 10.1002/pmic.201700403; 10.1128/jvi.00706-18; 10.1126/science.aav0758; 10.1038/s41598-019-49707-8; 10.1093/brain/awaa039; 10.1016/j.celrep.2020.108234; 10.15252/embr.201948317; 10.4049/jimmunol.1901511; 10.15252/embj.2020104948; 10.1038/s41467-020-16014-0; 10.3389/fimmu.2021.662989; 10.3390/microorganisms8060790; 10.1016/j.virs.2023.04.005; 10.1371/journal.ppat.1011186; 10.1016/j.celrep.2013.01.034; 10.1016/j.celrep.2013.01.033; 10.1016/j.str.2013.04.025; 10.1038/s41586-019-1000-2; 10.1038/nature05610; 10.1126/science.abd4570	NP_037386.1;XP_005268866.1;XP_005268867.1;	Q9UHD2;	CHEMBL5408;	DB12010;
1l3l	P33905	reviewed	TRAR_RHIRD	Transcriptional activator protein TraR	traR	Rhizobium radiobacter (Agrobacterium tumefaciens) (Agrobacterium radiobacter)	234	MQHWLDKLTDLAAIEGDECILKTGLADIADHFGFTGYAYLHIQHRHITAVTNYHRQWQSTYFDKKFEALDPVVKRARSRKHIFTWSGEHERPTLSKDERAFYDHASDFGIRSGITIPIKTANGFMSMFTMASDKPVIDLDREIDAVAAAATIGQIHARISFLRTTPTAEDAAWLDPKEATYLRWIAVGKTMEEIADVEGVKYNSVRVKLREAMKRFDVRSKAHLTALAIRRKLI	FUNCTION: Positive regulation of conjugal transfer of Ti plasmids. TraR activates target genes in the presence of AAI and also activates traR and traI themselves.		quorum sensing [GO:0009372]	protein-DNA complex [GO:0032993]	DNA-binding transcription activator activity [GO:0001216]; transcription cis-regulatory region binding [GO:0000976]	protein-DNA complex [GO:0032993]; DNA-binding transcription activator activity [GO:0001216]; transcription cis-regulatory region binding [GO:0000976]; quorum sensing [GO:0009372]	GO:0000976; GO:0001216; GO:0009372; GO:0032993	8188582	10.1128/jb.176.10.2796-2806.1994	NP_059701.1;WP_010892389.1;	P33905;	CHEMBL5865;	DB08081;
5ngz	Q9NPD8	reviewed	UBE2T_HUMAN	Ubiquitin-conjugating enzyme E2 T (EC 2.3.2.23) (Cell proliferation-inducing gene 50 protein) (E2 ubiquitin-conjugating enzyme T) (Ubiquitin carrier protein T) (Ubiquitin-protein ligase T)	UBE2T HSPC150 PIG50	Homo sapiens (Human)	197	MQRASRLKRELHMLATEPPPGITCWQDKDQMDDLRAQILGGANTPYEKGVFKLEVIIPERYPFEPPQIRFLTPIYHPNIDSAGRICLDVLKLPPKGAWRPSLNIATVLTSIQLLMSEPNPDDPLMADISSEFKYNKPAFLKNARQWTEKHARQKQKADEEEMLDNLPEAGDSRVHNSTQKRKASQLVGIEKKFHPDV	FUNCTION: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. Catalyzes monoubiquitination. Involved in mitomycin-C (MMC)-induced DNA repair. Acts as a specific E2 ubiquitin-conjugating enzyme for the Fanconi anemia complex by associating with E3 ubiquitin-protein ligase FANCL and catalyzing monoubiquitination of FANCD2, a key step in the DNA damage pathway (PubMed:16916645, PubMed:17938197, PubMed:19111657, PubMed:19589784, PubMed:28437106). Also mediates monoubiquitination of FANCL and FANCI (PubMed:16916645, PubMed:17938197, PubMed:19111657, PubMed:19589784). May contribute to ubiquitination and degradation of BRCA1 (PubMed:19887602). In vitro able to promote polyubiquitination using all 7 ubiquitin Lys residues, but may prefer 'Lys-11'-, 'Lys-27'-, 'Lys-48'- and 'Lys-63'-linked polyubiquitination (PubMed:20061386). {ECO:0000269|PubMed:16916645, ECO:0000269|PubMed:17938197, ECO:0000269|PubMed:19111657, ECO:0000269|PubMed:19589784, ECO:0000269|PubMed:19887602, ECO:0000269|PubMed:20061386, ECO:0000269|PubMed:28437106}.		DNA damage response [GO:0006974]; DNA repair [GO:0006281]; protein autoubiquitination [GO:0051865]; protein K11-linked ubiquitination [GO:0070979]; protein K27-linked ubiquitination [GO:0044314]; protein K29-linked ubiquitination [GO:0035519]; protein K48-linked ubiquitination [GO:0070936]; protein K6-linked ubiquitination [GO:0085020]; protein K63-linked ubiquitination [GO:0070534]; protein monoubiquitination [GO:0006513]; protein polyubiquitination [GO:0000209]	nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]	ATP binding [GO:0005524]; chromatin binding [GO:0003682]; ubiquitin conjugating enzyme activity [GO:0061631]; ubiquitin protein ligase binding [GO:0031625]; ubiquitin-protein transferase activity [GO:0004842]	nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; ATP binding [GO:0005524]; chromatin binding [GO:0003682]; ubiquitin conjugating enzyme activity [GO:0061631]; ubiquitin protein ligase binding [GO:0031625]; ubiquitin-protein transferase activity [GO:0004842]; DNA damage response [GO:0006974]; DNA repair [GO:0006281]; protein autoubiquitination [GO:0051865]; protein K11-linked ubiquitination [GO:0070979]; protein K27-linked ubiquitination [GO:0044314]; protein K29-linked ubiquitination [GO:0035519]; protein K48-linked ubiquitination [GO:0070936]; protein K6-linked ubiquitination [GO:0085020]; protein K63-linked ubiquitination [GO:0070534]; protein monoubiquitination [GO:0006513]; protein polyubiquitination [GO:0000209]	GO:0000209; GO:0003682; GO:0004842; GO:0005524; GO:0005634; GO:0005654; GO:0005730; GO:0006281; GO:0006513; GO:0006974; GO:0031625; GO:0035519; GO:0044314; GO:0051865; GO:0061631; GO:0070534; GO:0070936; GO:0070979; GO:0085020	10931946; 11042152; 14702039; 16710414; 15489334; 16916645; 17938197; 19111657; 18669648; 19887602; 19589784; 20061386; 21269460; 21775430; 21722982; 23186163; 26046368; 28112733; 22496338; 24389026; 28437106	10.1073/pnas.160270997; 10.1101/gr.140200; 10.1038/ng1285; 10.1038/nature04727; 10.1101/gr.2596504; 10.1016/j.molcel.2006.06.024; 10.1128/mcb.00504-07; 10.1016/j.molcel.2008.12.003; 10.1073/pnas.0805139105; 10.1158/0008-5472.can-09-1809; 10.1074/jbc.c109.038075; 10.1074/jbc.m109.089003; 10.1186/1752-0509-5-17; 10.1074/jbc.m111.244632; 10.1016/j.radonc.2011.05.059; 10.1021/pr300630k; 10.1016/j.ajhg.2015.04.022; 10.1038/nsmb.3366; 10.1074/mcp.o111.013706; 10.1016/j.str.2013.12.004; 10.1021/acs.jmedchem.7b00147	NP_001297255.1;NP_054895.1;	Q9NPD8;	CHEMBL4105763;	
1e8h	P56216	reviewed	VAOX_PENSI	Vanillyl-alcohol oxidase (EC 1.1.3.38) (4-allylphenol oxidase) (Aryl-alcohol oxidase)	VAOA	Penicillium simplicissimum	560	MSKTQEFRPLTLPPKLSLSDFNEFIQDIIRIVGSENVEVISSKDQIVDGSYMKPTHTHDPHHVMDQDYFLASAIVAPRNVADVQSIVGLANKFSFPLWPISIGRNSGYGGAAPRVSGSVVLDMGKNMNRVLEVNVEGAYCVVEPGVTYHDLHNYLEANNLRDKLWLDVPDLGGGSVLGNAVERGVGYTPYGDHWMMHSGMEVVLANGELLRTGMGALPDPKRPETMGLKPEDQPWSKIAHLFPYGFGPYIDGLFSQSNMGIVTKIGIWLMPNPRGYQSYLITLPKDGDLKQAVDIIRPLRLGMALQNVPTIRHILLDAAVLGDKRSYSSRTEPLSDEELDKIAKQLNLGRWNFYGALYGPEPIRRVLWETIKDAFSAIPGVKFYFPEDTPENSVLRVRDKTMQGIPTYDELKWIDWLPNGAHLFFSPIAKVSGEDAMMQYAVTKKRCQEAGLDFIGTFTVGMREMHHIVCIVFNKKDLIQKRKVQWLMRTLIDDCAANGWGEYRTHLAFMDQIMETYNWNNSSFLRFNEVLKNAVDPNGIIAPGKSGVWPSQYSHVTWKL	FUNCTION: Catalyzes the conversion of vanillin alcohol to vanillin, and also the conversion of a wide range of phenolic compounds bearing side chains of variable size at the para position of the aromatic ring. Crucial for the degradation of the secondary metabolites derived from the degradation of the lignin. Catalyzes besides the oxidation of 4-hydroxybenzyl alcohols, the oxidative deamination of 4-hydroxybenzylamines, the oxidative demethylation of 4-(methoxy-methyl)phenols and the oxidative hydration of 4-allylphenols. Most active with 4-allylphenols.		lactate catabolic process [GO:1903457]; methanol metabolic process [GO:0015945]; organic substance biosynthetic process [GO:1901576]	mitochondrion [GO:0005739]; peroxisome [GO:0005777]	D-lactate dehydrogenase (cytochrome) activity [GO:0004458]; D-lactate dehydrogenase activity [GO:0008720]; FAD binding [GO:0071949]; vanillyl-alcohol oxidase activity [GO:0018465]	mitochondrion [GO:0005739]; peroxisome [GO:0005777]; D-lactate dehydrogenase (cytochrome) activity [GO:0004458]; D-lactate dehydrogenase activity [GO:0008720]; FAD binding [GO:0071949]; vanillyl-alcohol oxidase activity [GO:0018465]; lactate catabolic process [GO:1903457]; methanol metabolic process [GO:0015945]; organic substance biosynthetic process [GO:1901576]	GO:0004458; GO:0005739; GO:0005777; GO:0008720; GO:0015945; GO:0018465; GO:0071949; GO:1901576; GO:1903457	9525880; 9141139; 10585424; 10809721; 10920192; 10984479; 9475171; 1396672; 8529652	10.1074/jbc.273.14.7865; 10.1002/(sici)1097-0134(199704)27:4<601::aid-prot12>3.0.co;2-o; 10.1074/jbc.274.50.35514; 10.1074/jbc.275.20.14799; 10.1073/pnas.160175897; 10.1074/jbc.m004753200; 10.1016/s0014-5793(97)01605-0; 10.1111/j.1432-1033.1992.tb17231.x; 10.1111/j.1432-1033.1995.271_c.x				
2e24	Q9AQS0	reviewed	XANLY_BACGL	Xanthan lyase (EC 4.2.2.12)	xly	Bacillus sp. (strain GL1)	930	MLSGILIAALLMTLWGGWQPDIAHASDEFDALRIKWATLLTGGPALDPADSDIAARTDKLAQDANDYWEDMDLSSSRTYIWYALRGNGTSDNVNAVYERLRTMALAATTVGSSLYGNADLKEDILDALDWLYVNSYNSTRSRSAYNWWHWQLGIPMSLNDIAVLLYDDISAARMATYMDTIDYFTPSIGLTGANRAWQAIVVGVRAVIVKDAVKLAAARNGLSGTGIFPYATGGDGFYADGSFVQHTTFAYTGGYGSSVLETTANLMYLLSGSTWSVSDPNQSNVWQWIYEAYRPLLYKGAMMDMVRGREISRSYAQDHAVGHGIVASIVRLAQFAPAPHAAAFKQIAKRVIQEDTFSSFYGDVSTDTIRLAKAIVDDPSIAPAAAPNLYKQYAAMDRAVLQRPGFALGLALYSTRISSYESINSENGRGWYTGAGATYLYNQDLAQYSEDYWPTVDAYRIPGTTVASGTPIASGTGTSSWTGGVSLAGQYGASGMDLSYGAYNLSARKSWFMFDDEIVALGSGISSTAGIPIETVVDNRKLNGAGDNAWTANGAALSTGLGVAQTLTGVNWVHLAGNTADGSDIGYYFPGGATLQTKREARTGTWKQINNRPATPSTAVTRNYETMWIDHGTNPSGASYGYVLLPNKTSAQVGAYAADPAIEIVVNTSGVQSVKEKTLGLVGANFWTDTTQTADLITSNKKASVMTREIADERLEASVSDPTQANNGTIAIELARSAEGYSADPGITVTQLAPTIKFTVNVNGAKGKSFHASFQLGEDTSGPVDPGEPELPSVIVDNADSAGVTRTGTWKTASTQTDRYGANYLHDDNAGKGTKSVTFTPNLPIAGSYEVYLMWPAHFNREDAVQVDVGHASGTTRTAVDQRSGGGVWHSIGTYEFLAGSGGSVTIRNDALGSPDGYVVADAVKFVAVG	FUNCTION: Plays a role in xanthan depolymerization pathway by cleaving the linkage between the terminal mannosyl and glucuronyl residues of the side chain of xanthan to liberate pyruvylated mannose. Is highly specific for pyruvylated side-chains of xanthan and is not effective with hyaluronate, chondroitin A, gellan, heparin or pectin. {ECO:0000269|PubMed:10347037, ECO:0000269|PubMed:11157235, ECO:0000269|PubMed:15979090, ECO:0000269|PubMed:9758797}.	MISCELLANEOUS: The 99 kDa precursor is converted to a mature form (77 kDa) through the removal of a C-terminal (22 kDa) fragment without any loss in activity. {ECO:0000305}.	polysaccharide metabolic process [GO:0005976]	extracellular region [GO:0005576]	calcium ion binding [GO:0005509]; mannose binding [GO:0005537]; xanthan lyase activity [GO:0047492]	extracellular region [GO:0005576]; calcium ion binding [GO:0005509]; mannose binding [GO:0005537]; xanthan lyase activity [GO:0047492]; polysaccharide metabolic process [GO:0005976]	GO:0005509; GO:0005537; GO:0005576; GO:0005976; GO:0047492	11157235; 9758797; 10347037; 12475987; 15979090; 17223699	10.1128/aem.67.2.713-720.2001; 10.1128/aem.64.10.3765-3768.1998; 10.1128/aem.65.6.2520-2526.1999; 10.1074/jbc.m208100200; 10.1016/j.jmb.2005.05.055; 10.1021/bi0619775				DB04386;DB04597;DB04596;
2hcj	Q1R5Y2	reviewed	EFTU1_ECOUT	Elongation factor Tu 1 (EF-Tu 1)	tuf1 tufB UTI89_C3795	Escherichia coli (strain UTI89 / UPEC)	394	MSKEKFERTKPHVNVGTIGHVDHGKTTLTAAITTVLAKTYGGAARAFDQIDNAPEEKARGITINTSHVEYDTPTRHYAHVDCPGHADYVKNMITGAAQMDGAILVVAATDGPMPQTREHILLGRQVGVPYIIVFLNKCDMVDDEELLELVEMEVRELLSQYDFPGDDTPIVRGSALKALEGDAEWEAKILELAGFLDSYIPEPERAIDKPFLLPIEDVFSISGRGTVVTGRVERGIIKVGEEVEIVGIKETQKSTCTGVEMFRKLLDEGRAGENVGVLLRGIKREEIERGQVLAKPGTIKPHTKFESEVYILSKDEGGRHTPFFKGYRPQFYFRTTDVTGTIELPEGVEMVMPGDNIKMVVTLIHPIAMDDGLRFAIREGGRTVGAGVVAKVLG	FUNCTION: This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis. {ECO:0000255|HAMAP-Rule:MF_00118}.			cytosol [GO:0005829]	GTP binding [GO:0005525]; GTPase activity [GO:0003924]; guanosine tetraphosphate binding [GO:0097216]; translation elongation factor activity [GO:0003746]	cytosol [GO:0005829]; GTP binding [GO:0005525]; GTPase activity [GO:0003924]; guanosine tetraphosphate binding [GO:0097216]; translation elongation factor activity [GO:0003746]	GO:0003746; GO:0003924; GO:0005525; GO:0005829; GO:0097216	16585510	10.1073/pnas.0600938103	WP_000031783.1;			
2hcj	P0CE47	reviewed	EFTU1_ECOLI	Elongation factor Tu 1 (EF-Tu 1) (Bacteriophage Q beta RNA-directed RNA polymerase subunit III) (P-43)	tufA b3339 JW3301	Escherichia coli (strain K12)	394	MSKEKFERTKPHVNVGTIGHVDHGKTTLTAAITTVLAKTYGGAARAFDQIDNAPEEKARGITINTSHVEYDTPTRHYAHVDCPGHADYVKNMITGAAQMDGAILVVAATDGPMPQTREHILLGRQVGVPYIIVFLNKCDMVDDEELLELVEMEVRELLSQYDFPGDDTPIVRGSALKALEGDAEWEAKILELAGFLDSYIPEPERAIDKPFLLPIEDVFSISGRGTVVTGRVERGIIKVGEEVEIVGIKETQKSTCTGVEMFRKLLDEGRAGENVGVLLRGIKREEIERGQVLAKPGTIKPHTKFESEVYILSKDEGGRHTPFFKGYRPQFYFRTTDVTGTIELPEGVEMVMPGDNIKMVVTLIHPIAMDDGLRFAIREGGRTVGAGVVAKVLG	FUNCTION: This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis.; FUNCTION: May play an important regulatory role in cell growth and in the bacterial response to nutrient deprivation.; FUNCTION: Plays a stimulatory role in trans-translation; binds tmRNA. {ECO:0000269|PubMed:15069072}.; FUNCTION: Protects glycyl-tRNA(Gly) from hydrolysis by E.coli D-aminoacyl-tRNA deacylase (dtd) (By similarity). {ECO:0000250|UniProtKB:Q5SHN6}.; FUNCTION: (Microbial infection) Upon infection by bacteriophage Qbeta, part of the viral RNA-dependent RNA polymerase complex. With EF-Ts may provide a stabilizing scaffold for the beta (catalytic) subunit. Helps separate the double-stranded RNA of the template and growing RNA during elongation. With the beta subunit helps form the exit tunnel for template RNA. {ECO:0000269|PubMed:816798, ECO:0000305}.; FUNCTION: (Microbial infection) Required for the tRNase activity of CdiA-CT from E.coli strain EC869; the toxic CT module is thought to cleave tRNA in the context of translationally active GTP EF-Tu-aa-tRNA complexes. GTP is required for tRNase activity but is not hydrolyzed. CdiA-CT is the toxic component of a toxin-immunity protein module, which functions as a cellular contact-dependent growth inhibition (CDI) system. CDI modules allow bacteria to communicate with and inhibit the growth of closely related neighboring bacteria in a contact-dependent fashion (PubMed:28223500). EF-Tu interacts with at least 2 different toxic CT domains, the 2 toxins are different and degrade tRNA at different positions (PubMed:28223500, PubMed:28973472). {ECO:0000269|PubMed:28223500, ECO:0000269|PubMed:28973472}.; FUNCTION: (Microbial infection) Required for the tRNase activity of CdiA-CT from E.coli strain NC101; the toxic CT module is thought to cleave tRNA in the context of translationally active GTP EF-Tu-aa-tRNA complexes. The toxin may remodel the EF-Tu-aa-tRNA complex to displace the 3'-end of the aa-tRNA so it can enter the toxin active site and be cleaved. GTP is required for tRNase activity but is not hydrolyzed. CdiA-CT is the toxic component of a toxin-immunity protein module, which functions as a cellular contact-dependent growth inhibition (CDI) system. CDI modules allow bacteria to communicate with and inhibit the growth of closely related neighboring bacteria in a contact-dependent fashion (PubMed:28223500). EF-Tu interacts with at least 2 different toxic CT domains, the 2 toxins are different and degrade tRNA at different positions (PubMed:28223500, PubMed:28973472). {ECO:0000269|PubMed:28223500, ECO:0000269|PubMed:28973472}.	MISCELLANEOUS: Present with about 70,000 molecules/cell. {ECO:0000305|PubMed:775340}.; MISCELLANEOUS: This chain is also used in bacteriophage Q-beta RNA polymerase. {ECO:0000269|PubMed:816798}.; MISCELLANEOUS: The antibiotic kirromycin inhibits protein biosynthesis by inhibiting the release of EF-Tu from the ribosome. {ECO:0000269|PubMed:7525272}.; MISCELLANEOUS: The antibiotic pulvomycin inhibits protein biosynthesis by disrupting the allosteric control mechanism of EF-Tu. {ECO:0000269|PubMed:7957075}.	response to antibiotic [GO:0046677]; translational elongation [GO:0006414]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; guanyl-nucleotide exchange factor complex [GO:0032045]; plasma membrane [GO:0005886]	GTP binding [GO:0005525]; GTPase activity [GO:0003924]; guanosine tetraphosphate binding [GO:0097216]; RNA binding [GO:0003723]; translation elongation factor activity [GO:0003746]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; guanyl-nucleotide exchange factor complex [GO:0032045]; plasma membrane [GO:0005886]; GTP binding [GO:0005525]; GTPase activity [GO:0003924]; guanosine tetraphosphate binding [GO:0097216]; RNA binding [GO:0003723]; translation elongation factor activity [GO:0003746]; response to antibiotic [GO:0046677]; translational elongation [GO:0006414]	GO:0003723; GO:0003746; GO:0003924; GO:0005525; GO:0005737; GO:0005829; GO:0005886; GO:0006414; GO:0032045; GO:0046677; GO:0097216	7011903; 9278503; 16738553; 6997043; 7021545; 389663; 2157708; 2022614; 9298646; 775340; 816798; 8416965; 3308869; 2684669; 2498311; 2508560; 8978702; 9298644; 9468511; 18723842; 7525272; 7957075; 15069072; 19150849; 24095282; 24141193; 28223500; 3908095; 9918724; 10625477; 16552145; 17057344; 28973472	10.1016/0378-1119(80)90012-8; 10.1126/science.277.5331.1453; 10.1038/msb4100049; 10.1111/j.1432-1033.1980.tb04748.x; 10.1016/s0021-9258(18)43394-7; 10.1016/0014-5793(79)80407-x; 10.1016/s0021-9258(19)39212-9; 10.1128/jb.173.10.3096-3100.1991; 10.1002/elps.1150180807; 10.1038/261023a0; 10.1016/s0021-9258(17)33551-2; 10.1016/s0021-9258(18)54193-4; 10.1016/s0021-9258(18)45170-8; 10.1111/j.1432-1033.1989.tb15121.x; 10.1016/s0021-9258(18)83183-0; 10.1016/0003-9861(89)90452-9; 10.1002/j.1460-2075.1996.tb01066.x; 10.1002/elps.1150180805; 10.1074/jbc.273.8.4556; 10.1074/mcp.m800187-mcp200; 10.1002/j.1460-2075.1994.tb06815.x; 10.1002/j.1460-2075.1994.tb06840.x; 10.1074/jbc.m314086200; 10.1126/science.1163806; 10.1016/j.molcel.2013.08.045; 10.1038/nchembio.1364; 10.1073/pnas.1619273114; 10.1002/j.1460-2075.1985.tb03943.x; 10.1006/jmbi.1998.2387; 10.1021/bi9913597; 10.1107/s0907444906004021; 10.1107/s0907444906035426; 10.1093/nar/gkx700	NP_417798.1;WP_000031783.1;			
3kc1	P09467	reviewed	F16P1_HUMAN	Fructose-1,6-bisphosphatase 1 (FBPase 1) (EC 3.1.3.11) (D-fructose-1,6-bisphosphate 1-phosphohydrolase 1) (Liver FBPase)	FBP1 FBP	Homo sapiens (Human)	338	MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYARDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ	FUNCTION: Catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate in the presence of divalent cations, acting as a rate-limiting enzyme in gluconeogenesis. Plays a role in regulating glucose sensing and insulin secretion of pancreatic beta-cells. Appears to modulate glycerol gluconeogenesis in liver. Important regulator of appetite and adiposity; increased expression of the protein in liver after nutrient excess increases circulating satiety hormones and reduces appetite-stimulating neuropeptides and thus seems to provide a feedback mechanism to limit weight gain. {ECO:0000269|PubMed:16497803, ECO:0000269|PubMed:18375435, ECO:0000269|PubMed:22517657}.		cellular hyperosmotic salinity response [GO:0071475]; cellular hypotonic salinity response [GO:0071477]; cellular response to cAMP [GO:0071320]; cellular response to insulin stimulus [GO:0032869]; cellular response to magnesium ion [GO:0071286]; cellular response to phorbol 13-acetate 12-myristate [GO:1904628]; cellular response to raffinose [GO:0097403]; cellular response to xenobiotic stimulus [GO:0071466]; dephosphorylation [GO:0016311]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose 6-phosphate metabolic process [GO:0006002]; fructose metabolic process [GO:0006000]; gluconeogenesis [GO:0006094]; negative regulation of cell growth [GO:0030308]; negative regulation of glycolytic process [GO:0045820]; negative regulation of Ras protein signal transduction [GO:0046580]; negative regulation of transcription by RNA polymerase II [GO:0000122]; regulation of gluconeogenesis [GO:0006111]; response to nutrient levels [GO:0031667]; sucrose biosynthetic process [GO:0005986]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]	AMP binding [GO:0016208]; fructose 1,6-bisphosphate 1-phosphatase activity [GO:0042132]; identical protein binding [GO:0042802]; metal ion binding [GO:0046872]; monosaccharide binding [GO:0048029]; RNA polymerase II-specific DNA-binding transcription factor binding [GO:0061629]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]; AMP binding [GO:0016208]; fructose 1,6-bisphosphate 1-phosphatase activity [GO:0042132]; identical protein binding [GO:0042802]; metal ion binding [GO:0046872]; monosaccharide binding [GO:0048029]; RNA polymerase II-specific DNA-binding transcription factor binding [GO:0061629]; cellular hyperosmotic salinity response [GO:0071475]; cellular hypotonic salinity response [GO:0071477]; cellular response to cAMP [GO:0071320]; cellular response to insulin stimulus [GO:0032869]; cellular response to magnesium ion [GO:0071286]; cellular response to phorbol 13-acetate 12-myristate [GO:1904628]; cellular response to raffinose [GO:0097403]; cellular response to xenobiotic stimulus [GO:0071466]; dephosphorylation [GO:0016311]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose 6-phosphate metabolic process [GO:0006002]; fructose metabolic process [GO:0006000]; gluconeogenesis [GO:0006094]; negative regulation of cell growth [GO:0030308]; negative regulation of glycolytic process [GO:0045820]; negative regulation of Ras protein signal transduction [GO:0046580]; negative regulation of transcription by RNA polymerase II [GO:0000122]; regulation of gluconeogenesis [GO:0006111]; response to nutrient levels [GO:0031667]; sucrose biosynthetic process [GO:0005986]	GO:0000122; GO:0005634; GO:0005737; GO:0005829; GO:0005986; GO:0006000; GO:0006002; GO:0006094; GO:0006111; GO:0016208; GO:0016311; GO:0030308; GO:0030388; GO:0031667; GO:0032869; GO:0042132; GO:0042802; GO:0045820; GO:0046580; GO:0046872; GO:0048029; GO:0061629; GO:0070062; GO:0071286; GO:0071320; GO:0071466; GO:0071475; GO:0071477; GO:0097403; GO:1904628	2842796; 8387495; 8135811; 7558035; 10222032; 15164053; 15489334; 7589895; 16497803; 17350621; 18375435; 22517657; 24275569; 8382525; 7809062; 16446092; 16442285; 18650089; 9382095; 12126934; 25601412	10.1073/pnas.85.18.6904; 10.1016/s0021-9258(18)98373-0; 10.1006/bbrc.1994.1283; 10.1006/geno.1995.1085; 10.1006/abbi.1999.1120; 10.1038/nature02465; 10.1101/gr.2596504; 10.1046/j.1432-0436.1995.5910051.x; 10.1210/en.2005-1498; 10.1016/j.febslet.2007.02.051; 10.2337/db07-1326; 10.2337/db11-1511; 10.1016/j.jprot.2013.11.014; 10.1021/bi00058a019; 10.1073/pnas.91.26.12482; 10.1016/j.bmcl.2006.01.014; 10.1016/j.bmcl.2006.01.015; 10.1016/j.bmcl.2008.06.103; 10.1086/514875; 10.1016/s1096-7192(02)00038-0; 10.1007/s10545-014-9804-6	NP_000498.2;NP_001121100.1;	P09467;	CHEMBL3975;	DB02778;DB07312;DB07321;DB08484;DB00131;DB04493;DB05518;DB05053;DB04175;DB07270;DB02848;
1d7j	P62942	reviewed	FKB1A_HUMAN	Peptidyl-prolyl cis-trans isomerase FKBP1A (PPIase FKBP1A) (EC 5.2.1.8) (12 kDa FK506-binding protein) (12 kDa FKBP) (FKBP-12) (Calstabin-1) (FK506-binding protein 1A) (FKBP-1A) (Immunophilin FKBP12) (Rotamase)	FKBP1A FKBP1 FKBP12	Homo sapiens (Human)	108	MGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLE	FUNCTION: Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand. Recruits SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. May modulate the RYR1 calcium channel activity. PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. {ECO:0000269|PubMed:16720724, ECO:0000269|PubMed:1696686, ECO:0000269|PubMed:1701173, ECO:0000269|PubMed:9233797}.		'de novo' protein folding [GO:0006458]; amyloid fibril formation [GO:1990000]; calcium ion transmembrane transport [GO:0070588]; heart morphogenesis [GO:0003007]; heart trabecula formation [GO:0060347]; negative regulation of activin receptor signaling pathway [GO:0032926]; negative regulation of phosphoprotein phosphatase activity [GO:0032515]; negative regulation of transforming growth factor beta receptor signaling pathway [GO:0030512]; positive regulation of canonical NF-kappaB signal transduction [GO:0043123]; positive regulation of protein binding [GO:0032092]; protein folding [GO:0006457]; protein maturation by protein folding [GO:0022417]; protein peptidyl-prolyl isomerization [GO:0000413]; protein refolding [GO:0042026]; regulation of amyloid precursor protein catabolic process [GO:1902991]; regulation of immune response [GO:0050776]; regulation of protein localization [GO:0032880]; regulation of ryanodine-sensitive calcium-release channel activity [GO:0060314]; supramolecular fiber organization [GO:0097435]; T cell activation [GO:0042110]; ventricular cardiac muscle tissue morphogenesis [GO:0055010]	cytoplasm [GO:0005737]; cytoplasmic side of membrane [GO:0098562]; cytosol [GO:0005829]; membrane [GO:0016020]; ryanodine receptor complex [GO:1990425]; sarcoplasmic reticulum [GO:0016529]; sarcoplasmic reticulum membrane [GO:0033017]; terminal cisterna [GO:0014802]; Z disc [GO:0030018]	activin receptor binding [GO:0070697]; FK506 binding [GO:0005528]; I-SMAD binding [GO:0070411]; macrolide binding [GO:0005527]; peptidyl-prolyl cis-trans isomerase activity [GO:0003755]; signaling receptor inhibitor activity [GO:0030547]; transforming growth factor beta receptor binding [GO:0005160]; transmembrane transporter binding [GO:0044325]; type I transforming growth factor beta receptor binding [GO:0034713]	cytoplasm [GO:0005737]; cytoplasmic side of membrane [GO:0098562]; cytosol [GO:0005829]; membrane [GO:0016020]; ryanodine receptor complex [GO:1990425]; sarcoplasmic reticulum [GO:0016529]; sarcoplasmic reticulum membrane [GO:0033017]; terminal cisterna [GO:0014802]; Z disc [GO:0030018]; activin receptor binding [GO:0070697]; FK506 binding [GO:0005528]; I-SMAD binding [GO:0070411]; macrolide binding [GO:0005527]; peptidyl-prolyl cis-trans isomerase activity [GO:0003755]; signaling receptor inhibitor activity [GO:0030547]; transforming growth factor beta receptor binding [GO:0005160]; transmembrane transporter binding [GO:0044325]; type I transforming growth factor beta receptor binding [GO:0034713]; 'de novo' protein folding [GO:0006458]; amyloid fibril formation [GO:1990000]; calcium ion transmembrane transport [GO:0070588]; heart morphogenesis [GO:0003007]; heart trabecula formation [GO:0060347]; negative regulation of activin receptor signaling pathway [GO:0032926]; negative regulation of phosphoprotein phosphatase activity [GO:0032515]; negative regulation of transforming growth factor beta receptor signaling pathway [GO:0030512]; positive regulation of canonical NF-kappaB signal transduction [GO:0043123]; positive regulation of protein binding [GO:0032092]; protein folding [GO:0006457]; protein maturation by protein folding [GO:0022417]; protein peptidyl-prolyl isomerization [GO:0000413]; protein refolding [GO:0042026]; regulation of amyloid precursor protein catabolic process [GO:1902991]; regulation of immune response [GO:0050776]; regulation of protein localization [GO:0032880]; regulation of ryanodine-sensitive calcium-release channel activity [GO:0060314]; supramolecular fiber organization [GO:0097435]; T cell activation [GO:0042110]; ventricular cardiac muscle tissue morphogenesis [GO:0055010]	GO:0000413; GO:0003007; GO:0003755; GO:0005160; GO:0005527; GO:0005528; GO:0005737; GO:0005829; GO:0006457; GO:0006458; GO:0014802; GO:0016020; GO:0016529; GO:0022417; GO:0030018; GO:0030512; GO:0030547; GO:0032092; GO:0032515; GO:0032880; GO:0032926; GO:0033017; GO:0034713; GO:0042026; GO:0042110; GO:0043123; GO:0044325; GO:0050776; GO:0055010; GO:0060314; GO:0060347; GO:0070411; GO:0070588; GO:0070697; GO:0097435; GO:0098562; GO:1902991; GO:1990000; GO:1990425	1695378; 1696686; 1716149; 7529739; 11780052; 15489334; 1701173; 2477715; 12665801; 8955134; 9233797; 10358090; 16720724; 21269460; 22100703; 1709363; 1709301; 1375171; 7682113; 1709302; 7678431; 10025408; 10656803	10.1073/pnas.87.14.5440; 10.1038/346671a0; 10.1021/bi00099a002; 10.1016/0378-1119(94)90434-0; 10.1038/414865a; 10.1101/gr.2596504; 10.1016/s0021-9258(17)45319-1; 10.1038/341758a0; 10.1038/nbt810; 10.1074/jbc.271.51.32923; 10.1093/emboj/16.13.3866; 10.1074/jbc.274.24.17297; 10.1677/jme.1.01966; 10.1186/1752-0509-5-17; 10.1016/j.abb.2011.11.004; 10.1021/bi00233a020; 10.1126/science.1709301; 10.1016/0014-5793(92)80292-o; 10.1002/bip.360330404; 10.1126/science.1709302; 10.1006/jmbi.1993.1012; 10.1016/s0092-8674(00)80555-3; 10.1006/jmbi.1999.3411	NP_000792.1;NP_463460.1;	P62942;	CHEMBL1902;	DB08520;DB04012;DB01712;DB04094;DB08597;DB02888;DB01951;DB05814;DB03338;DB03621;DB02311;DB08231;DB00337;DB00864;DB01723;
4ja8	P48735	reviewed	IDHP_HUMAN	Isocitrate dehydrogenase [NADP], mitochondrial (IDH) (EC 1.1.1.42) (ICD-M) (IDP) (NADP(+)-specific ICDH) (Oxalosuccinate decarboxylase)	IDH2	Homo sapiens (Human)	452	MAGYLRVVRSLCRASGSRPAWAPAALTAPTSQEQPRRHYADKRIKVAKPVVEMDGDEMTRIIWQFIKEKLILPHVDIQLKYFDLGLPNRDQTDDQVTIDSALATQKYSVAVKCATITPDEARVEEFKLKKMWKSPNGTIRNILGGTVFREPIICKNIPRLVPGWTKPITIGRHAHGDQYKATDFVADRAGTFKMVFTPKDGSGVKEWEVYNFPAGGVGMGMYNTDESISGFAHSCFQYAIQKKWPLYMSTKNTILKAYDGRFKDIFQEIFDKHYKTDFDKNKIWYEHRLIDDMVAQVLKSSGGFVWACKNYDGDVQSDILAQGFGSLGLMTSVLVCPDGKTIEAEAAHGTVTRHYREHQKGRPTSTNPIASIFAWTRGLEHRGKLDGNQDLIRFAQMLEKVCVETVESGAMTKDLAGCIHGLSNVKLNEHFLNTTDFLDTIKSNLDRALGRQ	FUNCTION: Plays a role in intermediary metabolism and energy production (PubMed:19228619, PubMed:22416140). It may tightly associate or interact with the pyruvate dehydrogenase complex (PubMed:19228619, PubMed:22416140). {ECO:0000269|PubMed:19228619, ECO:0000269|PubMed:22416140}.		2-oxoglutarate metabolic process [GO:0006103]; carbohydrate metabolic process [GO:0005975]; glyoxylate cycle [GO:0006097]; isocitrate metabolic process [GO:0006102]; NADP metabolic process [GO:0006739]; tricarboxylic acid cycle [GO:0006099]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; peroxisome [GO:0005777]	isocitrate dehydrogenase (NADP+) activity [GO:0004450]; magnesium ion binding [GO:0000287]; NAD binding [GO:0051287]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; peroxisome [GO:0005777]; isocitrate dehydrogenase (NADP+) activity [GO:0004450]; magnesium ion binding [GO:0000287]; NAD binding [GO:0051287]; 2-oxoglutarate metabolic process [GO:0006103]; carbohydrate metabolic process [GO:0005975]; glyoxylate cycle [GO:0006097]; isocitrate metabolic process [GO:0006102]; NADP metabolic process [GO:0006739]; tricarboxylic acid cycle [GO:0006099]	GO:0000287; GO:0004450; GO:0005739; GO:0005759; GO:0005777; GO:0005829; GO:0005975; GO:0006097; GO:0006099; GO:0006102; GO:0006103; GO:0006739; GO:0051287; GO:0070062	14702039; 16572171; 15489334; 19608861; 21269460; 22416140; 24275569; 25944712; 19228619; 20847235; 25495392; 26161668	10.1038/ng1285; 10.1038/nature04601; 10.1101/gr.2596504; 10.1126/science.1175371; 10.1186/1752-0509-5-17; 10.1074/jbc.m112.355206; 10.1016/j.jprot.2013.11.014; 10.1002/pmic.201400617; 10.1056/nejmoa0808710; 10.1126/science.1192632; 10.1111/neup.12187; 10.1371/journal.pone.0131998	NP_001276839.1 [P48735-2];NP_001277043.1;NP_002159.2 [P48735-1];	P48735;	CHEMBL3991501;	DB13874;DB01727;
4u5s	P52293	reviewed	IMA1_MOUSE	Importin subunit alpha-1 (Importin alpha P1) (Karyopherin subunit alpha-2) (Pendulin) (Pore targeting complex 58 kDa subunit) (PTAC58) (RAG cohort protein 1) (SRP1-alpha)	Kpna2 Rch1	Mus musculus (Mouse)	529	MSTNENANLPAARLNRFKNKGKDSTEMRRRRIEVNVELRKAKKDEQMLKRRNVSSFPDDATSPLQENRNNQGTVNWSVEDIVKGINSNNLESQLQATQAARKLLSREKQPPIDNIIRAGLIPKFVSFLGKTDCSPIQFESAWALTNIASGTSEQTKAVVDGGAIPAFISLLASPHAHISEQAVWALGNIAGDGSAFRDLVIKHGAIDPLLALLAVPDLSTLACGYLRNLTWTLSNLCRNKNPAPPLDAVEQILPTLVRLLHHNDPEVLADSCWAISYLTDGPNERIEMVVKKGVVPQLVKLLGATELPIVTPALRAIGNIVTGTDEQTQKVIDAGALAVFPSLLTNPKTNIQKEATWTMSNITAGRQDQIQQVVNHGLVPFLVGVLSKADFKTQKEAAWAITNYTSGGTVEQIVYLVHCGIIEPLMNLLSAKDTKIIQVILDAISNIFQAAEKLGETEKLSIMIEECGGLDKIEALQRHENESVYKASLNLIEKYFSVEEEEDQNVVPETTSEGFAFQVQDGAPGTFNF	FUNCTION: Functions in nuclear protein import as an adapter protein for nuclear receptor KPNB1. Binds specifically and directly to substrates containing either a simple or bipartite NLS motif. Docking of the importin/substrate complex to the nuclear pore complex (NPC) is mediated by KPNB1 through binding to nucleoporin FxFG repeats and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to importin-beta and the three components separate and importin-alpha and -beta are re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran from importin. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus.		entry of viral genome into host nucleus through nuclear pore complex via importin [GO:0075506]; NLS-bearing protein import into nucleus [GO:0006607]; positive regulation of viral life cycle [GO:1903902]; postsynapse to nucleus signaling pathway [GO:0099527]; protein import into nucleus [GO:0006606]	cytoplasmic stress granule [GO:0010494]; cytosol [GO:0005829]; glutamatergic synapse [GO:0098978]; host cell [GO:0043657]; NLS-dependent protein nuclear import complex [GO:0042564]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; postsynaptic density [GO:0014069]	DNA-binding transcription factor binding [GO:0140297]; nuclear import signal receptor activity [GO:0061608]; nuclear localization sequence binding [GO:0008139]	cytoplasmic stress granule [GO:0010494]; cytosol [GO:0005829]; glutamatergic synapse [GO:0098978]; host cell [GO:0043657]; NLS-dependent protein nuclear import complex [GO:0042564]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; postsynaptic density [GO:0014069]; DNA-binding transcription factor binding [GO:0140297]; nuclear import signal receptor activity [GO:0061608]; nuclear localization sequence binding [GO:0008139]; entry of viral genome into host nucleus through nuclear pore complex via importin [GO:0075506]; NLS-bearing protein import into nucleus [GO:0006607]; positive regulation of viral life cycle [GO:1903902]; postsynapse to nucleus signaling pathway [GO:0099527]; protein import into nucleus [GO:0006606]	GO:0005634; GO:0005654; GO:0005829; GO:0006606; GO:0006607; GO:0008139; GO:0010494; GO:0014069; GO:0042564; GO:0043657; GO:0061608; GO:0075506; GO:0098978; GO:0099527; GO:0140297; GO:1903902	7641681; 7565597; 8631802; 15489334; 10692581; 21183079; 21454664; 26689472; 10764582; 10201409; 11448961; 16222336	10.1002/j.1460-2075.1995.tb00031.x; 10.1007/bf02191602; 10.1074/jbc.271.13.7654; 10.1101/gr.2596504; 10.1016/s0014-5793(00)01218-7; 10.1016/j.cell.2010.12.001; 10.1074/jbc.m110.213579; 10.1016/j.freeradbiomed.2015.12.002; 10.1006/jmbi.2000.3642; 10.1038/7625; 10.1074/jbc.m103531200; 10.1038/sj.emboj.7600843	NP_034785.1;			
4iiy	Q47511	reviewed	MCCF_ECOLX	Microcin C7 self-immunity protein MccF	mccF	Escherichia coli	344	MMIQSHPLLAAPLAVGDTIGFFSSSAPATVTAKNRFFRGVEFLQRKGFKLVSGKLTGKTDFYRSGTIKERAQEFNELVYNPDITCIMSTIGGDNSNSLLPFLDYDAIIANPKIIIGYSDTTALLAGIYAKTGLITFYGPALIPSFGEHPPLVDITYESFIKILTRKQSGIYTYTLPEKWSDESINWNENKILRPKKLYKNNCAFYGSGKVEGRVIGGNLNTLTGIWGSEWMPEILNGDILFIEDSRKSIATIERLFSMLKLNRVFDKVSAIILGKHELFDCAGSKRRPYEVLTEVLDGKQIPVLDGFDCSHTHPMLTLPLGVKLAIDFDNKNISITEQYLSTEK	FUNCTION: Involved in specific self-immunity to microcin C7.		bacteriocin immunity [GO:0030153]		hydrolase activity [GO:0016787]; identical protein binding [GO:0042802]	hydrolase activity [GO:0016787]; identical protein binding [GO:0042802]; bacteriocin immunity [GO:0030153]	GO:0016787; GO:0030153; GO:0042802	8522520	10.1128/jb.177.24.7131-7140.1995	WP_000973426.1;		CHEMBL3596082;	
3v4t	P33038	reviewed	MURA_ENTCC	UDP-N-acetylglucosamine 1-carboxyvinyltransferase (EC 2.5.1.7) (Enoylpyruvate transferase) (UDP-N-acetylglucosamine enolpyruvyl transferase) (EPT)	murA murZ ECL_04571	Enterobacter cloacae subsp. cloacae (strain ATCC 13047 / DSM 30054 / NBRC 13535 / NCTC 10005 / WDCM 00083 / NCDC 279-56)	419	MDKFRVQGPTRLQGEVTISGAKNAALPILFAALLAEEPVEIQNVPKLKDIDTTMKLLTQLGTKVERNGSVWIDASNVNNFSAPYDLVKTMRASIWALGPLVARFGQGQVSLPGGCAIGARPVDLHIFGLEKLGAEIKLEEGYVKASVNGRLKGAHIVMDKVSVGATVTIMSAATLAEGTTIIENAAREPEIVDTANFLVALGAKISGQGTDRITIEGVERLGGGVYRVLPDRIETGTFLVAAAISGGKIVCRNAQPDTLDAVLAKLREAGADIETGEDWISLDMHGKRPKAVTVRTAPHPAFPTDMQAQFTLLNLVAEGTGVITETIFENRFMHVPELIRMGAHAEIESNTVICHGVEKLSGAQVMATDLRASASLVLAGCIAEGTTVVDRIYHIDRGYERIEDKLRALGANIERVKGE	FUNCTION: Cell wall formation. Adds enolpyruvyl to UDP-N-acetylglucosamine (PubMed:20392080, PubMed:22378791). Target for the antibiotic fosfomycin. {ECO:0000269|PubMed:20392080, ECO:0000269|PubMed:22378791}.		cell cycle [GO:0007049]; cell division [GO:0051301]; cell wall organization [GO:0071555]; peptidoglycan biosynthetic process [GO:0009252]; regulation of cell shape [GO:0008360]; UDP-N-acetylgalactosamine biosynthetic process [GO:0019277]	cytoplasm [GO:0005737]	UDP-N-acetylglucosamine 1-carboxyvinyltransferase activity [GO:0008760]	cytoplasm [GO:0005737]; UDP-N-acetylglucosamine 1-carboxyvinyltransferase activity [GO:0008760]; cell cycle [GO:0007049]; cell division [GO:0051301]; cell wall organization [GO:0071555]; peptidoglycan biosynthetic process [GO:0009252]; regulation of cell shape [GO:0008360]; UDP-N-acetylgalactosamine biosynthetic process [GO:0019277]	GO:0005737; GO:0007049; GO:0008360; GO:0008760; GO:0009252; GO:0019277; GO:0051301; GO:0071555	1577165; 20207761; 8805592; 10694381; 10842342; 20392080; 22378791	10.1016/0014-5793(92)80255-f; 10.1128/jb.00067-10; 10.1016/s0969-2126(96)00113-x; 10.1021/bi991091j; 10.1002/(sici)1097-0134(20000801)40:2<290::aid-prot90>3.0.co;2-0; 10.1021/bi100365b; 10.1074/jbc.m112.342725	WP_013098931.1;YP_003615048.1;	P33038;		DB01879;DB04174;DB04474;DB02435;DB02995;
3tym	P29476	reviewed	NOS1_RAT	Nitric oxide synthase 1 (EC 1.14.13.39) (Constitutive NOS) (NC-NOS) (NOS type I) (Neuronal NOS) (N-NOS) (nNOS) (Nitric oxide synthase, brain) (bNOS) (Peptidyl-cysteine S-nitrosylase NOS1)	Nos1 Bnos	Rattus norvegicus (Rat)	1429	MEENTFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQAGDIILAVNDRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTIRVTQPLGPPTKAVDLSHQPSASKDQSLAVDRVTGLGNGPQHAQGHGQGAGSVSQANGVAIDPTMKSTKANLQDIGEHDELLKEIEPVLSILNSGSKATNRGGPAKAEMKDTGIQVDRDLDGKSHKAPPLGGDNDRVFNDLWGKDNVPVILNNPYSEKEQSPTSGKQSPTKNGSPSRCPRFLKVKNWETDVVLTDTLHLKSTLETGCTEHICMGSIMLPSQHTRKPEDVRTKDQLFPLAKEFLDQYYSSIKRFGSKAHMDRLEEVNKEIESTSTYQLKDTELIYGAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKAPRGRFDVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFDWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMDLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHVWKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATETGKSQAYAKTLCEIFKHAFDAKAMSMEEYDIVHLEHEALVLVVTSTFGNGDPPENGEKFGCALMEMRHPNSVQEERKSYKVRFNSVSSYSDSRKSSGDGPDLRDNFESTGPLANVRFSVFGLGSRAYPHFCAFGHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKPNNSLISNDRSWKRNKFRLTYVAEAPDLTQGLSNVHKKRVSAARLLSRQNLQSPKFSRSTIFVRLHTNGNQELQYQPGDHLGVFPGNHEDLVNALIERLEDAPPANHVVKVEMLEERNTALGVISNWKDESRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATNEKEKQRLLVLSKGLQEYEEWKWGKNPTMVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIVSYHTRDGEGPVHHGVCSSWLNRIQADDVVPCFVRGAPSFHLPRNPQVPCILVGPGTGIAPFRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREETLQAKNKGVFRELYTAYSREPDRPKKYVQDVLQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQRIMTQQGKLSEEDAGVFISRLRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDADEVFSS	FUNCTION: Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter. Inhibitory transmitter for non-adrenergic and non-cholinergic nerves in the colorectum. Probably has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such SRR. Inhibitory transmitter for non-adrenergic and non-cholinergic nerves in the colorectum. {ECO:0000269|PubMed:15548660, ECO:0000269|PubMed:1712077, ECO:0000269|PubMed:35772285}.		arginine catabolic process [GO:0006527]; behavioral response to cocaine [GO:0048148]; calcium ion transport [GO:0006816]; cellular response to epinephrine stimulus [GO:0071872]; cellular response to growth factor stimulus [GO:0071363]; cellular response to mechanical stimulus [GO:0071260]; establishment of localization in cell [GO:0051649]; establishment of protein localization [GO:0045184]; female pregnancy [GO:0007565]; multicellular organismal response to stress [GO:0033555]; muscle contraction [GO:0006936]; negative regulation of apoptotic process [GO:0043066]; negative regulation of blood pressure [GO:0045776]; negative regulation of calcium ion transport [GO:0051926]; negative regulation of cell population proliferation [GO:0008285]; negative regulation of cytosolic calcium ion concentration [GO:0051481]; negative regulation of hepatic stellate cell contraction [GO:0061875]; negative regulation of insulin secretion [GO:0046676]; negative regulation of iron ion transmembrane transport [GO:0034760]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of potassium ion transport [GO:0043267]; negative regulation of serotonin uptake [GO:0051612]; negative regulation of vasoconstriction [GO:0045906]; nitric oxide biosynthetic process [GO:0006809]; nitric oxide mediated signal transduction [GO:0007263]; nitric oxide metabolic process [GO:0046209]; nitric oxide-cGMP-mediated signaling pathway [GO:0038060]; peptidyl-cysteine S-nitrosylation [GO:0018119]; positive regulation of adenylate cyclase-activating adrenergic receptor signaling pathway [GO:0071879]; positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway [GO:0106071]; positive regulation of DNA-templated transcription [GO:0045893]; positive regulation of long-term synaptic potentiation [GO:1900273]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of sodium ion transmembrane transport [GO:1902307]; positive regulation of the force of heart contraction [GO:0098735]; positive regulation of transcription by RNA polymerase II [GO:0045944]; potassium ion transport [GO:0006813]; regulation of neurogenesis [GO:0050767]; regulation of postsynaptic membrane potential [GO:0060078]; regulation of sodium ion transport [GO:0002028]; response to activity [GO:0014823]; response to estrogen [GO:0043627]; response to ethanol [GO:0045471]; response to heat [GO:0009408]; response to hormone [GO:0009725]; response to hypoxia [GO:0001666]; response to lead ion [GO:0010288]; response to lipopolysaccharide [GO:0032496]; response to nicotine [GO:0035094]; response to nitric oxide [GO:0071731]; response to nutrient levels [GO:0031667]; response to organic cyclic compound [GO:0014070]; response to organonitrogen compound [GO:0010243]; response to peptide hormone [GO:0043434]; response to vitamin E [GO:0033197]; retrograde trans-synaptic signaling by nitric oxide [GO:0098924]; striated muscle contraction [GO:0006941]; synaptic signaling by nitric oxide [GO:0099163]; vasodilation [GO:0042311]; xenobiotic catabolic process [GO:0042178]	azurophil granule [GO:0042582]; calyx of Held [GO:0044305]; cell periphery [GO:0071944]; cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; dendrite [GO:0030425]; dendritic spine [GO:0043197]; glutamatergic synapse [GO:0098978]; membrane raft [GO:0045121]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]; nuclear membrane [GO:0031965]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; photoreceptor inner segment [GO:0001917]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]; postsynaptic density, intracellular component [GO:0099092]; postsynaptic specialization, intracellular component [GO:0099091]; protein-containing complex [GO:0032991]; sarcolemma [GO:0042383]; sarcoplasmic reticulum [GO:0016529]; sarcoplasmic reticulum membrane [GO:0033017]; secretory granule [GO:0030141]; synapse [GO:0045202]; T-tubule [GO:0030315]; Z disc [GO:0030018]	ATPase binding [GO:0051117]; cadmium ion binding [GO:0046870]; calcium-dependent protein binding [GO:0048306]; calmodulin binding [GO:0005516]; enzyme binding [GO:0019899]; flavin adenine dinucleotide binding [GO:0050660]; FMN binding [GO:0010181]; heme binding [GO:0020037]; identical protein binding [GO:0042802]; NADP binding [GO:0050661]; NADPH binding [GO:0070402]; nitric-oxide synthase activity [GO:0004517]; phosphoprotein binding [GO:0051219]; scaffold protein binding [GO:0097110]; sodium channel regulator activity [GO:0017080]; transmembrane transporter binding [GO:0044325]; zinc ion binding [GO:0008270]	azurophil granule [GO:0042582]; calyx of Held [GO:0044305]; cell periphery [GO:0071944]; cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; dendrite [GO:0030425]; dendritic spine [GO:0043197]; glutamatergic synapse [GO:0098978]; membrane raft [GO:0045121]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]; nuclear membrane [GO:0031965]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; photoreceptor inner segment [GO:0001917]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]; postsynaptic density, intracellular component [GO:0099092]; postsynaptic specialization, intracellular component [GO:0099091]; protein-containing complex [GO:0032991]; sarcolemma [GO:0042383]; sarcoplasmic reticulum [GO:0016529]; sarcoplasmic reticulum membrane [GO:0033017]; secretory granule [GO:0030141]; synapse [GO:0045202]; T-tubule [GO:0030315]; Z disc [GO:0030018]; ATPase binding [GO:0051117]; cadmium ion binding [GO:0046870]; calcium-dependent protein binding [GO:0048306]; calmodulin binding [GO:0005516]; enzyme binding [GO:0019899]; flavin adenine dinucleotide binding [GO:0050660]; FMN binding [GO:0010181]; heme binding [GO:0020037]; identical protein binding [GO:0042802]; NADP binding [GO:0050661]; NADPH binding [GO:0070402]; nitric-oxide synthase activity [GO:0004517]; phosphoprotein binding [GO:0051219]; scaffold protein binding [GO:0097110]; sodium channel regulator activity [GO:0017080]; transmembrane transporter binding [GO:0044325]; zinc ion binding [GO:0008270]; arginine catabolic process [GO:0006527]; behavioral response to cocaine [GO:0048148]; calcium ion transport [GO:0006816]; cellular response to epinephrine stimulus [GO:0071872]; cellular response to growth factor stimulus [GO:0071363]; cellular response to mechanical stimulus [GO:0071260]; establishment of localization in cell [GO:0051649]; establishment of protein localization [GO:0045184]; female pregnancy [GO:0007565]; multicellular organismal response to stress [GO:0033555]; muscle contraction [GO:0006936]; negative regulation of apoptotic process [GO:0043066]; negative regulation of blood pressure [GO:0045776]; negative regulation of calcium ion transport [GO:0051926]; negative regulation of cell population proliferation [GO:0008285]; negative regulation of cytosolic calcium ion concentration [GO:0051481]; negative regulation of hepatic stellate cell contraction [GO:0061875]; negative regulation of insulin secretion [GO:0046676]; negative regulation of iron ion transmembrane transport [GO:0034760]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of potassium ion transport [GO:0043267]; negative regulation of serotonin uptake [GO:0051612]; negative regulation of vasoconstriction [GO:0045906]; nitric oxide biosynthetic process [GO:0006809]; nitric oxide mediated signal transduction [GO:0007263]; nitric oxide metabolic process [GO:0046209]; nitric oxide-cGMP-mediated signaling pathway [GO:0038060]; peptidyl-cysteine S-nitrosylation [GO:0018119]; positive regulation of adenylate cyclase-activating adrenergic receptor signaling pathway [GO:0071879]; positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway [GO:0106071]; positive regulation of DNA-templated transcription [GO:0045893]; positive regulation of long-term synaptic potentiation [GO:1900273]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of sodium ion transmembrane transport [GO:1902307]; positive regulation of the force of heart contraction [GO:0098735]; positive regulation of transcription by RNA polymerase II [GO:0045944]; potassium ion transport [GO:0006813]; regulation of neurogenesis [GO:0050767]; regulation of postsynaptic membrane potential [GO:0060078]; regulation of sodium ion transport [GO:0002028]; response to activity [GO:0014823]; response to estrogen [GO:0043627]; response to ethanol [GO:0045471]; response to heat [GO:0009408]; response to hormone [GO:0009725]; response to hypoxia [GO:0001666]; response to lead ion [GO:0010288]; response to lipopolysaccharide [GO:0032496]; response to nicotine [GO:0035094]; response to nitric oxide [GO:0071731]; response to nutrient levels [GO:0031667]; response to organic cyclic compound [GO:0014070]; response to organonitrogen compound [GO:0010243]; response to peptide hormone [GO:0043434]; response to vitamin E [GO:0033197]; retrograde trans-synaptic signaling by nitric oxide [GO:0098924]; striated muscle contraction [GO:0006941]; synaptic signaling by nitric oxide [GO:0099163]; vasodilation [GO:0042311]; xenobiotic catabolic process [GO:0042178]	GO:0001666; GO:0001917; GO:0002028; GO:0004517; GO:0005516; GO:0005634; GO:0005737; GO:0005739; GO:0005741; GO:0005829; GO:0005856; GO:0005886; GO:0006527; GO:0006809; GO:0006813; GO:0006816; GO:0006936; GO:0006941; GO:0007263; GO:0007565; GO:0008270; GO:0008285; GO:0009408; GO:0009725; GO:0010181; GO:0010243; GO:0010288; GO:0014069; GO:0014070; GO:0014823; GO:0016529; GO:0017080; GO:0018119; GO:0019899; GO:0020037; GO:0030018; GO:0030141; GO:0030315; GO:0030425; GO:0031667; GO:0031965; GO:0032496; GO:0032991; GO:0033017; GO:0033138; GO:0033197; GO:0033555; GO:0034760; GO:0035094; GO:0038060; GO:0042178; GO:0042311; GO:0042383; GO:0042582; GO:0042802; GO:0043066; GO:0043197; GO:0043267; GO:0043434; GO:0043524; GO:0043627; GO:0044305; GO:0044325; GO:0045121; GO:0045184; GO:0045202; GO:0045471; GO:0045776; GO:0045893; GO:0045906; GO:0045944; GO:0046209; GO:0046676; GO:0046870; GO:0048148; GO:0048306; GO:0048471; GO:0050660; GO:0050661; GO:0050767; GO:0051117; GO:0051219; GO:0051481; GO:0051612; GO:0051649; GO:0051926; GO:0060078; GO:0061875; GO:0070402; GO:0071260; GO:0071363; GO:0071731; GO:0071872; GO:0071879; GO:0071944; GO:0097110; GO:0098735; GO:0098924; GO:0098978; GO:0099091; GO:0099092; GO:0099163; GO:0106071; GO:1900273; GO:1902307	1712077; 8806605; 7520037; 7530005; 8864115; 11237702; 11086993; 11867766; 15105416; 15466472; 15548660; 17161399; 22673903; 23300088; 35772285; 10221915; 11473123; 15208315	10.1038/351714a0; 10.1006/bbrc.1996.1324; 10.1093/oxfordjournals.jbchem.a124382; 10.1006/bbrc.1995.1104; 10.1126/science.274.5288.774; 10.1006/bbrc.2001.4356; 10.1016/s0896-6273(00)00095-7; 10.1073/pnas.261705799; 10.1074/jbc.m401471200; 10.1074/jbc.m406926200; 10.1523/jneurosci.2265-04.2004; 10.1016/j.febslet.2006.11.061; 10.1038/ncomms1871; 10.1074/jbc.m112.412478; 10.1016/j.bmc.2022.116878; 10.1126/science.284.5415.812; 10.1074/jbc.m105503200; 10.1074/jbc.m406204200	NP_434686.1;	P29476;	CHEMBL3048;	
4d7o	P29476	reviewed	NOS1_RAT	Nitric oxide synthase 1 (EC 1.14.13.39) (Constitutive NOS) (NC-NOS) (NOS type I) (Neuronal NOS) (N-NOS) (nNOS) (Nitric oxide synthase, brain) (bNOS) (Peptidyl-cysteine S-nitrosylase NOS1)	Nos1 Bnos	Rattus norvegicus (Rat)	1429	MEENTFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQAGDIILAVNDRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTIRVTQPLGPPTKAVDLSHQPSASKDQSLAVDRVTGLGNGPQHAQGHGQGAGSVSQANGVAIDPTMKSTKANLQDIGEHDELLKEIEPVLSILNSGSKATNRGGPAKAEMKDTGIQVDRDLDGKSHKAPPLGGDNDRVFNDLWGKDNVPVILNNPYSEKEQSPTSGKQSPTKNGSPSRCPRFLKVKNWETDVVLTDTLHLKSTLETGCTEHICMGSIMLPSQHTRKPEDVRTKDQLFPLAKEFLDQYYSSIKRFGSKAHMDRLEEVNKEIESTSTYQLKDTELIYGAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKAPRGRFDVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFDWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMDLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHVWKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATETGKSQAYAKTLCEIFKHAFDAKAMSMEEYDIVHLEHEALVLVVTSTFGNGDPPENGEKFGCALMEMRHPNSVQEERKSYKVRFNSVSSYSDSRKSSGDGPDLRDNFESTGPLANVRFSVFGLGSRAYPHFCAFGHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKPNNSLISNDRSWKRNKFRLTYVAEAPDLTQGLSNVHKKRVSAARLLSRQNLQSPKFSRSTIFVRLHTNGNQELQYQPGDHLGVFPGNHEDLVNALIERLEDAPPANHVVKVEMLEERNTALGVISNWKDESRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATNEKEKQRLLVLSKGLQEYEEWKWGKNPTMVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIVSYHTRDGEGPVHHGVCSSWLNRIQADDVVPCFVRGAPSFHLPRNPQVPCILVGPGTGIAPFRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREETLQAKNKGVFRELYTAYSREPDRPKKYVQDVLQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQRIMTQQGKLSEEDAGVFISRLRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDADEVFSS	FUNCTION: Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter. Inhibitory transmitter for non-adrenergic and non-cholinergic nerves in the colorectum. Probably has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such SRR. Inhibitory transmitter for non-adrenergic and non-cholinergic nerves in the colorectum. {ECO:0000269|PubMed:15548660, ECO:0000269|PubMed:1712077, ECO:0000269|PubMed:35772285}.		arginine catabolic process [GO:0006527]; behavioral response to cocaine [GO:0048148]; calcium ion transport [GO:0006816]; cellular response to epinephrine stimulus [GO:0071872]; cellular response to growth factor stimulus [GO:0071363]; cellular response to mechanical stimulus [GO:0071260]; establishment of localization in cell [GO:0051649]; establishment of protein localization [GO:0045184]; female pregnancy [GO:0007565]; multicellular organismal response to stress [GO:0033555]; muscle contraction [GO:0006936]; negative regulation of apoptotic process [GO:0043066]; negative regulation of blood pressure [GO:0045776]; negative regulation of calcium ion transport [GO:0051926]; negative regulation of cell population proliferation [GO:0008285]; negative regulation of cytosolic calcium ion concentration [GO:0051481]; negative regulation of hepatic stellate cell contraction [GO:0061875]; negative regulation of insulin secretion [GO:0046676]; negative regulation of iron ion transmembrane transport [GO:0034760]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of potassium ion transport [GO:0043267]; negative regulation of serotonin uptake [GO:0051612]; negative regulation of vasoconstriction [GO:0045906]; nitric oxide biosynthetic process [GO:0006809]; nitric oxide mediated signal transduction [GO:0007263]; nitric oxide metabolic process [GO:0046209]; nitric oxide-cGMP-mediated signaling pathway [GO:0038060]; peptidyl-cysteine S-nitrosylation [GO:0018119]; positive regulation of adenylate cyclase-activating adrenergic receptor signaling pathway [GO:0071879]; positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway [GO:0106071]; positive regulation of DNA-templated transcription [GO:0045893]; positive regulation of long-term synaptic potentiation [GO:1900273]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of sodium ion transmembrane transport [GO:1902307]; positive regulation of the force of heart contraction [GO:0098735]; positive regulation of transcription by RNA polymerase II [GO:0045944]; potassium ion transport [GO:0006813]; regulation of neurogenesis [GO:0050767]; regulation of postsynaptic membrane potential [GO:0060078]; regulation of sodium ion transport [GO:0002028]; response to activity [GO:0014823]; response to estrogen [GO:0043627]; response to ethanol [GO:0045471]; response to heat [GO:0009408]; response to hormone [GO:0009725]; response to hypoxia [GO:0001666]; response to lead ion [GO:0010288]; response to lipopolysaccharide [GO:0032496]; response to nicotine [GO:0035094]; response to nitric oxide [GO:0071731]; response to nutrient levels [GO:0031667]; response to organic cyclic compound [GO:0014070]; response to organonitrogen compound [GO:0010243]; response to peptide hormone [GO:0043434]; response to vitamin E [GO:0033197]; retrograde trans-synaptic signaling by nitric oxide [GO:0098924]; striated muscle contraction [GO:0006941]; synaptic signaling by nitric oxide [GO:0099163]; vasodilation [GO:0042311]; xenobiotic catabolic process [GO:0042178]	azurophil granule [GO:0042582]; calyx of Held [GO:0044305]; cell periphery [GO:0071944]; cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; dendrite [GO:0030425]; dendritic spine [GO:0043197]; glutamatergic synapse [GO:0098978]; membrane raft [GO:0045121]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]; nuclear membrane [GO:0031965]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; photoreceptor inner segment [GO:0001917]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]; postsynaptic density, intracellular component [GO:0099092]; postsynaptic specialization, intracellular component [GO:0099091]; protein-containing complex [GO:0032991]; sarcolemma [GO:0042383]; sarcoplasmic reticulum [GO:0016529]; sarcoplasmic reticulum membrane [GO:0033017]; secretory granule [GO:0030141]; synapse [GO:0045202]; T-tubule [GO:0030315]; Z disc [GO:0030018]	ATPase binding [GO:0051117]; cadmium ion binding [GO:0046870]; calcium-dependent protein binding [GO:0048306]; calmodulin binding [GO:0005516]; enzyme binding [GO:0019899]; flavin adenine dinucleotide binding [GO:0050660]; FMN binding [GO:0010181]; heme binding [GO:0020037]; identical protein binding [GO:0042802]; NADP binding [GO:0050661]; NADPH binding [GO:0070402]; nitric-oxide synthase activity [GO:0004517]; phosphoprotein binding [GO:0051219]; scaffold protein binding [GO:0097110]; sodium channel regulator activity [GO:0017080]; transmembrane transporter binding [GO:0044325]; zinc ion binding [GO:0008270]	azurophil granule [GO:0042582]; calyx of Held [GO:0044305]; cell periphery [GO:0071944]; cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; dendrite [GO:0030425]; dendritic spine [GO:0043197]; glutamatergic synapse [GO:0098978]; membrane raft [GO:0045121]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]; nuclear membrane [GO:0031965]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; photoreceptor inner segment [GO:0001917]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]; postsynaptic density, intracellular component [GO:0099092]; postsynaptic specialization, intracellular component [GO:0099091]; protein-containing complex [GO:0032991]; sarcolemma [GO:0042383]; sarcoplasmic reticulum [GO:0016529]; sarcoplasmic reticulum membrane [GO:0033017]; secretory granule [GO:0030141]; synapse [GO:0045202]; T-tubule [GO:0030315]; Z disc [GO:0030018]; ATPase binding [GO:0051117]; cadmium ion binding [GO:0046870]; calcium-dependent protein binding [GO:0048306]; calmodulin binding [GO:0005516]; enzyme binding [GO:0019899]; flavin adenine dinucleotide binding [GO:0050660]; FMN binding [GO:0010181]; heme binding [GO:0020037]; identical protein binding [GO:0042802]; NADP binding [GO:0050661]; NADPH binding [GO:0070402]; nitric-oxide synthase activity [GO:0004517]; phosphoprotein binding [GO:0051219]; scaffold protein binding [GO:0097110]; sodium channel regulator activity [GO:0017080]; transmembrane transporter binding [GO:0044325]; zinc ion binding [GO:0008270]; arginine catabolic process [GO:0006527]; behavioral response to cocaine [GO:0048148]; calcium ion transport [GO:0006816]; cellular response to epinephrine stimulus [GO:0071872]; cellular response to growth factor stimulus [GO:0071363]; cellular response to mechanical stimulus [GO:0071260]; establishment of localization in cell [GO:0051649]; establishment of protein localization [GO:0045184]; female pregnancy [GO:0007565]; multicellular organismal response to stress [GO:0033555]; muscle contraction [GO:0006936]; negative regulation of apoptotic process [GO:0043066]; negative regulation of blood pressure [GO:0045776]; negative regulation of calcium ion transport [GO:0051926]; negative regulation of cell population proliferation [GO:0008285]; negative regulation of cytosolic calcium ion concentration [GO:0051481]; negative regulation of hepatic stellate cell contraction [GO:0061875]; negative regulation of insulin secretion [GO:0046676]; negative regulation of iron ion transmembrane transport [GO:0034760]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of potassium ion transport [GO:0043267]; negative regulation of serotonin uptake [GO:0051612]; negative regulation of vasoconstriction [GO:0045906]; nitric oxide biosynthetic process [GO:0006809]; nitric oxide mediated signal transduction [GO:0007263]; nitric oxide metabolic process [GO:0046209]; nitric oxide-cGMP-mediated signaling pathway [GO:0038060]; peptidyl-cysteine S-nitrosylation [GO:0018119]; positive regulation of adenylate cyclase-activating adrenergic receptor signaling pathway [GO:0071879]; positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway [GO:0106071]; positive regulation of DNA-templated transcription [GO:0045893]; positive regulation of long-term synaptic potentiation [GO:1900273]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of sodium ion transmembrane transport [GO:1902307]; positive regulation of the force of heart contraction [GO:0098735]; positive regulation of transcription by RNA polymerase II [GO:0045944]; potassium ion transport [GO:0006813]; regulation of neurogenesis [GO:0050767]; regulation of postsynaptic membrane potential [GO:0060078]; regulation of sodium ion transport [GO:0002028]; response to activity [GO:0014823]; response to estrogen [GO:0043627]; response to ethanol [GO:0045471]; response to heat [GO:0009408]; response to hormone [GO:0009725]; response to hypoxia [GO:0001666]; response to lead ion [GO:0010288]; response to lipopolysaccharide [GO:0032496]; response to nicotine [GO:0035094]; response to nitric oxide [GO:0071731]; response to nutrient levels [GO:0031667]; response to organic cyclic compound [GO:0014070]; response to organonitrogen compound [GO:0010243]; response to peptide hormone [GO:0043434]; response to vitamin E [GO:0033197]; retrograde trans-synaptic signaling by nitric oxide [GO:0098924]; striated muscle contraction [GO:0006941]; synaptic signaling by nitric oxide [GO:0099163]; vasodilation [GO:0042311]; xenobiotic catabolic process [GO:0042178]	GO:0001666; GO:0001917; GO:0002028; GO:0004517; GO:0005516; GO:0005634; GO:0005737; GO:0005739; GO:0005741; GO:0005829; GO:0005856; GO:0005886; GO:0006527; GO:0006809; GO:0006813; GO:0006816; GO:0006936; GO:0006941; GO:0007263; GO:0007565; GO:0008270; GO:0008285; GO:0009408; GO:0009725; GO:0010181; GO:0010243; GO:0010288; GO:0014069; GO:0014070; GO:0014823; GO:0016529; GO:0017080; GO:0018119; GO:0019899; GO:0020037; GO:0030018; GO:0030141; GO:0030315; GO:0030425; GO:0031667; GO:0031965; GO:0032496; GO:0032991; GO:0033017; GO:0033138; GO:0033197; GO:0033555; GO:0034760; GO:0035094; GO:0038060; GO:0042178; GO:0042311; GO:0042383; GO:0042582; GO:0042802; GO:0043066; GO:0043197; GO:0043267; GO:0043434; GO:0043524; GO:0043627; GO:0044305; GO:0044325; GO:0045121; GO:0045184; GO:0045202; GO:0045471; GO:0045776; GO:0045893; GO:0045906; GO:0045944; GO:0046209; GO:0046676; GO:0046870; GO:0048148; GO:0048306; GO:0048471; GO:0050660; GO:0050661; GO:0050767; GO:0051117; GO:0051219; GO:0051481; GO:0051612; GO:0051649; GO:0051926; GO:0060078; GO:0061875; GO:0070402; GO:0071260; GO:0071363; GO:0071731; GO:0071872; GO:0071879; GO:0071944; GO:0097110; GO:0098735; GO:0098924; GO:0098978; GO:0099091; GO:0099092; GO:0099163; GO:0106071; GO:1900273; GO:1902307	1712077; 8806605; 7520037; 7530005; 8864115; 11237702; 11086993; 11867766; 15105416; 15466472; 15548660; 17161399; 22673903; 23300088; 35772285; 10221915; 11473123; 15208315	10.1038/351714a0; 10.1006/bbrc.1996.1324; 10.1093/oxfordjournals.jbchem.a124382; 10.1006/bbrc.1995.1104; 10.1126/science.274.5288.774; 10.1006/bbrc.2001.4356; 10.1016/s0896-6273(00)00095-7; 10.1073/pnas.261705799; 10.1074/jbc.m401471200; 10.1074/jbc.m406926200; 10.1523/jneurosci.2265-04.2004; 10.1016/j.febslet.2006.11.061; 10.1038/ncomms1871; 10.1074/jbc.m112.412478; 10.1016/j.bmc.2022.116878; 10.1126/science.284.5415.812; 10.1074/jbc.m105503200; 10.1074/jbc.m406204200	NP_434686.1;	P29476;	CHEMBL3048;	
3ej8	P35228	reviewed	NOS2_HUMAN	Nitric oxide synthase, inducible (EC 1.14.13.39) (Hepatocyte NOS) (HEP-NOS) (Inducible NO synthase) (Inducible NOS) (iNOS) (NOS type II) (Peptidyl-cysteine S-nitrosylase NOS2)	NOS2 NOS2A	Homo sapiens (Human)	1153	MACPWKFLFKTKFHQYAMNGEKDINNNVEKAPCATSSPVTQDDLQYHNLSKQQNESPQPLVETGKKSPESLVKLDATPLSSPRHVRIKNWGSGMTFQDTLHHKAKGILTCRSKSCLGSIMTPKSLTRGPRDKPTPPDELLPQAIEFVNQYYGSFKEAKIEEHLARVEAVTKEIETTGTYQLTGDELIFATKQAWRNAPRCIGRIQWSNLQVFDARSCSTAREMFEHICRHVRYSTNNGNIRSAITVFPQRSDGKHDFRVWNAQLIRYAGYQMPDGSIRGDPANVEFTQLCIDLGWKPKYGRFDVVPLVLQANGRDPELFEIPPDLVLEVAMEHPKYEWFRELELKWYALPAVANMLLEVGGLEFPGCPFNGWYMGTEIGVRDFCDVQRYNILEEVGRRMGLETHKLASLWKDQAVVEINIAVLHSFQKQNVTIMDHHSAAESFMKYMQNEYRSRGGCPADWIWLVPPMSGSITPVFHQEMLNYVLSPFYYYQVEAWKTHVWQDEKRRPKRREIPLKVLVKAVLFACMLMRKTMASRVRVTILFATETGKSEALAWDLGALFSCAFNPKVVCMDKYRLSCLEEERLLLVVTSTFGNGDCPGNGEKLKKSLFMLKELNNKFRYAVFGLGSSMYPRFCAFAHDIDQKLSHLGASQLTPMGEGDELSGQEDAFRSWAVQTFKAACETFDVRGKQHIQIPKLYTSNVTWDPHHYRLVQDSQPLDLSKALSSMHAKNVFTMRLKSRQNLQSPTSSRATILVELSCEDGQGLNYLPGEHLGVCPGNQPALVQGILERVVDGPTPHQTVRLEALDESGSYWVSDKRLPPCSLSQALTYFLDITTPPTQLLLQKLAQVATEEPERQRLEALCQPSEYSKWKFTNSPTFLEVLEEFPSLRVSAGFLLSQLPILKPRFYSISSSRDHTPTEIHLTVAVVTYHTRDGQGPLHHGVCSTWLNSLKPQDPVPCFVRNASGFHLPEDPSHPCILIGPGTGIAPFRSFWQQRLHDSQHKGVRGGRMTLVFGCRRPDEDHIYQEEMLEMAQKGVLHAVHTAYSRLPGKPKVYVQDILRQQLASEVLRVLHKEPGHLYVCGDVRMARDVAHTLKQLVAAKLKLNEEQVEDYFFQLKSQKRYHEDIFGAVFPYEAKKDRVAVQPSSLEMSAL	FUNCTION: Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body (PubMed:7504305, PubMed:7531687, PubMed:7544004, PubMed:7682706). In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such PTGS2/COX2 (By similarity). As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-nitrosylation of GAPDH on 'Cys-247' implicated in regulation of the GAIT complex activity and probably multiple targets including ANXA5, EZR, MSN and VIM (PubMed:25417112). Involved in inflammation, enhances the synthesis of pro-inflammatory mediators such as IL6 and IL8 (PubMed:19688109). {ECO:0000250|UniProtKB:P29477, ECO:0000269|PubMed:19688109, ECO:0000269|PubMed:25417112, ECO:0000269|PubMed:7504305, ECO:0000269|PubMed:7531687, ECO:0000269|PubMed:7544004, ECO:0000269|PubMed:7682706}.		arginine catabolic process [GO:0006527]; cell redox homeostasis [GO:0045454]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to type II interferon [GO:0071346]; cellular response to xenobiotic stimulus [GO:0071466]; circadian rhythm [GO:0007623]; defense response to bacterium [GO:0042742]; defense response to Gram-negative bacterium [GO:0050829]; inflammatory response [GO:0006954]; innate immune response in mucosa [GO:0002227]; negative regulation of blood pressure [GO:0045776]; negative regulation of gene expression [GO:0010629]; negative regulation of protein catabolic process [GO:0042177]; nitric oxide biosynthetic process [GO:0006809]; nitric oxide mediated signal transduction [GO:0007263]; peptidyl-cysteine S-nitrosylation [GO:0018119]; positive regulation of interleukin-6 production [GO:0032755]; positive regulation of interleukin-8 production [GO:0032757]; positive regulation of killing of cells of another organism [GO:0051712]; positive regulation of leukocyte mediated cytotoxicity [GO:0001912]; prostaglandin secretion [GO:0032310]; regulation of cell population proliferation [GO:0042127]; regulation of cellular respiration [GO:0043457]; regulation of cytokine production involved in inflammatory response [GO:1900015]; regulation of insulin secretion [GO:0050796]; response to bacterium [GO:0009617]; response to hormone [GO:0009725]; response to hypoxia [GO:0001666]; response to lipopolysaccharide [GO:0032496]; superoxide metabolic process [GO:0006801]	cortical cytoskeleton [GO:0030863]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; peroxisomal matrix [GO:0005782]; peroxisome [GO:0005777]; plasma membrane [GO:0005886]	arginine binding [GO:0034618]; calmodulin binding [GO:0005516]; flavin adenine dinucleotide binding [GO:0050660]; FMN binding [GO:0010181]; heme binding [GO:0020037]; metal ion binding [GO:0046872]; NADP binding [GO:0050661]; nitric-oxide synthase activity [GO:0004517]; protein homodimerization activity [GO:0042803]; tetrahydrobiopterin binding [GO:0034617]	cortical cytoskeleton [GO:0030863]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; peroxisomal matrix [GO:0005782]; peroxisome [GO:0005777]; plasma membrane [GO:0005886]; arginine binding [GO:0034618]; calmodulin binding [GO:0005516]; flavin adenine dinucleotide binding [GO:0050660]; FMN binding [GO:0010181]; heme binding [GO:0020037]; metal ion binding [GO:0046872]; NADP binding [GO:0050661]; nitric-oxide synthase activity [GO:0004517]; protein homodimerization activity [GO:0042803]; tetrahydrobiopterin binding [GO:0034617]; arginine catabolic process [GO:0006527]; cell redox homeostasis [GO:0045454]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to type II interferon [GO:0071346]; cellular response to xenobiotic stimulus [GO:0071466]; circadian rhythm [GO:0007623]; defense response to bacterium [GO:0042742]; defense response to Gram-negative bacterium [GO:0050829]; inflammatory response [GO:0006954]; innate immune response in mucosa [GO:0002227]; negative regulation of blood pressure [GO:0045776]; negative regulation of gene expression [GO:0010629]; negative regulation of protein catabolic process [GO:0042177]; nitric oxide biosynthetic process [GO:0006809]; nitric oxide mediated signal transduction [GO:0007263]; peptidyl-cysteine S-nitrosylation [GO:0018119]; positive regulation of interleukin-6 production [GO:0032755]; positive regulation of interleukin-8 production [GO:0032757]; positive regulation of killing of cells of another organism [GO:0051712]; positive regulation of leukocyte mediated cytotoxicity [GO:0001912]; prostaglandin secretion [GO:0032310]; regulation of cell population proliferation [GO:0042127]; regulation of cellular respiration [GO:0043457]; regulation of cytokine production involved in inflammatory response [GO:1900015]; regulation of insulin secretion [GO:0050796]; response to bacterium [GO:0009617]; response to hormone [GO:0009725]; response to hypoxia [GO:0001666]; response to lipopolysaccharide [GO:0032496]; superoxide metabolic process [GO:0006801]	GO:0001666; GO:0001912; GO:0002227; GO:0004517; GO:0005516; GO:0005634; GO:0005654; GO:0005737; GO:0005777; GO:0005782; GO:0005829; GO:0005886; GO:0006527; GO:0006801; GO:0006809; GO:0006954; GO:0007263; GO:0007623; GO:0009617; GO:0009725; GO:0010181; GO:0010629; GO:0018119; GO:0020037; GO:0030863; GO:0032310; GO:0032496; GO:0032755; GO:0032757; GO:0034617; GO:0034618; GO:0042127; GO:0042177; GO:0042742; GO:0042803; GO:0043457; GO:0045454; GO:0045776; GO:0046872; GO:0048471; GO:0050660; GO:0050661; GO:0050796; GO:0050829; GO:0051712; GO:0071222; GO:0071346; GO:0071466; GO:1900015	7692964; 7682706; 7504305; 7522054; 7528017; 7531687; 7544004; 9160867; 15489334; 7532248; 7528267; 7558036; 9721329; 12080081; 12433515; 19688109; 21199876; 25417112; 25180171; 35772285; 10409685; 10074942; 19737939; 16959974; 24430113	10.1021/bi00094a017; 10.1073/pnas.90.8.3491; 10.1073/pnas.90.23.11419; 10.1016/0167-4838(94)90171-6; 10.1006/bbrc.1994.2633; 10.1093/oxfordjournals.jbchem.a124563; 10.1073/pnas.92.17.7809; 10.1006/jmcc.1996.0349; 10.1101/gr.2596504; 10.1038/ki.1994.365; 10.1046/j.1471-4159.1995.64010085.x; 10.1006/geno.1995.1086; 10.1074/jbc.m205764200; 10.1016/s0140-6736(02)11474-7; 10.1155/2009/345838; 10.1074/jbc.m110.190678; 10.1016/j.cell.2014.09.032; 10.1016/j.redox.2014.06.011; 10.1016/j.bmc.2022.116878; 10.1074/jbc.274.30.21276; 10.1038/6675; 10.1074/jbc.m109.031682; 10.1126/science.1133427; 10.1038/ctg.2013.17	NP_000616.3 [P35228-1];XP_011523161.1;	P35228;	CHEMBL4481;	DB07003;DB07007;DB07011;DB07405;DB08750;DB01997;DB07029;DB07008;DB08214;DB07002;DB01835;DB06879;DB04534;DB03100;DB02207;DB00125;DB00155;DB01234;DB14649;DB11327;DB00997;DB07306;DB07388;DB05252;DB01381;DB03366;DB05214;DB04400;DB09237;DB00244;DB01110;DB01017;DB03144;DB01686;DB03449;DB06916;DB07318;DB07389;DB02044;DB02644;DB05383;DB02234;DB03953;DB02462;DB08814;
1rs9	P29473	reviewed	NOS3_BOVIN	Nitric oxide synthase 3 (EC 1.14.13.39) (Constitutive NOS) (cNOS) (EC-NOS) (NOS type III) (NOSIII) (Nitric oxide synthase, endothelial) (Endothelial NOS) (eNOS)	NOS3	Bos taurus (Bovine)	1205	MGNLKSVGQEPGPPCGLGLGLGLGLCGKQGPASPAPEPSRAPAPATPHAPDHSPAPNSPTLTRPPEGPKFPRVKNWELGSITYDTLCAQSQQDGPCTPRCCLGSLVLPRKLQTRPSPGPPPAEQLLSQARDFINQYYSSIKRSGSQAHEERLQEVEAEVASTGTYHLRESELVFGAKQAWRNAPRCVGRIQWGKLQVFDARDCSSAQEMFTYICNHIKYATNRGNLRSAITVFPQRAPGRGDFRIWNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDEAPELFVLPPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFSAAPFSGWYMSTEIGTRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINLAVLHSFQLAKVTIVDHHAATVSFMKHLDNEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYILSPAFRYQPDPWKGSATKGAGITRKKTFKEVANAVKISASLMGTLMAKRVKATILYASETGRAQSYAQQLGRLFRKAFDPRVLCMDEYDVVSLEHEALVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSSPRPEQHKSYKIRFNSVSCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHFCAFARAVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAKAAFQASCETFCVGEEAKAAAQDIFSPKRSWKRQRYRLSTQAEGLQLLPGLIHVHRRKMFQATVLSVENLQSSKSTRATILVRLDTAGQEGLQYQPGDHIGICPPNRPGLVEALLSRVEDPPPPTESVAVEQLEKGSPGGPPPSWVRDPRLPPCTLRQALTFFLDITSPPSPRLLRLLSTLAEEPSEQQELETLSQDPRRYEEWKWFRCPTLLEVLEQFPSVALPAPLLLTQLPLLQPRYYSVSSAPNAHPGEVHLTVAVLAYRTQDGLGPLHYGVCSTWLSQLKTGDPVPCFIRGAPSFRLPPDPYVPCILVGPGTGIAPFRGFWQERLHDIESKGLQPAPMTLVFGCRCSQLDHLYRDEVQDAQERGVFGRVLTAFSREPDSPKTYVQDILRTELAAEVHRVLCLERGHMFVCGDVTMATSVLQTVQRILATEGDMELDEAGDVIGVLRDQQRYHEDIFGLTLRTQEVTSRIRTQSFSLQERHLRGAVPWAFDPPGPDTPGP	FUNCTION: Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets. {ECO:0000250|UniProtKB:P29474}.		arginine catabolic process [GO:0006527]; blood coagulation [GO:0007596]; cellular response to laminar fluid shear stress [GO:0071499]; mitochondrion organization [GO:0007005]; negative regulation of blood pressure [GO:0045776]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; negative regulation of leukocyte cell-cell adhesion [GO:1903038]; nitric oxide biosynthetic process [GO:0006809]; nitric oxide mediated signal transduction [GO:0007263]; positive regulation of guanylate cyclase activity [GO:0031284]; response to hormone [GO:0009725]; response to lipopolysaccharide [GO:0032496]	caveola [GO:0005901]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; Golgi apparatus [GO:0005794]; nucleus [GO:0005634]; plasma membrane [GO:0005886]	calmodulin binding [GO:0005516]; flavin adenine dinucleotide binding [GO:0050660]; FMN binding [GO:0010181]; heme binding [GO:0020037]; metal ion binding [GO:0046872]; NADP binding [GO:0050661]; nitric-oxide synthase activity [GO:0004517]	caveola [GO:0005901]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; Golgi apparatus [GO:0005794]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; calmodulin binding [GO:0005516]; flavin adenine dinucleotide binding [GO:0050660]; FMN binding [GO:0010181]; heme binding [GO:0020037]; metal ion binding [GO:0046872]; NADP binding [GO:0050661]; nitric-oxide synthase activity [GO:0004517]; arginine catabolic process [GO:0006527]; blood coagulation [GO:0007596]; cellular response to laminar fluid shear stress [GO:0071499]; mitochondrion organization [GO:0007005]; negative regulation of blood pressure [GO:0045776]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; negative regulation of leukocyte cell-cell adhesion [GO:1903038]; nitric oxide biosynthetic process [GO:0006809]; nitric oxide mediated signal transduction [GO:0007263]; positive regulation of guanylate cyclase activity [GO:0031284]; response to hormone [GO:0009725]; response to lipopolysaccharide [GO:0032496]	GO:0004517; GO:0005516; GO:0005634; GO:0005794; GO:0005829; GO:0005856; GO:0005886; GO:0005901; GO:0006527; GO:0006809; GO:0007005; GO:0007263; GO:0007596; GO:0009725; GO:0010181; GO:0020037; GO:0031284; GO:0032496; GO:0045776; GO:0046872; GO:0050660; GO:0050661; GO:0071499; GO:1902042; GO:1903038	1378626; 1385480; 1379225; 7682550; 8524847; 12384459; 17071725; 9875848; 11051558; 11331003; 11695891; 11331290; 11590164	10.1073/pnas.89.14.6348; 10.1172/jci116092; 10.1016/s0021-9258(19)49528-8; 10.1016/s0021-9258(18)52889-1; 10.1073/pnas.92.25.11776; 10.1152/ajpheart.00214.2002; 10.1152/ajpheart.00990.2006; 10.1016/s0092-8674(00)81718-3; 10.1016/s0162-0134(00)00099-4; 10.1021/bi002658v; 10.1021/bi010957u; 10.1074/jbc.m102255200; 10.1074/jbc.m011469200		P29473;	CHEMBL4802;	
4kcq	P29473	reviewed	NOS3_BOVIN	Nitric oxide synthase 3 (EC 1.14.13.39) (Constitutive NOS) (cNOS) (EC-NOS) (NOS type III) (NOSIII) (Nitric oxide synthase, endothelial) (Endothelial NOS) (eNOS)	NOS3	Bos taurus (Bovine)	1205	MGNLKSVGQEPGPPCGLGLGLGLGLCGKQGPASPAPEPSRAPAPATPHAPDHSPAPNSPTLTRPPEGPKFPRVKNWELGSITYDTLCAQSQQDGPCTPRCCLGSLVLPRKLQTRPSPGPPPAEQLLSQARDFINQYYSSIKRSGSQAHEERLQEVEAEVASTGTYHLRESELVFGAKQAWRNAPRCVGRIQWGKLQVFDARDCSSAQEMFTYICNHIKYATNRGNLRSAITVFPQRAPGRGDFRIWNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDEAPELFVLPPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFSAAPFSGWYMSTEIGTRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINLAVLHSFQLAKVTIVDHHAATVSFMKHLDNEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYILSPAFRYQPDPWKGSATKGAGITRKKTFKEVANAVKISASLMGTLMAKRVKATILYASETGRAQSYAQQLGRLFRKAFDPRVLCMDEYDVVSLEHEALVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSSPRPEQHKSYKIRFNSVSCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHFCAFARAVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAKAAFQASCETFCVGEEAKAAAQDIFSPKRSWKRQRYRLSTQAEGLQLLPGLIHVHRRKMFQATVLSVENLQSSKSTRATILVRLDTAGQEGLQYQPGDHIGICPPNRPGLVEALLSRVEDPPPPTESVAVEQLEKGSPGGPPPSWVRDPRLPPCTLRQALTFFLDITSPPSPRLLRLLSTLAEEPSEQQELETLSQDPRRYEEWKWFRCPTLLEVLEQFPSVALPAPLLLTQLPLLQPRYYSVSSAPNAHPGEVHLTVAVLAYRTQDGLGPLHYGVCSTWLSQLKTGDPVPCFIRGAPSFRLPPDPYVPCILVGPGTGIAPFRGFWQERLHDIESKGLQPAPMTLVFGCRCSQLDHLYRDEVQDAQERGVFGRVLTAFSREPDSPKTYVQDILRTELAAEVHRVLCLERGHMFVCGDVTMATSVLQTVQRILATEGDMELDEAGDVIGVLRDQQRYHEDIFGLTLRTQEVTSRIRTQSFSLQERHLRGAVPWAFDPPGPDTPGP	FUNCTION: Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets. {ECO:0000250|UniProtKB:P29474}.		arginine catabolic process [GO:0006527]; blood coagulation [GO:0007596]; cellular response to laminar fluid shear stress [GO:0071499]; mitochondrion organization [GO:0007005]; negative regulation of blood pressure [GO:0045776]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; negative regulation of leukocyte cell-cell adhesion [GO:1903038]; nitric oxide biosynthetic process [GO:0006809]; nitric oxide mediated signal transduction [GO:0007263]; positive regulation of guanylate cyclase activity [GO:0031284]; response to hormone [GO:0009725]; response to lipopolysaccharide [GO:0032496]	caveola [GO:0005901]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; Golgi apparatus [GO:0005794]; nucleus [GO:0005634]; plasma membrane [GO:0005886]	calmodulin binding [GO:0005516]; flavin adenine dinucleotide binding [GO:0050660]; FMN binding [GO:0010181]; heme binding [GO:0020037]; metal ion binding [GO:0046872]; NADP binding [GO:0050661]; nitric-oxide synthase activity [GO:0004517]	caveola [GO:0005901]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; Golgi apparatus [GO:0005794]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; calmodulin binding [GO:0005516]; flavin adenine dinucleotide binding [GO:0050660]; FMN binding [GO:0010181]; heme binding [GO:0020037]; metal ion binding [GO:0046872]; NADP binding [GO:0050661]; nitric-oxide synthase activity [GO:0004517]; arginine catabolic process [GO:0006527]; blood coagulation [GO:0007596]; cellular response to laminar fluid shear stress [GO:0071499]; mitochondrion organization [GO:0007005]; negative regulation of blood pressure [GO:0045776]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; negative regulation of leukocyte cell-cell adhesion [GO:1903038]; nitric oxide biosynthetic process [GO:0006809]; nitric oxide mediated signal transduction [GO:0007263]; positive regulation of guanylate cyclase activity [GO:0031284]; response to hormone [GO:0009725]; response to lipopolysaccharide [GO:0032496]	GO:0004517; GO:0005516; GO:0005634; GO:0005794; GO:0005829; GO:0005856; GO:0005886; GO:0005901; GO:0006527; GO:0006809; GO:0007005; GO:0007263; GO:0007596; GO:0009725; GO:0010181; GO:0020037; GO:0031284; GO:0032496; GO:0045776; GO:0046872; GO:0050660; GO:0050661; GO:0071499; GO:1902042; GO:1903038	1378626; 1385480; 1379225; 7682550; 8524847; 12384459; 17071725; 9875848; 11051558; 11331003; 11695891; 11331290; 11590164	10.1073/pnas.89.14.6348; 10.1172/jci116092; 10.1016/s0021-9258(19)49528-8; 10.1016/s0021-9258(18)52889-1; 10.1073/pnas.92.25.11776; 10.1152/ajpheart.00214.2002; 10.1152/ajpheart.00990.2006; 10.1016/s0092-8674(00)81718-3; 10.1016/s0162-0134(00)00099-4; 10.1021/bi002658v; 10.1021/bi010957u; 10.1074/jbc.m102255200; 10.1074/jbc.m011469200		P29473;	CHEMBL4802;	
3pdh	Q9WYW0	reviewed	NPD_THEMA	NAD-dependent protein deacetylase (EC 2.3.1.286) (Regulatory protein SIR2 homolog) (Sir2Tm)	cobB sir2 TM_0490	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	246	MKMKEFLDLLNESRLTVTLTGAGISTPSGIPDFRGPNGIYKKYSQNVFDIDFFYSHPEEFYRFAKEGIFPMLQAKPNLAHVLLAKLEEKGLIEAVITQNIDRLHQRAGSKKVIELHGNVEEYYCVRCEKKYTVEDVIKKLESSDVPLCDDCNSLIRPNIVFFGENLPQDALREAIGLSSRASLMIVLGSSLVVYPAAELPLITVRSGGKLVIVNLGETPFDDIATLKYNMDVVEFARRVMEEGGIS	FUNCTION: NAD-dependent protein deacetylase which modulates the activities of several enzymes which are inactive in their acetylated form. Has also depropionylation activity in vitro. Also able to ADP-ribosylate peptide substrates with Arg or Lys in the +2 position. The role of this function in vivo is not clear. {ECO:0000255|HAMAP-Rule:MF_01968, ECO:0000269|PubMed:16905097, ECO:0000269|PubMed:17684016, ECO:0000269|PubMed:19801667}.			cytoplasm [GO:0005737]	NAD+ binding [GO:0070403]; NAD-dependent histone deacetylase activity [GO:0017136]; transferase activity [GO:0016740]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; NAD+ binding [GO:0070403]; NAD-dependent histone deacetylase activity [GO:0017136]; transferase activity [GO:0016740]; zinc ion binding [GO:0008270]	GO:0005737; GO:0008270; GO:0016740; GO:0017136; GO:0070403	10360571; 17684016; 15780941; 16768447; 16905097; 18786399; 19801667; 21080423	10.1038/20601; 10.1074/jbc.m704409200; 10.1016/j.molcel.2005.02.022; 10.1021/bi0526332; 10.1016/j.str.2006.06.006; 10.1016/j.str.2008.05.015; 10.1074/jbc.m109.024521; 10.1002/pro.544	NP_228300.1;		CHEMBL3217404;	
3pdh	P04637	reviewed	P53_HUMAN	Cellular tumor antigen p53 (Antigen NY-CO-13) (Phosphoprotein p53) (Tumor suppressor p53)	TP53 P53	Homo sapiens (Human)	393	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	FUNCTION: Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17189187, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:9840937). Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:9840937). One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression (PubMed:12524540, PubMed:17189187). Its pro-apoptotic activity is activated via its interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this activity is inhibited when the interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-BMAL1-mediated transcriptional activation of PER2 (PubMed:24051492). {ECO:0000269|PubMed:11025664, ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:17189187, ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:20673990, ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24051492, ECO:0000269|PubMed:24652652, ECO:0000269|PubMed:9840937}.	MISCELLANEOUS: [Isoform 2]: Expressed in quiescent lymphocytes. Seems to be non-functional. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. {ECO:0000305}.; MISCELLANEOUS: [Isoform 3]: Expressed in quiescent lymphocytes. Seems to be non-functional. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. {ECO:0000305}.; MISCELLANEOUS: [Isoform 7]: Produced by alternative promoter usage. {ECO:0000305}.; MISCELLANEOUS: [Isoform 8]: Produced by alternative promoter usage and alternative splicing. {ECO:0000305}.; MISCELLANEOUS: [Isoform 9]: Produced by alternative promoter usage and alternative splicing. {ECO:0000305}.	autophagy [GO:0006914]; B cell lineage commitment [GO:0002326]; bone marrow development [GO:0048539]; cardiac muscle cell apoptotic process [GO:0010659]; cardiac septum morphogenesis [GO:0060411]; cellular response to actinomycin D [GO:0072717]; cellular response to gamma radiation [GO:0071480]; cellular response to glucose starvation [GO:0042149]; cellular response to hypoxia [GO:0071456]; cellular response to ionizing radiation [GO:0071479]; cellular response to UV [GO:0034644]; cellular response to UV-C [GO:0071494]; cellular response to xenobiotic stimulus [GO:0071466]; cellular senescence [GO:0090398]; cerebellum development [GO:0021549]; chromosome organization [GO:0051276]; circadian behavior [GO:0048512]; determination of adult lifespan [GO:0008340]; DNA damage response [GO:0006974]; DNA damage response, signal transduction by p53 class mediator [GO:0030330]; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest [GO:0006977]; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator [GO:0006978]; double-strand break repair [GO:0006302]; embryonic organ development [GO:0048568]; entrainment of circadian clock by photoperiod [GO:0043153]; ER overload response [GO:0006983]; fibroblast proliferation [GO:0048144]; gastrulation [GO:0007369]; glial cell proliferation [GO:0014009]; glucose catabolic process to lactate via pyruvate [GO:0019661]; hematopoietic progenitor cell differentiation [GO:0002244]; hematopoietic stem cell differentiation [GO:0060218]; in utero embryonic development [GO:0001701]; intrinsic apoptotic signaling pathway [GO:0097193]; intrinsic apoptotic signaling pathway by p53 class mediator [GO:0072332]; intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator [GO:0042771]; intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress [GO:0070059]; intrinsic apoptotic signaling pathway in response to hypoxia [GO:1990144]; mitochondrial DNA repair [GO:0043504]; mitophagy [GO:0000423]; mitotic G1 DNA damage checkpoint signaling [GO:0031571]; mRNA transcription [GO:0009299]; multicellular organism growth [GO:0035264]; necroptotic process [GO:0070266]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cell growth [GO:0030308]; negative regulation of cell population proliferation [GO:0008285]; negative regulation of DNA replication [GO:0008156]; negative regulation of DNA-templated transcription [GO:0045892]; negative regulation of fibroblast proliferation [GO:0048147]; negative regulation of G1 to G0 transition [GO:1903451]; negative regulation of glial cell proliferation [GO:0060253]; negative regulation of glucose catabolic process to lactate via pyruvate [GO:1904024]; negative regulation of helicase activity [GO:0051097]; negative regulation of miRNA processing [GO:1903799]; negative regulation of mitophagy [GO:1901525]; negative regulation of neuroblast proliferation [GO:0007406]; negative regulation of pentose-phosphate shunt [GO:1905856]; negative regulation of proteolysis [GO:0045861]; negative regulation of reactive oxygen species metabolic process [GO:2000378]; negative regulation of stem cell proliferation [GO:2000647]; negative regulation of telomere maintenance via telomerase [GO:0032211]; negative regulation of transcription by RNA polymerase II [GO:0000122]; negative regulation of transforming growth factor beta receptor signaling pathway [GO:0030512]; neuroblast proliferation [GO:0007405]; neuron apoptotic process [GO:0051402]; nucleotide-excision repair [GO:0006289]; oligodendrocyte apoptotic process [GO:0097252]; oxidative stress-induced premature senescence [GO:0090403]; positive regulation of apoptotic process [GO:0043065]; positive regulation of cardiac muscle cell apoptotic process [GO:0010666]; positive regulation of cellular senescence [GO:2000774]; positive regulation of DNA-templated transcription [GO:0045893]; positive regulation of execution phase of apoptosis [GO:1900119]; positive regulation of gene expression [GO:0010628]; positive regulation of intrinsic apoptotic signaling pathway [GO:2001244]; positive regulation of miRNA transcription [GO:1902895]; positive regulation of mitochondrial membrane permeability [GO:0035794]; positive regulation of neuron apoptotic process [GO:0043525]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of programmed necrotic cell death [GO:0062100]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; positive regulation of release of cytochrome c from mitochondria [GO:0090200]; positive regulation of RNA polymerase II transcription preinitiation complex assembly [GO:0045899]; positive regulation of thymocyte apoptotic process [GO:0070245]; positive regulation of transcription by RNA polymerase II [GO:0045944]; protein import into nucleus [GO:0006606]; protein localization [GO:0008104]; protein stabilization [GO:0050821]; protein tetramerization [GO:0051262]; protein-containing complex assembly [GO:0065003]; Ras protein signal transduction [GO:0007265]; reactive oxygen species metabolic process [GO:0072593]; regulation of apoptotic process [GO:0042981]; regulation of cell cycle [GO:0051726]; regulation of cell cycle G2/M phase transition [GO:1902749]; regulation of DNA damage response, signal transduction by p53 class mediator [GO:0043516]; regulation of DNA-templated transcription [GO:0006355]; regulation of fibroblast apoptotic process [GO:2000269]; regulation of intrinsic apoptotic signaling pathway by p53 class mediator [GO:1902253]; regulation of mitochondrial membrane permeability involved in apoptotic process [GO:1902108]; regulation of tissue remodeling [GO:0034103]; regulation of transcription by RNA polymerase II [GO:0006357]; release of cytochrome c from mitochondria [GO:0001836]; replicative senescence [GO:0090399]; response to antibiotic [GO:0046677]; response to gamma radiation [GO:0010332]; response to inorganic substance [GO:0010035]; response to ischemia [GO:0002931]; response to salt stress [GO:0009651]; response to X-ray [GO:0010165]; rRNA transcription [GO:0009303]; signal transduction by p53 class mediator [GO:0072331]; somitogenesis [GO:0001756]; stem cell proliferation [GO:0072089]; T cell differentiation in thymus [GO:0033077]; T cell lineage commitment [GO:0002360]; T cell proliferation involved in immune response [GO:0002309]; thymocyte apoptotic process [GO:0070242]; transcription initiation-coupled chromatin remodeling [GO:0045815]; transforming growth factor beta receptor signaling pathway [GO:0007179]; tumor necrosis factor-mediated signaling pathway [GO:0033209]; type II interferon-mediated signaling pathway [GO:0060333]; viral process [GO:0016032]	centrosome [GO:0005813]; chromatin [GO:0000785]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; germ cell nucleus [GO:0043073]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nuclear matrix [GO:0016363]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; PML body [GO:0016605]; protein-containing complex [GO:0032991]; replication fork [GO:0005657]; site of double-strand break [GO:0035861]; transcription regulator complex [GO:0005667]; transcription repressor complex [GO:0017053]	14-3-3 protein binding [GO:0071889]; ATP-dependent DNA/DNA annealing activity [GO:0036310]; chromatin binding [GO:0003682]; cis-regulatory region sequence-specific DNA binding [GO:0000987]; copper ion binding [GO:0005507]; core promoter sequence-specific DNA binding [GO:0001046]; disordered domain specific binding [GO:0097718]; DNA binding [GO:0003677]; DNA-binding transcription activator activity, RNA polymerase II-specific [GO:0001228]; DNA-binding transcription factor activity [GO:0003700]; DNA-binding transcription factor activity, RNA polymerase II-specific [GO:0000981]; DNA-binding transcription repressor activity, RNA polymerase II-specific [GO:0001227]; enzyme binding [GO:0019899]; general transcription initiation factor binding [GO:0140296]; histone deacetylase binding [GO:0042826]; histone deacetylase regulator activity [GO:0035033]; identical protein binding [GO:0042802]; MDM2/MDM4 family protein binding [GO:0097371]; molecular function activator activity [GO:0140677]; mRNA 3'-UTR binding [GO:0003730]; p53 binding [GO:0002039]; promoter-specific chromatin binding [GO:1990841]; protease binding [GO:0002020]; protein heterodimerization activity [GO:0046982]; protein phosphatase 2A binding [GO:0051721]; protein self-association [GO:0043621]; protein-folding chaperone binding [GO:0051087]; receptor tyrosine kinase binding [GO:0030971]; RNA polymerase II cis-regulatory region sequence-specific DNA binding [GO:0000978]; RNA polymerase II-specific DNA-binding transcription factor binding [GO:0061629]; TFIID-class transcription factor complex binding [GO:0001094]; transcription cis-regulatory region binding [GO:0000976]; ubiquitin protein ligase binding [GO:0031625]; zinc ion binding [GO:0008270]	centrosome [GO:0005813]; chromatin [GO:0000785]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; germ cell nucleus [GO:0043073]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nuclear matrix [GO:0016363]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; PML body [GO:0016605]; protein-containing complex [GO:0032991]; replication fork [GO:0005657]; site of double-strand break [GO:0035861]; transcription regulator complex [GO:0005667]; transcription repressor complex [GO:0017053]; 14-3-3 protein binding [GO:0071889]; ATP-dependent DNA/DNA annealing activity [GO:0036310]; chromatin binding [GO:0003682]; cis-regulatory region sequence-specific DNA binding [GO:0000987]; copper ion binding [GO:0005507]; core promoter sequence-specific DNA binding [GO:0001046]; disordered domain specific binding [GO:0097718]; DNA binding [GO:0003677]; DNA-binding transcription activator activity, RNA polymerase II-specific [GO:0001228]; DNA-binding transcription factor activity [GO:0003700]; DNA-binding transcription factor activity, RNA polymerase II-specific [GO:0000981]; DNA-binding transcription repressor activity, RNA polymerase II-specific [GO:0001227]; enzyme binding [GO:0019899]; general transcription initiation factor binding [GO:0140296]; histone deacetylase binding [GO:0042826]; histone deacetylase regulator activity [GO:0035033]; identical protein binding [GO:0042802]; MDM2/MDM4 family protein binding [GO:0097371]; molecular function activator activity [GO:0140677]; mRNA 3'-UTR binding [GO:0003730]; p53 binding [GO:0002039]; promoter-specific chromatin binding [GO:1990841]; protease binding [GO:0002020]; protein heterodimerization activity [GO:0046982]; protein phosphatase 2A binding [GO:0051721]; protein self-association [GO:0043621]; protein-folding chaperone binding [GO:0051087]; receptor tyrosine kinase binding [GO:0030971]; RNA polymerase II cis-regulatory region sequence-specific DNA binding [GO:0000978]; RNA polymerase II-specific DNA-binding transcription factor binding [GO:0061629]; TFIID-class transcription factor complex binding [GO:0001094]; transcription cis-regulatory region binding [GO:0000976]; ubiquitin protein ligase binding [GO:0031625]; zinc ion binding [GO:0008270]; autophagy [GO:0006914]; B cell lineage commitment [GO:0002326]; bone marrow development [GO:0048539]; cardiac muscle cell apoptotic process [GO:0010659]; cardiac septum morphogenesis [GO:0060411]; cellular response to actinomycin D [GO:0072717]; cellular response to gamma radiation [GO:0071480]; cellular response to glucose starvation [GO:0042149]; cellular response to hypoxia [GO:0071456]; cellular response to ionizing radiation [GO:0071479]; cellular response to UV [GO:0034644]; cellular response to UV-C [GO:0071494]; cellular response to xenobiotic stimulus [GO:0071466]; cellular senescence [GO:0090398]; cerebellum development [GO:0021549]; chromosome organization [GO:0051276]; circadian behavior [GO:0048512]; determination of adult lifespan [GO:0008340]; DNA damage response [GO:0006974]; DNA damage response, signal transduction by p53 class mediator [GO:0030330]; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest [GO:0006977]; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator [GO:0006978]; double-strand break repair [GO:0006302]; embryonic organ development [GO:0048568]; entrainment of circadian clock by photoperiod [GO:0043153]; ER overload response [GO:0006983]; fibroblast proliferation [GO:0048144]; gastrulation [GO:0007369]; glial cell proliferation [GO:0014009]; glucose catabolic process to lactate via pyruvate [GO:0019661]; hematopoietic progenitor cell differentiation [GO:0002244]; hematopoietic stem cell differentiation [GO:0060218]; in utero embryonic development [GO:0001701]; intrinsic apoptotic signaling pathway [GO:0097193]; intrinsic apoptotic signaling pathway by p53 class mediator [GO:0072332]; intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator [GO:0042771]; intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress [GO:0070059]; intrinsic apoptotic signaling pathway in response to hypoxia [GO:1990144]; mitochondrial DNA repair [GO:0043504]; mitophagy [GO:0000423]; mitotic G1 DNA damage checkpoint signaling [GO:0031571]; mRNA transcription [GO:0009299]; multicellular organism growth [GO:0035264]; necroptotic process [GO:0070266]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cell growth [GO:0030308]; negative regulation of cell population proliferation [GO:0008285]; negative regulation of DNA replication [GO:0008156]; negative regulation of DNA-templated transcription [GO:0045892]; negative regulation of fibroblast proliferation [GO:0048147]; negative regulation of G1 to G0 transition [GO:1903451]; negative regulation of glial cell proliferation [GO:0060253]; negative regulation of glucose catabolic process to lactate via pyruvate [GO:1904024]; negative regulation of helicase activity [GO:0051097]; negative regulation of miRNA processing [GO:1903799]; negative regulation of mitophagy [GO:1901525]; negative regulation of neuroblast proliferation [GO:0007406]; negative regulation of pentose-phosphate shunt [GO:1905856]; negative regulation of proteolysis [GO:0045861]; negative regulation of reactive oxygen species metabolic process [GO:2000378]; negative regulation of stem cell proliferation [GO:2000647]; negative regulation of telomere maintenance via telomerase [GO:0032211]; negative regulation of transcription by RNA polymerase II [GO:0000122]; negative regulation of transforming growth factor beta receptor signaling pathway [GO:0030512]; neuroblast proliferation [GO:0007405]; neuron apoptotic process [GO:0051402]; nucleotide-excision repair [GO:0006289]; oligodendrocyte apoptotic process [GO:0097252]; oxidative stress-induced premature senescence [GO:0090403]; positive regulation of apoptotic process [GO:0043065]; positive regulation of cardiac muscle cell apoptotic process [GO:0010666]; positive regulation of cellular senescence [GO:2000774]; positive regulation of DNA-templated transcription [GO:0045893]; positive regulation of execution phase of apoptosis [GO:1900119]; positive regulation of gene expression [GO:0010628]; positive regulation of intrinsic apoptotic signaling pathway [GO:2001244]; positive regulation of miRNA transcription [GO:1902895]; positive regulation of mitochondrial membrane permeability [GO:0035794]; positive regulation of neuron apoptotic process [GO:0043525]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of programmed necrotic cell death [GO:0062100]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; positive regulation of release of cytochrome c from mitochondria [GO:0090200]; positive regulation of RNA polymerase II transcription preinitiation complex assembly [GO:0045899]; positive regulation of thymocyte apoptotic process [GO:0070245]; positive regulation of transcription by RNA polymerase II [GO:0045944]; protein import into nucleus [GO:0006606]; protein localization [GO:0008104]; protein stabilization [GO:0050821]; protein tetramerization [GO:0051262]; protein-containing complex assembly [GO:0065003]; Ras protein signal transduction [GO:0007265]; reactive oxygen species metabolic process [GO:0072593]; regulation of apoptotic process [GO:0042981]; regulation of cell cycle [GO:0051726]; regulation of cell cycle G2/M phase transition [GO:1902749]; regulation of DNA damage response, signal transduction by p53 class mediator [GO:0043516]; regulation of DNA-templated transcription [GO:0006355]; regulation of fibroblast apoptotic process [GO:2000269]; regulation of intrinsic apoptotic signaling pathway by p53 class mediator [GO:1902253]; regulation of mitochondrial membrane permeability involved in apoptotic process [GO:1902108]; regulation of tissue remodeling [GO:0034103]; regulation of transcription by RNA polymerase II [GO:0006357]; release of cytochrome c from mitochondria [GO:0001836]; replicative senescence [GO:0090399]; response to antibiotic [GO:0046677]; response to gamma radiation [GO:0010332]; response to inorganic substance [GO:0010035]; response to ischemia [GO:0002931]; response to salt stress [GO:0009651]; response to X-ray [GO:0010165]; rRNA transcription [GO:0009303]; signal transduction by p53 class mediator [GO:0072331]; somitogenesis [GO:0001756]; stem cell proliferation [GO:0072089]; T cell differentiation in thymus [GO:0033077]; T cell lineage commitment [GO:0002360]; T cell proliferation involved in immune response [GO:0002309]; thymocyte apoptotic process [GO:0070242]; transcription initiation-coupled chromatin remodeling [GO:0045815]; transforming growth factor beta receptor signaling pathway [GO:0007179]; tumor necrosis factor-mediated signaling pathway [GO:0033209]; type II interferon-mediated signaling pathway [GO:0060333]; viral process [GO:0016032]	GO:0000122; GO:0000423; GO:0000785; GO:0000976; GO:0000978; GO:0000981; GO:0000987; GO:0001046; GO:0001094; GO:0001227; GO:0001228; GO:0001701; GO:0001756; GO:0001836; GO:0002020; GO:0002039; GO:0002244; GO:0002309; GO:0002326; GO:0002360; GO:0002931; GO:0003677; GO:0003682; GO:0003700; GO:0003730; GO:0005507; GO:0005634; GO:0005654; GO:0005657; GO:0005667; GO:0005730; GO:0005737; GO:0005739; GO:0005759; GO:0005783; GO:0005813; GO:0005829; GO:0006289; GO:0006302; GO:0006355; GO:0006357; GO:0006606; GO:0006914; GO:0006974; GO:0006977; GO:0006978; GO:0006983; GO:0007179; GO:0007265; GO:0007369; GO:0007405; GO:0007406; GO:0008104; GO:0008156; GO:0008270; GO:0008285; GO:0008340; GO:0009299; GO:0009303; GO:0009651; GO:0010035; GO:0010165; GO:0010332; GO:0010628; GO:0010659; GO:0010666; GO:0014009; GO:0016032; GO:0016363; GO:0016605; GO:0017053; GO:0019661; GO:0019899; GO:0021549; GO:0030308; GO:0030330; GO:0030512; GO:0030971; GO:0031571; GO:0031625; GO:0032211; GO:0032991; GO:0033077; GO:0033209; GO:0034103; GO:0034644; GO:0035033; GO:0035264; GO:0035794; GO:0035861; GO:0036310; GO:0042149; GO:0042771; GO:0042802; GO:0042826; GO:0042981; GO:0043065; GO:0043066; GO:0043073; GO:0043153; GO:0043504; GO:0043516; GO:0043525; GO:0043621; GO:0045815; GO:0045861; GO:0045892; GO:0045893; GO:0045899; GO:0045944; GO:0046677; GO:0046982; GO:0048144; GO:0048147; GO:0048512; GO:0048539; GO:0048568; GO:0050731; GO:0050821; GO:0051087; GO:0051097; GO:0051262; GO:0051276; GO:0051402; GO:0051721; GO:0051726; GO:0060218; GO:0060253; GO:0060333; GO:0060411; GO:0061629; GO:0062100; GO:0065003; GO:0070059; GO:0070242; GO:0070245; GO:0070266; GO:0071456; GO:0071466; GO:0071479; GO:0071480; GO:0071494; GO:0071889; GO:0072089; GO:0072331; GO:0072332; GO:0072593; GO:0072717; GO:0090200; GO:0090398; GO:0090399; GO:0090403; GO:0097193; GO:0097252; GO:0097371; GO:0097718; GO:0140296; GO:0140677; GO:1900119; GO:1901525; GO:1902108; GO:1902253; GO:1902749; GO:1902895; GO:1903451; GO:1903799; GO:1904024; GO:1905856; GO:1990144; GO:1990841; GO:2000269; GO:2000378; GO:2000379; GO:2000647; GO:2000774; GO:2001244	4006916; 2946935; 3894933; 3025664; 2905688; 1915267; 8316628; 11058590; 16131611; 11023613; 14702039; 16625196; 15489334; 14660794; 6396087; 19011621; 2175676; 2156209; 2141171; 1705009; 1848668; 8632903; 8632915; 9372954; 9840937; 10606744; 10551826; 10570149; 10722742; 10656795; 10884347; 11025664; 10644996; 10951572; 11554448; 11554766; 11672523; 11007800; 11447225; 11551930; 11124955; 11546806; 11239457; 12507430; 11706030; 11925430; 11740489; 11780126; 12750254; 12724314; 12810724; 12851404; 12944468; 12524540; 12702766; 15109303; 15186775; 15136035; 15053879; 15053880; 15340061; 15525938; 15448695; 14702041; 15687255; 16322561; 15701641; 32144153; 15855171; 16219768; 15866171; 17108107; 16704422; 16376338; 16377624; 17189187; 17108971; 16845383; 16415881; 17145718; 17254968; 17719541; 17170702; 17245430; 17904127; 18022393; 17467953; 17121812; 17317671; 17591690; 17332504; 17349958; 17805299; 17707234; 17525332; 18249187; 18585004; 18690848; 18206965; 17954561; 17967874; 19413330; 19536131; 19473992; 19033443; 19837670; 19776115; 19854137; 19509332; 19556538; 19608861; 20096117; 20096447; 20673990; 20041275; 20385133; 19880522; 20118233; 20124405; 20228809; 20173098; 20660729; 21269460; 21952639; 21597459; 20959462; 35122041; 21946351; 21317932; 22726440; 22214662; 22522597; 22945289; 22864287; 24051492; 23431171; 24625977; 23752197; 24652652; 25422469; 25168243; 26634371; 25591766; 25772236; 27323408; 28842590; 28807825; 33591310; 30146126; 29681526; 29474172; 31527692; 34523970; 34404770; 8023159; 7773777; 9321402; 8023157; 7878469; 8875929; 8875926; 14534297; 16793544; 16474402; 16402859; 20870725; 8266092; 1905840; 8829653; 17015838; 18453682; 18650397; 18996393; 19515728; 20142040; 20364130; 32442400; 1999338; 1933902; 1978757; 2259385; 1737852; 1565144; 1694291; 1699228; 2263646; 1647768; 1868473; 1849234; 1672732; 1394225; 1327751; 1459726; 1303181; 1437144; 1631151; 7682763; 8402617; 8336944; 8118819; 8013454; 7887414; 8718514; 8825920; 8829627; 9101296; 9419979; 9450901; 9452042; 10484981; 10549356; 11481490; 12085209; 16959974; 17224074; 17311302; 25732823; 27657329	10.1002/j.1460-2075.1985.tb03768.x; 10.1128/mcb.6.5.1379-1385.1986; 10.1128/mcb.5.7.1601-1610.1985; 10.1128/mcb.6.12.4650-4656.1986; 10.1016/0378-1119(88)90196-5; 10.1002/j.1460-2075.1991.tb07837.x; 10.2307/3578196; 10.1074/jbc.m007140200; 10.1101/gad.1339905; 10.1667/0033-7587(2000)154[0473:htftmg]2.0.co;2; 10.1038/ng1285; 10.1038/nature04689; 10.1101/gr.2596504; 10.1073/pnas.2536558100; 10.1002/j.1460-2075.1984.tb02287.x; 10.1038/ncb1802; 10.1016/0092-8674(90)90409-8; 10.1073/pnas.87.12.4766; 10.1128/mcb.11.3.1598-1606.1991; 10.1128/mcb.11.4.1996-2003.1991; 10.1128/mcb.17.12.7220; 10.1038/sj.onc.1202504; 10.1016/s0014-5793(99)01647-6; 10.1074/jbc.274.46.32699; 10.1073/pnas.96.24.13777; 10.1074/jbc.275.12.8945; 10.1006/jmbi.1999.3415; 10.1006/jmbi.2000.3830; 10.1038/35036365; 10.1038/sj.onc.1203250; 10.1038/sj.onc.1203709; 10.1089/15230860152542961; 10.1006/bbrc.2001.5627; 10.1016/s0092-8674(01)00527-x; 10.1074/jbc.m008231200; 10.1074/jbc.m104157200; 10.1074/jbc.m106050200; 10.1074/jbc.m009476200; 10.1074/jbc.m105669200; 10.1016/s1097-2765(01)00176-9; 10.1016/s0092-8674(02)01199-6; 10.1074/jbc.m108535200; 10.1074/jbc.m200153200; 10.1038/ncb715; 10.1038/ncb714; 10.1074/jbc.m212574200; 10.1074/jbc.m301264200; 10.1074/jbc.m301979200; 10.1128/mcb.23.18.6396-6405.2003; 10.1038/ng1070; 10.1073/pnas.0530308100; 10.1042/bj20040337; 10.1016/j.cell.2004.05.009; 10.1016/j.jmb.2004.03.071; 10.1016/s1097-2765(04)00123-6; 10.1016/s1097-2765(04)00157-1; 10.1128/mcb.24.18.7987-7997.2004; 10.1038/nature03117; 10.1038/ncb1170; 10.1038/ng1279; 10.1101/gad.319905; 10.1101/gad.351205; 10.1074/jbc.m413200200; 10.1074/jbc.w120.012894; 10.1074/jbc.m414172200; 10.1074/jbc.m505590200; 10.1016/j.molcel.2005.03.027; 10.1158/0008-5472.can-06-0999; 10.1111/j.1742-4658.2006.05256.x; 10.1016/j.febslet.2005.12.024; 10.1074/jbc.m512074200; 10.1016/j.molcel.2006.11.026; 10.1038/nature05287; 10.1038/ncb1442; 10.1038/nsmb1045; 10.1093/nar/gkl878; 10.1016/j.cell.2006.11.050; 10.1016/j.cell.2007.06.013; 10.1038/sj.emboj.7601490; 10.1038/sj.emboj.7601519; 10.1016/j.febslet.2007.09.025; 10.1016/j.febslet.2007.11.022; 10.1016/j.ygeno.2007.02.003; 10.1074/jbc.m610793200; 10.1074/jbc.m608974200; 10.1242/jcs.03468; 10.1091/mbc.e06-08-0747; 10.1016/j.molcel.2007.02.007; 10.1038/nature06092; 10.1016/j.molcel.2007.07.012; 10.1126/science.1140321; 10.1016/j.bbrc.2008.01.114; 10.1016/j.cellsig.2008.05.012; 10.2174/156800908785133196; 10.1016/j.molcel.2007.11.031; 10.1128/mcb.00662-07; 10.1128/mcb.00983-07; 10.1021/ac9004309; 10.1038/emboj.2009.164; 10.1074/jbc.c109.001560; 10.1074/jbc.m805658200; 10.1074/jbc.m109.056499; 10.1128/jvi.00304-09; 10.1016/j.molcel.2009.07.031; 10.1073/pnas.0901864106; 10.1073/pnas.0813177106; 10.1126/science.1175371; 10.1186/1471-2199-11-10; 10.1016/j.cell.2009.12.032; 10.1016/j.cell.2010.06.040; 10.1007/s00018-009-0236-7; 10.1016/j.febslet.2010.04.006; 10.1074/jbc.m109.064212; 10.1074/jbc.m109.062588; 10.1074/jbc.m109.094243; 10.1038/ncb2038; 10.1073/pnas.0912094107; 10.1073/pnas.1009559107; 10.1186/1752-0509-5-17; 10.4161/cc.10.19.17176; 10.1038/cdd.2011.57; 10.1074/jbc.m110.174755; 10.1038/s43018-020-0086-7; 10.1038/ng.926; 10.1038/onc.2011.19; 10.1016/j.cell.2012.05.014; 10.4161/cc.11.2.18999; 10.1038/cdd.2012.40; 10.1002/eji.201242530; 10.1038/nsmb.2353; 10.1038/ncomms3444; 10.1073/pnas.1300490110; 10.1038/cddis.2014.100; 10.1038/onc.2013.213; 10.1093/jnci/dju053; 10.1073/pnas.1403383111; 10.1038/cdd.2014.135; 10.1007/s12192-015-0661-5; 10.1159/000369691; 10.1038/onc.2015.63; 10.18632/oncotarget.9959; 10.1038/s41598-017-09779-w; 10.1016/j.bbrc.2017.08.036; 10.1093/nar/gkab084; 10.1016/j.ajhg.2018.07.020; 10.1016/j.chembiol.2018.03.010; 10.7554/elife.32127; 10.1038/s41598-019-49821-7; 10.1128/jvi.01459-21; 10.1038/s41467-021-24932-w; 10.1126/science.8023159; 10.1038/nsb1294-877; 10.1093/emboj/16.20.6230; 10.1126/science.8023157; 10.1126/science.7878469; 10.1126/science.274.5289.948; 10.1126/science.274.5289.1001; 10.1074/jbc.m309732200; 10.1016/j.molcel.2006.05.015; 10.1038/nsmb1067; 10.1371/journal.pbio.0040027; 10.1074/jbc.m110.139527; 10.1126/science.8266092; 10.1126/science.1905840; 10.1002/(sici)1098-1004(1996)7:3<202::aid-humu4>3.0.co;2-c; 10.1073/pnas.0607286103; 10.1107/s0907444908003338; 10.1073/pnas.0805326105; 10.1016/j.jmb.2008.10.063; 10.1093/protein/gzp018; 10.1016/j.chembiol.2009.12.011; 10.1038/nsmb.1800; 10.1016/j.str.2020.05.001; 10.1007/bf00201836; 10.1126/science.1978757; 10.1038/348747a0; 10.1172/jci115630; 10.1056/nejm199205143262002; 10.1073/pnas.87.19.7555; 10.1073/pnas.87.24.9958; 10.1016/0006-291x(91)90623-f; 10.1038/350427a0; 10.1038/350429a0; 10.1002/j.1460-2075.1992.tb05487.x; 10.1002/ijc.2910520606; 10.1093/hmg/1.3.207; 10.1073/pnas.89.14.6516; 10.1002/j.1460-2075.1994.tb06543.x; 10.1136/jmg.32.12.942; 10.1002/(sici)1098-1004(1996)7:2<109::aid-humu4>3.0.co;2-7; 10.1002/(sici)1098-1004(1997)9:4<348::aid-humu8>3.0.co;2-1; 10.1038/sj.onc.1201668; 10.1002/(sici)1098-1004(1998)11:1<39::aid-humu6>3.0.co;2-g; 10.1002/humu.1380110121; 10.1016/s0165-4608(98)00276-3; 10.1016/s0065-230x(08)60785-x; 10.1073/pnas.161479898; 10.1038/sj.bjc.6600269; 10.1126/science.1133427; 10.1186/bcr1637; 10.1002/humu.20495; 10.1016/j.celrep.2015.01.066; 10.1371/journal.pbio.1002555	NP_000537.3 [P04637-1];NP_001119584.1 [P04637-1];NP_001119585.1 [P04637-3];NP_001119586.1 [P04637-2];NP_001119587.1 [P04637-7];NP_001119588.1 [P04637-8];NP_001119589.1 [P04637-9];NP_001119590.1 [P04637-4];NP_001263624.1 [P04637-6];NP_001263625.1 [P04637-5];NP_001263626.1;NP_001263627.1;NP_001263628.1;NP_001263689.1 [P04637-4];NP_001263690.1 [P04637-4];	P04637;	CHEMBL4096;	DB08363;DB00945;DB05404;DB03347;DB01593;DB14487;DB14533;DB14548;
1umd	Q5SLR3	reviewed	ODBB_THET8	2-oxoisovalerate dehydrogenase subunit beta (EC 1.2.4.4) (Branched-chain alpha-keto acid dehydrogenase E1 component beta chain) (BCKDH E1-beta)	TTHA0230	Thermus thermophilus (strain ATCC 27634 / DSM 579 / HB8)	324	MALMTMVQALNRALDEEMAKDPRVVVLGEDVGKRGGVFLVTEGLLQKYGPDRVMDTPLSEAAIVGAALGMAAHGLRPVAEIQFADYIFPGFDQLVSQVAKLRYRSGGQFTAPLVVRMPSGGGVRGGHHHSQSPEAHFVHTAGLKVVAVSTPYDAKGLLKAAIRDEDPVVFLEPKRLYRSVKEEVPEEDYTLPIGKAALRREGKDLTLIGYGTVMPEVLQAAAELAKAGVSAEVLDLRTLMPWDYEAVMNSVAKTGRVVLVSDAPRHASFVSEVAATIAEDLLDMLLAPPIRVTGFDTPYPYAQDKLYLPTVTRILNAAKRALDY	FUNCTION: The branched-chain alpha-keto dehydrogenase complex catalyzes the overall conversion of alpha-keto acids to acyl-CoA and CO(2). It contains multiple copies of three enzymatic components: branched-chain alpha-keto acid decarboxylase (E1), lipoamide acyltransferase (E2) and lipoamide dehydrogenase (E3) (By similarity). {ECO:0000250|UniProtKB:P37941}.		branched-chain amino acid catabolic process [GO:0009083]; response to nutrient [GO:0007584]		3-methyl-2-oxobutanoate dehydrogenase (2-methylpropanoyl-transferring) activity [GO:0003863]	3-methyl-2-oxobutanoate dehydrogenase (2-methylpropanoyl-transferring) activity [GO:0003863]; branched-chain amino acid catabolic process [GO:0009083]; response to nutrient [GO:0007584]	GO:0003863; GO:0007584; GO:0009083	15033367	10.1016/j.jmb.2004.02.011	WP_011227794.1;YP_143496.1;			
1umd	Q5SLR4	reviewed	ODBA_THET8	2-oxoisovalerate dehydrogenase subunit alpha (EC 1.2.4.4) (Branched-chain alpha-keto acid dehydrogenase E1 component alpha chain) (BCKDH E1-alpha)	TTHA0229	Thermus thermophilus (strain ATCC 27634 / DSM 579 / HB8)	367	MVKETHRFETFTEEPIRLIGEEGEWLGDFPLDLEGEKLRRLYRDMLAARMLDERYTILIRTGKTSFIAPAAGHEAAQVAIAHAIRPGFDWVFPYYRDHGLALALGIPLKELLGQMLATKADPNKGRQMPEHPGSKALNFFTVASPIASHVPPAAGAAISMKLLRTGQVAVCTFGDGATSEGDWYAGINFAAVQGAPAVFIAENNFYAISVDYRHQTHSPTIADKAHAFGIPGYLVDGMDVLASYYVVKEAVERARRGEGPSLVELRVYRYGPHSSADDDSRYRPKEEVAFWRKKDPIPRFRRFLEARGLWNEEWEEDVREEIRAELERGLKEAEEAGPVPPEWMFEDVFAEKPWHLLRQEALLKEEL	FUNCTION: The branched-chain alpha-keto dehydrogenase complex catalyzes the overall conversion of alpha-keto acids to acyl-CoA and CO(2). It contains multiple copies of three enzymatic components: branched-chain alpha-keto acid decarboxylase (E1), lipoamide acyltransferase (E2) and lipoamide dehydrogenase (E3) (By similarity). {ECO:0000250|UniProtKB:P37940}.		branched-chain amino acid catabolic process [GO:0009083]		3-methyl-2-oxobutanoate dehydrogenase (2-methylpropanoyl-transferring) activity [GO:0003863]; metal ion binding [GO:0046872]	3-methyl-2-oxobutanoate dehydrogenase (2-methylpropanoyl-transferring) activity [GO:0003863]; metal ion binding [GO:0046872]; branched-chain amino acid catabolic process [GO:0009083]	GO:0003863; GO:0009083; GO:0046872	15033367	10.1016/j.jmb.2004.02.011	WP_011227793.1;YP_143495.1;			
4pxz	P0ABE7	reviewed	C562_ECOLX	Soluble cytochrome b562 (Cytochrome b-562)	cybC	Escherichia coli	128	MRKSLLAILAVSSLVFSSASFAADLEDNMETLNDNLKVIEKADNAAQVKDALTKMRAAALDAQKATPPKLEDKSPDSPEMKDFRHGFDILVGQIDDALKLANEGKVKEAQAAAEQLKTTRNAYHQKYR	FUNCTION: Electron-transport protein of unknown function.		electron transport chain [GO:0022900]	periplasmic space [GO:0042597]	electron transfer activity [GO:0009055]; heme binding [GO:0020037]; iron ion binding [GO:0005506]	periplasmic space [GO:0042597]; electron transfer activity [GO:0009055]; heme binding [GO:0020037]; iron ion binding [GO:0005506]; electron transport chain [GO:0022900]	GO:0005506; GO:0009055; GO:0020037; GO:0022900; GO:0042597	1761034; 8499452; 4882876; 368073; 7031264; 7723042; 11914078; 10393541; 11669612	10.1111/j.1432-1033.1991.tb16377.x; 10.1016/0005-2728(93)90223-3; 10.1016/0006-291x(68)90130-7; 10.1016/s0021-9258(17)37829-8; 10.1016/0022-2836(81)90185-6; 10.1006/jmbi.1995.0192; 10.1021/bi012066s; 10.1021/bi982785f; 10.1021/bi0101300	WP_001232240.1;			DB02182;DB08440;
4pxz	Q9H244	reviewed	P2Y12_HUMAN	P2Y purinoceptor 12 (P2Y12) (ADP-glucose receptor) (ADPG-R) (P2T(AC)) (P2Y(AC)) (P2Y(cyc)) (P2Y12 platelet ADP receptor) (P2Y(ADP)) (SP1999)	P2RY12 HORK3	Homo sapiens (Human)	342	MQAVDNLTSAPGNTSLCTRDYKITQVLFPLLYTVLFFVGLITNGLAMRIFFQIRSKSNFIIFLKNTVISDLLMILTFPFKILSDAKLGTGPLRTFVCQVTSVIFYFTMYISISFLGLITIDRYQKTTRPFKTSNPKNLLGAKILSVVIWAFMFLLSLPNMILTNRQPRDKNVKKCSFLKSEFGLVWHEIVNYICQVIFWINFLIVIVCYTLITKELYRSYVRTRGVGKVPRKKVNVKVFIIIAVFFICFVPFHFARIPYTLSQTRDVFDCTAENTLFYVKESTLWLTSLNACLDPFIYFFLCKSFRNSLISMLKCPNSATSLSQDNRKKEQDGGDPNEETPM	FUNCTION: Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation. {ECO:0000269|PubMed:11104774, ECO:0000269|PubMed:11196645, ECO:0000269|PubMed:11502873, ECO:0000269|PubMed:12578987, ECO:0000269|PubMed:24670650, ECO:0000269|PubMed:24784220}.		adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway [GO:0007193]; calcium-mediated signaling [GO:0019722]; calcium-mediated signaling using extracellular calcium source [GO:0035585]; cell projection organization [GO:0030030]; cellular response to ATP [GO:0071318]; cerebral cortex radial glia-guided migration [GO:0021801]; establishment of localization in cell [GO:0051649]; G protein-coupled receptor signaling pathway [GO:0007186]; hemostasis [GO:0007599]; lamellipodium assembly [GO:0030032]; monoatomic ion transport [GO:0006811]; phospholipase C-activating G protein-coupled receptor signaling pathway [GO:0007200]; platelet activation [GO:0030168]; platelet aggregation [GO:0070527]; positive regulation of cell adhesion mediated by integrin [GO:0033630]; positive regulation of chemotaxis [GO:0050921]; positive regulation of integrin activation by cell surface receptor linked signal transduction [GO:0033626]; positive regulation of microglial cell migration [GO:1904141]; positive regulation of monoatomic ion transport [GO:0043270]; positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction [GO:0051897]; positive regulation of ruffle assembly [GO:1900029]; regulation of chemotaxis [GO:0050920]; regulation of microglial cell migration [GO:1904139]; response to axon injury [GO:0048678]; substrate-dependent cell migration, cell extension [GO:0006930]; visual system development [GO:0150063]	cell body membrane [GO:0044298]; cell projection membrane [GO:0031253]; cell surface [GO:0009986]; membrane [GO:0016020]; plasma membrane [GO:0005886]	G protein-coupled adenosine receptor activity [GO:0001609]; G protein-coupled ADP receptor activity [GO:0001621]; G protein-coupled purinergic nucleotide receptor activity [GO:0045028]; guanyl-nucleotide exchange factor activity [GO:0005085]	cell body membrane [GO:0044298]; cell projection membrane [GO:0031253]; cell surface [GO:0009986]; membrane [GO:0016020]; plasma membrane [GO:0005886]; G protein-coupled adenosine receptor activity [GO:0001609]; G protein-coupled ADP receptor activity [GO:0001621]; G protein-coupled purinergic nucleotide receptor activity [GO:0045028]; guanyl-nucleotide exchange factor activity [GO:0005085]; adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway [GO:0007193]; calcium-mediated signaling [GO:0019722]; calcium-mediated signaling using extracellular calcium source [GO:0035585]; cell projection organization [GO:0030030]; cellular response to ATP [GO:0071318]; cerebral cortex radial glia-guided migration [GO:0021801]; establishment of localization in cell [GO:0051649]; G protein-coupled receptor signaling pathway [GO:0007186]; hemostasis [GO:0007599]; lamellipodium assembly [GO:0030032]; monoatomic ion transport [GO:0006811]; phospholipase C-activating G protein-coupled receptor signaling pathway [GO:0007200]; platelet activation [GO:0030168]; platelet aggregation [GO:0070527]; positive regulation of cell adhesion mediated by integrin [GO:0033630]; positive regulation of chemotaxis [GO:0050921]; positive regulation of integrin activation by cell surface receptor linked signal transduction [GO:0033626]; positive regulation of microglial cell migration [GO:1904141]; positive regulation of monoatomic ion transport [GO:0043270]; positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction [GO:0051897]; positive regulation of ruffle assembly [GO:1900029]; regulation of chemotaxis [GO:0050920]; regulation of microglial cell migration [GO:1904139]; response to axon injury [GO:0048678]; substrate-dependent cell migration, cell extension [GO:0006930]; visual system development [GO:0150063]	GO:0001609; GO:0001621; GO:0005085; GO:0005886; GO:0006811; GO:0006930; GO:0007186; GO:0007193; GO:0007200; GO:0007599; GO:0009986; GO:0016020; GO:0019722; GO:0021801; GO:0030030; GO:0030032; GO:0030168; GO:0031253; GO:0033626; GO:0033630; GO:0035585; GO:0043270; GO:0044298; GO:0045028; GO:0048678; GO:0050920; GO:0050921; GO:0051649; GO:0051897; GO:0070527; GO:0071318; GO:0150063; GO:1900029; GO:1904139; GO:1904141	11196645; 11104774; 11502873; 12044878; 15489334; 24670650; 24784220; 12578987; 25428217	10.1038/35051599; 10.1074/jbc.m009718200; 10.1016/s0014-5793(02)02775-8; 10.1101/gr.2596504; 10.1038/nature13083; 10.1038/nature13288; 10.1073/pnas.0437879100; 10.1182/blood-2013-07-517896	NP_073625.1;NP_795345.1;XP_016862558.1;	Q9H244;	CHEMBL2001;	DB06441;DB00758;DB06350;DB01240;DB06209;DB01069;DB05553;DB15163;DB08816;DB00208;DB00374;DB16349;
2gns	P59071	reviewed	PA2B8_DABRR	Basic phospholipase A2 VRV-PL-VIIIa (svPLA2) (EC 3.1.1.4) (DPLA2) (P1) (Phosphatidylcholine 2-acylhydrolase) (Phospholipase A2 4) (PLA24)		Daboia russelii (Russel's viper) (Vipera russelii)	121	SLLEFGKMILEETGKLAIPSYSSYGCYCGWGGKGTPKDATDRCCFVHDCCYGNLPDCNPKSDRYKYKRVNGAIVCEKGTSCENRICECDKAAAICFRQNLNTYSKKYMLYPDFLCKGELKC	FUNCTION: Snake venom phospholipase A2 (PLA2) that shows weak neurotoxicity and medium anticoagulant effects by binding to factor Xa (F10) and inhibiting the prothrombinase activity (IC(50) is 130 nM) (PubMed:18062812). It also damages vital organs such as lung, liver and kidney, displays edema-inducing activities when injected into the foot pads of mice and induces necrosis of muscle cells when injected into the thigh muscle. Has a low enzymatic activity. PLA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. {ECO:0000269|PubMed:18062812, ECO:0000269|PubMed:2115497, ECO:0000269|PubMed:8835338}.	MISCELLANEOUS: D.russelli pulchella is synonymous with D.russelii. {ECO:0000305|PubMed:15544328, ECO:0000305|PubMed:16596639}.	arachidonic acid secretion [GO:0050482]; lipid catabolic process [GO:0016042]; negative regulation of T cell proliferation [GO:0042130]; phospholipid metabolic process [GO:0006644]	extracellular region [GO:0005576]	calcium ion binding [GO:0005509]; calcium-dependent phospholipase A2 activity [GO:0047498]; phospholipid binding [GO:0005543]; toxin activity [GO:0090729]	extracellular region [GO:0005576]; calcium ion binding [GO:0005509]; calcium-dependent phospholipase A2 activity [GO:0047498]; phospholipid binding [GO:0005543]; toxin activity [GO:0090729]; arachidonic acid secretion [GO:0050482]; lipid catabolic process [GO:0016042]; negative regulation of T cell proliferation [GO:0042130]; phospholipid metabolic process [GO:0006644]	GO:0005509; GO:0005543; GO:0005576; GO:0006644; GO:0016042; GO:0042130; GO:0047498; GO:0050482; GO:0090729	7940574; 8835338; 20203422; 2718191; 2115497; 18062812; 10686108; 11717491; 12351825; 12206661; 12186870; 15544328; 16596639; 25541253	10.1016/0041-0101(94)90336-0; 10.1016/0041-0101(95)00114-x; 10.2220/biomedres.31.71; 10.1016/0041-0101(89)90136-0; 10.1186/1472-6807-7-82; 10.1006/jmbi.2000.3537; 10.1107/s0907444901014524; 10.1107/s0907444902013720; 10.1021/bi0258593; 10.1074/jbc.m206130200; 10.1021/bi0483561; 10.1002/prot.20970; 10.1016/j.bbapap.2014.12.017		P59071;	CHEMBL3784910;	
1ai4	P06875	reviewed	PAC_ECOLX	Penicillin G acylase (EC 3.5.1.11) (Penicillin G amidase) (Penicillin G amidohydrolase) [Cleaved into: Penicillin G acylase subunit alpha; Penicillin G acylase subunit beta]	pac	Escherichia coli	846	MKNRNRMIVNCVTASLMYYWSLPALAEQSSSEIKIVRDEYGMPHIYANDTWHLFYGYGYVVAQDRLFQMEMARRSTQGTVAEVLGKDFVKFDKDIRRNYWPDAIRAQIAALSPEDMSILQGYADGMNAWIDKVNTNPETLLPKQFNTFGFTPKRWEPFDVAMIFVGTMANRFSDSTSEIDNLALLTALKDKYGVSQGMAVFNQLKWLVNPSAPTTIAVQESNYPLKFNQQNSQTAALLPRYDLPAPMLDRPAKGADGALLALTAGKNRETIAAQFAQGGANGLAGYPTTSNMWVIGKSKAQDAKAIMVNGPQFGWYAPAYTYGIGLHGAGYDVTGNTPFAYPGLVFGHNGVISWGSTAGFGDDVDIFAERLSAEKPGYYLHNGKWVKMLSREETITVKNGQAETFTVWRTVHGNILQTDQTTQTAYAKSRAWDGKEVASLLAWTHQMKAKNWQEWTQQAAKQALTINWYYADVNGNIGYVHTGAYPDRQSGHDPRLPVPGTGKWDWKGLLPFEMNPKVYNPQSGYIANWNNSPQKDYPASDLFAFLWGGADRVTEIDRLLEQKPRLTADQAWDVIRQTSRQDLNLRLFLPTLQAATSGLTQSDPRRQLVETLTRWDGINLLNDDGKTWQQPGSAILNVWLTSMLKRTVVAAVPMPFDKWYSASGYETTQDGPTGSLNISVGAKILYEAVQGDKSPIPQAVDLFAGKPQQEVVLAALEDTWETLSKRYGNNVSNWKTPAMALTFRANNFFGVPQAAAEETRHQAEYQNRGTENDMIVFSPTTSDRPVLAWDVVAPGQSGFIAPDGTVDKHYEDQLKMYENFGRKSLWLTKQDVEAHKESQEVLHVQR			antibiotic biosynthetic process [GO:0017000]; response to antibiotic [GO:0046677]	periplasmic space [GO:0042597]	metal ion binding [GO:0046872]; penicillin amidase activity [GO:0008953]	periplasmic space [GO:0042597]; metal ion binding [GO:0046872]; penicillin amidase activity [GO:0008953]; antibiotic biosynthetic process [GO:0017000]; response to antibiotic [GO:0046677]	GO:0008953; GO:0017000; GO:0042597; GO:0046677; GO:0046872	3016663; 3315861; 3005131; 3556321; 2989404; 1849824; 2205499; 7816145; 11601852	10.1093/nar/14.14.5713; 10.1016/0378-1119(87)90161-2; 10.1016/0378-1119(85)90018-6; 10.1016/0378-1119(86)90316-1; 10.1111/j.1432-1033.1991.tb15884.x; 10.1111/j.1432-1033.1990.tb19207.x; 10.1038/373264a0; 10.1006/jmbi.2001.5043	WP_000797400.1;			DB01702;DB08193;DB08327;DB08559;DB07331;
5mma	P14350	reviewed	POL_FOAMV	Pro-Pol polyprotein (Pr125Pol) [Cleaved into: Protease/Reverse transcriptase/ribonuclease H (EC 2.7.7.49) (EC 2.7.7.7) (EC 3.1.26.4) (EC 3.4.23.-) (p87Pro-RT-RNaseH); Protease/Reverse transcriptase (EC 2.7.7.49) (EC 2.7.7.7) (EC 3.4.23.-) (p65Pro-RT); Ribonuclease H (RNase H) (EC 3.1.26.4); Integrase (IN) (EC 2.7.7.-) (EC 3.1.-.-) (p42In)]	pol	Human spumaretrovirus (SFVcpz(hu)) (Human foamy virus)	1143	MNPLQLLQPLPAEIKGTKLLAHWDSGATITCIPESFLEDEQPIKKTLIKTIHGEKQQNVYYVTFKVKGRKVEAEVIASPYEYILLSPTDVPWLTQQPLQLTILVPLQEYQEKILSKTALPEDQKQQLKTLFVKYDNLWQHWENQVGHRKIRPHNIATGDYPPRPQKQYPINPKAKPSIQIVIDDLLKQGVLTPQNSTMNTPVYPVPKPDGRWRMVLDYREVNKTIPLTAAQNQHSAGILATIVRQKYKTTLDLANGFWAHPITPESYWLTAFTWQGKQYCWTRLPQGFLNSPALFTADVVDLLKEIPNVQVYVDDIYLSHDDPKEHVQQLEKVFQILLQAGYVVSLKKSEIGQKTVEFLGFNITKEGRGLTDTFKTKLLNITPPKDLKQLQSILGLLNFARNFIPNFAELVQPLYNLIASAKGKYIEWSEENTKQLNMVIEALNTASNLEERLPEQRLVIKVNTSPSAGYVRYYNETGKKPIMYLNYVFSKAELKFSMLEKLLTTMHKALIKAMDLAMGQEILVYSPIVSMTKIQKTPLPERKALPIRWITWMTYLEDPRIQFHYDKTLPELKHIPDVYTSSQSPVKHPSQYEGVFYTDGSAIKSPDPTKSNNAGMGIVHATYKPEYQVLNQWSIPLGNHTAQMAEIAAVEFACKKALKIPGPVLVITDSFYVAESANKELPYWKSNGFVNNKKKPLKHISKWKSIAECLSMKPDITIQHEKGISLQIPVFILKGNALADKLATQGSYVVNCNTKKPNLDAELDQLLQGHYIKGYPKQYTYFLEDGKVKVSRPEGVKIIPPQSDRQKIVLQAHNLAHTGREATLLKIANLYWWPNMRKDVVKQLGRCQQCLITNASNKASGPILRPDRPQKPFDKFFIDYIGPLPPSQGYLYVLVVVDGMTGFTWLYPTKAPSTSATVKSLNVLTSIAIPKVIHSDQGAAFTSSTFAEWAKERGIHLEFSTPYHPQSGSKVERKNSDIKRLLTKLLVGRPTKWYDLLPVVQLALNNTYSPVLKYTPHQLLFGIDSNTPFANQDTLDLTREEELSLLQEIRTSLYHPSTPPASSRSWSPVVGQLVQERVARPASLRPRWHKPSTVLKVLNPRTVVILDHLGNNRTVSIDNLKPTSHQNGTTNDTATMDHLEKNE	FUNCTION: The aspartyl protease activity mediates proteolytic cleavages of Gag and Pol polyproteins. The reverse transcriptase (RT) activity converts the viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell (early reverse transcription) or after proviral DNA transcription (late reverse transcription). RT consists of a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA-Lys1,2 binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for a polypurine tract (PPT) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPT that has not been removed by RNase H as primer. PPT and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends (By similarity). {ECO:0000250}.; FUNCTION: Integrase catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising at least the viral genome, matrix protein, and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from the 3' end of the viral DNA right (U5) end, leaving the left (U3) intact. In the second step, the PIC enters cell nucleus. This process is mediated through the integrase and allows the virus to infect both dividing (nuclear membrane disassembled) and G1/S-arrested cells (active translocation), but with no viral gene expression in the latter. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. It is however not clear how integration then proceeds to resolve the asymmetrical cleavage of viral DNA (By similarity). {ECO:0000250}.	MISCELLANEOUS: The reverse transcriptase is an error-prone enzyme that lacks a proof-reading function. High mutations rate is a direct consequence of this characteristic. RT also displays frequent template switching leading to high recombination rate. Recombination mostly occurs between homologous regions of the two copackaged RNA genomes. If these two RNA molecules derive from different viral strains, reverse transcription will give rise to highly recombinated proviral DNAs.; MISCELLANEOUS: Foamy viruses are distinct from other retroviruses in many respects. Their protease is active as an uncleaved Pro-Pol protein. Mature particles do not include the usual processed retroviral structural protein (MA, CA and NC), but instead contain two large Gag proteins. Their functional nucleic acid appears to be either RNA or dsDNA (up to 20% of extracellular particles), because they probably proceed either to an early (before integration) or late reverse transcription (after assembly). Foamy viruses have the ability to retrotranspose intracellularly with high efficiency. They bud predominantly into the endoplasmic reticulum (ER) and occasionally at the plasma membrane. Budding requires the presence of Env proteins. Most viral particles probably remain within the infected cell.	DNA integration [GO:0015074]; DNA recombination [GO:0006310]; establishment of integrated proviral latency [GO:0075713]; proteolysis [GO:0006508]; symbiont entry into host cell [GO:0046718]; viral genome integration into host DNA [GO:0044826]; viral penetration into host nucleus [GO:0075732]	host cell [GO:0043657]; host cell cytoplasm [GO:0030430]; host cell nucleus [GO:0042025]; virion component [GO:0044423]	aspartic-type endopeptidase activity [GO:0004190]; DNA-directed DNA polymerase activity [GO:0003887]; metal ion binding [GO:0046872]; RNA binding [GO:0003723]; RNA-directed DNA polymerase activity [GO:0003964]; RNA-DNA hybrid ribonuclease activity [GO:0004523]	host cell [GO:0043657]; host cell cytoplasm [GO:0030430]; host cell nucleus [GO:0042025]; virion component [GO:0044423]; aspartic-type endopeptidase activity [GO:0004190]; DNA-directed DNA polymerase activity [GO:0003887]; metal ion binding [GO:0046872]; RNA binding [GO:0003723]; RNA-directed DNA polymerase activity [GO:0003964]; RNA-DNA hybrid ribonuclease activity [GO:0004523]; DNA integration [GO:0015074]; DNA recombination [GO:0006310]; establishment of integrated proviral latency [GO:0075713]; proteolysis [GO:0006508]; symbiont entry into host cell [GO:0046718]; viral genome integration into host DNA [GO:0044826]; viral penetration into host nucleus [GO:0075732]	GO:0003723; GO:0003887; GO:0003964; GO:0004190; GO:0004523; GO:0006310; GO:0006508; GO:0015074; GO:0030430; GO:0042025; GO:0043657; GO:0044423; GO:0044826; GO:0046718; GO:0046872; GO:0075713; GO:0075732	2451755; 2820721; 7474150; 7544460; 8551561; 9696869; 11086125; 12829852; 14963145; 12908768; 15358259; 23872492	10.1128/jvi.62.5.1590-1597.1988; 10.1002/j.1460-2075.1987.tb02473.x; 10.1128/jvi.69.11.7264-7268.1995; 10.1093/nar/23.14.2621; 10.1128/jvi.70.2.1033-1040.1996; 10.1128/jvi.72.9.7648-7652.1998; 10.1099/0022-1317-81-12-2941; 10.1128/jvi.77.14.8141-8146.2003; 10.1128/jvi.78.5.2472-2477.2004; 10.1007/978-3-642-55701-9_3; 10.1016/j.mib.2004.06.009; 10.3390/v5071850				
2cy0	Q5SJF8	reviewed	AROE_THET8	Shikimate dehydrogenase (NADP(+)) (SDH) (EC 1.1.1.25)	aroE TTHA1050	Thermus thermophilus (strain ATCC 27634 / DSM 579 / HB8)	263	MLRFAVLGHPVAHSLSPAMHAFALESLGLEGSYEAWDTPLEALPGRLKEVRRAFRGVNLTLPLKEAALAHLDWVSPEAQRIGAVNTVLQVEGRLFGFNTDAPGFLEALKAGGIPLKGPALVLGAGGAGRAVAFALREAGLEVWVWNRTPQRALALAEEFGLRAVPLEKAREARLLVNATRVGLEDPSASPLPAELFPEEGAAVDLVYRPLWTRFLREAKAKGLKVQTGLPMLAWQGALAFRLWTGLLPDPSGMEEAARRALGV	FUNCTION: Involved in the biosynthesis of the chorismate, which leads to the biosynthesis of aromatic amino acids. Catalyzes the reversible NADPH linked reduction of 3-dehydroshikimate (DHSA) to yield shikimate (SA). {ECO:0000255|HAMAP-Rule:MF_00222}.		amino acid biosynthetic process [GO:0008652]; aromatic amino acid family biosynthetic process [GO:0009073]; chorismate biosynthetic process [GO:0009423]; shikimate metabolic process [GO:0019632]	cytosol [GO:0005829]	NADP binding [GO:0050661]; shikimate 3-dehydrogenase (NADP+) activity [GO:0004764]	cytosol [GO:0005829]; NADP binding [GO:0050661]; shikimate 3-dehydrogenase (NADP+) activity [GO:0004764]; amino acid biosynthetic process [GO:0008652]; aromatic amino acid family biosynthetic process [GO:0009073]; chorismate biosynthetic process [GO:0009423]; shikimate metabolic process [GO:0019632]	GO:0004764; GO:0005829; GO:0008652; GO:0009073; GO:0009423; GO:0019632; GO:0050661	17825835	10.1016/j.jmb.2007.08.017	WP_011228401.1;YP_144316.1;			
3w83	Q4D3W2	reviewed	PYRD_TRYCC	Dihydroorotate dehydrogenase (fumarate) (DHOD) (DHODase) (DHOdehase) (EC 1.3.98.1) (Dihydroorotate oxidase)	pyr4 tcdhod2 Tc00.1047053508375.50	Trypanosoma cruzi (strain CL Brener)	314	MMCLKLNLLDHVFANPFMNAAGVLCSTEEDLRCMTASSSGALVSKSCTSAPRDGNPEPRYMAFPLGSINSMGLPNLGFDFYLKYASDLHDYSKKPLFLSISGLSVEENVAMVRRLAPVAQEKGVLLELNLSCPNVPGKPQVAYDFEAMRTYLQQVSLAYGLPFGVKMPPYFDIAHFDTAAAVLNEFPLVKFVTCVNSVGNGLVIDAESESVVIKPKQGFGGLGGKYILPTALANVNAFYRRCPDKLVFGCGGVYSGEDAFLHILAGASMVQVGTALQEEGPGIFTRLEDELLEIMARKGYRTLEEFRGRVKTIE	FUNCTION: Catalyzes the conversion of dihydroorotate to orotate with fumarate as the electron acceptor. Molecular oxygen can replace fumarate in vitro.		'de novo' pyrimidine nucleobase biosynthetic process [GO:0006207]; 'de novo' UMP biosynthetic process [GO:0044205]	cytoplasm [GO:0005737]	dihydroorotate dehydrogenase (fumarate) activity [GO:1990663]	cytoplasm [GO:0005737]; dihydroorotate dehydrogenase (fumarate) activity [GO:1990663]; 'de novo' pyrimidine nucleobase biosynthetic process [GO:0006207]; 'de novo' UMP biosynthetic process [GO:0044205]	GO:0005737; GO:0006207; GO:0044205; GO:1990663	16020725; 9878395; 16172019; 18808149; 18302934	10.1126/science.1112631; 10.1006/jmbi.1998.2293; 10.1016/j.parint.2005.08.001; 10.1021/bi800413r; 10.1016/j.bbrc.2008.02.074	XP_809064.1;			
2e6d	Q4D3W2	reviewed	PYRD_TRYCC	Dihydroorotate dehydrogenase (fumarate) (DHOD) (DHODase) (DHOdehase) (EC 1.3.98.1) (Dihydroorotate oxidase)	pyr4 tcdhod2 Tc00.1047053508375.50	Trypanosoma cruzi (strain CL Brener)	314	MMCLKLNLLDHVFANPFMNAAGVLCSTEEDLRCMTASSSGALVSKSCTSAPRDGNPEPRYMAFPLGSINSMGLPNLGFDFYLKYASDLHDYSKKPLFLSISGLSVEENVAMVRRLAPVAQEKGVLLELNLSCPNVPGKPQVAYDFEAMRTYLQQVSLAYGLPFGVKMPPYFDIAHFDTAAAVLNEFPLVKFVTCVNSVGNGLVIDAESESVVIKPKQGFGGLGGKYILPTALANVNAFYRRCPDKLVFGCGGVYSGEDAFLHILAGASMVQVGTALQEEGPGIFTRLEDELLEIMARKGYRTLEEFRGRVKTIE	FUNCTION: Catalyzes the conversion of dihydroorotate to orotate with fumarate as the electron acceptor. Molecular oxygen can replace fumarate in vitro.		'de novo' pyrimidine nucleobase biosynthetic process [GO:0006207]; 'de novo' UMP biosynthetic process [GO:0044205]	cytoplasm [GO:0005737]	dihydroorotate dehydrogenase (fumarate) activity [GO:1990663]	cytoplasm [GO:0005737]; dihydroorotate dehydrogenase (fumarate) activity [GO:1990663]; 'de novo' pyrimidine nucleobase biosynthetic process [GO:0006207]; 'de novo' UMP biosynthetic process [GO:0044205]	GO:0005737; GO:0006207; GO:0044205; GO:1990663	16020725; 9878395; 16172019; 18808149; 18302934	10.1126/science.1112631; 10.1006/jmbi.1998.2293; 10.1016/j.parint.2005.08.001; 10.1021/bi800413r; 10.1016/j.bbrc.2008.02.074	XP_809064.1;			
4rv4	Q81WF6	reviewed	PYRE_BACAN	Orotate phosphoribosyltransferase (OPRT) (OPRTase) (EC 2.4.2.10)	pyrE BA_4021 GBAA_4021 BAS3733	Bacillus anthracis	210	MKKEIASHLLEIGAVFLQPNDPFTWSSGMKSPIYCDNRLTLSYPKVRQTIAAGLEELIKEHFPTVEVIAGTATAGIAHAAWVSDRMDLPMCYVRSKAKGHGKGNQIEGKAEKGQKVVVVEDLISTGGSAITCVEALREAGCEVLGIVSIFTYELEAGKEKLEAANVASYSLSDYSALTEVAAEKGIIGQAETKKLQEWRKNPADEAWITA	FUNCTION: Catalyzes the transfer of a ribosyl phosphate group from 5-phosphoribose 1-diphosphate to orotate, leading to the formation of orotidine monophosphate (OMP). {ECO:0000255|HAMAP-Rule:MF_01208}.		'de novo' UMP biosynthetic process [GO:0044205]; pyrimidine nucleobase biosynthetic process [GO:0019856]		magnesium ion binding [GO:0000287]; orotate phosphoribosyltransferase activity [GO:0004588]; orotidine-5'-phosphate decarboxylase activity [GO:0004590]	magnesium ion binding [GO:0000287]; orotate phosphoribosyltransferase activity [GO:0004588]; orotidine-5'-phosphate decarboxylase activity [GO:0004590]; 'de novo' UMP biosynthetic process [GO:0044205]; pyrimidine nucleobase biosynthetic process [GO:0019856]	GO:0000287; GO:0004588; GO:0004590; GO:0019856; GO:0044205	12721629; 18952800	10.1038/nature01586; 10.1128/jb.01347-08	NP_846262.1;WP_000711466.1;YP_029984.1;			
5d7n	Q9NTG7	reviewed	SIR3_HUMAN	NAD-dependent protein deacetylase sirtuin-3, mitochondrial (hSIRT3) (EC 2.3.1.286) (Regulatory protein SIR2 homolog 3) (SIR2-like protein 3)	SIRT3 SIR2L3	Homo sapiens (Human)	399	MAFWGWRAAAALRLWGRVVERVEAGGGVGPFQACGCRLVLGGRDDVSAGLRGSHGARGEPLDPARPLQRPPRPEVPRAFRRQPRAAAPSFFFSSIKGGRRSISFSVGASSVVGSGGSSDKGKLSLQDVAELIRARACQRVVVMVGAGISTPSGIPDFRSPGSGLYSNLQQYDLPYPEAIFELPFFFHNPKPFFTLAKELYPGNYKPNVTHYFLRLLHDKGLLLRLYTQNIDGLERVSGIPASKLVEAHGTFASATCTVCQRPFPGEDIRADVMADRVPRCPVCTGVVKPDIVFFGEPLPQRFLLHVVDFPMADLLLILGTSLEVEPFASLTEAVRSSVPRLLINRDLVGPLAWHPRSRDVAQLGDVVHGVESLVELLGWTEEMRDLVQRETGKLDGPDK	FUNCTION: NAD-dependent protein deacetylase (PubMed:12186850, PubMed:12374852, PubMed:16788062, PubMed:18680753, PubMed:18794531, PubMed:19535340, PubMed:23283301, PubMed:24121500, PubMed:24252090). Activates or deactivates mitochondrial target proteins by deacetylating key lysine residues (PubMed:12186850, PubMed:12374852, PubMed:16788062, PubMed:18680753, PubMed:18794531, PubMed:23283301, PubMed:24121500, PubMed:24252090). Known targets include ACSS1, IDH, GDH, SOD2, PDHA1, LCAD, SDHA and the ATP synthase subunit ATP5PO (PubMed:16788062, PubMed:18680753, PubMed:19535340, PubMed:24121500, PubMed:24252090). Contributes to the regulation of the cellular energy metabolism (PubMed:24252090). Important for regulating tissue-specific ATP levels (PubMed:18794531). In response to metabolic stress, deacetylates transcription factor FOXO3 and recruits FOXO3 and mitochondrial RNA polymerase POLRMT to mtDNA to promote mtDNA transcription (PubMed:23283301). Acts as a regulator of ceramide metabolism by mediating deacetylation of ceramide synthases CERS1, CERS2 and CERS6, thereby increasing their activity and promoting mitochondrial ceramide accumulation (By similarity). Regulates hepatic lipogenesis. Uses NAD(+) substrate imported by SLC25A47, triggering downstream activation of PRKAA1/AMPK-alpha signaling cascade that ultimately downregulates sterol regulatory element-binding protein (SREBP) transcriptional activities and ATP-consuming lipogenesis to restore cellular energy balance. {ECO:0000250|UniProtKB:Q8R104, ECO:0000269|PubMed:12186850, ECO:0000269|PubMed:12374852, ECO:0000269|PubMed:16788062, ECO:0000269|PubMed:18680753, ECO:0000269|PubMed:18794531, ECO:0000269|PubMed:19535340, ECO:0000269|PubMed:23283301, ECO:0000269|PubMed:24121500, ECO:0000269|PubMed:24252090}.	MISCELLANEOUS: Has some ability to deacetylate histones in vitro, but seeing its subcellular location, this is unlikely in vivo. {ECO:0000269|PubMed:12374852}.	aerobic respiration [GO:0009060]; negative regulation of ERK1 and ERK2 cascade [GO:0070373]; negative regulation of reactive oxygen species metabolic process [GO:2000378]; peptidyl-lysine deacetylation [GO:0034983]; positive regulation of catalase activity [GO:1902553]; positive regulation of ceramide biosynthetic process [GO:2000304]; positive regulation of insulin secretion [GO:0032024]; positive regulation of superoxide dismutase activity [GO:1901671]; protein deacetylation [GO:0006476]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; protein-containing complex [GO:0032991]	enzyme binding [GO:0019899]; NAD+ binding [GO:0070403]; NAD-dependent histone deacetylase activity [GO:0017136]; NAD-dependent protein deacetylase activity [GO:0034979]; sequence-specific DNA binding [GO:0043565]; transferase activity [GO:0016740]; zinc ion binding [GO:0008270]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; protein-containing complex [GO:0032991]; enzyme binding [GO:0019899]; NAD+ binding [GO:0070403]; NAD-dependent histone deacetylase activity [GO:0017136]; NAD-dependent protein deacetylase activity [GO:0034979]; sequence-specific DNA binding [GO:0043565]; transferase activity [GO:0016740]; zinc ion binding [GO:0008270]; aerobic respiration [GO:0009060]; negative regulation of ERK1 and ERK2 cascade [GO:0070373]; negative regulation of reactive oxygen species metabolic process [GO:2000378]; peptidyl-lysine deacetylation [GO:0034983]; positive regulation of catalase activity [GO:1902553]; positive regulation of ceramide biosynthetic process [GO:2000304]; positive regulation of insulin secretion [GO:0032024]; positive regulation of superoxide dismutase activity [GO:1901671]; protein deacetylation [GO:0006476]	GO:0005634; GO:0005654; GO:0005739; GO:0005759; GO:0006476; GO:0008270; GO:0009060; GO:0016740; GO:0017136; GO:0019899; GO:0032024; GO:0032991; GO:0034979; GO:0034983; GO:0043565; GO:0070373; GO:0070403; GO:1901671; GO:1902553; GO:2000304; GO:2000378	10381378; 14702039; 16554811; 15489334; 17974005; 12186850; 12374852; 16079181; 16788062; 18215119; 18680753; 18794531; 19690332; 21172655; 23283301; 24121500; 23438705; 24252090; 24275569; 25944712; 29445193; 19535340; 23897466	10.1006/bbrc.1999.0897; 10.1038/ng1285; 10.1038/nature04632; 10.1101/gr.2596504; 10.1186/1471-2164-8-399; 10.1083/jcb.200205057; 10.1073/pnas.222538099; 10.1091/mbc.e05-01-0033; 10.1073/pnas.0603968103; 10.1042/bj20071624; 10.1016/j.jmb.2008.07.048; 10.1073/pnas.0803790105; 10.1126/scisignal.2000007; 10.1016/j.molcel.2010.12.013; 10.1007/s00018-012-1244-6; 10.1074/jbc.m113.510354; 10.1016/j.mito.2013.02.002; 10.1089/ars.2013.5420; 10.1016/j.jprot.2013.11.014; 10.1002/pmic.201400617; 10.1038/s41419-018-0336-0; 10.1074/jbc.m109.014928; 10.1107/s0907444913015448	NP_001017524.1 [Q9NTG7-2];NP_036371.1 [Q9NTG7-1];XP_016872919.1;	Q9NTG7;	CHEMBL4461;	DB02059;
5mgl	Q9UIF9	reviewed	BAZ2A_HUMAN	Bromodomain adjacent to zinc finger domain protein 2A (Transcription termination factor I-interacting protein 5) (TTF-I-interacting protein 5) (Tip5) (hWALp3)	BAZ2A KIAA0314 TIP5	Homo sapiens (Human)	1905	MEMEANDHFNFTGLPPAPAASGLKPSPSSGEGLYTNGSPMNFPQQGKSLNGDVNVNGLSTVSHTTTSGILNSAPHSSSTSHLHHPSVAYDCLWNYSQYPSANPGSNLKDPPLLSQFSGGQYPLNGILGGSRQPSSPSHNTNLRAGSQEFWANGTQSPMGLNFDSQELYDSFPDQNFEVMPNGPPSFFTSPQTSPMLGSSIQTFAPSQEVGSGIHPDEAAEKEMTSVVAENGTGLVGSLELEEEQPELKMCGYNGSVPSVESLHQEVSVLVPDPTVSCLDDPSHLPDQLEDTPILSEDSLEPFNSLAPEPVSGGLYGIDDTELMGAEDKLPLEDSPVISALDCPSLNNATAFSLLADDSQTSTSIFASPTSPPVLGESVLQDNSFDLNNGSDAEQEEMETQSSDFPPSLTQPAPDQSSTIQLHPATSPAVSPTTSPAVSLVVSPAASPEISPEVCPAASTVVSPAVFSVVSPASSAVLPAVSLEVPLTASVTSPKASPVTSPAAAFPTASPANKDVSSFLETTADVEEITGEGLTASGSGDVMRRRIATPEEVRLPLQHGWRREVRIKKGSHRWQGETWYYGPCGKRMKQFPEVIKYLSRNVVHSVRREHFSFSPRMPVGDFFEERDTPEGLQWVQLSAEEIPSRIQAITGKRGRPRNTEKAKTKEVPKVKRGRGRPPKVKITELLNKTDNRPLKKLEAQETLNEEDKAKIAKSKKKMRQKVQRGECQTTIQGQARNKRKQETKSLKQKEAKKKSKAEKEKGKTKQEKLKEKVKREKKEKVKMKEKEEVTKAKPACKADKTLATQRRLEERQRQQMILEEMKKPTEDMCLTDHQPLPDFSRVPGLTLPSGAFSDCLTIVEFLHSFGKVLGFDPAKDVPSLGVLQEGLLCQGDSLGEVQDLLVRLLKAALHDPGFPSYCQSLKILGEKVSEIPLTRDNVSEILRCFLMAYGVEPALCDRLRTQPFQAQPPQQKAAVLAFLVHELNGSTLIINEIDKTLESMSSYRKNKWIVEGRLRRLKTVLAKRTGRSEVEMEGPEECLGRRRSSRIMEETSGMEEEEEEESIAAVPGRRGRRDGEVDATASSIPELERQIEKLSKRQLFFRKKLLHSSQMLRAVSLGQDRYRRRYWVLPYLAGIFVEGTEGNLVPEEVIKKETDSLKVAAHASLNPALFSMKMELAGSNTTASSPARARGRPRKTKPGSMQPRHLKSPVRGQDSEQPQAQLQPEAQLHAPAQPQPQLQLQLQSHKGFLEQEGSPLSLGQSQHDLSQSAFLSWLSQTQSHSSLLSSSVLTPDSSPGKLDPAPSQPPEEPEPDEAESSPDPQALWFNISAQMPCNAAPTPPPAVSEDQPTPSPQQLASSKPMNRPSAANPCSPVQFSSTPLAGLAPKRRAGDPGEMPQSPTGLGQPKRRGRPPSKFFKQMEQRYLTQLTAQPVPPEMCSGWWWIRDPEMLDAMLKALHPRGIREKALHKHLNKHRDFLQEVCLRPSADPIFEPRQLPAFQEGIMSWSPKEKTYETDLAVLQWVEELEQRVIMSDLQIRGWTCPSPDSTREDLAYCEHLSDSQEDITWRGRGREGLAPQRKTTNPLDLAVMRLAALEQNVERRYLREPLWPTHEVVLEKALLSTPNGAPEGTTTEISYEITPRIRVWRQTLERCRSAAQVCLCLGQLERSIAWEKSVNKVTCLVCRKGDNDEFLLLCDGCDRGCHIYCHRPKMEAVPEGDWFCTVCLAQQVEGEFTQKPGFPKRGQKRKSGYSLNFSEGDGRRRRVLLRGRESPAAGPRYSEEGLSPSKRRRLSMRNHHSDLTFCEIILMEMESHDAAWPFLEPVNPRLVSGYRRIIKNPMDFSTMRERLLRGGYTSSEEFAADALLVFDNCQTFNEDDSEVGKAGHIMRRFFESRWEEFYQGKQANL	FUNCTION: Regulatory subunit of the ATP-dependent NoRC-1 and NoRC-5 ISWI chromatin remodeling complexes, which form ordered nucleosome arrays on chromatin and facilitate access to DNA during DNA-templated processes such as DNA replication, transcription, and repair (PubMed:28801535). Both complexes regulate the spacing of nucleosomes along the chromatin and have the ability to slide mononucleosomes to the center of a DNA template (PubMed:28801535). Directly stimulates the ATPase activity of SMARCA5 in the NoRC-5 ISWI chromatin remodeling complex (PubMed:28801535). The NoRC-1 ISWI chromatin remodeling complex has a lower ATP hydrolysis rate than the NoRC-5 ISWI chromatin remodeling complex (PubMed:28801535). Within the NoRC-5 ISWI chromatin remodeling complex, mediates silencing of a fraction of rDNA by recruiting histone-modifying enzymes and DNA methyltransferases, leading to heterochromatin formation and transcriptional silencing (By similarity). In the complex, it plays a central role by being recruited to rDNA and by targeting chromatin modifying enzymes such as HDAC1, leading to repress RNA polymerase I transcription (By similarity). Recruited to rDNA via its interaction with TTF1 and its ability to recognize and bind histone H4 acetylated on 'Lys-16' (H4K16ac), leading to deacetylation of H4K5ac, H4K8ac, H4K12ac but not H4K16ac (By similarity). Specifically binds pRNAs, 150-250 nucleotide RNAs that are complementary in sequence to the rDNA promoter; pRNA-binding is required for heterochromatin formation and rDNA silencing (By similarity). {ECO:0000250|UniProtKB:Q91YE5, ECO:0000269|PubMed:28801535}.		chromatin remodeling [GO:0006338]; DNA-templated transcription [GO:0006351]; heterochromatin formation [GO:0031507]; negative regulation of transcription by RNA polymerase I [GO:0016479]; rDNA heterochromatin formation [GO:0000183]; regulation of DNA methylation [GO:0044030]; regulation of DNA-templated transcription [GO:0006355]; RNA polymerase I preinitiation complex assembly [GO:0001188]	chromatin silencing complex [GO:0005677]; cytosol [GO:0005829]; NoRC complex [GO:0090536]; nuclear speck [GO:0016607]; nucleolus [GO:0005730]; nucleus [GO:0005634]; rDNA heterochromatin [GO:0033553]	DNA binding [GO:0003677]; histone binding [GO:0042393]; lysine-acetylated histone binding [GO:0070577]; metal ion binding [GO:0046872]; nuclear receptor binding [GO:0016922]; RNA binding [GO:0003723]	chromatin silencing complex [GO:0005677]; cytosol [GO:0005829]; NoRC complex [GO:0090536]; nuclear speck [GO:0016607]; nucleolus [GO:0005730]; nucleus [GO:0005634]; rDNA heterochromatin [GO:0033553]; DNA binding [GO:0003677]; histone binding [GO:0042393]; lysine-acetylated histone binding [GO:0070577]; metal ion binding [GO:0046872]; nuclear receptor binding [GO:0016922]; RNA binding [GO:0003723]; chromatin remodeling [GO:0006338]; DNA-templated transcription [GO:0006351]; heterochromatin formation [GO:0031507]; negative regulation of transcription by RNA polymerase I [GO:0016479]; rDNA heterochromatin formation [GO:0000183]; regulation of DNA methylation [GO:0044030]; regulation of DNA-templated transcription [GO:0006355]; RNA polymerase I preinitiation complex assembly [GO:0001188]	GO:0000183; GO:0001188; GO:0003677; GO:0003723; GO:0005634; GO:0005677; GO:0005730; GO:0005829; GO:0006338; GO:0006351; GO:0006355; GO:0016479; GO:0016607; GO:0016922; GO:0031507; GO:0033553; GO:0042393; GO:0044030; GO:0046872; GO:0070577; GO:0090536	10662543; 17974005; 16541075; 9205841; 14702039; 15489334; 17081983; 17525332; 18669648; 19413330; 19578370; 19690332; 20068231; 21406692; 23186163; 24275569; 25772364; 25593309; 26100909; 28801535; 28112733	10.1006/geno.1999.6071; 10.1186/1471-2164-8-399; 10.1038/nature04569; 10.1093/dnares/4.2.141; 10.1038/ng1285; 10.1101/gr.2596504; 10.1016/j.cell.2006.09.026; 10.1126/science.1140321; 10.1073/pnas.0805139105; 10.1021/ac9004309; 10.1038/ncb1914; 10.1126/scisignal.2000007; 10.1126/scisignal.2000475; 10.1126/scisignal.2001570; 10.1021/pr300630k; 10.1016/j.jprot.2013.11.014; 10.1016/j.celrep.2015.02.033; 10.1101/gad.252189.114; 10.1073/pnas.1424705112; 10.15252/embr.201744011; 10.1038/nsmb.3366	NP_038477.2 [Q9UIF9-1];	Q9UIF9;	CHEMBL3108642;	
1h36	P33247	reviewed	SQHC_ALIAD	Squalene--hopene cyclase (EC 4.2.1.129) (EC 5.4.99.17) (Squalene--hopanol cyclase)	shc Aaci_2443	Alicyclobacillus acidocaldarius subsp. acidocaldarius (strain ATCC 27009 / DSM 446 / BCRC 14685 / JCM 5260 / KCTC 1825 / NBRC 15652 / NCIMB 11725 / NRRL B-14509 / 104-IA) (Bacillus acidocaldarius)	631	MAEQLVEAPAYARTLDRAVEYLLSCQKDEGYWWGPLLSNVTMEAEYVLLCHILDRVDRDRMEKIRRYLLHEQREDGTWALYPGGPPDLDTTIEAYVALKYIGMSRDEEPMQKALRFIQSQGGIESSRVFTRMWLALVGEYPWEKVPMVPPEIMFLGKRMPLNIYEFGSWARATVVALSIVMSRQPVFPLPERARVPELYETDVPPRRRGAKGGGGWIFDALDRALHGYQKLSVHPFRRAAEIRALDWLLERQAGDGSWGGIQPPWFYALIALKILDMTQHPAFIKGWEGLELYGVELDYGGWMFQASISPVWDTGLAVLALRAAGLPADHDRLVKAGEWLLDRQITVPGDWAVKRPNLKPGGFAFQFDNVYYPDVDDTAVVVWALNTLRLPDERRRRDAMTKGFRWIVGMQSSNGGWGAYDVDNTSDLPNHIPFCDFGEVTDPPSEDVTAHVLECFGSFGYDDAWKVIRRAVEYLKREQKPDGSWFGRWGVNYLYGTGAVVSALKAVGIDTREPYIQKALDWVEQHQNPDGGWGEDCRSYEDPAYAGKGASTPSQTAWALMALIAGGRAESEAARRGVQYLVETQRPDGGWDEPYYTGTGFPGDFYLGYTMYRHVFPTLALGRYKQAIERR	FUNCTION: Catalyzes the cyclization of squalene into hopene.		cholesterol biosynthetic process [GO:0006695]; ergosterol biosynthetic process [GO:0006696]; triterpenoid biosynthetic process [GO:0016104]	lipid droplet [GO:0005811]; plasma membrane [GO:0005886]	lanosterol synthase activity [GO:0000250]; lyase activity [GO:0016829]; squalene-hopene cyclase activity [GO:0051007]	lipid droplet [GO:0005811]; plasma membrane [GO:0005886]; lanosterol synthase activity [GO:0000250]; lyase activity [GO:0016829]; squalene-hopene cyclase activity [GO:0051007]; cholesterol biosynthetic process [GO:0006695]; ergosterol biosynthetic process [GO:0006696]; triterpenoid biosynthetic process [GO:0016104]	GO:0000250; GO:0005811; GO:0005886; GO:0006695; GO:0006696; GO:0016104; GO:0016829; GO:0051007	1729216; 9532806; 2253626; 9295270; 9931258	10.1128/jb.174.1.298-302.1992; 10.1271/bbb.62.407; 10.1111/j.1432-1033.1990.tb19429.x; 10.1126/science.277.5333.1811; 10.1006/jmbi.1998.2470	WP_012811690.1;	P33247;	CHEMBL3569;	DB02139;DB03234;DB08458;DB03874;DB04233;DB03771;DB02339;DB04147;DB03748;DB02544;DB03888;
4gvd	P18827	reviewed	SDC1_HUMAN	Syndecan-1 (SYND1) (CD antigen CD138)	SDC1 SDC	Homo sapiens (Human)	310	MRRAALWLWLCALALSLQPALPQIVATNLPPEDQDGSGDDSDNFSGSGAGALQDITLSQQTPSTWKDTQLLTAIPTSPEPTGLEATAASTSTLPAGEGPKEGEAVVLPEVEPGLTAREQEATPRPRETTQLPTTHLASTTTATTAQEPATSHPHRDMQPGHHETSTPAGPSQADLHTPHTEDGGPSATERAAEDGASSQLPAAEGSGEQDFTFETSGENTAVVAVEPDRRNQSPVDQGATGASQGLLDRKEVLGGVIAGGLVGLIFAVCLVGFMLYRMKKKDEGSYSLEEPKQANGGAYQKPTKQEEFYA	FUNCTION: Cell surface proteoglycan that contains both heparan sulfate and chondroitin sulfate and that links the cytoskeleton to the interstitial matrix (By similarity). Regulates exosome biogenesis in concert with SDCBP and PDCD6IP (PubMed:22660413). Able to induce its own expression in dental mesenchymal cells and also in the neighboring dental epithelial cells via an MSX1-mediated pathway (By similarity). {ECO:0000250|UniProtKB:P18828, ECO:0000269|PubMed:22660413}.		canonical Wnt signaling pathway [GO:0060070]; cell migration [GO:0016477]; myoblast development [GO:0048627]; positive regulation of exosomal secretion [GO:1903543]; positive regulation of extracellular exosome assembly [GO:1903553]; receptor-mediated endocytosis [GO:0006898]; response to calcium ion [GO:0051592]; response to cAMP [GO:0051591]; response to glucocorticoid [GO:0051384]; response to hydrogen peroxide [GO:0042542]; response to toxic substance [GO:0009636]; Sertoli cell development [GO:0060009]; striated muscle cell development [GO:0055002]; ureteric bud development [GO:0001657]	cell surface [GO:0009986]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; Golgi lumen [GO:0005796]; lysosomal lumen [GO:0043202]; plasma membrane [GO:0005886]; protein-containing complex [GO:0032991]	cargo receptor activity [GO:0038024]; identical protein binding [GO:0042802]	cell surface [GO:0009986]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; Golgi lumen [GO:0005796]; lysosomal lumen [GO:0043202]; plasma membrane [GO:0005886]; protein-containing complex [GO:0032991]; cargo receptor activity [GO:0038024]; identical protein binding [GO:0042802]; canonical Wnt signaling pathway [GO:0060070]; cell migration [GO:0016477]; myoblast development [GO:0048627]; positive regulation of exosomal secretion [GO:1903543]; positive regulation of extracellular exosome assembly [GO:1903553]; receptor-mediated endocytosis [GO:0006898]; response to calcium ion [GO:0051592]; response to cAMP [GO:0051591]; response to glucocorticoid [GO:0051384]; response to hydrogen peroxide [GO:0042542]; response to toxic substance [GO:0009636]; Sertoli cell development [GO:0060009]; striated muscle cell development [GO:0055002]; ureteric bud development [GO:0001657]	GO:0001657; GO:0005796; GO:0005886; GO:0006898; GO:0009636; GO:0009897; GO:0009986; GO:0016477; GO:0032991; GO:0038024; GO:0042542; GO:0042802; GO:0043202; GO:0048627; GO:0051384; GO:0051591; GO:0051592; GO:0055002; GO:0060009; GO:0060070; GO:0070062; GO:1903543; GO:1903553	1339431; 2324102; 15177497; 15815621; 15489334; 9050911; 9169435; 16007225; 21269460; 22660413; 23186163; 24275569; 32337544; 36213313; 23395182	10.1016/s0021-9258(18)48404-9; 10.1016/s0021-9258(19)39232-4; 10.1016/j.ejca.2004.01.038; 10.1038/nature03466; 10.1101/gr.2596504; 10.1007/s004390050360; 10.1074/jbc.272.23.14713; 10.1038/sj.onc.1208582; 10.1186/1752-0509-5-17; 10.1038/ncb2502; 10.1021/pr300630k; 10.1016/j.jprot.2013.11.014; 10.1093/glycob/cwaa039; 10.1007/s42485-022-00092-3; 10.1016/j.str.2013.01.004	NP_001006947.1;NP_002988.3;		CHEMBL3712898;	
4gvd	Q13009	reviewed	TIAM1_HUMAN	Rho guanine nucleotide exchange factor TIAM1 (T-lymphoma invasion and metastasis-inducing protein 1) (TIAM-1)	TIAM1	Homo sapiens (Human)	1591	MGNAESQHVEHEFYGEKHASLGRKHTSRSLRLSHKTRRTRHASSGKVIHRNSEVSTRSSSTPSIPQSLAENGLEPFSQDGTLEDFGSPIWVDRVDMGLRPVSYTDSSVTPSVDSSIVLTAASVQSMPDTEESRLYGDDATYLAEGGRRQHSYTSNGPTFMETASFKKKRSKSADIWREDSLEFSLSDLSQEHLTSNEEILGSAEEKDCEEARGMETRASPRQLSTCQRANSLGDLYAQKNSGVTANGGPGSKFAGYCRNLVSDIPNLANHKMPPAAAEETPPYSNYNTLPCRKSHCLSEGATNPQISHSNSMQGRRAKTTQDVNAGEGSEFADSGIEGATTDTDLLSRRSNATNSSYSPTTGRAFVGSDSGSSSTGDAARQGVYENFRRELEMSTTNSESLEEAGSAHSDEQSSGTLSSPGQSDILLTAAQGTVRKAGALAVKNFLVHKKNKKVESATRRKWKHYWVSLKGCTLFFYESDGRSGIDHNSIPKHAVWVENSIVQAVPEHPKKDFVFCLSNSLGDAFLFQTTSQTELENWITAIHSACATAVARHHHKEDTLRLLKSEIKKLEQKIDMDEKMKKMGEMQLSSVTDSKKKKTILDQIFVWEQNLEQFQMDLFRFRCYLASLQGGELPNPKRLLAFASRPTKVAMGRLGIFSVSSFHALVAARTGETGVRRRTQAMSRSASKRRSRFSSLWGLDTTSKKKQGRPSINQVFGEGTEAVKKSLEGIFDDIVPDGKREKEVVLPNVHQHNPDCDIWVHEYFTPSWFCLPNNQPALTVVRPGDTARDTLELICKTHQLDHSAHYLRLKFLIENKMQLYVPQPEEDIYELLYKEIEICPKVTQSIHIEKSDTAADTYGFSLSSVEEDGIRRLYVNSVKETGLASKKGLKAGDEILEINNRAADALNSSMLKDFLSQPSLGLLVRTYPELEEGVELLESPPHRVDGPADLGESPLAFLTSNPGHSLCSEQGSSAETAPEETEGPDLESSDETDHSSKSTEQVAAFCRSLHEMNPSDQSPSPQDSTGPQLATMRQLSDADKLRKVICELLETERTYVKDLNCLMERYLKPLQKETFLTQDELDVLFGNLTEMVEFQVEFLKTLEDGVRLVPDLEKLEKVDQFKKVLFSLGGSFLYYADRFKLYSAFCASHTKVPKVLVKAKTDTAFKAFLDAQNPKQQHSSTLESYLIKPIQRILKYPLLLRELFALTDAESEEHYHLDVAIKTMNKVASHINEMQKIHEEFGAVFDQLIAEQTGEKKEVADLSMGDLLLHTTVIWLNPPASLGKWKKEPELAAFVFKTAVVLVYKDGSKQKKKLVGSHRLSIYEDWDPFRFRHMIPTEALQVRALASADAEANAVCEIVHVKSESEGRPERVFHLCCSSPESRKDFLKAVHSILRDKHRRQLLKTESLPSSQQYVPFGGKRLCALKGARPAMSRAVSAPSKSLGRRRRRLARNRFTIDSDAVSASSPEKESQQPPGGGDTDRWVEEQFDLAQYEEQDDIKETDILSDDDEFCESVKGASVDRDLQERLQATSISQRERGRKTLDSHASRMAQLKKQAALSGINGGLESASEEVIWVRREDFAPSRKLNTEI	FUNCTION: Guanyl-nucleotide exchange factor that activates RHO-like proteins and connects extracellular signals to cytoskeletal activities. Activates RAC1, CDC42, and to a lesser extent RHOA and their downstream signaling to regulate processes like cell adhesion and cell migration. {ECO:0000269|PubMed:20361982, ECO:0000269|PubMed:25684205}.		activation of GTPase activity [GO:0090630]; cardiac muscle hypertrophy [GO:0003300]; cell migration [GO:0016477]; cell-matrix adhesion [GO:0007160]; ephrin receptor signaling pathway [GO:0048013]; neuron projection extension [GO:1990138]; positive regulation of axonogenesis [GO:0050772]; positive regulation of cell migration [GO:0030335]; positive regulation of cell population proliferation [GO:0008284]; positive regulation of dendritic spine morphogenesis [GO:0061003]; positive regulation of epithelial to mesenchymal transition [GO:0010718]; positive regulation of protein binding [GO:0032092]; positive regulation of Schwann cell chemotaxis [GO:1904268]; protein localization to membrane [GO:0072657]; protein-containing complex assembly [GO:0065003]; Rac protein signal transduction [GO:0016601]; regulation of dopaminergic neuron differentiation [GO:1904338]; regulation of epithelial to mesenchymal transition [GO:0010717]; regulation of ERK1 and ERK2 cascade [GO:0070372]; regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0061178]; regulation of modification of postsynaptic actin cytoskeleton [GO:1905274]; regulation of non-canonical Wnt signaling pathway [GO:2000050]; regulation of small GTPase mediated signal transduction [GO:0051056]; response to cocaine [GO:0042220]; small GTPase-mediated signal transduction [GO:0007264]; Wnt signaling pathway, planar cell polarity pathway [GO:0060071]	axonal growth cone [GO:0044295]; cell-cell contact zone [GO:0044291]; cell-cell junction [GO:0005911]; cytosol [GO:0005829]; dendritic spine [GO:0043197]; extrinsic component of postsynaptic density membrane [GO:0099147]; glutamatergic synapse [GO:0098978]; main axon [GO:0044304]; microtubule [GO:0005874]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]; ruffle membrane [GO:0032587]; synapse [GO:0045202]	guanyl-nucleotide exchange factor activity [GO:0005085]; kinase binding [GO:0019900]; lipid binding [GO:0008289]; microtubule binding [GO:0008017]; receptor tyrosine kinase binding [GO:0030971]	axonal growth cone [GO:0044295]; cell-cell contact zone [GO:0044291]; cell-cell junction [GO:0005911]; cytosol [GO:0005829]; dendritic spine [GO:0043197]; extrinsic component of postsynaptic density membrane [GO:0099147]; glutamatergic synapse [GO:0098978]; main axon [GO:0044304]; microtubule [GO:0005874]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]; ruffle membrane [GO:0032587]; synapse [GO:0045202]; guanyl-nucleotide exchange factor activity [GO:0005085]; kinase binding [GO:0019900]; lipid binding [GO:0008289]; microtubule binding [GO:0008017]; receptor tyrosine kinase binding [GO:0030971]; activation of GTPase activity [GO:0090630]; cardiac muscle hypertrophy [GO:0003300]; cell migration [GO:0016477]; cell-matrix adhesion [GO:0007160]; ephrin receptor signaling pathway [GO:0048013]; neuron projection extension [GO:1990138]; positive regulation of axonogenesis [GO:0050772]; positive regulation of cell migration [GO:0030335]; positive regulation of cell population proliferation [GO:0008284]; positive regulation of dendritic spine morphogenesis [GO:0061003]; positive regulation of epithelial to mesenchymal transition [GO:0010718]; positive regulation of protein binding [GO:0032092]; positive regulation of Schwann cell chemotaxis [GO:1904268]; protein localization to membrane [GO:0072657]; protein-containing complex assembly [GO:0065003]; Rac protein signal transduction [GO:0016601]; regulation of dopaminergic neuron differentiation [GO:1904338]; regulation of epithelial to mesenchymal transition [GO:0010717]; regulation of ERK1 and ERK2 cascade [GO:0070372]; regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0061178]; regulation of modification of postsynaptic actin cytoskeleton [GO:1905274]; regulation of non-canonical Wnt signaling pathway [GO:2000050]; regulation of small GTPase mediated signal transduction [GO:0051056]; response to cocaine [GO:0042220]; small GTPase-mediated signal transduction [GO:0007264]; Wnt signaling pathway, planar cell polarity pathway [GO:0060071]	GO:0003300; GO:0005085; GO:0005829; GO:0005874; GO:0005886; GO:0005911; GO:0007160; GO:0007264; GO:0008017; GO:0008284; GO:0008289; GO:0010717; GO:0010718; GO:0016477; GO:0016601; GO:0019900; GO:0030335; GO:0030971; GO:0032092; GO:0032587; GO:0042220; GO:0043025; GO:0043197; GO:0044291; GO:0044295; GO:0044304; GO:0045202; GO:0048013; GO:0050772; GO:0051056; GO:0060071; GO:0061003; GO:0061178; GO:0065003; GO:0070372; GO:0072657; GO:0090630; GO:0098978; GO:0099147; GO:1904268; GO:1904338; GO:1905274; GO:1990138; GO:2000050	7731688; 10830953; 15489334; 7753201; 7736788; 15899863; 19413330; 19369195; 19690332; 20332120; 20496116; 21406692; 25684205; 20361982; 23832200; 23395182; 16959974; 22100072; 35240055	10.1038/35012518; 10.1101/gr.2596504; 10.1038/375338a0; 10.1159/000133989; 10.1128/mcb.25.11.4602-4614.2005; 10.1021/ac9004309; 10.1074/mcp.m800588-mcp200; 10.1126/scisignal.2000007; 10.1242/jcs.059329; 10.1007/s10059-010-0075-2; 10.1126/scisignal.2001570; 10.1016/j.molcel.2014.12.040; 10.1016/j.jmb.2010.03.047; 10.1107/s1744309113014206; 10.1016/j.str.2013.01.004; 10.1126/science.1133427; 10.1016/j.ajhg.2011.10.011; 10.1016/j.ajhg.2022.01.020	NP_003244.2 [Q13009-1];XP_005261094.1;XP_005261095.1;XP_011528013.1;XP_011528014.1;XP_011528015.1;XP_016883936.1;XP_016883937.1;XP_016883938.1;XP_016883939.1;XP_016883940.1;XP_016883941.1;XP_016883942.1;		CHEMBL3232697;	
4tos	O95271	reviewed	TNKS1_HUMAN	Poly [ADP-ribose] polymerase tankyrase-1 (EC 2.4.2.30) (ADP-ribosyltransferase diphtheria toxin-like 5) (ARTD5) (Poly [ADP-ribose] polymerase 5A) (Protein poly-ADP-ribosyltransferase tankyrase-1) (EC 2.4.2.-) (TNKS-1) (TRF1-interacting ankyrin-related ADP-ribose polymerase) (Tankyrase I) (Tankyrase-1) (TANK1)	TNKS PARP5A PARPL TIN1 TINF1 TNKS1	Homo sapiens (Human)	1327	MAASRRSQHHHHHHQQQLQPAPGASAPPPPPPPPLSPGLAPGTTPASPTASGLAPFASPRHGLALPEGDGSRDPPDRPRSPDPVDGTSCCSTTSTICTVAAAPVVPAVSTSSAAGVAPNPAGSGSNNSPSSSSSPTSSSSSSPSSPGSSLAESPEAAGVSSTAPLGPGAAGPGTGVPAVSGALRELLEACRNGDVSRVKRLVDAANVNAKDMAGRKSSPLHFAAGFGRKDVVEHLLQMGANVHARDDGGLIPLHNACSFGHAEVVSLLLCQGADPNARDNWNYTPLHEAAIKGKIDVCIVLLQHGADPNIRNTDGKSALDLADPSAKAVLTGEYKKDELLEAARSGNEEKLMALLTPLNVNCHASDGRKSTPLHLAAGYNRVRIVQLLLQHGADVHAKDKGGLVPLHNACSYGHYEVTELLLKHGACVNAMDLWQFTPLHEAASKNRVEVCSLLLSHGADPTLVNCHGKSAVDMAPTPELRERLTYEFKGHSLLQAAREADLAKVKKTLALEIINFKQPQSHETALHCAVASLHPKRKQVTELLLRKGANVNEKNKDFMTPLHVAAERAHNDVMEVLHKHGAKMNALDTLGQTALHRAALAGHLQTCRLLLSYGSDPSIISLQGFTAAQMGNEAVQQILSESTPIRTSDVDYRLLEASKAGDLETVKQLCSSQNVNCRDLEGRHSTPLHFAAGYNRVSVVEYLLHHGADVHAKDKGGLVPLHNACSYGHYEVAELLVRHGASVNVADLWKFTPLHEAAAKGKYEICKLLLKHGADPTKKNRDGNTPLDLVKEGDTDIQDLLRGDAALLDAAKKGCLARVQKLCTPENINCRDTQGRNSTPLHLAAGYNNLEVAEYLLEHGADVNAQDKGGLIPLHNAASYGHVDIAALLIKYNTCVNATDKWAFTPLHEAAQKGRTQLCALLLAHGADPTMKNQEGQTPLDLATADDIRALLIDAMPPEALPTCFKPQATVVSASLISPASTPSCLSAASSIDNLTGPLAELAVGGASNAGDGAAGTERKEGEVAGLDMNISQFLKSLGLEHLRDIFETEQITLDVLADMGHEELKEIGINAYGHRHKLIKGVERLLGGQQGTNPYLTFHCVNQGTILLDLAPEDKEYQSVEEEMQSTIREHRDGGNAGGIFNRYNVIRIQKVVNKKLRERFCHRQKEVSEENHNHHNERMLFHGSPFINAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPTHKDRSCYICHRQMLFCRVTLGKSFLQFSTMKMAHAPPGHHSVIGRPSVNGLAYAEYVIYRGEQAYPEYLITYQIMKPEAPSQTATAAEQKT	FUNCTION: Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking (PubMed:10988299, PubMed:11739745, PubMed:16076287, PubMed:19759537, PubMed:21478859, PubMed:22864114, PubMed:23622245, PubMed:25043379, PubMed:28619731). Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation (PARsylation) of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation (PubMed:19759537, PubMed:21478859). Also mediates PARsylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination (PubMed:21478859). Mediates PARsylation of TERF1, thereby contributing to the regulation of telomere length (PubMed:11739745). Involved in centrosome maturation during prometaphase by mediating PARsylation of HEPACAM2/MIKI (PubMed:22864114). May also regulate vesicle trafficking and modulate the subcellular distribution of SLC2A4/GLUT4-vesicles (PubMed:10988299). May be involved in spindle pole assembly through PARsylation of NUMA1 (PubMed:16076287). Stimulates 26S proteasome activity (PubMed:23622245). {ECO:0000269|PubMed:10988299, ECO:0000269|PubMed:11739745, ECO:0000269|PubMed:16076287, ECO:0000269|PubMed:19759537, ECO:0000269|PubMed:21478859, ECO:0000269|PubMed:22864114, ECO:0000269|PubMed:23622245, ECO:0000269|PubMed:25043379, ECO:0000269|PubMed:28619731}.		cell division [GO:0051301]; mitotic spindle organization [GO:0007052]; mRNA transport [GO:0051028]; negative regulation of maintenance of mitotic sister chromatid cohesion, telomeric [GO:1904908]; negative regulation of telomere maintenance via telomere lengthening [GO:1904357]; negative regulation of telomeric DNA binding [GO:1904743]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-threonine phosphorylation [GO:0018107]; positive regulation of canonical Wnt signaling pathway [GO:0090263]; positive regulation of telomerase activity [GO:0051973]; positive regulation of telomere capping [GO:1904355]; positive regulation of telomere maintenance via telomerase [GO:0032212]; positive regulation of transcription by RNA polymerase II [GO:0045944]; protein auto-ADP-ribosylation [GO:0070213]; protein localization to chromosome, telomeric region [GO:0070198]; protein poly-ADP-ribosylation [GO:0070212]; protein polyubiquitination [GO:0000209]; protein transport [GO:0015031]; regulation of telomere maintenance via telomerase [GO:0032210]; spindle assembly [GO:0051225]; Wnt signaling pathway [GO:0016055]	chromosome, telomeric region [GO:0000781]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; Golgi apparatus [GO:0005794]; Golgi membrane [GO:0000139]; mitotic spindle pole [GO:0097431]; nuclear body [GO:0016604]; nuclear membrane [GO:0031965]; nuclear pore [GO:0005643]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; pericentriolar material [GO:0000242]	histone binding [GO:0042393]; NAD+ ADP-ribosyltransferase activity [GO:0003950]; NAD+-protein ADP-ribosyltransferase activity [GO:1990404]; nucleotidyltransferase activity [GO:0016779]; zinc ion binding [GO:0008270]	chromosome, telomeric region [GO:0000781]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; Golgi apparatus [GO:0005794]; Golgi membrane [GO:0000139]; mitotic spindle pole [GO:0097431]; nuclear body [GO:0016604]; nuclear membrane [GO:0031965]; nuclear pore [GO:0005643]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; pericentriolar material [GO:0000242]; histone binding [GO:0042393]; NAD+ ADP-ribosyltransferase activity [GO:0003950]; NAD+-protein ADP-ribosyltransferase activity [GO:1990404]; nucleotidyltransferase activity [GO:0016779]; zinc ion binding [GO:0008270]; cell division [GO:0051301]; mitotic spindle organization [GO:0007052]; mRNA transport [GO:0051028]; negative regulation of maintenance of mitotic sister chromatid cohesion, telomeric [GO:1904908]; negative regulation of telomere maintenance via telomere lengthening [GO:1904357]; negative regulation of telomeric DNA binding [GO:1904743]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-threonine phosphorylation [GO:0018107]; positive regulation of canonical Wnt signaling pathway [GO:0090263]; positive regulation of telomerase activity [GO:0051973]; positive regulation of telomere capping [GO:1904355]; positive regulation of telomere maintenance via telomerase [GO:0032212]; positive regulation of transcription by RNA polymerase II [GO:0045944]; protein auto-ADP-ribosylation [GO:0070213]; protein localization to chromosome, telomeric region [GO:0070198]; protein poly-ADP-ribosylation [GO:0070212]; protein polyubiquitination [GO:0000209]; protein transport [GO:0015031]; regulation of telomere maintenance via telomerase [GO:0032210]; spindle assembly [GO:0051225]; Wnt signaling pathway [GO:0016055]	GO:0000139; GO:0000209; GO:0000242; GO:0000781; GO:0003950; GO:0005634; GO:0005643; GO:0005654; GO:0005737; GO:0005794; GO:0005829; GO:0007052; GO:0008270; GO:0015031; GO:0016055; GO:0016604; GO:0016779; GO:0018105; GO:0018107; GO:0031965; GO:0032210; GO:0032212; GO:0042393; GO:0045944; GO:0051028; GO:0051225; GO:0051301; GO:0051973; GO:0070198; GO:0070212; GO:0070213; GO:0090263; GO:0097431; GO:1904355; GO:1904357; GO:1904743; GO:1904908; GO:1990404	9822378; 16421571; 15489334; 10523501; 10988299; 12080061; 11739745; 12768206; 16076287; 19759537; 20106667; 21478859; 21799911; 22864114; 23622245; 25043379; 18436240; 28619731; 33361107	10.1126/science.282.5393.1484; 10.1038/nature04406; 10.1101/gr.2596504; 10.1242/jcs.112.21.3649; 10.1074/jbc.m007635200; 10.1074/jbc.m203916200; 10.1128/mcb.22.1.332-342.2002; 10.1038/nature01688; 10.1042/bj20050885; 10.1038/nature08356; 10.1016/j.tibs.2009.12.003; 10.1038/ncb2222; 10.1371/journal.pone.0022595; 10.1016/j.molcel.2012.06.033; 10.1016/j.cell.2013.03.040; 10.1038/ncomms5426; 10.1016/j.jmb.2008.03.058; 10.1101/gad.300889.117; 10.1074/jbc.ra120.016573	NP_003738.2 [O95271-1];	O95271;	CHEMBL6164;	
5aeh	Q9H2K2	reviewed	TNKS2_HUMAN	Poly [ADP-ribose] polymerase tankyrase-2 (EC 2.4.2.30) (ADP-ribosyltransferase diphtheria toxin-like 6) (ARTD6) (Poly [ADP-ribose] polymerase 5B) (Protein poly-ADP-ribosyltransferase tankyrase-2) (EC 2.4.2.-) (TNKS-2) (TRF1-interacting ankyrin-related ADP-ribose polymerase 2) (Tankyrase II) (Tankyrase-2) (TANK2) (Tankyrase-like protein) (Tankyrase-related protein)	TNKS2 PARP5B TANK2 TNKL	Homo sapiens (Human)	1166	MSGRRCAGGGAACASAAAEAVEPAARELFEACRNGDVERVKRLVTPEKVNSRDTAGRKSTPLHFAAGFGRKDVVEYLLQNGANVQARDDGGLIPLHNACSFGHAEVVNLLLRHGADPNARDNWNYTPLHEAAIKGKIDVCIVLLQHGAEPTIRNTDGRTALDLADPSAKAVLTGEYKKDELLESARSGNEEKMMALLTPLNVNCHASDGRKSTPLHLAAGYNRVKIVQLLLQHGADVHAKDKGDLVPLHNACSYGHYEVTELLVKHGACVNAMDLWQFTPLHEAASKNRVEVCSLLLSYGADPTLLNCHNKSAIDLAPTPQLKERLAYEFKGHSLLQAAREADVTRIKKHLSLEMVNFKHPQTHETALHCAAASPYPKRKQICELLLRKGANINEKTKEFLTPLHVASEKAHNDVVEVVVKHEAKVNALDNLGQTSLHRAAYCGHLQTCRLLLSYGCDPNIISLQGFTALQMGNENVQQLLQEGISLGNSEADRQLLEAAKAGDVETVKKLCTVQSVNCRDIEGRQSTPLHFAAGYNRVSVVEYLLQHGADVHAKDKGGLVPLHNACSYGHYEVAELLVKHGAVVNVADLWKFTPLHEAAAKGKYEICKLLLQHGADPTKKNRDGNTPLDLVKDGDTDIQDLLRGDAALLDAAKKGCLARVKKLSSPDNVNCRDTQGRHSTPLHLAAGYNNLEVAEYLLQHGADVNAQDKGGLIPLHNAASYGHVDVAALLIKYNACVNATDKWAFTPLHEAAQKGRTQLCALLLAHGADPTLKNQEGQTPLDLVSADDVSALLTAAMPPSALPSCYKPQVLNGVRSPGATADALSSGPSSPSSLSAASSLDNLSGSFSELSSVVSSSGTEGASSLEKKEVPGVDFSITQFVRNLGLEHLMDIFEREQITLDVLVEMGHKELKEIGINAYGHRHKLIKGVERLISGQQGLNPYLTLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAMKMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEGMVDG	FUNCTION: Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking (PubMed:11739745, PubMed:11802774, PubMed:19759537, PubMed:21478859, PubMed:23622245, PubMed:25043379). Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation (PubMed:19759537, PubMed:21478859). Also mediates poly-ADP-ribosylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination (PubMed:21478859). Mediates poly-ADP-ribosylation of TERF1, thereby contributing to the regulation of telomere length (PubMed:11739745). Stimulates 26S proteasome activity (PubMed:23622245). {ECO:0000269|PubMed:11739745, ECO:0000269|PubMed:11802774, ECO:0000269|PubMed:19759537, ECO:0000269|PubMed:21478859, ECO:0000269|PubMed:23622245, ECO:0000269|PubMed:25043379}.		negative regulation of telomere maintenance via telomere lengthening [GO:1904357]; positive regulation of canonical Wnt signaling pathway [GO:0090263]; positive regulation of telomere capping [GO:1904355]; positive regulation of telomere maintenance via telomerase [GO:0032212]; protein auto-ADP-ribosylation [GO:0070213]; protein localization to chromosome, telomeric region [GO:0070198]; protein poly-ADP-ribosylation [GO:0070212]; protein polyubiquitination [GO:0000209]; Wnt signaling pathway [GO:0016055]	chromosome, telomeric region [GO:0000781]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; Golgi membrane [GO:0000139]; nuclear envelope [GO:0005635]; nucleus [GO:0005634]; pericentriolar material [GO:0000242]; perinuclear region of cytoplasm [GO:0048471]	enzyme binding [GO:0019899]; metal ion binding [GO:0046872]; NAD+ ADP-ribosyltransferase activity [GO:0003950]; NAD+-protein ADP-ribosyltransferase activity [GO:1990404]; nucleotidyltransferase activity [GO:0016779]	chromosome, telomeric region [GO:0000781]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; Golgi membrane [GO:0000139]; nuclear envelope [GO:0005635]; nucleus [GO:0005634]; pericentriolar material [GO:0000242]; perinuclear region of cytoplasm [GO:0048471]; enzyme binding [GO:0019899]; metal ion binding [GO:0046872]; NAD+ ADP-ribosyltransferase activity [GO:0003950]; NAD+-protein ADP-ribosyltransferase activity [GO:1990404]; nucleotidyltransferase activity [GO:0016779]; negative regulation of telomere maintenance via telomere lengthening [GO:1904357]; positive regulation of canonical Wnt signaling pathway [GO:0090263]; positive regulation of telomere capping [GO:1904355]; positive regulation of telomere maintenance via telomerase [GO:0032212]; protein auto-ADP-ribosylation [GO:0070213]; protein localization to chromosome, telomeric region [GO:0070198]; protein poly-ADP-ribosylation [GO:0070212]; protein polyubiquitination [GO:0000209]; Wnt signaling pathway [GO:0016055]	GO:0000139; GO:0000209; GO:0000242; GO:0000781; GO:0003950; GO:0005634; GO:0005635; GO:0005737; GO:0005829; GO:0016055; GO:0016779; GO:0019899; GO:0032212; GO:0046872; GO:0048471; GO:0070198; GO:0070212; GO:0070213; GO:0090263; GO:1904355; GO:1904357; GO:1990404	11205898; 11294570; 11278563; 11454873; 11802774; 14702039; 15164054; 12080061; 11739745; 18936059; 19759537; 20106667; 21478859; 21799911; 23622245; 25043379; 33361107; 21251231	10.1038/sj.gene.6363722; 10.1074/jbc.m009756200; 10.1074/jbc.m105968200; 10.1042/0264-6021:3610451; 10.1038/ng1285; 10.1038/nature02462; 10.1074/jbc.m203916200; 10.1128/mcb.22.1.332-342.2002; 10.1074/mcp.m800340-mcp200; 10.1038/nature08356; 10.1016/j.tibs.2009.12.003; 10.1038/ncb2222; 10.1371/journal.pone.0022595; 10.1016/j.cell.2013.03.040; 10.1038/ncomms5426; 10.1074/jbc.ra120.016573; 10.1111/j.1742-4658.2011.08022.x	NP_079511.1;	Q9H2K2;	CHEMBL6154;	
4h3c	P60472	reviewed	UPPS_ECOLI	Ditrans,polycis-undecaprenyl-diphosphate synthase ((2E,6E)-farnesyl-diphosphate specific) (EC 2.5.1.31) (Ditrans,polycis-undecaprenylcistransferase) (Undecaprenyl diphosphate synthase) (UDS) (Undecaprenyl pyrophosphate synthase) (UPP synthase)	ispU rth uppS yaeS b0174 JW0169	Escherichia coli (strain K12)	253	MMLSATQPLSEKLPAHGCRHVAIIMDGNGRWAKKQGKIRAFGHKAGAKSVRRAVSFAANNGIEALTLYAFSSENWNRPAQEVSALMELFVWALDSEVKSLHRHNVRLRIIGDTSRFNSRLQERIRKSEALTAGNTGLTLNIAANYGGRWDIVQGVRQLAEKVQQGNLQPDQIDEEMLNQHVCMHELAPVDLVIRTGGEHRISNFLLWQIAYAELYFTDVLWPDFDEQDFEGALNAFANRERRFGGTEPGDETA	FUNCTION: Generates ditrans,octacis-undecaprenyl pyrophosphate (UPP) from isopentenyl pyrophosphate (IPP) and farnesyl diphosphate (FPP). UPP is the precursor of glycosyl carrier lipid in the biosynthesis of bacterial cell wall polysaccharide components such as peptidoglycan and lipopolysaccharide. {ECO:0000269|PubMed:12756244}.		cell cycle [GO:0007049]; cell division [GO:0051301]; cell wall organization [GO:0071555]; Gram-negative-bacterium-type cell wall biogenesis [GO:0043164]; peptidoglycan biosynthetic process [GO:0009252]; polyprenol biosynthetic process [GO:0016094]; regulation of cell shape [GO:0008360]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; plasma membrane [GO:0005886]	di-trans,poly-cis-undecaprenyl-diphosphate synthase activity [GO:0008834]; magnesium ion binding [GO:0000287]; manganese ion binding [GO:0030145]; polyprenyltransferase activity [GO:0002094]; protein homodimerization activity [GO:0042803]; small molecule binding [GO:0036094]; Z-farnesyl diphosphate synthase activity [GO:0033850]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; plasma membrane [GO:0005886]; di-trans,poly-cis-undecaprenyl-diphosphate synthase activity [GO:0008834]; magnesium ion binding [GO:0000287]; manganese ion binding [GO:0030145]; polyprenyltransferase activity [GO:0002094]; protein homodimerization activity [GO:0042803]; small molecule binding [GO:0036094]; Z-farnesyl diphosphate synthase activity [GO:0033850]; cell cycle [GO:0007049]; cell division [GO:0051301]; cell wall organization [GO:0071555]; Gram-negative-bacterium-type cell wall biogenesis [GO:0043164]; peptidoglycan biosynthetic process [GO:0009252]; polyprenol biosynthetic process [GO:0016094]; regulation of cell shape [GO:0008360]	GO:0000287; GO:0002094; GO:0005737; GO:0005829; GO:0005886; GO:0007049; GO:0008360; GO:0008834; GO:0009252; GO:0016094; GO:0030145; GO:0033850; GO:0036094; GO:0042803; GO:0043164; GO:0051301; GO:0071555	9278503; 16738553; 9882662; 10217761; 11076526; 11744728; 20828539; 11581264; 12756244; 15044730; 15788389; 17535895; 21294851	10.1126/science.277.5331.1453; 10.1038/msb4100049; 10.1128/jb.181.2.483-492.1999; 10.1128/jb.181.9.2733-2738.1999; 10.1021/bi001226h; 10.1074/jbc.m110014200; 10.1016/j.bbrc.2010.09.001; 10.1074/jbc.m106747200; 10.1074/jbc.m302687200; 10.1110/ps.03519904; 10.1074/jbc.m502121200; 10.1073/pnas.0702254104; 10.1111/j.1747-0285.2011.01101.x	NP_414716.1;	P60472;	CHEMBL4295580;	DB07409;DB07426;DB07410;DB07404;DB07780;DB04695;DB04714;
4rlu	P9WFK1	reviewed	Y635_MYCTU	UPF0336 protein Rv0635	Rv0635 MTCY20H10.16	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	158	MALSADIVGMHYRYPDHYEVEREKIREYAVAVQNDDAWYFEEDGAAELGYKGLLAPLTFICVFGYKAQAAFFKHANIATAEAQIVQVDQVLKFEKPIVAGDKLYCDVYVDSVREAHGTQIIVTKNIVTNEEGDLVQETYTTLAGRAGEDGEGFSDGAA		MISCELLANEOUS: Was identified as a high-confidence drug target.	fatty acid biosynthetic process [GO:0006633]	plasma membrane [GO:0005886]	(3R)-hydroxyacyl-[acyl-carrier-protein] dehydratase activity [GO:0019171]	plasma membrane [GO:0005886]; (3R)-hydroxyacyl-[acyl-carrier-protein] dehydratase activity [GO:0019171]; fatty acid biosynthetic process [GO:0006633]	GO:0005886; GO:0006633; GO:0019171	9634230; 19099550; 21969609	10.1038/31159; 10.1186/1752-0509-2-109; 10.1074/mcp.m111.011445	NP_215149.1;WP_003403277.1;			
4rlu	I6WYY7	unreviewed	I6WYY7_MYCTU	(3R)-hydroxyacyl-ACP dehydratase subunit HadB	hadB Rv0636	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	142	MALREFSSVKVGDQLPEKTYPLTRQDLVNYAGVSGDLNPIHWDDEIAKVVGLDTAIAHGMLTMGIGGGYVTSWVGDPGAVTEYNVRFTAVVPVPNDGKGAELVFNGRVKSVDPESKSVTIALTATTGGKKIFGRAIASAKLA								9634230; 21969609; 26081470; 36325756; 35175661	10.1038/31159; 10.1074/mcp.M111.011445; 10.1007/s13238-015-0181-1; 10.1021/acsinfecdis.2c00392; 10.1111/febs.16405	NP_215150.1;WP_003903106.1;			
4xli	Q4JIM5	reviewed	ABL2_MOUSE	Tyrosine-protein kinase ABL2 (EC 2.7.10.2) (Abelson murine leukemia viral oncogene homolog 2) (Abelson tyrosine-protein kinase 2) (Abelson-related gene protein) (Tyrosine-protein kinase ARG)	Abl2 Arg	Mus musculus (Mouse)	1182	MGQQVGRVGEAPGLQQPQPRGIRGSSAARPSGRRRDPAGRTADAGFNVFTQHDHFASCVEDGFEGDKTGGSSPEVLHRPFGCDAESQALNEAIRWSSKENLLGATESDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNQNGEWSEVRSKNGQGWVPSNYITPVNSLEKHSWYHGPVSRSAAEYLLSSLINGSFLVRESESSPGQLSISLRYEGRVYHYRINTTTDSKVYVTAESRFSTLAELVHHHSTVADGLVTTLHYPAPKCNKPTVYGVSPIHDKWEMERTDITMKHKLGGGQYGEVYVGVWKKYSLTVAVKTFKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTLEPPFYIVTEYMPYGNLLDYLRECSREEVTAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHVVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNTFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYDLLEKGYRMEQPEGCPPKVYELMRACWKWSPADRPSFAETHQAFETMFHDSSISEEVAEELGRTASSSSVVPYLPRLPLLPSKTRTLRKQGENKENLDGGLDAAESLASSSAPAGFIRSTQASSGSPALPRKQRDKSPSSLLEDAKETCFTRDRKGGFFSSFMKKRNAPTPPKRSSSFREMENQPHKKYELTGNFSPVASLQNADGFSVAPSQQEPNLVPAKCYGGSFAQRNLCADDDSGGGGGSGTAGGGWSGITGFFTPRLIKKTLGLRAGKPTASDDTSKPFPRSNSTSSMSSGLPEQDRMAMTLPRNCQRSKLQLERTVSTSSQPEENVDRANDMLPKKSEEGAAPARERPKAKLLPRGATALPLRAPDPAITESDSPGVGVAGVAAAPKGKERNGGTRLGVAGVPEDGEQLGWSSPAKAVAVLPTTHNHKVPVLISPTLKHTPADVQLIGTDSQGNKFKLLSEHQVTSSGDKDRPRRVKPKCAPPPPPVMRLLQHPSTCSDPEEEPTAPPAGQHTPETQEGGKKAAPGPVPSSGKPGRPVMPPPQVPLPTSSISPAKMANGTAGTKVALRKTKQAAEKISADKISKEALLECADLLSSAITEPVPNSQLVDTGHQLLDYCSGYVDSIPQTRNKFAFREAVSKLELSLQELQVSSTAAGVPGTNPVLNNLLSCVQEISDVVQR	FUNCTION: Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like MYH10 (involved in movement); CTTN (involved in signaling); or TUBA1 and TUBB (microtubule subunits). Binds directly F-actin and regulates actin cytoskeletal structure through its F-actin-bundling activity. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as CRK, CRKL or DOK1. Required for adhesion-dependent phosphorylation of ARHGAP35 which promotes its association with RASA1, resulting in recruitment of ARHGAP35 to the cell periphery where it inhibits RHO. Phosphorylates multiple receptor tyrosine kinases like PDGFRB and other substrates which are involved in endocytosis regulation such as RIN1. In brain, may regulate neurotransmission by phosphorylating proteins at the synapse. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Positively regulates chemokine-mediated T-cell migration, polarization, and homing to lymph nodes and immune-challenged tissues, potentially via activation of NEDD9/HEF1 and RAP1 (PubMed:22810897). {ECO:0000269|PubMed:11279004, ECO:0000269|PubMed:11752434, ECO:0000269|PubMed:12748290, ECO:0000269|PubMed:14993293, ECO:0000269|PubMed:16971514, ECO:0000269|PubMed:17892306, ECO:0000269|PubMed:22810897, ECO:0000269|PubMed:9883720}.		actin cytoskeleton organization [GO:0030036]; actin filament bundle assembly [GO:0051017]; actin filament organization [GO:0007015]; adult walking behavior [GO:0007628]; aggressive behavior [GO:0002118]; alpha-beta T cell differentiation [GO:0046632]; auditory behavior [GO:0031223]; Bergmann glial cell differentiation [GO:0060020]; canonical NF-kappaB signal transduction [GO:0007249]; cell-cell adhesion [GO:0098609]; cerebellum morphogenesis [GO:0021587]; circulatory system development [GO:0072359]; dendrite morphogenesis [GO:0048813]; dendritic spine maintenance [GO:0097062]; DN4 thymocyte differentiation [GO:1904157]; epidermal growth factor receptor signaling pathway [GO:0007173]; establishment of localization in cell [GO:0051649]; exploration behavior [GO:0035640]; learning [GO:0007612]; multicellular organism growth [GO:0035264]; negative regulation of cell-cell adhesion [GO:0022408]; negative regulation of endothelial cell apoptotic process [GO:2000352]; negative regulation of Rho protein signal transduction [GO:0035024]; neural tube closure [GO:0001843]; neuroepithelial cell differentiation [GO:0060563]; neuromuscular process controlling balance [GO:0050885]; neuron differentiation [GO:0030182]; neuron remodeling [GO:0016322]; peptidyl-tyrosine phosphorylation [GO:0018108]; phagocytosis [GO:0006909]; platelet-derived growth factor receptor signaling pathway [GO:0048008]; positive regulation of canonical NF-kappaB signal transduction [GO:0043123]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of establishment of T cell polarity [GO:1903905]; positive regulation of interleukin-2 production [GO:0032743]; positive regulation of neuron projection development [GO:0010976]; positive regulation of T cell migration [GO:2000406]; positive regulation of type II interferon production [GO:0032729]; positive regulation of Wnt signaling pathway, planar cell polarity pathway [GO:2000096]; post-embryonic development [GO:0009791]; protein localization [GO:0008104]; protein phosphorylation [GO:0006468]; regulation of extracellular matrix organization [GO:1903053]; reproductive process [GO:0022414]; Rho protein signal transduction [GO:0007266]; substrate-dependent cell migration, cell extension [GO:0006930]; synapse maturation [GO:0060074]; visual learning [GO:0008542]	actin cytoskeleton [GO:0015629]; cytoplasmic vesicle [GO:0031410]; dendritic spine [GO:0043197]; glutamatergic synapse [GO:0098978]; lamellipodium [GO:0030027]; phagocytic cup [GO:0001891]; postsynapse [GO:0098794]	ATP binding [GO:0005524]; magnesium ion binding [GO:0000287]; manganese ion binding [GO:0030145]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; protein tyrosine kinase activity [GO:0004713]	actin cytoskeleton [GO:0015629]; cytoplasmic vesicle [GO:0031410]; dendritic spine [GO:0043197]; glutamatergic synapse [GO:0098978]; lamellipodium [GO:0030027]; phagocytic cup [GO:0001891]; postsynapse [GO:0098794]; ATP binding [GO:0005524]; magnesium ion binding [GO:0000287]; manganese ion binding [GO:0030145]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; protein tyrosine kinase activity [GO:0004713]; actin cytoskeleton organization [GO:0030036]; actin filament bundle assembly [GO:0051017]; actin filament organization [GO:0007015]; adult walking behavior [GO:0007628]; aggressive behavior [GO:0002118]; alpha-beta T cell differentiation [GO:0046632]; auditory behavior [GO:0031223]; Bergmann glial cell differentiation [GO:0060020]; canonical NF-kappaB signal transduction [GO:0007249]; cell-cell adhesion [GO:0098609]; cerebellum morphogenesis [GO:0021587]; circulatory system development [GO:0072359]; dendrite morphogenesis [GO:0048813]; dendritic spine maintenance [GO:0097062]; DN4 thymocyte differentiation [GO:1904157]; epidermal growth factor receptor signaling pathway [GO:0007173]; establishment of localization in cell [GO:0051649]; exploration behavior [GO:0035640]; learning [GO:0007612]; multicellular organism growth [GO:0035264]; negative regulation of cell-cell adhesion [GO:0022408]; negative regulation of endothelial cell apoptotic process [GO:2000352]; negative regulation of Rho protein signal transduction [GO:0035024]; neural tube closure [GO:0001843]; neuroepithelial cell differentiation [GO:0060563]; neuromuscular process controlling balance [GO:0050885]; neuron differentiation [GO:0030182]; neuron remodeling [GO:0016322]; peptidyl-tyrosine phosphorylation [GO:0018108]; phagocytosis [GO:0006909]; platelet-derived growth factor receptor signaling pathway [GO:0048008]; positive regulation of canonical NF-kappaB signal transduction [GO:0043123]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of establishment of T cell polarity [GO:1903905]; positive regulation of interleukin-2 production [GO:0032743]; positive regulation of neuron projection development [GO:0010976]; positive regulation of T cell migration [GO:2000406]; positive regulation of type II interferon production [GO:0032729]; positive regulation of Wnt signaling pathway, planar cell polarity pathway [GO:2000096]; post-embryonic development [GO:0009791]; protein localization [GO:0008104]; protein phosphorylation [GO:0006468]; regulation of extracellular matrix organization [GO:1903053]; reproductive process [GO:0022414]; Rho protein signal transduction [GO:0007266]; substrate-dependent cell migration, cell extension [GO:0006930]; synapse maturation [GO:0060074]; visual learning [GO:0008542]	GO:0000287; GO:0001843; GO:0001891; GO:0002118; GO:0004713; GO:0004715; GO:0005524; GO:0006468; GO:0006909; GO:0006930; GO:0007015; GO:0007173; GO:0007204; GO:0007249; GO:0007266; GO:0007612; GO:0007628; GO:0008104; GO:0008542; GO:0009791; GO:0010976; GO:0015629; GO:0016322; GO:0018108; GO:0021587; GO:0022408; GO:0022414; GO:0030027; GO:0030036; GO:0030145; GO:0030182; GO:0031223; GO:0031410; GO:0032729; GO:0032743; GO:0035024; GO:0035264; GO:0035640; GO:0043123; GO:0043197; GO:0046632; GO:0048008; GO:0048813; GO:0050885; GO:0051017; GO:0051649; GO:0060020; GO:0060074; GO:0060563; GO:0070374; GO:0072359; GO:0097062; GO:0098609; GO:0098794; GO:0098978; GO:1903053; GO:1903905; GO:1904157; GO:2000096; GO:2000352; GO:2000406	11752434; 12748290; 9883720; 11279004; 12775773; 14993293; 14729179; 16971514; 17892306; 18182299; 19144319; 21183079; 20841568; 22810897	10.1073/pnas.251249298; 10.1128/mcb.23.11.3884-3896.2003; 10.1016/s0896-6273(00)80646-7; 10.1074/jbc.m100095200; 10.1242/jcs.00622; 10.1128/mcb.24.6.2573-2583.2004; 10.1016/j.tcb.2003.11.003; 10.1091/mbc.e06-02-0132; 10.1021/bi701119s; 10.1016/j.tibs.2007.10.006; 10.1016/j.immuni.2008.11.006; 10.1016/j.cell.2010.12.001; 10.1126/scisignal.3139re6; 10.1126/scisignal.2002632			CHEMBL5222;	
3l3n	P12821	reviewed	ACE_HUMAN	Angiotensin-converting enzyme (ACE) (EC 3.4.15.1) (Dipeptidyl carboxypeptidase I) (Kininase II) (CD antigen CD143) [Cleaved into: Angiotensin-converting enzyme, soluble form]	ACE DCP DCP1	Homo sapiens (Human)	1306	MGAASGRRGPGLLLPLPLLLLLPPQPALALDPGLQPGNFSADEAGAQLFAQSYNSSAEQVLFQSVAASWAHDTNITAENARRQEEAALLSQEFAEAWGQKAKELYEPIWQNFTDPQLRRIIGAVRTLGSANLPLAKRQQYNALLSNMSRIYSTAKVCLPNKTATCWSLDPDLTNILASSRSYAMLLFAWEGWHNAAGIPLKPLYEDFTALSNEAYKQDGFTDTGAYWRSWYNSPTFEDDLEHLYQQLEPLYLNLHAFVRRALHRRYGDRYINLRGPIPAHLLGDMWAQSWENIYDMVVPFPDKPNLDVTSTMLQQGWNATHMFRVAEEFFTSLELSPMPPEFWEGSMLEKPADGREVVCHASAWDFYNRKDFRIKQCTRVTMDQLSTVHHEMGHIQYYLQYKDLPVSLRRGANPGFHEAIGDVLALSVSTPEHLHKIGLLDRVTNDTESDINYLLKMALEKIAFLPFGYLVDQWRWGVFSGRTPPSRYNFDWWYLRTKYQGICPPVTRNETHFDAGAKFHVPNVTPYIRYFVSFVLQFQFHEALCKEAGYEGPLHQCDIYRSTKAGAKLRKVLQAGSSRPWQEVLKDMVGLDALDAQPLLKYFQPVTQWLQEQNQQNGEVLGWPEYQWHPPLPDNYPEGIDLVTDEAEASKFVEEYDRTSQVVWNEYAEANWNYNTNITTETSKILLQKNMQIANHTLKYGTQARKFDVNQLQNTTIKRIIKKVQDLERAALPAQELEEYNKILLDMETTYSVATVCHPNGSCLQLEPDLTNVMATSRKYEDLLWAWEGWRDKAGRAILQFYPKYVELINQAARLNGYVDAGDSWRSMYETPSLEQDLERLFQELQPLYLNLHAYVRRALHRHYGAQHINLEGPIPAHLLGNMWAQTWSNIYDLVVPFPSAPSMDTTEAMLKQGWTPRRMFKEADDFFTSLGLLPVPPEFWNKSMLEKPTDGREVVCHASAWDFYNGKDFRIKQCTTVNLEDLVVAHHEMGHIQYFMQYKDLPVALREGANPGFHEAIGDVLALSVSTPKHLHSLNLLSSEGGSDEHDINFLMKMALDKIAFIPFSYLVDQWRWRVFDGSITKENYNQEWWSLRLKYQGLCPPVPRTQGDFDPGAKFHIPSSVPYIRYFVSFIIQFQFHEALCQAAGHTGPLHKCDIYQSKEAGQRLATAMKLGFSRPWPEAMQLITGQPNMSASAMLSYFKPLLDWLRTENELHGEKLGWPQYNWTPNSARSEGPLPDSGRVSFLGLDLDAQQARVGQWLLLFLGIALLVATLGLSQRLFSIRHRSLHRHSHGPQFGSEVELRHS	FUNCTION: Dipeptidyl carboxypeptidase that removes dipeptides from the C-terminus of a variety of circulating hormones, such as angiotensin I, bradykinin or enkephalins, thereby playing a key role in the regulation of blood pressure, electrolyte homeostasis or synaptic plasticity (PubMed:15615692, PubMed:20826823, PubMed:2558109, PubMed:4322742, PubMed:7523412, PubMed:7683654). Composed of two similar catalytic domains, each possessing a functional active site, with different selectivity for substrates (PubMed:10913258, PubMed:1320019, PubMed:1851160, PubMed:19773553, PubMed:7683654, PubMed:7876104). Plays a major role in the angiotensin-renin system that regulates blood pressure and sodium retention by the kidney by converting angiotensin I to angiotensin II, resulting in an increase of the vasoconstrictor activity of angiotensin (PubMed:11432860, PubMed:1851160, PubMed:19773553, PubMed:23056909, PubMed:4322742). Also able to inactivate bradykinin, a potent vasodilator, and therefore enhance the blood pressure response (PubMed:15615692, PubMed:2558109, PubMed:4322742, PubMed:6055465, PubMed:6270633, PubMed:7683654). Acts as a regulator of synaptic transmission by mediating cleavage of neuropeptide hormones, such as substance P, neurotensin or enkephalins (PubMed:15615692, PubMed:6208535, PubMed:6270633, PubMed:656131). Catalyzes degradation of different enkephalin neuropeptides (Met-enkephalin, Leu-enkephalin, Met-enkephalin-Arg-Phe and possibly Met-enkephalin-Arg-Gly-Leu) (PubMed:2982830, PubMed:6270633, PubMed:656131). Acts as a regulator of synaptic plasticity in the nucleus accumbens of the brain by mediating cleavage of Met-enkephalin-Arg-Phe, a strong ligand of Mu-type opioid receptor OPRM1, into Met-enkephalin (By similarity). Met-enkephalin-Arg-Phe cleavage by ACE decreases activation of OPRM1, leading to long-term synaptic potentiation of glutamate release (By similarity). Also acts as a regulator of hematopoietic stem cell differentiation by mediating degradation of hemoregulatory peptide N-acetyl-SDKP (AcSDKP) (PubMed:26403559, PubMed:7876104, PubMed:8257427, PubMed:8609242). Acts as a regulator of cannabinoid signaling pathway by mediating degradation of hemopressin, an antagonist peptide of the cannabinoid receptor CNR1 (PubMed:18077343). Involved in amyloid-beta metabolism by catalyzing degradation of Amyloid-beta protein 40 and Amyloid-beta protein 42 peptides, thereby preventing plaque formation (PubMed:11604391, PubMed:16154999, PubMed:19773553). Catalyzes cleavage of cholecystokinin (maturation of Cholecystokinin-8 and Cholecystokinin-5) and Gonadoliberin-1 (both maturation and degradation) hormones (PubMed:10336644, PubMed:2983326, PubMed:7683654, PubMed:9371719). Degradation of hemoregulatory peptide N-acetyl-SDKP (AcSDKP) and amyloid-beta proteins is mediated by the N-terminal catalytic domain, while angiotensin I and cholecystokinin cleavage is mediated by the C-terminal catalytic region (PubMed:10336644, PubMed:19773553, PubMed:7876104). {ECO:0000250|UniProtKB:P09470, ECO:0000269|PubMed:10336644, ECO:0000269|PubMed:10913258, ECO:0000269|PubMed:11432860, ECO:0000269|PubMed:11604391, ECO:0000269|PubMed:1320019, ECO:0000269|PubMed:15615692, ECO:0000269|PubMed:16154999, ECO:0000269|PubMed:18077343, ECO:0000269|PubMed:1851160, ECO:0000269|PubMed:19773553, ECO:0000269|PubMed:20826823, ECO:0000269|PubMed:23056909, ECO:0000269|PubMed:2558109, ECO:0000269|PubMed:26403559, ECO:0000269|PubMed:2982830, ECO:0000269|PubMed:2983326, ECO:0000269|PubMed:4322742, ECO:0000269|PubMed:6055465, ECO:0000269|PubMed:6208535, ECO:0000269|PubMed:6270633, ECO:0000269|PubMed:656131, ECO:0000269|PubMed:7523412, ECO:0000269|PubMed:7683654, ECO:0000269|PubMed:7876104, ECO:0000269|PubMed:8257427, ECO:0000269|PubMed:8609242, ECO:0000269|PubMed:9371719}.; FUNCTION: [Angiotensin-converting enzyme, soluble form]: Soluble form that is released in blood plasma and other body fluids following proteolytic cleavage in the juxtamembrane stalk region. {ECO:0000269|PubMed:10769174, ECO:0000269|PubMed:11274151, ECO:0000269|PubMed:7499427, ECO:0000269|PubMed:8253769}.; FUNCTION: [Isoform Testis-specific]: Isoform produced by alternative promoter usage that is specifically expressed in spermatocytes and adult testis, and which is required for male fertility (PubMed:1651327, PubMed:1668266). In contrast to somatic isoforms, only contains one catalytic domain (PubMed:1651327, PubMed:1668266). Acts as a dipeptidyl carboxypeptidase that removes dipeptides from the C-terminus of substrates (PubMed:1668266, PubMed:24297181). The identity of substrates that are needed for male fertility is unknown (By similarity). May also have a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. The GPIase activity was reported to be essential for the egg-binding ability of the sperm (By similarity). This activity is however unclear and has been challenged by other groups, suggesting that it may be indirect (By similarity). {ECO:0000250|UniProtKB:P09470, ECO:0000269|PubMed:1651327, ECO:0000269|PubMed:1668266, ECO:0000269|PubMed:24297181}.	MISCELLANEOUS: Inhibitors of ACE are commonly used to treat hypertension and some types of renal and cardiac dysfunction.; MISCELLANEOUS: [Isoform Somatic-2]: Incomplete sequence. {ECO:0000305}.	amyloid-beta metabolic process [GO:0050435]; angiogenesis involved in coronary vascular morphogenesis [GO:0060978]; angiotensin maturation [GO:0002003]; angiotensin-activated signaling pathway [GO:0038166]; animal organ regeneration [GO:0031100]; antigen processing and presentation of peptide antigen via MHC class I [GO:0002474]; arachidonic acid secretion [GO:0050482]; blood vessel diameter maintenance [GO:0097746]; blood vessel remodeling [GO:0001974]; bradykinin catabolic process [GO:0010815]; cell proliferation in bone marrow [GO:0071838]; cellular response to aldosterone [GO:1904045]; cellular response to glucose stimulus [GO:0071333]; eating behavior [GO:0042755]; embryo development ending in birth or egg hatching [GO:0009792]; female pregnancy [GO:0007565]; heart contraction [GO:0060047]; hematopoietic stem cell differentiation [GO:0060218]; hormone catabolic process [GO:0042447]; hormone metabolic process [GO:0042445]; kidney development [GO:0001822]; lung alveolus development [GO:0048286]; male gonad development [GO:0008584]; mononuclear cell proliferation [GO:0032943]; negative regulation of calcium ion import [GO:0090281]; negative regulation of gap junction assembly [GO:1903597]; negative regulation of gene expression [GO:0010629]; negative regulation of glucose import [GO:0046325]; neutrophil mediated immunity [GO:0002446]; peptide catabolic process [GO:0043171]; positive regulation of apoptotic process [GO:0043065]; positive regulation of neurogenesis [GO:0050769]; positive regulation of peptidyl-cysteine S-nitrosylation [GO:2000170]; positive regulation of systemic arterial blood pressure [GO:0003084]; positive regulation of vasoconstriction [GO:0045907]; post-transcriptional regulation of gene expression [GO:0010608]; proteolysis [GO:0006508]; regulation of angiotensin metabolic process [GO:0060177]; regulation of blood pressure [GO:0008217]; regulation of heart rate by cardiac conduction [GO:0086091]; regulation of hematopoietic stem cell proliferation [GO:1902033]; regulation of renal output by angiotensin [GO:0002019]; regulation of smooth muscle cell migration [GO:0014910]; regulation of synaptic plasticity [GO:0048167]; regulation of systemic arterial blood pressure by renin-angiotensin [GO:0003081]; regulation of vasoconstriction [GO:0019229]; response to dexamethasone [GO:0071548]; response to hypoxia [GO:0001666]; response to laminar fluid shear stress [GO:0034616]; response to lipopolysaccharide [GO:0032496]; response to nutrient levels [GO:0031667]; response to thyroid hormone [GO:0097066]; response to xenobiotic stimulus [GO:0009410]; spermatogenesis [GO:0007283]; substance P catabolic process [GO:0010814]; vasoconstriction [GO:0042310]	basal plasma membrane [GO:0009925]; brush border membrane [GO:0031526]; endosome [GO:0005768]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; lysosome [GO:0005764]; plasma membrane [GO:0005886]; sperm midpiece [GO:0097225]	actin binding [GO:0003779]; bradykinin receptor binding [GO:0031711]; calmodulin binding [GO:0005516]; carboxypeptidase activity [GO:0004180]; chloride ion binding [GO:0031404]; endopeptidase activity [GO:0004175]; exopeptidase activity [GO:0008238]; heterocyclic compound binding [GO:1901363]; metallodipeptidase activity [GO:0070573]; metalloendopeptidase activity [GO:0004222]; metallopeptidase activity [GO:0008237]; mitogen-activated protein kinase binding [GO:0051019]; mitogen-activated protein kinase kinase binding [GO:0031434]; peptidase activity [GO:0008233]; peptidyl-dipeptidase activity [GO:0008241]; tripeptidyl-peptidase activity [GO:0008240]; zinc ion binding [GO:0008270]	basal plasma membrane [GO:0009925]; brush border membrane [GO:0031526]; endosome [GO:0005768]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; lysosome [GO:0005764]; plasma membrane [GO:0005886]; sperm midpiece [GO:0097225]; actin binding [GO:0003779]; bradykinin receptor binding [GO:0031711]; calmodulin binding [GO:0005516]; carboxypeptidase activity [GO:0004180]; chloride ion binding [GO:0031404]; endopeptidase activity [GO:0004175]; exopeptidase activity [GO:0008238]; heterocyclic compound binding [GO:1901363]; metallodipeptidase activity [GO:0070573]; metalloendopeptidase activity [GO:0004222]; metallopeptidase activity [GO:0008237]; mitogen-activated protein kinase binding [GO:0051019]; mitogen-activated protein kinase kinase binding [GO:0031434]; peptidase activity [GO:0008233]; peptidyl-dipeptidase activity [GO:0008241]; tripeptidyl-peptidase activity [GO:0008240]; zinc ion binding [GO:0008270]; amyloid-beta metabolic process [GO:0050435]; angiogenesis involved in coronary vascular morphogenesis [GO:0060978]; angiotensin maturation [GO:0002003]; angiotensin-activated signaling pathway [GO:0038166]; animal organ regeneration [GO:0031100]; antigen processing and presentation of peptide antigen via MHC class I [GO:0002474]; arachidonic acid secretion [GO:0050482]; blood vessel diameter maintenance [GO:0097746]; blood vessel remodeling [GO:0001974]; bradykinin catabolic process [GO:0010815]; cell proliferation in bone marrow [GO:0071838]; cellular response to aldosterone [GO:1904045]; cellular response to glucose stimulus [GO:0071333]; eating behavior [GO:0042755]; embryo development ending in birth or egg hatching [GO:0009792]; female pregnancy [GO:0007565]; heart contraction [GO:0060047]; hematopoietic stem cell differentiation [GO:0060218]; hormone catabolic process [GO:0042447]; hormone metabolic process [GO:0042445]; kidney development [GO:0001822]; lung alveolus development [GO:0048286]; male gonad development [GO:0008584]; mononuclear cell proliferation [GO:0032943]; negative regulation of calcium ion import [GO:0090281]; negative regulation of gap junction assembly [GO:1903597]; negative regulation of gene expression [GO:0010629]; negative regulation of glucose import [GO:0046325]; neutrophil mediated immunity [GO:0002446]; peptide catabolic process [GO:0043171]; positive regulation of apoptotic process [GO:0043065]; positive regulation of neurogenesis [GO:0050769]; positive regulation of peptidyl-cysteine S-nitrosylation [GO:2000170]; positive regulation of systemic arterial blood pressure [GO:0003084]; positive regulation of vasoconstriction [GO:0045907]; post-transcriptional regulation of gene expression [GO:0010608]; proteolysis [GO:0006508]; regulation of angiotensin metabolic process [GO:0060177]; regulation of blood pressure [GO:0008217]; regulation of heart rate by cardiac conduction [GO:0086091]; regulation of hematopoietic stem cell proliferation [GO:1902033]; regulation of renal output by angiotensin [GO:0002019]; regulation of smooth muscle cell migration [GO:0014910]; regulation of synaptic plasticity [GO:0048167]; regulation of systemic arterial blood pressure by renin-angiotensin [GO:0003081]; regulation of vasoconstriction [GO:0019229]; response to dexamethasone [GO:0071548]; response to hypoxia [GO:0001666]; response to laminar fluid shear stress [GO:0034616]; response to lipopolysaccharide [GO:0032496]; response to nutrient levels [GO:0031667]; response to thyroid hormone [GO:0097066]; response to xenobiotic stimulus [GO:0009410]; spermatogenesis [GO:0007283]; substance P catabolic process [GO:0010814]; vasoconstriction [GO:0042310]	GO:0001666; GO:0001822; GO:0001974; GO:0002003; GO:0002019; GO:0002446; GO:0002474; GO:0003081; GO:0003084; GO:0003779; GO:0004175; GO:0004180; GO:0004222; GO:0005516; GO:0005576; GO:0005615; GO:0005764; GO:0005768; GO:0005886; GO:0006508; GO:0007283; GO:0007565; GO:0008217; GO:0008233; GO:0008237; GO:0008238; GO:0008240; GO:0008241; GO:0008270; GO:0008584; GO:0009410; GO:0009792; GO:0009897; GO:0009925; GO:0010608; GO:0010629; GO:0010814; GO:0010815; GO:0014910; GO:0019229; GO:0031100; GO:0031404; GO:0031434; GO:0031526; GO:0031667; GO:0031711; GO:0032496; GO:0032943; GO:0034616; GO:0038166; GO:0042310; GO:0042445; GO:0042447; GO:0042755; GO:0043065; GO:0043171; GO:0045907; GO:0046325; GO:0048167; GO:0048286; GO:0050435; GO:0050482; GO:0050769; GO:0051019; GO:0060047; GO:0060177; GO:0060218; GO:0060978; GO:0070062; GO:0070573; GO:0071333; GO:0071548; GO:0071838; GO:0086091; GO:0090281; GO:0097066; GO:0097225; GO:0097746; GO:1901363; GO:1902033; GO:1903597; GO:1904045; GO:2000170	2849100; 2547653; 2554286; 10319862; 14702039; 16625196; 2558109; 9642152; 6055465; 4322742; 656131; 6270633; 6208535; 2982830; 2983326; 1649623; 1651327; 1668266; 1851160; 1320019; 8257427; 7683654; 8253769; 7523412; 7961923; 7876104; 7499427; 8755737; 8626443; 8609242; 9371719; 9013598; 10336644; 10913258; 10769174; 10969042; 10924499; 11076943; 11432860; 11274151; 11604391; 12386153; 12459472; 12542396; 15151696; 15671045; 15615692; 16154999; 16335952; 16476786; 18077343; 19773553; 19159218; 21269460; 21901117; 12540854; 15236580; 16476442; 20826823; 21810173; 23056909; 24297181; 26403559; 10099885; 10391210; 11551873; 14694062; 15534175; 15277638; 16116425; 25787250	10.1073/pnas.85.24.9386; 10.1016/0014-5793(89)80897-x; 10.1073/pnas.86.20.7741; 10.1038/8760; 10.1038/ng1285; 10.1038/nature04689; 10.1093/oxfordjournals.jbchem.a122871; 10.1006/bbrc.1998.8813; 10.1038/2151402a0; 10.1016/0005-2795(70)90017-6; 10.1016/0006-2952(78)90542-7; 10.1016/s0196-9781(81)80027-7; 10.1016/0196-9781(84)90020-2; 10.1016/s0021-9258(18)89410-8; 10.1073/pnas.82.4.1025; 10.1021/bi00243a012; 10.1016/s0021-9258(18)98626-6; 10.1016/1046-5928(91)90001-y; 10.1016/s0021-9258(18)31543-6; 10.1016/s0021-9258(18)42224-7; 10.1042/bj2960373; 10.1016/s0021-9258(18)98378-x; 10.1016/s0021-9258(19)74332-4; 10.1016/s0021-9258(18)47091-3; 10.1016/s0021-9258(18)43897-5; 10.1074/jbc.270.8.3656; 10.1074/jbc.270.48.28962; 10.1021/bi960243x; 10.1074/jbc.271.11.6429; 10.1172/jci118484; 10.1042/bj3280587; 10.1074/jbc.272.6.3511; 10.1046/j.1432-1327.1999.00419.x; 10.1021/bi9928905; 10.1042/bj3470711; 10.1161/01.res.87.5.e1; 10.1074/jbc.m002615200; 10.1074/jbc.m007706200; 10.1074/jbc.m101495200; 10.1074/jbc.m100339200; 10.1074/jbc.m104068200; 10.1161/01.res.0000038114.17939.c8; 10.1016/s0014-5793(02)03640-2; 10.1042/bj20021842; 10.1186/1741-7015-2-19; 10.1093/eurheartj/ehi114; 10.1074/jbc.m412638200; 10.1074/jbc.m508460200; 10.1021/pr0502065; 10.1124/mol.105.020636; 10.1073/pnas.0706980105; 10.1074/jbc.m109.011437; 10.1021/pr8008012; 10.1186/1752-0509-5-17; 10.1371/journal.pone.0022803; 10.1038/nature01370; 10.1021/bi049480n; 10.1016/j.jmb.2006.01.048; 10.1074/jbc.m110.167866; 10.1111/j.1742-4658.2011.08276.x; 10.1038/srep00717; 10.1074/jbc.m113.512335; 10.1038/srep13742; 10.1038/10297; 10.1161/hc3601.095932; 10.1212/01.wnl.0000098990.12845.da; 10.1001/archneur.61.11.1652; 10.1212/01.wnl.0000130200.12993.0c; 10.1038/ng1623; 10.1073/pnas.1503696112	NP_000780.1 [P12821-1];NP_001171528.1 [P12821-4];NP_690043.1 [P12821-3];	P12821;	CHEMBL1808;	DB00542;DB00616;DB01197;DB01340;DB15565;DB00584;DB09477;DB02032;DB00492;DB00722;DB00691;DB03740;DB00886;DB00790;DB00881;DB00178;DB01180;DB01348;DB08836;DB00519;DB13166;
5tjn	P16442	reviewed	BGAT_HUMAN	Histo-blood group ABO system transferase (Fucosylglycoprotein 3-alpha-galactosyltransferase) (Fucosylglycoprotein alpha-N-acetylgalactosaminyltransferase) (Glycoprotein-fucosylgalactoside alpha-N-acetylgalactosaminyltransferase) (EC 2.4.1.40) (Glycoprotein-fucosylgalactoside alpha-galactosyltransferase) (EC 2.4.1.37) (Histo-blood group A transferase) (A transferase) (Histo-blood group B transferase) (B transferase) (NAGAT) [Cleaved into: Fucosylglycoprotein alpha-N-acetylgalactosaminyltransferase soluble form]	ABO	Homo sapiens (Human)	354	MAEVLRTLAGKPKCHALRPMILFLIMLVLVLFGYGVLSPRSLMPGSLERGFCMAVREPDHLQRVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPGFYGSSREAFTYERRPQSQAYIPKDEGDFYYLGGFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNP	FUNCTION: This protein is the basis of the ABO blood group system. The histo-blood group ABO involves three carbohydrate antigens: A, B, and H. A, B, and AB individuals express a glycosyltransferase activity that converts the H antigen to the A antigen (by addition of UDP-GalNAc) or to the B antigen (by addition of UDP-Gal), whereas O individuals lack such activity.; FUNCTION: Glycosyltransferase that catalyzes the transfer of carbohydrates to H antigen, forming the antigenic structures of the ABO blood group. {ECO:0000269|PubMed:2121736}.		carbohydrate metabolic process [GO:0005975]; lipid glycosylation [GO:0030259]; protein glycosylation [GO:0006486]	extracellular region [GO:0005576]; Golgi apparatus [GO:0005794]; Golgi cisterna membrane [GO:0032580]; Golgi membrane [GO:0000139]; vesicle [GO:0031982]	antigen binding [GO:0003823]; fucosylgalactoside 3-alpha-galactosyltransferase activity [GO:0004381]; glycoprotein-fucosylgalactoside alpha-N-acetylgalactosaminyltransferase activity [GO:0004380]; manganese ion binding [GO:0030145]; nucleotide binding [GO:0000166]	extracellular region [GO:0005576]; Golgi apparatus [GO:0005794]; Golgi cisterna membrane [GO:0032580]; Golgi membrane [GO:0000139]; vesicle [GO:0031982]; antigen binding [GO:0003823]; fucosylgalactoside 3-alpha-galactosyltransferase activity [GO:0004381]; glycoprotein-fucosylgalactoside alpha-N-acetylgalactosaminyltransferase activity [GO:0004380]; manganese ion binding [GO:0030145]; nucleotide binding [GO:0000166]; carbohydrate metabolic process [GO:0005975]; lipid glycosylation [GO:0030259]; protein glycosylation [GO:0006486]	GO:0000139; GO:0000166; GO:0003823; GO:0004380; GO:0004381; GO:0005576; GO:0005794; GO:0005975; GO:0006486; GO:0030145; GO:0030259; GO:0031982; GO:0032580	2104828; 2333095; 7598760; 7779106; 16533287; 17764507; 18513251; 15164053; 15489334; 12829588; 8839869; 9800297; 15104652; 1449469; 2121736; 10462501; 12198488; 12529355; 12972418; 15475562; 16326711; 17259183	10.1016/s0021-9258(19)40170-1; 10.1038/345229a0; 10.1006/bbrc.1995.1044; 10.1006/bbrc.1995.1817; 10.1111/j.1537-2995.2006.00740.x; 10.1111/j.1537-2995.2007.01475.x; 10.1111/j.1537-2995.2008.01782.x; 10.1038/nature02465; 10.1101/gr.2596504; 10.1182/blood-2003-03-0955; 10.1046/j.1365-3148.1998.00161.x; 10.1111/j.1537-2995.2004.03346.x; 10.1016/0006-291x(92)91538-2; 10.1016/s0021-9258(17)30652-x; 10.1006/bbrc.1999.1246; 10.1038/nsb832; 10.1074/jbc.m212002200; 10.1074/jbc.m308770200; 10.1074/jbc.m410245200; 10.1074/jbc.m507620200; 10.1074/jbc.m610998200	NP_065202.2;	P16442;	CHEMBL2321639;	DB04141;DB03772;DB07357;DB07378;DB04681;DB04680;DB03501;DB04678;DB04679;DB07341;DB07633;DB03435;DB02196;
5liu	O60218	reviewed	AK1BA_HUMAN	Aldo-keto reductase family 1 member B10 (EC 1.1.1.300) (EC 1.1.1.54) (ARL-1) (Aldose reductase-like) (Aldose reductase-related protein) (ARP) (hARP) (Small intestine reductase) (SI reductase)	AKR1B10 AKR1B11	Homo sapiens (Human)	316	MATFVELSTKAKMPIVGLGTWKSPLGKVKEAVKVAIDAGYRHIDCAYVYQNEHEVGEAIQEKIQEKAVKREDLFIVSKLWPTFFERPLVRKAFEKTLKDLKLSYLDVYLIHWPQGFKSGDDLFPKDDKGNAIGGKATFLDAWEAMEELVDEGLVKALGVSNFSHFQIEKLLNKPGLKYKPVTNQVECHPYLTQEKLIQYCHSKGITVTAYSPLGSPDRPWAKPEDPSLLEDPKIKEIAAKHKKTAAQVLIRFHIQRNVIVIPKSVTPARIVENIQVFDFKLSDEEMATILSFNRNWRACNVLQSSHLEDYPFNAEY	FUNCTION: Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols (PubMed:12732097, PubMed:18087047, PubMed:19013440, PubMed:19563777, PubMed:9565553). Displays strong enzymatic activity toward all-trans-retinal, 9-cis-retinal, and 13-cis-retinal (PubMed:12732097, PubMed:18087047). Plays a critical role in detoxifying dietary and lipid-derived unsaturated carbonyls, such as crotonaldehyde, 4-hydroxynonenal, trans-2-hexenal, trans-2,4-hexadienal and their glutathione-conjugates carbonyls (GS-carbonyls) (PubMed:19013440, PubMed:19563777). Displays no reductase activity towards glucose (PubMed:12732097). {ECO:0000269|PubMed:12732097, ECO:0000269|PubMed:18087047, ECO:0000269|PubMed:19013440, ECO:0000269|PubMed:19563777, ECO:0000269|PubMed:9565553}.	MISCELLANEOUS: Has no counterpart in murine and rat species. {ECO:0000305}.	cellular detoxification of aldehyde [GO:0110095]; daunorubicin metabolic process [GO:0044597]; doxorubicin metabolic process [GO:0044598]; farnesol catabolic process [GO:0016488]; retinoid metabolic process [GO:0001523]	cytosol [GO:0005829]; extracellular region [GO:0005576]; lysosome [GO:0005764]; mitochondrion [GO:0005739]	alcohol dehydrogenase (NADP+) activity [GO:0008106]; alditol:NADP+ 1-oxidoreductase activity [GO:0004032]; aldo-keto reductase (NADP) activity [GO:0004033]; allyl-alcohol dehydrogenase activity [GO:0047655]; geranylgeranyl reductase activity [GO:0045550]; indanol dehydrogenase activity [GO:0047718]; NADP-retinol dehydrogenase activity [GO:0052650]; retinal dehydrogenase activity [GO:0001758]	cytosol [GO:0005829]; extracellular region [GO:0005576]; lysosome [GO:0005764]; mitochondrion [GO:0005739]; alcohol dehydrogenase (NADP+) activity [GO:0008106]; alditol:NADP+ 1-oxidoreductase activity [GO:0004032]; aldo-keto reductase (NADP) activity [GO:0004033]; allyl-alcohol dehydrogenase activity [GO:0047655]; geranylgeranyl reductase activity [GO:0045550]; indanol dehydrogenase activity [GO:0047718]; NADP-retinol dehydrogenase activity [GO:0052650]; retinal dehydrogenase activity [GO:0001758]; cellular detoxification of aldehyde [GO:0110095]; daunorubicin metabolic process [GO:0044597]; doxorubicin metabolic process [GO:0044598]; farnesol catabolic process [GO:0016488]; retinoid metabolic process [GO:0001523]	GO:0001523; GO:0001758; GO:0004032; GO:0004033; GO:0005576; GO:0005739; GO:0005764; GO:0005829; GO:0008106; GO:0016488; GO:0044597; GO:0044598; GO:0045550; GO:0047655; GO:0047718; GO:0052650; GO:0110095	9565553; 9765596; 12853948; 12690205; 15489334; 9537432; 12732097; 15755999; 19608861; 21585341; 19563777; 19013440; 18087047; 21269460	10.1074/jbc.273.19.11429; 10.1016/s0167-4781(98)00109-2; 10.1038/nature01782; 10.1126/science.1083423; 10.1101/gr.2596504; 10.1002/hep.510270408; 10.1042/bj20021818; 10.1158/1078-0432.ccr-04-1238; 10.1126/science.1175371; 10.1042/bj20110111; 10.1016/j.bbrc.2009.06.123; 10.1016/j.cbi.2008.10.021; 10.1073/pnas.0705659105; 10.1186/1752-0509-5-17	NP_064695.3;	O60218;	CHEMBL5983;	DB00997;DB06246;DB02021;DB06077;DB03461;DB00605;DB02383;DB08772;
3o96	P31749	reviewed	AKT1_HUMAN	RAC-alpha serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase B) (PKB) (Protein kinase B alpha) (PKB alpha) (Proto-oncogene c-Akt) (RAC-PK-alpha)	AKT1 PKB RAC	Homo sapiens (Human)	480	MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA	FUNCTION: AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis (PubMed:11882383, PubMed:15526160, PubMed:15861136, PubMed:21432781, PubMed:21620960, PubMed:31204173). This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates (PubMed:11882383, PubMed:15526160, PubMed:21432781, PubMed:21620960, PubMed:31204173). Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported (PubMed:11882383, PubMed:15526160, PubMed:21432781, PubMed:21620960). AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface (By similarity). Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling (By similarity). Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport (PubMed:11994271). AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity (By similarity). Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven (By similarity). AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase) (PubMed:11154276). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis (PubMed:11154276). AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating the mTORC1 signaling pathway, and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1 (PubMed:12150915, PubMed:12172553). Also regulates the mTORC1 signaling pathway by catalyzing phosphorylation of CASTOR1 and DEPDC5 (PubMed:31548394, PubMed:33594058). AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization (PubMed:10358075). In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319' (PubMed:10358075). FOXO3 and FOXO4 are phosphorylated on equivalent sites (PubMed:10358075). AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein) (PubMed:9829964). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1 (PubMed:9829964). AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis (By similarity). Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis (By similarity). Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity (By similarity). The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth (By similarity). AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation (By similarity). Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I) (PubMed:12176338, PubMed:12964941). AKT mediates the antiapoptotic effects of IGF-I (By similarity). Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly (PubMed:19934221). May be involved in the regulation of the placental development (By similarity). Phosphorylates STK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its: kinase activity, nuclear translocation, autophosphorylation and ability to phosphorylate FOXO3 (PubMed:17726016). Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its: cleavage, kinase activity, autophosphorylation at Thr-180, binding to RASSF1 and nuclear translocation (PubMed:20086174, PubMed:20231902). Phosphorylates SRPK2 and enhances its kinase activity towards SRSF2 and ACIN1 and promotes its nuclear translocation (PubMed:19592491). Phosphorylates RAF1 at 'Ser-259' and negatively regulates its activity (PubMed:10576742). Phosphorylation of BAD stimulates its pro-apoptotic activity (PubMed:10926925). Phosphorylates KAT6A at 'Thr-369' and this phosphorylation inhibits the interaction of KAT6A with PML and negatively regulates its acetylation activity towards p53/TP53 (PubMed:23431171). Phosphorylates palladin (PALLD), modulating cytoskeletal organization and cell motility (PubMed:20471940). Phosphorylates prohibitin (PHB), playing an important role in cell metabolism and proliferation (PubMed:18507042). Phosphorylates CDKN1A, for which phosphorylation at 'Thr-145' induces its release from CDK2 and cytoplasmic relocalization (PubMed:16982699). These recent findings indicate that the AKT1 isoform has a more specific role in cell motility and proliferation (PubMed:16139227). Phosphorylates CLK2 thereby controlling cell survival to ionizing radiation (PubMed:20682768). Phosphorylates PCK1 at 'Ser-90', reducing the binding affinity of PCK1 to oxaloacetate and changing PCK1 into an atypical protein kinase activity using GTP as donor (PubMed:32322062). Also acts as an activator of TMEM175 potassium channel activity in response to growth factors: forms the lysoK(GF) complex together with TMEM175 and acts by promoting TMEM175 channel activation, independently of its protein kinase activity (PubMed:32228865). Acts as an inhibitor of tRNA methylation by mediating phosphorylation of the N-terminus of METTL1, thereby inhibiting METTL1 methyltransferase activity (PubMed:15861136). In response to LPAR1 receptor pathway activation, phosphorylates Rabin8/RAB3IP which alters its activity and phosphorylates WDR44 which induces WDR44 binding to Rab11, thereby switching Rab11 vesicular function from preciliary trafficking to endocytic recycling (PubMed:31204173). {ECO:0000250|UniProtKB:P31750, ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:10358075, ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10926925, ECO:0000269|PubMed:11154276, ECO:0000269|PubMed:11994271, ECO:0000269|PubMed:12150915, ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:12964941, ECO:0000269|PubMed:15861136, ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:16982699, ECO:0000269|PubMed:17726016, ECO:0000269|PubMed:18507042, ECO:0000269|PubMed:19592491, ECO:0000269|PubMed:19934221, ECO:0000269|PubMed:20086174, ECO:0000269|PubMed:20231902, ECO:0000269|PubMed:20471940, ECO:0000269|PubMed:20682768, ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:31204173, ECO:0000269|PubMed:31548394, ECO:0000269|PubMed:32228865, ECO:0000269|PubMed:32322062, ECO:0000269|PubMed:33594058, ECO:0000269|PubMed:9829964, ECO:0000303|PubMed:11882383, ECO:0000303|PubMed:15526160, ECO:0000303|PubMed:21432781, ECO:0000303|PubMed:21620960}.		activation-induced cell death of T cells [GO:0006924]; anoikis [GO:0043276]; apoptotic mitochondrial changes [GO:0008637]; behavioral response to pain [GO:0048266]; canonical NF-kappaB signal transduction [GO:0007249]; cell differentiation [GO:0030154]; cell migration involved in sprouting angiogenesis [GO:0002042]; cell population proliferation [GO:0008283]; cellular response to cadmium ion [GO:0071276]; cellular response to decreased oxygen levels [GO:0036294]; cellular response to epidermal growth factor stimulus [GO:0071364]; cellular response to granulocyte macrophage colony-stimulating factor stimulus [GO:0097011]; cellular response to insulin stimulus [GO:0032869]; cellular response to nerve growth factor stimulus [GO:1990090]; cellular response to oxidised low-density lipoprotein particle stimulus [GO:0140052]; cellular response to prostaglandin E stimulus [GO:0071380]; cellular response to reactive oxygen species [GO:0034614]; cellular response to tumor necrosis factor [GO:0071356]; cellular response to vascular endothelial growth factor stimulus [GO:0035924]; cytokine-mediated signaling pathway [GO:0019221]; epidermal growth factor receptor signaling pathway [GO:0007173]; establishment of protein localization to mitochondrion [GO:0072655]; excitatory postsynaptic potential [GO:0060079]; execution phase of apoptosis [GO:0097194]; fibroblast migration [GO:0010761]; G protein-coupled receptor signaling pathway [GO:0007186]; gene expression [GO:0010467]; glucose homeostasis [GO:0042593]; glucose metabolic process [GO:0006006]; glycogen biosynthetic process [GO:0005978]; glycogen cell differentiation involved in embryonic placenta development [GO:0060709]; inflammatory response [GO:0006954]; insulin receptor signaling pathway [GO:0008286]; insulin-like growth factor receptor signaling pathway [GO:0048009]; interleukin-18-mediated signaling pathway [GO:0035655]; intracellular signal transduction [GO:0035556]; labyrinthine layer blood vessel development [GO:0060716]; lipopolysaccharide-mediated signaling pathway [GO:0031663]; maintenance of protein location in mitochondrion [GO:0072656]; mammalian oogenesis stage [GO:0022605]; mammary gland epithelial cell differentiation [GO:0060644]; maternal placenta development [GO:0001893]; negative regulation of apoptotic process [GO:0043066]; negative regulation of autophagy [GO:0010507]; negative regulation of cGAS/STING signaling pathway [GO:0160049]; negative regulation of cilium assembly [GO:1902018]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of endopeptidase activity [GO:0010951]; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand [GO:2001240]; negative regulation of fatty acid beta-oxidation [GO:0031999]; negative regulation of gene expression [GO:0010629]; negative regulation of leukocyte cell-cell adhesion [GO:1903038]; negative regulation of long-chain fatty acid import across plasma membrane [GO:0010748]; negative regulation of lymphocyte migration [GO:2000402]; negative regulation of macroautophagy [GO:0016242]; negative regulation of Notch signaling pathway [GO:0045746]; negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902176]; negative regulation of protein binding [GO:0032091]; negative regulation of protein kinase activity [GO:0006469]; negative regulation of protein localization to lysosome [GO:0150033]; negative regulation of protein serine/threonine kinase activity [GO:0071901]; negative regulation of protein ubiquitination [GO:0031397]; negative regulation of proteolysis [GO:0045861]; negative regulation of release of cytochrome c from mitochondria [GO:0090201]; nitric oxide biosynthetic process [GO:0006809]; non-canonical NF-kappaB signal transduction [GO:0038061]; osteoblast differentiation [GO:0001649]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-threonine phosphorylation [GO:0018107]; peripheral nervous system myelin maintenance [GO:0032287]; phosphatidylinositol 3-kinase/protein kinase B signal transduction [GO:0043491]; phosphorylation [GO:0016310]; positive regulation of blood vessel endothelial cell migration [GO:0043536]; positive regulation of cell growth [GO:0030307]; positive regulation of cyclin-dependent protein serine/threonine kinase activity [GO:0045737]; positive regulation of DNA-binding transcription factor activity [GO:0051091]; positive regulation of DNA-templated transcription [GO:0045893]; positive regulation of endodeoxyribonuclease activity [GO:0032079]; positive regulation of endothelial cell migration [GO:0010595]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of fat cell differentiation [GO:0045600]; positive regulation of fibroblast migration [GO:0010763]; positive regulation of G1/S transition of mitotic cell cycle [GO:1900087]; positive regulation of gene expression [GO:0010628]; positive regulation of glucose import [GO:0046326]; positive regulation of glucose metabolic process [GO:0010907]; positive regulation of glycogen biosynthetic process [GO:0045725]; positive regulation of I-kappaB phosphorylation [GO:1903721]; positive regulation of lipid biosynthetic process [GO:0046889]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of nitric-oxide synthase activity [GO:0051000]; positive regulation of organ growth [GO:0046622]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of proteasomal ubiquitin-dependent protein catabolic process [GO:0032436]; positive regulation of protein localization to cell surface [GO:2000010]; positive regulation of protein localization to endoplasmic reticulum [GO:1905552]; positive regulation of protein localization to nucleus [GO:1900182]; positive regulation of protein localization to plasma membrane [GO:1903078]; positive regulation of protein metabolic process [GO:0051247]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of sodium ion transport [GO:0010765]; positive regulation of TORC1 signaling [GO:1904263]; positive regulation of transcription by RNA polymerase II [GO:0045944]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; protein autophosphorylation [GO:0046777]; protein import into nucleus [GO:0006606]; protein phosphorylation [GO:0006468]; protein ubiquitination [GO:0016567]; regulation of apoptotic process [GO:0042981]; regulation of cell migration [GO:0030334]; regulation of glycogen biosynthetic process [GO:0005979]; regulation of mRNA stability [GO:0043488]; regulation of myelination [GO:0031641]; regulation of neuron projection development [GO:0010975]; regulation of postsynapse organization [GO:0099175]; regulation of signal transduction by p53 class mediator [GO:1901796]; regulation of translation [GO:0006417]; regulation of tRNA methylation [GO:0110002]; regulation of type B pancreatic cell development [GO:2000074]; response to fluid shear stress [GO:0034405]; response to food [GO:0032094]; response to growth factor [GO:0070848]; response to growth hormone [GO:0060416]; response to heat [GO:0009408]; response to insulin-like growth factor stimulus [GO:1990418]; response to oxidative stress [GO:0006979]; response to UV-A [GO:0070141]; signal transduction [GO:0007165]; sphingosine-1-phosphate receptor signaling pathway [GO:0003376]; striated muscle cell differentiation [GO:0051146]; T cell costimulation [GO:0031295]; TOR signaling [GO:0031929]; virus-mediated perturbation of host defense response [GO:0019049]	cell cortex [GO:0005938]; cell-cell junction [GO:0005911]; ciliary basal body [GO:0036064]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; glutamatergic synapse [GO:0098978]; lamellipodium [GO:0030027]; membrane [GO:0016020]; microtubule cytoskeleton [GO:0015630]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; postsynapse [GO:0098794]; protein-containing complex [GO:0032991]; spindle [GO:0005819]; vesicle [GO:0031982]	14-3-3 protein binding [GO:0071889]; ATP binding [GO:0005524]; calmodulin binding [GO:0005516]; enzyme binding [GO:0019899]; identical protein binding [GO:0042802]; kinase activity [GO:0016301]; nitric-oxide synthase regulator activity [GO:0030235]; phosphatidylinositol-3,4,5-trisphosphate binding [GO:0005547]; phosphatidylinositol-3,4-bisphosphate binding [GO:0043325]; potassium channel activator activity [GO:0099104]; protein homodimerization activity [GO:0042803]; protein kinase activity [GO:0004672]; protein kinase binding [GO:0019901]; protein serine kinase activity [GO:0106310]; protein serine/threonine kinase activity [GO:0004674]; protein serine/threonine kinase inhibitor activity [GO:0030291]; protein serine/threonine/tyrosine kinase activity [GO:0004712]	cell cortex [GO:0005938]; cell-cell junction [GO:0005911]; ciliary basal body [GO:0036064]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; glutamatergic synapse [GO:0098978]; lamellipodium [GO:0030027]; membrane [GO:0016020]; microtubule cytoskeleton [GO:0015630]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; postsynapse [GO:0098794]; protein-containing complex [GO:0032991]; spindle [GO:0005819]; vesicle [GO:0031982]; 14-3-3 protein binding [GO:0071889]; ATP binding [GO:0005524]; calmodulin binding [GO:0005516]; enzyme binding [GO:0019899]; identical protein binding [GO:0042802]; kinase activity [GO:0016301]; nitric-oxide synthase regulator activity [GO:0030235]; phosphatidylinositol-3,4,5-trisphosphate binding [GO:0005547]; phosphatidylinositol-3,4-bisphosphate binding [GO:0043325]; potassium channel activator activity [GO:0099104]; protein homodimerization activity [GO:0042803]; protein kinase activity [GO:0004672]; protein kinase binding [GO:0019901]; protein serine kinase activity [GO:0106310]; protein serine/threonine kinase activity [GO:0004674]; protein serine/threonine kinase inhibitor activity [GO:0030291]; protein serine/threonine/tyrosine kinase activity [GO:0004712]; activation-induced cell death of T cells [GO:0006924]; anoikis [GO:0043276]; apoptotic mitochondrial changes [GO:0008637]; behavioral response to pain [GO:0048266]; canonical NF-kappaB signal transduction [GO:0007249]; cell differentiation [GO:0030154]; cell migration involved in sprouting angiogenesis [GO:0002042]; cell population proliferation [GO:0008283]; cellular response to cadmium ion [GO:0071276]; cellular response to decreased oxygen levels [GO:0036294]; cellular response to epidermal growth factor stimulus [GO:0071364]; cellular response to granulocyte macrophage colony-stimulating factor stimulus [GO:0097011]; cellular response to insulin stimulus [GO:0032869]; cellular response to nerve growth factor stimulus [GO:1990090]; cellular response to oxidised low-density lipoprotein particle stimulus [GO:0140052]; cellular response to prostaglandin E stimulus [GO:0071380]; cellular response to reactive oxygen species [GO:0034614]; cellular response to tumor necrosis factor [GO:0071356]; cellular response to vascular endothelial growth factor stimulus [GO:0035924]; cytokine-mediated signaling pathway [GO:0019221]; epidermal growth factor receptor signaling pathway [GO:0007173]; establishment of protein localization to mitochondrion [GO:0072655]; excitatory postsynaptic potential [GO:0060079]; execution phase of apoptosis [GO:0097194]; fibroblast migration [GO:0010761]; G protein-coupled receptor signaling pathway [GO:0007186]; gene expression [GO:0010467]; glucose homeostasis [GO:0042593]; glucose metabolic process [GO:0006006]; glycogen biosynthetic process [GO:0005978]; glycogen cell differentiation involved in embryonic placenta development [GO:0060709]; inflammatory response [GO:0006954]; insulin receptor signaling pathway [GO:0008286]; insulin-like growth factor receptor signaling pathway [GO:0048009]; interleukin-18-mediated signaling pathway [GO:0035655]; intracellular signal transduction [GO:0035556]; labyrinthine layer blood vessel development [GO:0060716]; lipopolysaccharide-mediated signaling pathway [GO:0031663]; maintenance of protein location in mitochondrion [GO:0072656]; mammalian oogenesis stage [GO:0022605]; mammary gland epithelial cell differentiation [GO:0060644]; maternal placenta development [GO:0001893]; negative regulation of apoptotic process [GO:0043066]; negative regulation of autophagy [GO:0010507]; negative regulation of cGAS/STING signaling pathway [GO:0160049]; negative regulation of cilium assembly [GO:1902018]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of endopeptidase activity [GO:0010951]; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand [GO:2001240]; negative regulation of fatty acid beta-oxidation [GO:0031999]; negative regulation of gene expression [GO:0010629]; negative regulation of leukocyte cell-cell adhesion [GO:1903038]; negative regulation of long-chain fatty acid import across plasma membrane [GO:0010748]; negative regulation of lymphocyte migration [GO:2000402]; negative regulation of macroautophagy [GO:0016242]; negative regulation of Notch signaling pathway [GO:0045746]; negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902176]; negative regulation of protein binding [GO:0032091]; negative regulation of protein kinase activity [GO:0006469]; negative regulation of protein localization to lysosome [GO:0150033]; negative regulation of protein serine/threonine kinase activity [GO:0071901]; negative regulation of protein ubiquitination [GO:0031397]; negative regulation of proteolysis [GO:0045861]; negative regulation of release of cytochrome c from mitochondria [GO:0090201]; nitric oxide biosynthetic process [GO:0006809]; non-canonical NF-kappaB signal transduction [GO:0038061]; osteoblast differentiation [GO:0001649]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-threonine phosphorylation [GO:0018107]; peripheral nervous system myelin maintenance [GO:0032287]; phosphatidylinositol 3-kinase/protein kinase B signal transduction [GO:0043491]; phosphorylation [GO:0016310]; positive regulation of blood vessel endothelial cell migration [GO:0043536]; positive regulation of cell growth [GO:0030307]; positive regulation of cyclin-dependent protein serine/threonine kinase activity [GO:0045737]; positive regulation of DNA-binding transcription factor activity [GO:0051091]; positive regulation of DNA-templated transcription [GO:0045893]; positive regulation of endodeoxyribonuclease activity [GO:0032079]; positive regulation of endothelial cell migration [GO:0010595]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of fat cell differentiation [GO:0045600]; positive regulation of fibroblast migration [GO:0010763]; positive regulation of G1/S transition of mitotic cell cycle [GO:1900087]; positive regulation of gene expression [GO:0010628]; positive regulation of glucose import [GO:0046326]; positive regulation of glucose metabolic process [GO:0010907]; positive regulation of glycogen biosynthetic process [GO:0045725]; positive regulation of I-kappaB phosphorylation [GO:1903721]; positive regulation of lipid biosynthetic process [GO:0046889]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of nitric-oxide synthase activity [GO:0051000]; positive regulation of organ growth [GO:0046622]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of proteasomal ubiquitin-dependent protein catabolic process [GO:0032436]; positive regulation of protein localization to cell surface [GO:2000010]; positive regulation of protein localization to endoplasmic reticulum [GO:1905552]; positive regulation of protein localization to nucleus [GO:1900182]; positive regulation of protein localization to plasma membrane [GO:1903078]; positive regulation of protein metabolic process [GO:0051247]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of sodium ion transport [GO:0010765]; positive regulation of TORC1 signaling [GO:1904263]; positive regulation of transcription by RNA polymerase II [GO:0045944]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; protein autophosphorylation [GO:0046777]; protein import into nucleus [GO:0006606]; protein phosphorylation [GO:0006468]; protein ubiquitination [GO:0016567]; regulation of apoptotic process [GO:0042981]; regulation of cell migration [GO:0030334]; regulation of glycogen biosynthetic process [GO:0005979]; regulation of mRNA stability [GO:0043488]; regulation of myelination [GO:0031641]; regulation of neuron projection development [GO:0010975]; regulation of postsynapse organization [GO:0099175]; regulation of signal transduction by p53 class mediator [GO:1901796]; regulation of translation [GO:0006417]; regulation of tRNA methylation [GO:0110002]; regulation of type B pancreatic cell development [GO:2000074]; response to fluid shear stress [GO:0034405]; response to food [GO:0032094]; response to growth factor [GO:0070848]; response to growth hormone [GO:0060416]; response to heat [GO:0009408]; response to insulin-like growth factor stimulus [GO:1990418]; response to oxidative stress [GO:0006979]; response to UV-A [GO:0070141]; signal transduction [GO:0007165]; sphingosine-1-phosphate receptor signaling pathway [GO:0003376]; striated muscle cell differentiation [GO:0051146]; T cell costimulation [GO:0031295]; TOR signaling [GO:0031929]; virus-mediated perturbation of host defense response [GO:0019049]	GO:0001649; GO:0001893; GO:0001934; GO:0001938; GO:0002042; GO:0003376; GO:0004672; GO:0004674; GO:0004712; GO:0005516; GO:0005524; GO:0005547; GO:0005634; GO:0005654; GO:0005737; GO:0005739; GO:0005819; GO:0005829; GO:0005886; GO:0005911; GO:0005938; GO:0005978; GO:0005979; GO:0006006; GO:0006417; GO:0006468; GO:0006469; GO:0006606; GO:0006809; GO:0006924; GO:0006954; GO:0006979; GO:0007165; GO:0007173; GO:0007186; GO:0007249; GO:0008283; GO:0008286; GO:0008637; GO:0009408; GO:0010467; GO:0010507; GO:0010595; GO:0010628; GO:0010629; GO:0010748; GO:0010761; GO:0010763; GO:0010765; GO:0010907; GO:0010951; GO:0010975; GO:0015630; GO:0016020; GO:0016242; GO:0016301; GO:0016310; GO:0016567; GO:0018105; GO:0018107; GO:0019049; GO:0019221; GO:0019899; GO:0019901; GO:0022605; GO:0030027; GO:0030154; GO:0030235; GO:0030291; GO:0030307; GO:0030334; GO:0031295; GO:0031397; GO:0031641; GO:0031663; GO:0031929; GO:0031982; GO:0031999; GO:0032079; GO:0032091; GO:0032094; GO:0032287; GO:0032436; GO:0032869; GO:0032991; GO:0033138; GO:0034405; GO:0034614; GO:0035556; GO:0035655; GO:0035924; GO:0036064; GO:0036294; GO:0038061; GO:0042593; GO:0042802; GO:0042803; GO:0042981; GO:0043066; GO:0043154; GO:0043161; GO:0043276; GO:0043325; GO:0043488; GO:0043491; GO:0043536; GO:0045429; GO:0045600; GO:0045725; GO:0045737; GO:0045746; GO:0045861; GO:0045893; GO:0045944; GO:0046326; GO:0046622; GO:0046777; GO:0046889; GO:0048009; GO:0048266; GO:0048661; GO:0051000; GO:0051091; GO:0051146; GO:0051247; GO:0060079; GO:0060416; GO:0060644; GO:0060709; GO:0060716; GO:0070141; GO:0070848; GO:0071276; GO:0071356; GO:0071364; GO:0071380; GO:0071889; GO:0071901; GO:0072655; GO:0072656; GO:0090201; GO:0097011; GO:0097194; GO:0098794; GO:0098978; GO:0099104; GO:0099175; GO:0106310; GO:0110002; GO:0140052; GO:0150033; GO:0160049; GO:1900087; GO:1900182; GO:1901796; GO:1902018; GO:1902176; GO:1903038; GO:1903078; GO:1903721; GO:1904263; GO:1905552; GO:1990090; GO:1990418; GO:2000010; GO:2000074; GO:2000402; GO:2001240	1851997; 11508278; 14702039; 19054851; 12508121; 15489334; 1718748; 1533586; 9829964; 9736715; 8978681; 9512493; 10358075; 10576742; 10926925; 10983986; 10716693; 11154276; 11598301; 11994271; 12042314; 12149249; 12150915; 11839817; 12172553; 12244301; 12878163; 14761976; 15047712; 14749367; 15118108; 16266983; 16139227; 15861136; 15718470; 17013611; 16792529; 16417524; 17081983; 16540465; 16982699; 17932490; 17726016; 18507042; 18669648; 20059950; 19592491; 19934221; 19713527; 20086174; 19940129; 27825096; 20682768; 20471940; 20231902; 20333297; 21269460; 21333377; 21329884; 23251525; 23152800; 23186163; 23676467; 15526160; 11882383; 20978158; 21620960; 21432781; 21464307; 21775285; 22410793; 22629392; 23799035; 23431171; 23300339; 24275569; 26440888; 24784001; 28147277; 31204173; 31548394; 32322062; 32228865; 33594058; 12176338; 12964941; 18456494; 20810279; 20481595; 20886116; 21392984; 17611497; 18954143; 21793738; 23246288	10.1073/pnas.88.10.4171; 10.1007/s001250100577; 10.1038/ng1285; 10.1038/nmeth.1273; 10.1038/nature01348; 10.1101/gr.2596504; 10.1111/j.1432-1033.1991.tb16305.x; 10.1074/jbc.273.49.32377; 10.1073/pnas.95.19.11211; 10.1002/j.1460-2075.1996.tb01045.x; 10.1042/bj3310299; 10.1074/jbc.274.24.17179; 10.1126/science.286.5445.1741; 10.1074/jbc.m001753200; 10.1016/s1097-2765(00)00039-3; 10.1073/pnas.97.7.3028; 10.1128/mcb.21.3.893-901.2001; 10.1126/science.1062030; 10.1074/jbc.c200198200; 10.1074/jbc.m203668200; 10.1074/jbc.m203387200; 10.1016/s1097-2765(02)00568-3; 10.1128/mcb.22.5.1513-1525.2002; 10.1038/ncb839; 10.1038/nm759; 10.1016/s0014-4827(03)00206-4; 10.1074/jbc.m312175200; 10.1074/jbc.m314192200; 10.1128/mcb.24.4.1493-1504.2004; 10.1073/pnas.0400921101; 10.1158/0008-5472.can-05-0422; 10.1016/j.devcel.2005.08.001; 10.1038/sj.emboj.7600648; 10.1126/science.1106148; 10.1007/s00401-006-0128-y; 10.1042/bj20060511; 10.1042/bj20051794; 10.1016/j.cell.2006.09.026; 10.1074/jbc.m601384200; 10.1128/mcb.00201-06; 10.1038/sj.emboj.7601872; 10.1074/jbc.m704542200; 10.1073/pnas.0805139105; 10.1016/j.devcel.2009.09.007; 10.1074/jbc.m109.026237; 10.1242/jcs.053728; 10.1126/science.1175065; 10.1158/0008-5472.can-09-3147; 10.1074/jbc.m109.059675; 10.1074/jbc.a109.059675; 10.1074/jbc.m110.122044; 10.1016/j.molcel.2010.02.031; 10.1371/journal.pone.0009616; 10.1371/journal.pone.0009646; 10.1186/1752-0509-5-17; 10.1016/j.ejcb.2010.12.001; 10.1016/j.molcel.2011.02.007; 10.1371/journal.pone.0051413; 10.1371/journal.pone.0048770; 10.1021/pr300630k; 10.18632/oncotarget.1027; 10.1007/s00018-004-4189-6; 10.1016/s0898-6568(01)00271-6; 10.1158/1535-7163.mct-10-0730; 10.1016/j.cellsig.2011.05.004; 10.14670/hh-26.651; 10.1073/pnas.1016132108; 10.1126/scisignal.2001465; 10.1038/cr.2012.38; 10.1371/journal.pone.0037427; 10.1371/journal.pone.0065679; 10.1073/pnas.1300490110; 10.1126/scisignal.2003295; 10.1016/j.jprot.2013.11.014; 10.1016/j.celrep.2015.09.007; 10.1016/j.neo.2014.03.008; 10.1016/j.celrep.2017.01.009; 10.1016/j.devcel.2019.05.022; 10.1073/pnas.1904774116; 10.1038/s41586-020-2183-2; 10.7554/elife.53430; 10.1038/s41467-021-21206-3; 10.1016/s0960-9822(02)00972-7; 10.1042/bj20031229; 10.1016/j.bmcl.2008.04.034; 10.1016/j.bmcl.2010.08.053; 10.1021/jm1003842; 10.1371/journal.pone.0012913; 10.1016/j.bmcl.2011.02.073; 10.1038/nature05933; 10.1021/bi801683k; 10.1056/nejmoa1104017; 10.1016/j.ajhg.2012.10.021	NP_001014431.1 [P31749-1];NP_001014432.1 [P31749-1];NP_005154.2 [P31749-1];XP_005267458.1;	P31749;	CHEMBL4282;	DB07585;DB05971;DB01169;DB00171;DB12218;DB06486;DB01645;DB01863;DB07584;DB06641;DB02709;
4qlk	Q75I93	reviewed	BGL07_ORYSJ	Beta-glucosidase 7 (Os3bglu7) (EC 3.2.1.21)	BGLU7 BGLU1 Os03g0703000 LOC_Os03g49600 OSJNBa0004L11.16	Oryza sativa subsp. japonica (Rice)	504	MAARRANCALVLVLALALLAARDAGAAAVPKPNWLGGLSRAAFPKRFVFGTATSAYQVEGMAASGGRGPSIWDAFAHTPGNVAGNQNGDVATDQYHRYKEDVNLMKSLNFDAYRFSISWSRIFPDGEGRVNQEGVAYYNNLINYLLQKGITPYVNLYHYDLPLALEKKYGGWLNAKMADLFTEYADFCFKTFGNRVKHWFTFNEPRIVALLGYDQGTNPPKRCTKCAAGGNSATEPYIVAHNFLLSHAAAVARYRTKYQAAQQGKVGIVLDFNWYEALSNSTEDQAAAQRARDFHIGWYLDPLINGHYPQIMQDLVKDRLPKFTPEQARLVKGSADYIGINQYTASYMKGQQLMQQTPTSYSADWQVTYVFAKNGKPIGPQANSNWLYIVPWGMYGCVNYIKQKYGNPTVVITENGMDQPANLSRDQYLRDTTRVHFYRSYLTQLKKAIDEGANVAGYFAWSLLDNFEWLSGYTSKFGIVYVDFNTLERHPKASAYWFRDMLKH	FUNCTION: Hydrolyzes p-nitrophenyl beta-D-glucoside, p-nitrophenyl beta-D-mannoside, p-nitrophenyl beta-D-galactoside, p-nitrophenyl beta-D-xyloside, p-nitrophenyl beta-D-fucoside, p-nitrophenyl beta-L-arabinoside, oligosaccharides, pyridoxine beta-D-glucoside and the cyanogenic glucosides amygdalin, prunasin and dhurrin. Possesses pyridoxine transglucosylation activity. {ECO:0000269|PubMed:14692878, ECO:0000269|PubMed:18308333, ECO:0000269|PubMed:19766588}.		carbohydrate metabolic process [GO:0005975]	extracellular region [GO:0005576]	amygdalin beta-glucosidase activity [GO:0047668]; beta-D-fucosidase activity [GO:0033907]; beta-galactosidase activity [GO:0004565]; beta-gentiobiose beta-glucosidase activity [GO:0080083]; beta-glucosidase activity [GO:0008422]; beta-L-arabinosidase activity [GO:0047701]; beta-mannosidase activity [GO:0004567]; cellobiose glucosidase activity [GO:0080079]; glucan endo-1,3-beta-D-glucosidase activity [GO:0042973]; protein homodimerization activity [GO:0042803]; prunasin beta-glucosidase activity [GO:0050224]; scopolin beta-glucosidase activity [GO:0102483]	extracellular region [GO:0005576]; amygdalin beta-glucosidase activity [GO:0047668]; beta-D-fucosidase activity [GO:0033907]; beta-galactosidase activity [GO:0004565]; beta-gentiobiose beta-glucosidase activity [GO:0080083]; beta-glucosidase activity [GO:0008422]; beta-L-arabinosidase activity [GO:0047701]; beta-mannosidase activity [GO:0004567]; cellobiose glucosidase activity [GO:0080079]; glucan endo-1,3-beta-D-glucosidase activity [GO:0042973]; protein homodimerization activity [GO:0042803]; prunasin beta-glucosidase activity [GO:0050224]; scopolin beta-glucosidase activity [GO:0102483]; carbohydrate metabolic process [GO:0005975]	GO:0004565; GO:0004567; GO:0005576; GO:0005975; GO:0008422; GO:0033907; GO:0042803; GO:0042973; GO:0047668; GO:0047701; GO:0050224; GO:0080079; GO:0080083; GO:0102483	16109971; 16100779; 18089549; 24280374; 12869764; 14692878; 17196101; 19766588; 22341501; 18308333; 20884352; 25252199	10.1101/gr.3869505; 10.1038/nature03895; 10.1093/nar/gkm978; 10.1186/1939-8433-6-4; 10.1126/science.1081288; 10.1042/bj20031485; 10.1186/1471-2229-6-33; 10.1016/j.abb.2009.09.004; 10.1016/j.carres.2012.01.010; 10.1016/j.jmb.2008.01.076; 10.1016/j.jsb.2010.09.021; 10.1002/pro.2556	XP_015630897.1;			
3hy9	Q9UNA0	reviewed	ATS5_HUMAN	A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAM-TS 5) (ADAM-TS5) (ADAMTS-5) (EC 3.4.24.-) (A disintegrin and metalloproteinase with thrombospondin motifs 11) (ADAM-TS 11) (ADAMTS-11) (ADMP-2) (Aggrecanase-2)	ADAMTS5 ADAMTS11 ADMP2	Homo sapiens (Human)	930	MLLGWASLLLCAFRLPLAAVGPAATPAQDKAGQPPTAAAAAQPRRRQGEEVQERAEPPGHPHPLAQRRRSKGLVQNIDQLYSGGGKVGYLVYAGGRRFLLDLERDGSVGIAGFVPAGGGTSAPWRHRSHCFYRGTVDGSPRSLAVFDLCGGLDGFFAVKHARYTLKPLLRGPWAEEEKGRVYGDGSARILHVYTREGFSFEALPPRASCETPASTPEAHEHAPAHSNPSGRAALASQLLDQSALSPAGGSGPQTWWRRRRRSISRARQVELLLVADASMARLYGRGLQHYLLTLASIANRLYSHASIENHIRLAVVKVVVLGDKDKSLEVSKNAATTLKNFCKWQHQHNQLGDDHEEHYDAAILFTREDLCGHHSCDTLGMADVGTICSPERSCAVIEDDGLHAAFTVAHEIGHLLGLSHDDSKFCEETFGSTEDKRLMSSILTSIDASKPWSKCTSATITEFLDDGHGNCLLDLPRKQILGPEELPGQTYDATQQCNLTFGPEYSVCPGMDVCARLWCAVVRQGQMVCLTKKLPAVEGTPCGKGRICLQGKCVDKTKKKYYSTSSHGNWGSWGSWGQCSRSCGGGVQFAYRHCNNPAPRNNGRYCTGKRAIYRSCSLMPCPPNGKSFRHEQCEAKNGYQSDAKGVKTFVEWVPKYAGVLPADVCKLTCRAKGTGYYVVFSPKVTDGTECRLYSNSVCVRGKCVRTGCDGIIGSKLQYDKCGVCGGDNSSCTKIVGTFNKKSKGYTDVVRIPEGATHIKVRQFKAKDQTRFTAYLALKKKNGEYLINGKYMISTSETIIDINGTVMNYSGWSHRDDFLHGMGYSATKEILIVQILATDPTKPLDVRYSFFVPKKSTPKVNSVTSHGSNKVGSHTSQPQWVTGPWLACSRTCDTGWHTRTVQCQDGNRKLAKGCPLSQRPSAFKQCLLKKC	FUNCTION: Metalloproteinase that plays an important role in connective tissue organization, development, inflammation and cell migration. Extracellular matrix (ECM) degrading enzyme that show proteolytic activity toward the hyalectan group of chondroitin sulfate proteoglycans (CSPGs) including ACAN, VCAN, BCAN and NCAN (PubMed:16133547, PubMed:18992360). Cleavage within the hyalectans occurs at Glu-Xaa recognition motifs. Plays a role in embryonic development, including limb and cardiac morphogenesis, and skeletal muscle development through its VCAN remodeling properties. Cleaves VCAN in the pericellular matrix surrounding myoblasts, facilitating myoblast contact and fusion which is required for skeletal muscle development and regeneration (By similarity). Participates in development of brown adipose tissue and browning of white adipose tissue (By similarity). Plays an important role for T-lymphocyte migration from draining lymph nodes following viral infection. {ECO:0000250|UniProtKB:Q9R001, ECO:0000269|PubMed:16133547, ECO:0000269|PubMed:18992360}.		aortic valve morphogenesis [GO:0003180]; defense response to bacterium [GO:0042742]; endocardial cushion morphogenesis [GO:0003203]; extracellular matrix disassembly [GO:0022617]; extracellular matrix organization [GO:0030198]; myoblast fusion [GO:0007520]; negative regulation of cold-induced thermogenesis [GO:0120163]; proteolysis [GO:0006508]; pulmonary valve morphogenesis [GO:0003184]	collagen-containing extracellular matrix [GO:0062023]; endoplasmic reticulum lumen [GO:0005788]; extracellular matrix [GO:0031012]; extracellular region [GO:0005576]; extracellular space [GO:0005615]	endopeptidase activity [GO:0004175]; extracellular matrix binding [GO:0050840]; heparin binding [GO:0008201]; identical protein binding [GO:0042802]; integrin binding [GO:0005178]; metalloendopeptidase activity [GO:0004222]; metallopeptidase activity [GO:0008237]; peptidase activity [GO:0008233]; zinc ion binding [GO:0008270]	collagen-containing extracellular matrix [GO:0062023]; endoplasmic reticulum lumen [GO:0005788]; extracellular matrix [GO:0031012]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; endopeptidase activity [GO:0004175]; extracellular matrix binding [GO:0050840]; heparin binding [GO:0008201]; identical protein binding [GO:0042802]; integrin binding [GO:0005178]; metalloendopeptidase activity [GO:0004222]; metallopeptidase activity [GO:0008237]; peptidase activity [GO:0008233]; zinc ion binding [GO:0008270]; aortic valve morphogenesis [GO:0003180]; defense response to bacterium [GO:0042742]; endocardial cushion morphogenesis [GO:0003203]; extracellular matrix disassembly [GO:0022617]; extracellular matrix organization [GO:0030198]; myoblast fusion [GO:0007520]; negative regulation of cold-induced thermogenesis [GO:0120163]; proteolysis [GO:0006508]; pulmonary valve morphogenesis [GO:0003184]	GO:0003180; GO:0003184; GO:0003203; GO:0004175; GO:0004222; GO:0005178; GO:0005576; GO:0005615; GO:0005788; GO:0006508; GO:0007520; GO:0008201; GO:0008233; GO:0008237; GO:0008270; GO:0022617; GO:0030198; GO:0031012; GO:0042742; GO:0042802; GO:0050840; GO:0062023; GO:0120163	10438522; 10830953; 15489334; 10464288; 16133547; 18992360; 19671700; 18042673	10.1074/jbc.274.33.23443; 10.1038/35012518; 10.1101/gr.2596504; 10.1074/jbc.274.36.25555; 10.1007/s00401-005-1032-6; 10.1016/j.biocel.2008.10.008; 10.1074/jbc.m109.038059; 10.1110/ps.073287008	NP_008969.2;	Q9UNA0;	CHEMBL2285;	DB06837;DB03880;DB06945;
4bel	Q9Y5Z0	reviewed	BACE2_HUMAN	Beta-secretase 2 (EC 3.4.23.45) (Aspartic-like protease 56 kDa) (Aspartyl protease 1) (ASP1) (Asp 1) (Beta-site amyloid precursor protein cleaving enzyme 2) (Beta-site APP cleaving enzyme 2) (Down region aspartic protease) (DRAP) (Memapsin-1) (Membrane-associated aspartic protease 1) (Theta-secretase)	BACE2 AEPLC ALP56 ASP21 CDA13 UNQ418/PRO852	Homo sapiens (Human)	518	MGALARALLLPLLAQWLLRAAPELAPAPFTLPLRVAAATNRVVAPTPGPGTPAERHADGLALALEPALASPAGAANFLAMVDNLQGDSGRGYYLEMLIGTPPQKLQILVDTGSSNFAVAGTPHSYIDTYFDTERSSTYRSKGFDVTVKYTQGSWTGFVGEDLVTIPKGFNTSFLVNIATIFESENFFLPGIKWNGILGLAYATLAKPSSSLETFFDSLVTQANIPNVFSMQMCGAGLPVAGSGTNGGSLVLGGIEPSLYKGDIWYTPIKEEWYYQIEILKLEIGGQSLNLDCREYNADKAIVDSGTTLLRLPQKVFDAVVEAVARASLIPEFSDGFWTGSQLACWTNSETPWSYFPKISIYLRDENSSRSFRITILPQLYIQPMMGAGLNYECYRFGISPSTNALVIGATVMEGFYVIFDRAQKRVGFAASPCAEIAGAAVSEISGPFSTEDVASNCVPAQSLSEPILWIVSYALMSVCGAILLVLIVLLLLPFRCQRRPRDPEVVNDESSLVRHRWK	FUNCTION: Responsible for the proteolytic processing of the amyloid precursor protein (APP). Cleaves APP, between residues 690 and 691, leading to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase. It has also been shown that it can cleave APP between residues 671 and 672 (PubMed:10591213, PubMed:11083922, PubMed:11423558, PubMed:15857888, PubMed:16816112). Involved in the proteolytic shedding of PMEL at early stages of melanosome biogenesis. Cleaves PMEL within the M-beta fragment to release the amyloidogenic PMEL luminal fragment containing M-alpha and a small portion of M-beta N-terminus. This is a prerequisite step for subsequent processing and assembly of PMEL fibrils into amyloid sheets (PubMed:23754390). Responsible also for the proteolytic processing of CLTRN in pancreatic beta cells (PubMed:21907142). {ECO:0000269|PubMed:10591213, ECO:0000269|PubMed:11083922, ECO:0000269|PubMed:11423558, ECO:0000269|PubMed:15857888, ECO:0000269|PubMed:16816112, ECO:0000269|PubMed:21907142, ECO:0000269|PubMed:23754390}.		amyloid-beta metabolic process [GO:0050435]; glucose homeostasis [GO:0042593]; melanosome organization [GO:0032438]; membrane protein ectodomain proteolysis [GO:0006509]; negative regulation of amyloid precursor protein biosynthetic process [GO:0042985]; peptide hormone processing [GO:0016486]; protein processing [GO:0016485]; proteolysis [GO:0006508]	endoplasmic reticulum [GO:0005783]; endosome [GO:0005768]; Golgi apparatus [GO:0005794]; melanosome membrane [GO:0033162]; membrane [GO:0016020]; plasma membrane [GO:0005886]; trans-Golgi network [GO:0005802]	aspartic-type endopeptidase activity [GO:0004190]	endoplasmic reticulum [GO:0005783]; endosome [GO:0005768]; Golgi apparatus [GO:0005794]; melanosome membrane [GO:0033162]; membrane [GO:0016020]; plasma membrane [GO:0005886]; trans-Golgi network [GO:0005802]; aspartic-type endopeptidase activity [GO:0004190]; amyloid-beta metabolic process [GO:0050435]; glucose homeostasis [GO:0042593]; melanosome organization [GO:0032438]; membrane protein ectodomain proteolysis [GO:0006509]; negative regulation of amyloid precursor protein biosynthetic process [GO:0042985]; peptide hormone processing [GO:0016486]; protein processing [GO:0016485]; proteolysis [GO:0006508]	GO:0004190; GO:0005768; GO:0005783; GO:0005794; GO:0005802; GO:0005886; GO:0006508; GO:0006509; GO:0016020; GO:0016485; GO:0016486; GO:0032438; GO:0033162; GO:0042593; GO:0042985; GO:0050435	10591213; 10838186; 10965118; 10683441; 10749877; 11083922; 10677483; 12975309; 14702039; 10830953; 15489334; 15857888; 11423558; 16816112; 16305800; 11316808; 16965550; 21907142; 23754390	10.1038/990107; 10.1016/s0925-4439(00)00014-4; 10.1159/000015608; 10.1016/s0014-5793(00)01192-3; 10.1074/jbc.m002688200; 10.1006/mcne.2000.0884; 10.1073/pnas.97.4.1456; 10.1101/gr.1293003; 10.1038/ng1285; 10.1038/35012518; 10.1101/gr.2596504; 10.1096/fj.04-3426com; 10.1074/jbc.m105583200; 10.1096/fj.05-5632com; 10.1016/j.jmb.2005.10.027; 10.1074/jbc.m101069200; 10.1111/j.1460-9568.2006.05005.x; 10.1016/j.cmet.2011.06.018; 10.1073/pnas.1220748110	NP_036237.2 [Q9Y5Z0-1];NP_620476.1 [Q9Y5Z0-2];NP_620477.1 [Q9Y5Z0-3];	Q9Y5Z0;	CHEMBL2525;	
3nfb	Q52VH2	reviewed	BAPA_SPHXN	Beta-peptidyl aminopeptidase BapA (EC 3.4.11.25) [Cleaved into: Beta-peptidyl aminopeptidase BapA alpha subunit; Beta-peptidyl aminopeptidase BapA beta subunit]	bapA	Sphingosinicella xenopeptidilytica	402	MTSTQRLWSGALPLLTALIVSIAATASLAGPRARDLGVPFEGTPGALNAITDVAGVEVGHTTVISGDGAMVIGKGPYRTGVTIIHPLGKTSLDGVAAGRAVINGTGEWTGMHLVDEVGQFLGPIALTGTGNVGLVHQSMMDWSVGKVPEEALFSRLLPVVAETLDNRLNDVFGHGLTRDHVFAALDGAKGGPVAEGNVGGGTGMIAYTFKGGIGTSSRVVSAGDTRYTVGVLVQANHGDRNDLRIAGVQIGKEIKGAWPEVNGIVAAGPDAGKPQDKNSLLIVIATDAPLMPHQLERMARRAALGVGRNGSTAGALSGEFALAFSTSHVIPLGGKPRLPAIINDTDSETMNALFRGVVQATEEALVNQLVASETMTGANNAKVYGIPHDQLARIMKARFPRR	FUNCTION: Beta-aminopeptidase that can cleave synthetic beta-peptides which consist of backbone-elongated beta-amino acid residues that are not processed by common proteolytic enzymes. Can cleave the beta-peptides beta-homoVal-beta-homoAla-beta-homoLeu and beta-homoAla-beta-homoLeu. Requires a beta-amino acid at the N-terminus of peptide substrates and cleaves the peptide bond between the N-terminal beta-amino acid and the amino acid at the second position of tripeptidic substrates of the general structure H-betahXaa-Ile-betahTyr-OH according to the following preferences with regard to the side chain of the N-terminal beta-amino acid: aliphatic and aromatic > OH-containing > hydrogen, basic and polar. {ECO:0000269|PubMed:16109932, ECO:0000269|PubMed:17064315}.		proteolysis [GO:0006508]	periplasmic space [GO:0042597]	aminopeptidase activity [GO:0004177]; identical protein binding [GO:0042802]	periplasmic space [GO:0042597]; aminopeptidase activity [GO:0004177]; identical protein binding [GO:0042802]; proteolysis [GO:0006508]	GO:0004177; GO:0006508; GO:0042597; GO:0042802	16109932; 17064315; 22980995; 22961926	10.1128/jb.187.17.5910-5917.2005; 10.1111/j.1742-4658.2006.05519.x; 10.1016/j.str.2012.07.017; 10.1002/cbic.201200393				
4m7t	Q8G907	reviewed	BTRN_NIACI	S-adenosyl-L-methionine-dependent 2-deoxy-scyllo-inosamine dehydrogenase (EC 1.1.99.38) (Butirosin biosynthesis protein N) (Radical S-adenosylmethionine dehydrogenase BtrN) (RS dehydrogenase BtrN) (Radical SAM dehydrogenase BtrN)	btrN	Niallia circulans (Bacillus circulans)	250	MDKLFSMIEVEVNSQCNRTCWYCPNSVSKRKETGEMDPALYKTLMEQLSSLDFAGRISFHFYGEPLLCKNLDLFVGMTTEYIPRARPIIYTNGDFLTEKRLQTLTELGIQKFIVTQHAGAKHKFRGVYDQLAGADKEKVVYLDHSDLVLSNRGGILDNIPQASKANMSCMVPSNLAVVTVLGNVLPCFEDFNQKMVMGNIGEQHISDIWHNDKFTSFRKMLKEGHRGKSDLCKNCNNVSVQTEEQYDYVL	FUNCTION: Catalyzes the radical S-adenosyl-L-methionine (SAM)-dependent two-electron oxidation of 2-deoxy-scyllo-inosamine (DOIA) to amino-dideoxy-scyllo-inosose (amino-DOI) in the biosynthetic pathway of butirosin. {ECO:0000269|PubMed:18001019}.		antibiotic biosynthetic process [GO:0017000]		4 iron, 4 sulfur cluster binding [GO:0051539]; metal ion binding [GO:0046872]; oxidoreductase activity [GO:0016491]	4 iron, 4 sulfur cluster binding [GO:0051539]; metal ion binding [GO:0046872]; oxidoreductase activity [GO:0016491]; antibiotic biosynthetic process [GO:0017000]	GO:0016491; GO:0017000; GO:0046872; GO:0051539	11132962; 18001019; 18672902; 20377206	10.7164/antibiotics.53.1158; 10.1021/ja072481t; 10.1021/bi800509x; 10.1021/bi9022126				
3u9f	P62577	reviewed	CAT_ECOLX	Chloramphenicol acetyltransferase (CAT) (EC 2.3.1.28)	cat	Escherichia coli	219	MEKKITGYTTVDISQWHRKEHFEAFQSVAQCTYNQTVQLDITAFLKTVKKNKHKFYPAFIHILARLMNAHPEFRMAMKDGELVIWDSVHPCYTVFHEQTETFSSLWSEYHDDFRQFLHIYSQDVACYGENLAYFPKGFIENMFFVSANPWVSFTSFDLNVANMDNFFAPVFTMGKYYTQGDKVLMPLAIQVHHAVCDGFHVGRMLNELQQYCDEWQGGA	FUNCTION: This enzyme is an effector of chloramphenicol resistance in bacteria.	MISCELLANEOUS: Transposon Tncam204 is derived from the R plasmid NR1. {ECO:0000305|PubMed:7353655}.	response to antibiotic [GO:0046677]		chloramphenicol O-acetyltransferase activity [GO:0008811]	chloramphenicol O-acetyltransferase activity [GO:0008811]; response to antibiotic [GO:0046677]	GO:0008811; GO:0046677	390404; 390403; 7353655; 9334294	10.1038/282870a0; 10.1038/282864a0; 10.1016/0014-5793(80)80011-1; 10.1126/science.278.5337.425	WP_000412211.1;YP_001096419.1;YP_001816591.1;YP_008995272.1;YP_008997430.1;YP_009068571.1;YP_009071093.1;YP_009071408.1;YP_025721.1;			
4aua	Q00534	reviewed	CDK6_HUMAN	Cyclin-dependent kinase 6 (EC 2.7.11.22) (Cell division protein kinase 6) (Serine/threonine-protein kinase PLSTIRE)	CDK6 CDKN6	Homo sapiens (Human)	326	MEKDGLCRADQQYECVAEIGEGAYGKVFKARDLKNGGRFVALKRVRVQTGEEGMPLSTIREVAVLRHLETFEHPNVVRLFDVCTVSRTDRETKLTLVFEHVDQDLTTYLDKVPEPGVPTETIKDMMFQLLRGLDFLHSHRVVHRDLKPQNILVTSSGQIKLADFGLARIYSFQMALTSVVVTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMFRRKPLFRGSSDVDQLGKILDVIGLPGEEDWPRDVALPRQAFHSKSAQPIEKFVTDIDELGKDLLLKCLTFNPAKRISAYSALSHPYFQDLERCKENLDSHLPPSQNTSELNTA	FUNCTION: Serine/threonine-protein kinase involved in the control of the cell cycle and differentiation; promotes G1/S transition. Phosphorylates pRB/RB1 and NPM1. Interacts with D-type G1 cyclins during interphase at G1 to form a pRB/RB1 kinase and controls the entrance into the cell cycle. Involved in initiation and maintenance of cell cycle exit during cell differentiation; prevents cell proliferation and negatively regulates cell differentiation, but is required for the proliferation of specific cell types (e.g. erythroid and hematopoietic cells). Essential for cell proliferation within the dentate gyrus of the hippocampus and the subventricular zone of the lateral ventricles. Required during thymocyte development. Promotes the production of newborn neurons, probably by modulating G1 length. Promotes, at least in astrocytes, changes in patterns of gene expression, changes in the actin cytoskeleton including loss of stress fibers, and enhanced motility during cell differentiation. Prevents myeloid differentiation by interfering with RUNX1 and reducing its transcription transactivation activity, but promotes proliferation of normal myeloid progenitors. Delays senescence. Promotes the proliferation of beta-cells in pancreatic islets of Langerhans. May play a role in the centrosome organization during the cell cycle phases (PubMed:23918663). {ECO:0000269|PubMed:12833137, ECO:0000269|PubMed:14985467, ECO:0000269|PubMed:15254224, ECO:0000269|PubMed:15809340, ECO:0000269|PubMed:17420273, ECO:0000269|PubMed:17431401, ECO:0000269|PubMed:20333249, ECO:0000269|PubMed:20668294, ECO:0000269|PubMed:23918663, ECO:0000269|PubMed:8114739}.	MISCELLANEOUS: Over-expressed in some leukemias and malignancies (including sarcoma, glioma, breast tumors, lymphoma and melanoma) as a consequence of nearby translocations.; MISCELLANEOUS: Enhances beta-cells engraftment in pancreatic islets of Langerhans of diabetic patients.	astrocyte development [GO:0014002]; cell dedifferentiation [GO:0043697]; cell division [GO:0051301]; dentate gyrus development [GO:0021542]; G1/S transition of mitotic cell cycle [GO:0000082]; generation of neurons [GO:0048699]; gliogenesis [GO:0042063]; hematopoietic stem cell differentiation [GO:0060218]; lateral ventricle development [GO:0021670]; negative regulation of cell cycle [GO:0045786]; negative regulation of cell differentiation [GO:0045596]; negative regulation of cell population proliferation [GO:0008285]; negative regulation of cellular senescence [GO:2000773]; negative regulation of epithelial cell proliferation [GO:0050680]; negative regulation of monocyte differentiation [GO:0045656]; negative regulation of myeloid cell differentiation [GO:0045638]; negative regulation of osteoblast differentiation [GO:0045668]; negative regulation of transcription by RNA polymerase II [GO:0000122]; Notch signaling pathway [GO:0007219]; positive regulation of cell-matrix adhesion [GO:0001954]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of gene expression [GO:0010628]; protein phosphorylation [GO:0006468]; regulation of cell cycle [GO:0051726]; regulation of cell motility [GO:2000145]; regulation of erythrocyte differentiation [GO:0045646]; regulation of G2/M transition of mitotic cell cycle [GO:0010389]; regulation of gene expression [GO:0010468]; regulation of hematopoietic stem cell differentiation [GO:1902036]; response to organic substance [GO:0010033]; response to virus [GO:0009615]; signal transduction [GO:0007165]; T cell differentiation in thymus [GO:0033077]; type B pancreatic cell development [GO:0003323]	centrosome [GO:0005813]; cyclin D2-CDK6 complex [GO:0097132]; cyclin-dependent protein kinase holoenzyme complex [GO:0000307]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; ruffle [GO:0001726]	ATP binding [GO:0005524]; cyclin binding [GO:0030332]; cyclin-dependent protein serine/threonine kinase activity [GO:0004693]; FBXO family protein binding [GO:0098770]; protein serine kinase activity [GO:0106310]	centrosome [GO:0005813]; cyclin D2-CDK6 complex [GO:0097132]; cyclin-dependent protein kinase holoenzyme complex [GO:0000307]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; ruffle [GO:0001726]; ATP binding [GO:0005524]; cyclin binding [GO:0030332]; cyclin-dependent protein serine/threonine kinase activity [GO:0004693]; FBXO family protein binding [GO:0098770]; protein serine kinase activity [GO:0106310]; astrocyte development [GO:0014002]; cell dedifferentiation [GO:0043697]; cell division [GO:0051301]; dentate gyrus development [GO:0021542]; G1/S transition of mitotic cell cycle [GO:0000082]; generation of neurons [GO:0048699]; gliogenesis [GO:0042063]; hematopoietic stem cell differentiation [GO:0060218]; lateral ventricle development [GO:0021670]; negative regulation of cell cycle [GO:0045786]; negative regulation of cell differentiation [GO:0045596]; negative regulation of cell population proliferation [GO:0008285]; negative regulation of cellular senescence [GO:2000773]; negative regulation of epithelial cell proliferation [GO:0050680]; negative regulation of monocyte differentiation [GO:0045656]; negative regulation of myeloid cell differentiation [GO:0045638]; negative regulation of osteoblast differentiation [GO:0045668]; negative regulation of transcription by RNA polymerase II [GO:0000122]; Notch signaling pathway [GO:0007219]; positive regulation of cell-matrix adhesion [GO:0001954]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of gene expression [GO:0010628]; protein phosphorylation [GO:0006468]; regulation of cell cycle [GO:0051726]; regulation of cell motility [GO:2000145]; regulation of erythrocyte differentiation [GO:0045646]; regulation of G2/M transition of mitotic cell cycle [GO:0010389]; regulation of gene expression [GO:0010468]; regulation of hematopoietic stem cell differentiation [GO:1902036]; response to organic substance [GO:0010033]; response to virus [GO:0009615]; signal transduction [GO:0007165]; T cell differentiation in thymus [GO:0033077]; type B pancreatic cell development [GO:0003323]	GO:0000082; GO:0000122; GO:0000307; GO:0001726; GO:0001954; GO:0003323; GO:0004693; GO:0005524; GO:0005634; GO:0005654; GO:0005737; GO:0005813; GO:0005829; GO:0006468; GO:0007165; GO:0007219; GO:0008285; GO:0009615; GO:0010033; GO:0010389; GO:0010468; GO:0010628; GO:0014002; GO:0021542; GO:0021670; GO:0030332; GO:0033077; GO:0042063; GO:0043697; GO:0045596; GO:0045638; GO:0045646; GO:0045656; GO:0045668; GO:0045786; GO:0048146; GO:0048699; GO:0050680; GO:0051301; GO:0051726; GO:0060218; GO:0097132; GO:0098770; GO:0106310; GO:1902036; GO:2000145; GO:2000773	1639063; 14702039; 12853948; 12690205; 15489334; 8114739; 9482106; 12833137; 14985467; 15254224; 16096642; 15809340; 15592455; 16548883; 17431401; 17420273; 19139263; 19369195; 19690332; 19608861; 20668294; 20333249; 16294322; 19238148; 21269460; 22814378; 23918663; 9751050; 11124804; 11828325; 15689157; 16789739; 21038853; 17344846	10.1002/j.1460-2075.1992.tb05360.x; 10.1038/ng1285; 10.1038/nature01782; 10.1126/science.1083423; 10.1101/gr.2596504; 10.1128/mcb.14.3.2077-2086.1994; 10.1038/sj.onc.1201570; 10.1038/sj.onc.1206484; 10.1128/mcb.24.15.6560-6568.2004; 10.1038/sj.emboj.7600775; 10.1093/jb/mvi050; 10.1038/nbt1046; 10.1111/j.1462-5822.2005.00644.x; 10.1038/sj.emboj.7601675; 10.1128/mcb.02286-06; 10.1083/jcb.200801009; 10.1074/mcp.m800588-mcp200; 10.1126/scisignal.2000007; 10.1126/science.1175371; 10.2337/db09-1776; 10.1371/journal.ppat.1000818; 10.1002/jcb.20712; 10.1038/nrc2602; 10.1186/1752-0509-5-17; 10.1073/pnas.1210303109; 10.1093/hmg/ddt374; 10.1038/26155; 10.1101/gad.851100; 10.1038/nsb756; 10.1021/jm049353p; 10.1021/jm0600388; 10.1021/jm100571n; 10.1038/nature05610	NP_001138778.1;NP_001250.1;XP_006715898.1;	Q00534;	CHEMBL2508;	DB07379;DB12001;DB03496;DB07795;DB09073;DB11730;DB15442;
2f2c	Q01043	reviewed	CGH2_SHV21	Cyclin homolog (V-cyclin)	72 ECLF2	Saimiriine herpesvirus 2 (strain 11) (SaHV-2) (Herpesvirus saimiri)	254	MADSPNRLNRAKIDSTTMKDPRVLNNLKLRELLLPKFTSLWEIQTEVTVDNRTILLTWMHLLCESFELDKSVFPLSVSILDRYLCKKQGTKKTLQKIGAACVLIGSKIRTVKPMTVSKLTYLSCDCFTNLELINQEKDILEALKWDTEAVLATDFLIPLCNALKIPEDLWPQLYEAASTTICKALIQPNIALLSPGLICAGGLLTTIETDNTNCRPWTCYLEDLSSILNFSTNTVRTVKDQVSEAFSLYDLEIL	FUNCTION: May be highly relevant to the process of cellular transformation and rapid T-cell proliferation effected by HVS during latent infections of T-cells in susceptible hosts.		cell cycle [GO:0007049]; cell division [GO:0051301]	cyclin-dependent protein kinase holoenzyme complex [GO:0000307]; cytoplasm [GO:0005737]	cyclin-dependent protein serine/threonine kinase regulator activity [GO:0016538]	cyclin-dependent protein kinase holoenzyme complex [GO:0000307]; cytoplasm [GO:0005737]; cyclin-dependent protein serine/threonine kinase regulator activity [GO:0016538]; cell cycle [GO:0007049]; cell division [GO:0051301]	GO:0000307; GO:0005737; GO:0007049; GO:0016538; GO:0051301	1321287; 1314457; 1309943; 10368294	10.1128/jvi.66.8.5047-5058.1992; 10.1016/0042-6822(92)90759-i; 10.1038/355362a0; 10.1016/s0969-2126(99)80035-5	NP_040274.1;	Q01043;		DB07379;DB07795;
2f2c	Q00534	reviewed	CDK6_HUMAN	Cyclin-dependent kinase 6 (EC 2.7.11.22) (Cell division protein kinase 6) (Serine/threonine-protein kinase PLSTIRE)	CDK6 CDKN6	Homo sapiens (Human)	326	MEKDGLCRADQQYECVAEIGEGAYGKVFKARDLKNGGRFVALKRVRVQTGEEGMPLSTIREVAVLRHLETFEHPNVVRLFDVCTVSRTDRETKLTLVFEHVDQDLTTYLDKVPEPGVPTETIKDMMFQLLRGLDFLHSHRVVHRDLKPQNILVTSSGQIKLADFGLARIYSFQMALTSVVVTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMFRRKPLFRGSSDVDQLGKILDVIGLPGEEDWPRDVALPRQAFHSKSAQPIEKFVTDIDELGKDLLLKCLTFNPAKRISAYSALSHPYFQDLERCKENLDSHLPPSQNTSELNTA	FUNCTION: Serine/threonine-protein kinase involved in the control of the cell cycle and differentiation; promotes G1/S transition. Phosphorylates pRB/RB1 and NPM1. Interacts with D-type G1 cyclins during interphase at G1 to form a pRB/RB1 kinase and controls the entrance into the cell cycle. Involved in initiation and maintenance of cell cycle exit during cell differentiation; prevents cell proliferation and negatively regulates cell differentiation, but is required for the proliferation of specific cell types (e.g. erythroid and hematopoietic cells). Essential for cell proliferation within the dentate gyrus of the hippocampus and the subventricular zone of the lateral ventricles. Required during thymocyte development. Promotes the production of newborn neurons, probably by modulating G1 length. Promotes, at least in astrocytes, changes in patterns of gene expression, changes in the actin cytoskeleton including loss of stress fibers, and enhanced motility during cell differentiation. Prevents myeloid differentiation by interfering with RUNX1 and reducing its transcription transactivation activity, but promotes proliferation of normal myeloid progenitors. Delays senescence. Promotes the proliferation of beta-cells in pancreatic islets of Langerhans. May play a role in the centrosome organization during the cell cycle phases (PubMed:23918663). {ECO:0000269|PubMed:12833137, ECO:0000269|PubMed:14985467, ECO:0000269|PubMed:15254224, ECO:0000269|PubMed:15809340, ECO:0000269|PubMed:17420273, ECO:0000269|PubMed:17431401, ECO:0000269|PubMed:20333249, ECO:0000269|PubMed:20668294, ECO:0000269|PubMed:23918663, ECO:0000269|PubMed:8114739}.	MISCELLANEOUS: Over-expressed in some leukemias and malignancies (including sarcoma, glioma, breast tumors, lymphoma and melanoma) as a consequence of nearby translocations.; MISCELLANEOUS: Enhances beta-cells engraftment in pancreatic islets of Langerhans of diabetic patients.	astrocyte development [GO:0014002]; cell dedifferentiation [GO:0043697]; cell division [GO:0051301]; dentate gyrus development [GO:0021542]; G1/S transition of mitotic cell cycle [GO:0000082]; generation of neurons [GO:0048699]; gliogenesis [GO:0042063]; hematopoietic stem cell differentiation [GO:0060218]; lateral ventricle development [GO:0021670]; negative regulation of cell cycle [GO:0045786]; negative regulation of cell differentiation [GO:0045596]; negative regulation of cell population proliferation [GO:0008285]; negative regulation of cellular senescence [GO:2000773]; negative regulation of epithelial cell proliferation [GO:0050680]; negative regulation of monocyte differentiation [GO:0045656]; negative regulation of myeloid cell differentiation [GO:0045638]; negative regulation of osteoblast differentiation [GO:0045668]; negative regulation of transcription by RNA polymerase II [GO:0000122]; Notch signaling pathway [GO:0007219]; positive regulation of cell-matrix adhesion [GO:0001954]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of gene expression [GO:0010628]; protein phosphorylation [GO:0006468]; regulation of cell cycle [GO:0051726]; regulation of cell motility [GO:2000145]; regulation of erythrocyte differentiation [GO:0045646]; regulation of G2/M transition of mitotic cell cycle [GO:0010389]; regulation of gene expression [GO:0010468]; regulation of hematopoietic stem cell differentiation [GO:1902036]; response to organic substance [GO:0010033]; response to virus [GO:0009615]; signal transduction [GO:0007165]; T cell differentiation in thymus [GO:0033077]; type B pancreatic cell development [GO:0003323]	centrosome [GO:0005813]; cyclin D2-CDK6 complex [GO:0097132]; cyclin-dependent protein kinase holoenzyme complex [GO:0000307]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; ruffle [GO:0001726]	ATP binding [GO:0005524]; cyclin binding [GO:0030332]; cyclin-dependent protein serine/threonine kinase activity [GO:0004693]; FBXO family protein binding [GO:0098770]; protein serine kinase activity [GO:0106310]	centrosome [GO:0005813]; cyclin D2-CDK6 complex [GO:0097132]; cyclin-dependent protein kinase holoenzyme complex [GO:0000307]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; ruffle [GO:0001726]; ATP binding [GO:0005524]; cyclin binding [GO:0030332]; cyclin-dependent protein serine/threonine kinase activity [GO:0004693]; FBXO family protein binding [GO:0098770]; protein serine kinase activity [GO:0106310]; astrocyte development [GO:0014002]; cell dedifferentiation [GO:0043697]; cell division [GO:0051301]; dentate gyrus development [GO:0021542]; G1/S transition of mitotic cell cycle [GO:0000082]; generation of neurons [GO:0048699]; gliogenesis [GO:0042063]; hematopoietic stem cell differentiation [GO:0060218]; lateral ventricle development [GO:0021670]; negative regulation of cell cycle [GO:0045786]; negative regulation of cell differentiation [GO:0045596]; negative regulation of cell population proliferation [GO:0008285]; negative regulation of cellular senescence [GO:2000773]; negative regulation of epithelial cell proliferation [GO:0050680]; negative regulation of monocyte differentiation [GO:0045656]; negative regulation of myeloid cell differentiation [GO:0045638]; negative regulation of osteoblast differentiation [GO:0045668]; negative regulation of transcription by RNA polymerase II [GO:0000122]; Notch signaling pathway [GO:0007219]; positive regulation of cell-matrix adhesion [GO:0001954]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of gene expression [GO:0010628]; protein phosphorylation [GO:0006468]; regulation of cell cycle [GO:0051726]; regulation of cell motility [GO:2000145]; regulation of erythrocyte differentiation [GO:0045646]; regulation of G2/M transition of mitotic cell cycle [GO:0010389]; regulation of gene expression [GO:0010468]; regulation of hematopoietic stem cell differentiation [GO:1902036]; response to organic substance [GO:0010033]; response to virus [GO:0009615]; signal transduction [GO:0007165]; T cell differentiation in thymus [GO:0033077]; type B pancreatic cell development [GO:0003323]	GO:0000082; GO:0000122; GO:0000307; GO:0001726; GO:0001954; GO:0003323; GO:0004693; GO:0005524; GO:0005634; GO:0005654; GO:0005737; GO:0005813; GO:0005829; GO:0006468; GO:0007165; GO:0007219; GO:0008285; GO:0009615; GO:0010033; GO:0010389; GO:0010468; GO:0010628; GO:0014002; GO:0021542; GO:0021670; GO:0030332; GO:0033077; GO:0042063; GO:0043697; GO:0045596; GO:0045638; GO:0045646; GO:0045656; GO:0045668; GO:0045786; GO:0048146; GO:0048699; GO:0050680; GO:0051301; GO:0051726; GO:0060218; GO:0097132; GO:0098770; GO:0106310; GO:1902036; GO:2000145; GO:2000773	1639063; 14702039; 12853948; 12690205; 15489334; 8114739; 9482106; 12833137; 14985467; 15254224; 16096642; 15809340; 15592455; 16548883; 17431401; 17420273; 19139263; 19369195; 19690332; 19608861; 20668294; 20333249; 16294322; 19238148; 21269460; 22814378; 23918663; 9751050; 11124804; 11828325; 15689157; 16789739; 21038853; 17344846	10.1002/j.1460-2075.1992.tb05360.x; 10.1038/ng1285; 10.1038/nature01782; 10.1126/science.1083423; 10.1101/gr.2596504; 10.1128/mcb.14.3.2077-2086.1994; 10.1038/sj.onc.1201570; 10.1038/sj.onc.1206484; 10.1128/mcb.24.15.6560-6568.2004; 10.1038/sj.emboj.7600775; 10.1093/jb/mvi050; 10.1038/nbt1046; 10.1111/j.1462-5822.2005.00644.x; 10.1038/sj.emboj.7601675; 10.1128/mcb.02286-06; 10.1083/jcb.200801009; 10.1074/mcp.m800588-mcp200; 10.1126/scisignal.2000007; 10.1126/science.1175371; 10.2337/db09-1776; 10.1371/journal.ppat.1000818; 10.1002/jcb.20712; 10.1038/nrc2602; 10.1186/1752-0509-5-17; 10.1073/pnas.1210303109; 10.1093/hmg/ddt374; 10.1038/26155; 10.1101/gad.851100; 10.1038/nsb756; 10.1021/jm049353p; 10.1021/jm0600388; 10.1021/jm100571n; 10.1038/nature05610	NP_001138778.1;NP_001250.1;XP_006715898.1;	Q00534;	CHEMBL2508;	DB07379;DB12001;DB03496;DB07795;DB09073;DB11730;DB15442;
3chc	Q873X9	reviewed	CHIB1_ASPFM	Endochitinase B1 (EC 3.2.1.14) (Chitinase B1)	chiB1	Aspergillus fumigatus (Neosartorya fumigata)	433	MRFATSTIVKVALLLSSLCVDAAVMWNRDTSSTDLEARASSGYRSVVYFVNWAIYGRNHNPQDLPVERLTHVLYAFANVRPETGEVYMTDSWADIEKHYPGDSWSDTGNNVYGCIKQLYLLKKQNRNLKVLLSIGGWTYSPNFAPAASTDAGRKNFAKTAVKLLQDLGFDGLDIDWEYPENDQQANDFVLLLKEVRTALDSYSAANAGGQHFLLTVASPAGPDKIKVLHLKDMDQQLDFWNLMAYDYAGSFSSLSGHQANVYNDTSNPLSTPFNTQTALDLYRAGGVPANKIVLGMPLYGRSFANTDGPGKPYNGVGQGSWENGVWDYKALPQAGATEHVLPDIMASYSYDATNKFLISYDNPQVANLKSGYIKSLGLGGAMWWDSSSDKTGSDSLITTVVNALGGTGVFEQSQNELDYPVSQYDNLRNGMQT	FUNCTION: Major secreted chitinase involved in the degradation of chitin, a component of the cell walls of fungi and exoskeletal elements of some animals (including worms and arthropods). Plays a role in the morphogenesis and autolysis (By similarity). {ECO:0000250}.		chitin catabolic process [GO:0006032]; polysaccharide catabolic process [GO:0000272]	extracellular region [GO:0005576]	chitin binding [GO:0008061]; chitinase activity [GO:0004568]	extracellular region [GO:0005576]; chitin binding [GO:0008061]; chitinase activity [GO:0004568]; chitin catabolic process [GO:0006032]; polysaccharide catabolic process [GO:0000272]	GO:0000272; GO:0004568; GO:0005576; GO:0006032; GO:0008061	14523125; 15103145; 16096835; 18975073; 15664516; 16183021; 16844689; 18355729	10.1099/mic.0.26476-0; 10.1107/s0907444904005190; 10.1007/s00203-005-0028-x; 10.1007/s10719-008-9203-z; 10.1016/j.chembiol.2004.10.013; 10.1016/j.chembiol.2005.07.009; 10.1074/jbc.m604048200; 10.1016/j.chembiol.2008.02.015		Q873X9;	CHEMBL4638;	DB04350;DB03632;
1k9t	P07254	reviewed	CHIA_SERMA	Chitinase A (EC 3.2.1.14)	chiA	Serratia marcescens	563	MRKFNKPLLALLIGSTLCSAAQAAAPGKPTIAWGNTKFAIVEVDQAATAYNNLVKVKNAADVSVSWNLWNGDAGTTAKILLNGKEAWSGPSTGSSGTANFKVNKGGRYQMQVALCNADGCTASDATEIVVADTDGSHLAPLKEPLLEKNKPYKQNSGKVVGSYFVEWGVYGRNFTVDKIPAQNLTHLLYGFIPICGGNGINDSLKEIEGSFQALQRSCQGREDFKVSIHDPFAALQKAQKGVTAWDDPYKGNFGQLMALKQAHPDLKILPSIGGWTLSDPFFFMGDKVKRDRFVGSVKEFLQTWKFFDGVDIDWEFPGGKGANPNLGSPQDGETYVLLMKELRAMLDQLSAETGRKYELTSAISAGKDKIDKVAYNVAQNSMDHIFLMSYDFYGPFDLKNLGHQTALNAPAWKPDTAYTTVNGVNALLAQGVKPGKVVVGTAMYGRGWTGVNGYQNNIPFTGTATGPVKGTWKNGIVDYRQIAGQFMSGEWQYTYDATAEAPYVFKPSTGDLITFDDARSVQAKGKYVLDKQLGGLFSWEIDADNGDILNSMNASLGNSAGVQ			chitin catabolic process [GO:0006032]; polysaccharide catabolic process [GO:0000272]	extracellular region [GO:0005576]	chitin binding [GO:0008061]; chitinase activity [GO:0004568]	extracellular region [GO:0005576]; chitin binding [GO:0008061]; chitinase activity [GO:0004568]; chitin catabolic process [GO:0006032]; polysaccharide catabolic process [GO:0000272]	GO:0000272; GO:0004568; GO:0005576; GO:0006032; GO:0008061	16453672; 7851747; 7704527	10.1002/j.1460-2075.1986.tb04235.x; 10.1111/j.1574-6968.1994.tb07315.x; 10.1016/s0969-2126(94)00119-7	WP_021504113.1;	P07254;	CHEMBL5423;	DB03109;DB04628;DB04404;
1h0i	P11797	reviewed	CHIB_SERMA	Chitinase B (EC 3.2.1.14)	chiB	Serratia marcescens	499	MSTRKAVIGYYFIPTNQINNYTETDTSVVPFPVSNITPAKAKQLTHINFSFLDINSNLECAWDPATNDAKARDVVNRLTALKAHNPSLRIMFSIGGWYYSNDLGVSHANYVNAVKTPAARTKFAQSCVRIMKDYGFDGVDIDWEYPQAAEVDGFIAALQEIRTLLNQQTIADGRQALPYQLTIAGAGGAFFLSRYYSKLAQIVAPLDYINLMTYDLAGPWEKITNHQAALFGDAAGPTFYNALREANLGWSWEELTRAFPSPFSLTVDAAVQQHLMMEGVPSAKIVMGVPFYGRAFKGVSGGNGGQYSSHSTPGEDPYPNADYWLVGCDECVRDKDPRIASYRQLEQMLQGNYGYQRLWNDKTKTPYLYHAQNGLFVTYDDAESFKYKAKYIKQQQLGGVMFWHLGQDNRNGDLLAALDRYFNAADYDDSQLDMGTGLRYTGVGPGNLPIMTAPAYVPGTTYAQGALVSYQGYVWQTKWGYITSAPGSDSAWLKVGRLA			chitin catabolic process [GO:0006032]; polysaccharide catabolic process [GO:0000272]	extracellular region [GO:0005576]	carbohydrate binding [GO:0030246]; chitin binding [GO:0008061]; chitinase activity [GO:0004568]	extracellular region [GO:0005576]; carbohydrate binding [GO:0030246]; chitin binding [GO:0008061]; chitinase activity [GO:0004568]; chitin catabolic process [GO:0006032]; polysaccharide catabolic process [GO:0000272]	GO:0000272; GO:0004568; GO:0005576; GO:0006032; GO:0008061; GO:0030246	2668886; 9371460	10.1093/nar/17.13.5395; 10.1128/jb.179.22.7111-7117.1997	WP_016926761.1;	P11797;	CHEMBL5348;	DB04520;DB02813;DB03109;DB04628;DB04404;DB02414;DB04541;DB04157;DB04433;
4z2g	P11797	reviewed	CHIB_SERMA	Chitinase B (EC 3.2.1.14)	chiB	Serratia marcescens	499	MSTRKAVIGYYFIPTNQINNYTETDTSVVPFPVSNITPAKAKQLTHINFSFLDINSNLECAWDPATNDAKARDVVNRLTALKAHNPSLRIMFSIGGWYYSNDLGVSHANYVNAVKTPAARTKFAQSCVRIMKDYGFDGVDIDWEYPQAAEVDGFIAALQEIRTLLNQQTIADGRQALPYQLTIAGAGGAFFLSRYYSKLAQIVAPLDYINLMTYDLAGPWEKITNHQAALFGDAAGPTFYNALREANLGWSWEELTRAFPSPFSLTVDAAVQQHLMMEGVPSAKIVMGVPFYGRAFKGVSGGNGGQYSSHSTPGEDPYPNADYWLVGCDECVRDKDPRIASYRQLEQMLQGNYGYQRLWNDKTKTPYLYHAQNGLFVTYDDAESFKYKAKYIKQQQLGGVMFWHLGQDNRNGDLLAALDRYFNAADYDDSQLDMGTGLRYTGVGPGNLPIMTAPAYVPGTTYAQGALVSYQGYVWQTKWGYITSAPGSDSAWLKVGRLA			chitin catabolic process [GO:0006032]; polysaccharide catabolic process [GO:0000272]	extracellular region [GO:0005576]	carbohydrate binding [GO:0030246]; chitin binding [GO:0008061]; chitinase activity [GO:0004568]	extracellular region [GO:0005576]; carbohydrate binding [GO:0030246]; chitin binding [GO:0008061]; chitinase activity [GO:0004568]; chitin catabolic process [GO:0006032]; polysaccharide catabolic process [GO:0000272]	GO:0000272; GO:0004568; GO:0005576; GO:0006032; GO:0008061; GO:0030246	2668886; 9371460	10.1093/nar/17.13.5395; 10.1128/jb.179.22.7111-7117.1997	WP_016926761.1;	P11797;	CHEMBL5348;	DB04520;DB02813;DB03109;DB04628;DB04404;DB02414;DB04541;DB04157;DB04433;
3af2	P9WPA7	reviewed	COAA_MYCTU	Pantothenate kinase (EC 2.7.1.33) (Pantothenic acid kinase)	coaA Rv1092c MTV017.45c	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	312	MSRLSEPSPYVEFDRRQWRALRMSTPLALTEEELVGLRGLGEQIDLLEVEEVYLPLARLIHLQVAARQRLFAATAEFLGEPQQNPDRPVPFIIGVAGSVAVGKSTTARVLQALLARWDHHPRVDLVTTDGFLYPNAELQRRNLMHRKGFPESYNRRALMRFVTSVKSGSDYACAPVYSHLHYDIIPGAEQVVRHPDILILEGLNVLQTGPTLMVSDLFDFSLYVDARIEDIEQWYVSRFLAMRTTAFADPESHFHHYAAFSDSQAVVAAREIWRTINRPNLVENILPTRPRATLVLRKDADHSINRLRLRKL		MISCELLANEOUS: Was identified as a high-confidence drug target.	coenzyme A biosynthetic process [GO:0015937]; phosphorylation [GO:0016310]	cytoplasm [GO:0005737]; plasma membrane [GO:0005886]	ATP binding [GO:0005524]; pantothenate kinase activity [GO:0004594]	cytoplasm [GO:0005737]; plasma membrane [GO:0005886]; ATP binding [GO:0005524]; pantothenate kinase activity [GO:0004594]; coenzyme A biosynthetic process [GO:0015937]; phosphorylation [GO:0016310]	GO:0004594; GO:0005524; GO:0005737; GO:0005886; GO:0015937; GO:0016310	9634230; 19099550; 21969609	10.1038/31159; 10.1186/1752-0509-2-109; 10.1074/mcp.m111.011445	NP_215608.1;WP_003405790.1;	P9WPA7;		
1jn2	P02866	reviewed	CONA_CANEN	Concanavalin-A (Con A)		Canavalia ensiformis (Jack bean) (Dolichos ensiformis)	290	MAISKKSSLFLPIFTFITMFLMVVNKVSSSTHETNALHFMFNQFSKDQKDLILQGDATTGTDGNLELTRVSSNGSPQGSSVGRALFYAPVHIWESSAVVASFEATFTFLIKSPDSHPADGIAFFISNIDSSIPSGSTGRLLGLFPDANVIRNSTTIDFNAAYNADTIVAVELDTYPNTDIGDPSYPHIGIDIKSVRSKKTAKWNMQNGKVGTAHIIYNSVDKRLSAVVSYPNADSATVSYDVDLDNVLPEWVRVGLSASTGLYKETNTILSWSFTSKLKSNEIPDIATVV	FUNCTION: D-mannose specific lectin (PubMed:2792084). Displays antiviral activity and therefore may contribute to defense against infections (PubMed:7481093). {ECO:0000269|PubMed:2792084, ECO:0000269|PubMed:7481093}.	MISCELLANEOUS: Binds one manganese (or another transition metal) ion and one calcium ion (PubMed:1112815). The metal ions are essential for the saccharide-binding and cell-agglutinating activities (PubMed:2792084). {ECO:0000269|PubMed:1112815, ECO:0000269|PubMed:2792084}.; MISCELLANEOUS: Displays strong antiviral activity against herpes simplex virus type 1 (MIC=0.32 ug/ml) and the rubella virus (MIC=7.2 ug/ml). {ECO:0000269|PubMed:7481093}.	defense response [GO:0006952]; regulation of defense response to virus [GO:0050688]		mannose binding [GO:0005537]; metal ion binding [GO:0046872]	mannose binding [GO:0005537]; metal ion binding [GO:0046872]; defense response [GO:0006952]; regulation of defense response to virus [GO:0050688]	GO:0005537; GO:0006952; GO:0046872; GO:0050688	3965973; 1112814; 1112813; 7481093; 4638345; 1112815; 1112816; 2792084; 15299577; 10748006; 34235541	10.1038/313064a0; 10.1016/s0021-9258(19)41841-3; 10.1016/s0021-9258(19)41840-1; 10.1016/0923-2516(96)80581-4; 10.1021/bi00776a006; 10.1016/s0021-9258(19)41842-5; 10.1016/s0021-9258(19)41843-7; 10.1002/j.1460-2075.1989.tb08341.x; 10.1107/s0907444996009237; 10.1074/jbc.m001251200; 10.1093/plcell/koab130		P02866;	CHEMBL5820;	
3li4	Q7SIG4	reviewed	DFPA_LOLVU	Diisopropyl-fluorophosphatase (DFPase) (EC 3.8.2.2)		Loligo vulgaris (Common European squid)	314	MEIPVIEPLFTKVTEDIPGAEGPVFDKNGDFYIVAPEVEVNGKPAGEILRIDLKTGKKTVICKPEVNGYGGIPAGCQCDRDANQLFVADMRLGLLVVQTDGTFEEIAKKDSEGRRMQGCNDCAFDYEGNLWITAPAGEVAPADYTRSMQEKFGSIYCFTTDGQMIQVDTAFQFPNGIAVRHMNDGRPYQLIVAETPTKKLWSYDIKGPAKIENKKVWGHIPGTHEGGADGMDFDEDNNLLVANWGSSHIEVFGPDGGQPKMRIRCPFEKPSNLHFKPQTKTIFVTEHENNAVWKFEWQRNGKKQYCETLKFGIF	FUNCTION: Biological function and substrate unknown. However, it is capable of acting on phosphorus anhydride bonds (such as phosphorus-halide and phosphorus-cyanide) in organophosphorus compounds (including nerve gases). {ECO:0000269|PubMed:15966726}.				calcium ion binding [GO:0005509]; diisopropyl-fluorophosphatase activity [GO:0047862]	calcium ion binding [GO:0005509]; diisopropyl-fluorophosphatase activity [GO:0047862]	GO:0005509; GO:0047862	11295437; 11171055; 15966726; 11134940; 11435114; 14501113	10.1016/s0167-4838(01)00153-4; 10.1042/0264-6021:3530579; 10.1021/bi0500675; 10.1107/s0907444900014232; 10.1016/s0969-2126(01)00610-4; 10.1107/s0907444903016135				
3pnm	P76015	reviewed	DHAK_ECOLI	PEP-dependent dihydroxyacetone kinase, dihydroxyacetone-binding subunit DhaK (EC 2.7.1.121)	dhaK ycgT b1200 JW5187	Escherichia coli (strain K12)	356	MKKLINDVQDVLDEQLAGLAKAHPSLTLHQDPVYVTRADAPVAGKVALLSGGGSGHEPMHCGYIGQGMLSGACPGEIFTSPTPDKIFECAMQVDGGEGVLLIIKNYTGDILNFETATELLHDSGVKVTTVVIDDDVAVKDSLYTAGRRGVANTVLIEKLVGAAAERGDSLDACAELGRKLNNQGHSIGIALGACTVPAAGKPSFTLADNEMEFGVGIHGEPGIDRRPFSSLDQTVDEMFDTLLVNGSYHRTLRFWDYQQGSWQEEQQTKQPLQSGDRVIALVNNLGATPLSELYGVYNRLTTRCQQAGLTIERNLIGAYCTSLDMTGFSITLLKVDDETLALWDAPVHTPALNWGK	FUNCTION: Dihydroxyacetone binding subunit of the dihydroxyacetone kinase, which is responsible for the phosphoenolpyruvate (PEP)-dependent phosphorylation of dihydroxyacetone via a phosphoryl group transfer from DhaL-ATP (PubMed:11350937, PubMed:15476397). Binds covalently dihydroxyacetone in hemiaminal linkage (PubMed:15476397). DhaK acts also as corepressor of the transcription activator DhaR by binding to the sensor domain of DhaR (PubMed:24440518). In the presence of dihydroxyacetone, DhaL-ADP displaces DhaK and stimulates DhaR activity (PubMed:24440518). In the absence of dihydroxyacetone, DhaL-ADP is converted by the PTS to DhaL-ATP, which does not bind to DhaR (PubMed:24440518). {ECO:0000269|PubMed:11350937, ECO:0000269|PubMed:15476397, ECO:0000269|PubMed:24440518}.	MISCELLANEOUS: Unlike the carbohydrate-specific transporters of the PTS, the complex DhaKML has no transport activity. {ECO:0000305|PubMed:15476397}.	carbohydrate phosphorylation [GO:0046835]; DNA damage response [GO:0006974]; glycerol catabolic process [GO:0019563]; glycerol to glycerone phosphate metabolic process [GO:0061610]; ketone catabolic process [GO:0042182]; monosaccharide catabolic process [GO:0046365]; pyruvate metabolic process [GO:0006090]	cytosol [GO:0005829]; transferase complex [GO:1990234]	glycerone kinase activity [GO:0004371]; identical protein binding [GO:0042802]; phosphoenolpyruvate-glycerone phosphotransferase activity [GO:0047324]; protein homodimerization activity [GO:0042803]	cytosol [GO:0005829]; transferase complex [GO:1990234]; glycerone kinase activity [GO:0004371]; identical protein binding [GO:0042802]; phosphoenolpyruvate-glycerone phosphotransferase activity [GO:0047324]; protein homodimerization activity [GO:0042803]; carbohydrate phosphorylation [GO:0046835]; DNA damage response [GO:0006974]; glycerol catabolic process [GO:0019563]; glycerol to glycerone phosphate metabolic process [GO:0061610]; ketone catabolic process [GO:0042182]; monosaccharide catabolic process [GO:0046365]; pyruvate metabolic process [GO:0006090]	GO:0004371; GO:0005829; GO:0006090; GO:0006974; GO:0019563; GO:0042182; GO:0042802; GO:0042803; GO:0046365; GO:0046835; GO:0047324; GO:0061610; GO:1990234	8905232; 9278503; 16738553; 11350937; 15616579; 12813127; 15476397; 21209328; 24440518	10.1093/dnares/3.3.137; 10.1126/science.277.5331.1453; 10.1038/msb4100049; 10.1093/emboj/20.10.2480; 10.1038/sj.emboj.7600517; 10.1073/pnas.0932787100; 10.1021/bi048575m; 10.1073/pnas.1012596108; 10.1016/j.str.2013.11.012	NP_415718.6;WP_000733715.1;			
1afs	P23457	reviewed	DIDH_RAT	3-alpha-hydroxysteroid dehydrogenase (3-alpha-HSD) (EC 1.1.1.50) (Hydroxyprostaglandin dehydrogenase)	Akr1c9	Rattus norvegicus (Rat)	322	MDSISLRVALNDGNFIPVLGFGTTVPEKVAKDEVIKATKIAIDNGFRHFDSAYLYEVEEEVGQAIRSKIEDGTVKREDIFYTSKLWSTFHRPELVRTCLEKTLKSTQLDYVDLYIIHFPMALQPGDIFFPRDEHGKLLFETVDICDTWEAMEKCKDAGLAKSIGVSNFNCRQLERILNKPGLKYKPVCNQVECHLYLNQSKMLDYCKSKDIILVSYCTLGSSRDKTWVDQKSPVLLDDPVLCAIAKKYKQTPALVALRYQLQRGVVPLIRSFNAKRIKELTQVFEFQLASEDMKALDGLNRNFRYNNAKYFDDHPNHPFTDE	FUNCTION: Besides being a 3-alpha-hydroxysteroid dehydrogenase, the enzyme can accomplish diverse functions: as quinone reductase, as an aromatic alcohol dehydrogenase, as dihydrodiol dehydrogenase, and as 9-, 11-, and 15-hydroxyprostaglandin dehydrogenase.		daunorubicin metabolic process [GO:0044597]; doxorubicin metabolic process [GO:0044598]; hippocampus development [GO:0021766]; progesterone metabolic process [GO:0042448]; prostaglandin metabolic process [GO:0006693]; steroid metabolic process [GO:0008202]	cytosol [GO:0005829]	alditol:NADP+ 1-oxidoreductase activity [GO:0004032]; androsterone dehydrogenase (B-specific) activity [GO:0047042]; androsterone dehydrogenase activity [GO:0047023]; bile acid binding [GO:0032052]; ketosteroid monooxygenase activity [GO:0047086]; steroid dehydrogenase activity [GO:0016229]	cytosol [GO:0005829]; alditol:NADP+ 1-oxidoreductase activity [GO:0004032]; androsterone dehydrogenase (B-specific) activity [GO:0047042]; androsterone dehydrogenase activity [GO:0047023]; bile acid binding [GO:0032052]; ketosteroid monooxygenase activity [GO:0047086]; steroid dehydrogenase activity [GO:0016229]; daunorubicin metabolic process [GO:0044597]; doxorubicin metabolic process [GO:0044598]; hippocampus development [GO:0021766]; progesterone metabolic process [GO:0042448]; prostaglandin metabolic process [GO:0006693]; steroid metabolic process [GO:0008202]	GO:0004032; GO:0005829; GO:0006693; GO:0008202; GO:0016229; GO:0021766; GO:0032052; GO:0042448; GO:0044597; GO:0044598; GO:0047023; GO:0047042; GO:0047086	1840601; 1714456; 1922097; 7515872; 10619355; 15489334; 7998972; 1793046; 2026597; 7626489; 8146147; 8718859; 9261071	10.1016/s0021-9258(18)31521-7; 10.1016/s0021-9258(18)98610-2; 10.1210/mend-5-6-823; 10.1093/oxfordjournals.jbchem.a124323; 10.1016/s0960-0760(99)00122-3; 10.1101/gr.2596504; 10.1042/bj3040385; 10.1007/bf01993305; 10.1016/s0021-9258(18)31522-9; 10.1016/0960-0760(95)00019-v; 10.1073/pnas.91.7.2517; 10.1021/bi9604688; 10.1016/s0969-2126(97)00234-7	NP_612556.1;		CHEMBL1075221;	
4azf	Q92630	reviewed	DYRK2_HUMAN	Dual specificity tyrosine-phosphorylation-regulated kinase 2 (EC 2.7.12.1)	DYRK2	Homo sapiens (Human)	601	MLTRKPSAAAPAAYPTGRGGDSAVRQLQASPGLGAGATRSGVGTGPPSPIALPPLRASNAAAAAHTIGGSKHTMNDHLHVGSHAHGQIQVQQLFEDNSNKRTVLTTQPNGLTTVGKTGLPVVPERQLDSIHRRQGSSTSLKSMEGMGKVKATPMTPEQAMKQYMQKLTAFEHHEIFSYPEIYFLGLNAKKRQGMTGGPNNGGYDDDQGSYVQVPHDHVAYRYEVLKVIGKGSFGQVVKAYDHKVHQHVALKMVRNEKRFHRQAAEEIRILEHLRKQDKDNTMNVIHMLENFTFRNHICMTFELLSMNLYELIKKNKFQGFSLPLVRKFAHSILQCLDALHKNRIIHCDLKPENILLKQQGRSGIKVIDFGSSCYEHQRVYTYIQSRFYRAPEVILGARYGMPIDMWSLGCILAELLTGYPLLPGEDEGDQLACMIELLGMPSQKLLDASKRAKNFVSSKGYPRYCTVTTLSDGSVVLNGGRSRRGKLRGPPESREWGNALKGCDDPLFLDFLKQCLEWDPAVRMTPGQALRHPWLRRRLPKPPTGEKTSVKRITESTGAITSISKLPPPSSSASKLRTNLAQMTDANGNIQQRTVLPKLVS	FUNCTION: Serine/threonine-protein kinase involved in the regulation of the mitotic cell cycle, cell proliferation, apoptosis, organization of the cytoskeleton and neurite outgrowth. Functions in part via its role in ubiquitin-dependent proteasomal protein degradation. Functions downstream of ATM and phosphorylates p53/TP53 at 'Ser-46', and thereby contributes to the induction of apoptosis in response to DNA damage. Phosphorylates NFATC1, and thereby inhibits its accumulation in the nucleus and its transcription factor activity. Phosphorylates EIF2B5 at 'Ser-544', enabling its subsequent phosphorylation and inhibition by GSK3B. Likewise, phosphorylation of NFATC1, CRMP2/DPYSL2 and CRMP4/DPYSL3 promotes their subsequent phosphorylation by GSK3B. May play a general role in the priming of GSK3 substrates. Inactivates GYS1 by phosphorylation at 'Ser-641', and potentially also a second phosphorylation site, thus regulating glycogen synthesis. Mediates EDVP E3 ligase complex formation and is required for the phosphorylation and subsequent degradation of KATNA1. Phosphorylates TERT at 'Ser-457', promoting TERT ubiquitination by the EDVP complex. Phosphorylates SIAH2, and thereby increases its ubiquitin ligase activity. Promotes the proteasomal degradation of MYC and JUN, and thereby regulates progress through the mitotic cell cycle and cell proliferation. Promotes proteasomal degradation of GLI2 and GLI3, and thereby plays a role in smoothened and sonic hedgehog signaling. Plays a role in cytoskeleton organization and neurite outgrowth via its phosphorylation of DCX and DPYSL2. Phosphorylates CRMP2/DPYSL2, CRMP4/DPYSL3, DCX, EIF2B5, EIF4EBP1, GLI2, GLI3, GYS1, JUN, MDM2, MYC, NFATC1, p53/TP53, TAU/MAPT and KATNA1. Can phosphorylate histone H1, histone H3 and histone H2B (in vitro). Can phosphorylate CARHSP1 (in vitro). {ECO:0000269|PubMed:11311121, ECO:0000269|PubMed:12588975, ECO:0000269|PubMed:14593110, ECO:0000269|PubMed:15910284, ECO:0000269|PubMed:16511445, ECO:0000269|PubMed:16611631, ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:18455992, ECO:0000269|PubMed:18599021, ECO:0000269|PubMed:19287380, ECO:0000269|PubMed:22307329, ECO:0000269|PubMed:22878263, ECO:0000269|PubMed:23362280, ECO:0000269|PubMed:9748265}.		DNA damage response [GO:0006974]; intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator [GO:0042771]; negative regulation of calcineurin-NFAT signaling cascade [GO:0070885]; positive regulation of glycogen biosynthetic process [GO:0045725]; protein phosphorylation [GO:0006468]; regulation of signal transduction by p53 class mediator [GO:1901796]; smoothened signaling pathway [GO:0007224]	cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; ribonucleoprotein complex [GO:1990904]; ubiquitin ligase complex [GO:0000151]	ATP binding [GO:0005524]; magnesium ion binding [GO:0000287]; manganese ion binding [GO:0030145]; protein serine kinase activity [GO:0106310]; protein serine/threonine kinase activity [GO:0004674]; protein serine/threonine/tyrosine kinase activity [GO:0004712]; protein tyrosine kinase activity [GO:0004713]	cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; ribonucleoprotein complex [GO:1990904]; ubiquitin ligase complex [GO:0000151]; ATP binding [GO:0005524]; magnesium ion binding [GO:0000287]; manganese ion binding [GO:0030145]; protein serine kinase activity [GO:0106310]; protein serine/threonine kinase activity [GO:0004674]; protein serine/threonine/tyrosine kinase activity [GO:0004712]; protein tyrosine kinase activity [GO:0004713]; DNA damage response [GO:0006974]; intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator [GO:0042771]; negative regulation of calcineurin-NFAT signaling cascade [GO:0070885]; positive regulation of glycogen biosynthetic process [GO:0045725]; protein phosphorylation [GO:0006468]; regulation of signal transduction by p53 class mediator [GO:1901796]; smoothened signaling pathway [GO:0007224]	GO:0000151; GO:0000287; GO:0004674; GO:0004712; GO:0004713; GO:0005524; GO:0005634; GO:0005654; GO:0005737; GO:0005829; GO:0005856; GO:0006468; GO:0006974; GO:0007224; GO:0030145; GO:0042771; GO:0045725; GO:0070885; GO:0106310; GO:1901796; GO:1990904	9748265; 14702039; 15489334; 11311121; 12874018; 12588975; 14593110; 14623875; 15910284; 16611631; 16511445; 17349958; 18599021; 18455992; 18539531; 19796173; 19287380; 20836251; 19965871; 22307329; 22878263; 23362280; 23186163; 22998443; 23665168; 17344846	10.1074/jbc.273.40.25893; 10.1038/ng1285; 10.1101/gr.2596504; 10.1042/bj3550609; 10.1128/mcb.23.5.1546-1557.2003; 10.1074/jbc.m301769200; 10.1074/jbc.m310794200; 10.1042/bj20050733; 10.1074/jbc.m513344200; 10.1038/nature04631; 10.1016/j.molcel.2007.02.007; 10.1016/j.bcp.2008.05.021; 10.1016/j.cell.2008.02.047; 10.1016/j.molmed.2008.05.003; 10.1111/j.1742-4658.2009.07346.x; 10.1038/ncb1848; 10.1016/j.bmcl.2010.04.150; 10.1074/jbc.m109.042341; 10.1172/jci60818; 10.1093/jmcb/mjs047; 10.1074/jbc.m112.416792; 10.1021/pr300630k; 10.1021/jm301034u; 10.1016/j.str.2013.03.012; 10.1038/nature05610	NP_003574.1 [Q92630-2];NP_006473.2 [Q92630-1];XP_016875521.1 [Q92630-2];	Q92630;	CHEMBL4376;	
2pc8	P29717	reviewed	EXG1_CANAL	Glucan 1,3-beta-glucosidase (EC 2.4.1.-) (EC 3.2.1.58) (Exo-1,3-beta-glucanase)	XOG1 EXG EXG1 XOG CAALFM_C102990CA Ca49C10.05 CaO19.10507 CaO19.2990	Candida albicans (strain SC5314 / ATCC MYA-2876) (Yeast)	438	MQLSFILTSSVFILLLEFVKASVISNPFKPNGNLKFKRGGGHNVAWDYDNNVIRGVNLGGWFVLEPYMTPSLFEPFQNGNDQSGVPVDEYHWTQTLGKEAASRILQKHWSTWITEQDFKQISNLGLNFVRIPIGYWAFQLLDNDPYVQGQVQYLEKALGWARKNNIRVWIDLHGAPGSQNGFDNSGLRDSYNFQNGDNTQVTLNVLNTIFKKYGGNEYSDVVIGIELLNEPLGPVLNMDKLKQFFLDGYNSLRQTGSVTPVIIHDAFQVFGYWNNFLTVAEGQWNVVVDHHHYQVFSGGELSRNINDHISVACNWGWDAKKESHWNVAGEWSAALTDCAKWLNGVNRGARYEGAYDNAPYIGSCQPMLDISQWSDEHKTDTRRYIEAQLDAFEYTGGWVFWSWKTENAPEWSFQTLTYNGLFPQPVTDRQFPNQCGFH	FUNCTION: Major glucan 1,3-beta-glucosidase required for cell wall integrity. Beta-glucanases participate in the metabolism of beta-glucan, the main structural component of the cell wall. Can also function biosynthetically as a transglycosylase. Functions to deliver glucan from the cell to the extracellular matrix. Does not appear to impact cell wall glucan content of biofilm cells, nor is it necessary for filamentation or biofilm formation. Involved in cell-substrate and cell-cell adhesion. Adhesion to host-cell surfaces is the first critical step during mucosal infection. XOG1 is target of human antimicrobial peptide LL-37 for inhibition of cell adhesion. {ECO:0000269|PubMed:21713010, ECO:0000269|PubMed:22876186}.		cell-substrate adhesion [GO:0031589]; fungal-type cell wall organization [GO:0031505]; glucan catabolic process [GO:0009251]; glucan metabolic process [GO:0044042]; single-species biofilm formation in or on host organism [GO:0044407]; single-species biofilm formation on inanimate substrate [GO:0044011]	cell surface [GO:0009986]; extracellular region [GO:0005576]; extracellular vesicle [GO:1903561]	cell adhesion molecule binding [GO:0050839]; glucan exo-1,3-beta-glucosidase activity [GO:0004338]; transferase activity [GO:0016740]	cell surface [GO:0009986]; extracellular region [GO:0005576]; extracellular vesicle [GO:1903561]; cell adhesion molecule binding [GO:0050839]; glucan exo-1,3-beta-glucosidase activity [GO:0004338]; transferase activity [GO:0016740]; cell-substrate adhesion [GO:0031589]; fungal-type cell wall organization [GO:0031505]; glucan catabolic process [GO:0009251]; glucan metabolic process [GO:0044042]; single-species biofilm formation in or on host organism [GO:0044407]; single-species biofilm formation on inanimate substrate [GO:0044011]	GO:0004338; GO:0005576; GO:0009251; GO:0009986; GO:0016740; GO:0031505; GO:0031589; GO:0044011; GO:0044042; GO:0044407; GO:0050839; GO:1903561	8436950; 15123810; 17419877; 24025428; 1789004; 9013549; 10469155; 14731272; 17030998; 19555771; 20402792; 20167299; 20392151; 20641015; 21622905; 21713010; 22876186; 23243062; 23136884; 10610795; 20875088	10.1099/00221287-139-2-325; 10.1073/pnas.0401648101; 10.1186/gb-2007-8-4-r52; 10.1186/gb-2013-14-9-r97; 10.1002/yea.320070808; 10.1074/jbc.272.6.3161; 10.1046/j.1432-1327.1999.00581.x; 10.1111/j.1365-2958.2003.03879.x; 10.1128/ec.00186-06; 10.1016/j.fgb.2009.06.005; 10.1111/j.1567-1364.2010.00626.x; 10.1016/j.jprot.2010.02.008; 10.3109/13693780903405782; 10.1002/yea.1775; 10.1128/ec.05011-11; 10.1371/journal.pone.0021394; 10.1371/journal.ppat.1002848; 10.1128/ec.00278-12; 10.1111/mmi.12087; 10.1006/jmbi.1999.3287; 10.1111/j.1742-4658.2010.07869.x	XP_721488.2;			DB01816;
